var title_f23_16_23808="Dermoid cyst ovary2";
var content_f23_16_23808=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transvaginal image of the right adnexa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Benign cystic teratoma (dermoid tumor) of the right ovary. The complex nature of this small tumor is demonstrated. The long arrow indicates the solid hyperechoic echogenic portion with shadowing of the ultrasound beam distal to the echogenic portion. The short arrow demonstrates the anechoic cystic portion with post cyst enhancement of the ultrasound beam.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas D Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_16_23808=[""].join("\n");
var outline_f23_16_23808=null;
var title_f23_16_23809="Psoriatic arthritis foot";
var content_f23_16_23809=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Psoriatic arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph of the foot of a patient with psoriatic arthritis shows the early separation of the nails (onycholysis), swelling of the entire second toe (dactylitis), and some psoriatic skin lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Daniel Z Sands, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_16_23809=[""].join("\n");
var outline_f23_16_23809=null;
var title_f23_16_23810="Vitiligo - periocular";
var content_f23_16_23810=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vitiligo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A depigmented patch of vitiligo is present on the periocular skin. Note associated loss of pigment in the eyebrow and eyelashes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_16_23810=[""].join("\n");
var outline_f23_16_23810=null;
var title_f23_16_23811="Churg Strauss CT";
var content_f23_16_23811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Supine high-resolution CT scan through the right lower and middle lobes in a patient with&nbsp;eosinophilic granulomatosis with polyangiitis (Churg-Strauss) demonstrates a thickened major fissure and thickened&nbsp;septal lines&nbsp;in the subpleural parenchyma. Enlarged pulmonary arteries are also present in this area. The adjacent bronchi are normal in size with some peribronchiolar thickening. Small patchy opacities are present in the pulmonary parenchyma and are believed to correlate with the eosinophilic pneumonitis that is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_16_23811=[""].join("\n");
var outline_f23_16_23811=null;
var title_f23_16_23812="Types of APBJ";
var content_f23_16_23812=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Types of anomalous pancreaticobiliary junction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     B-P: bileopancreatic type; P-B: pancreaticobiliary type.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Moises Guelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_16_23812=[""].join("\n");
var outline_f23_16_23812=null;
var title_f23_16_23813="Recovery after coronary artery bypass graft surgery (CABG)";
var content_f23_16_23813=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?23/16/23813/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/16/23813/contributors\" id=\"au6237\">",
"       Julian M Aroesty, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?23/16/23813/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/16/23813/contributors\" id=\"se4323\">",
"       Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?23/16/23813/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/16/23813/contributors\" id=\"de1101\">",
"       Gordon M Saperia, MD, FACC",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?23/16/23813?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BYPASS SURGERY OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Coronary artery bypass graft surgery, also known as CABG or bypass surgery, can help to restore blood flow to an area of the heart. However, surgery does not stop the progression of atherosclerosis (coronary heart disease), which deposits fatty material into artery walls, narrowing them and eventually limiting blood flow.",
"    </p>",
"    <p>",
"     Patients and healthcare providers must work together after surgery to treat the underlying atherosclerosis and the factors that can cause progression of heart disease. (See",
"     <a class=\"local\" href=\"#H11\">",
"      'Reduce cardiac risk factors'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     This topic review discusses treatments that are recommended after coronary artery bypass graft surgery. These treatments can help to:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Reduce the risk of developing complications of coronary heart disease, including having a subsequent heart attack or dying",
"      </li>",
"      <li>",
"       Help a person to feel better and have more energy.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     An overview of coronary artery bypass graft surgery is discussed in detail separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=see_link\">",
"      \"Patient information: Coronary artery bypass graft surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CARE AT HOME AFTER BYPASS SURGERY",
"     </span>",
"    </p>",
"    <p>",
"     Care after bypass surgery aims to reduce the risk factors for heart disease and includes strategies to help patients and family members to stop smoking, control high blood pressure, improve cholesterol levels, begin exercising regularly, and reduce stress. Some of these changes can be made by adjusting lifestyle habits through diet and exercise. However, lifestyle changes alone may not be adequate and medications are often needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Discharge from the hospital",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients with an uncomplicated heart attack usually go home after about five days in the hospital. In some cases, the hospital stay is longer. If complications have occurred, discharge is delayed until the person's condition is stable.",
"    </p>",
"    <p>",
"     Before leaving the hospital, it is important for the patient and family to participate in and understand the discharge plan. Make sure all questions are answered and obtain written directions for how to take all medications (new and old). After bypass surgery, it is common to start new medications and stop or adjust the doses of previous medications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people who have had bypass surgery are sent home with prescriptions for several medications, most of which are taken every day. Some of these drugs improve survival and some help to prevent or treat recurrent chest pain.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Antiplatelet therapy &mdash; Clopidogrel (brand name: Plavix&reg;) and aspirin are antiplatelet medications that are given to help prevent the formation of blood clots that can block either the graft or your own arteries. Clopidogrel is continued for at least one year after surgery while aspirin is usually recommended indefinitely. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?39/54/40803?source=see_link\">",
"        \"Patient information: Aspirin and cardiovascular disease (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Beta blockers &mdash; Beta blockers slow the heart rate, lower blood pressure, and decrease the heart's demand for oxygen. They are given to some patients with high blood pressure, heart failure, or a heart attack, and to some patients in whom CABG is not expected to relieve all symptoms of angina. If a person cannot tolerate a beta blocker, a calcium channel blocker may be substituted.",
"      </li>",
"      <li>",
"       Nitrates &mdash; A nitrate, either as short-acting nitroglycerin, or as a long-acting preparation (isosorbide mononitrate or dinitrate). These drugs dilate coronary blood vessels, bringing more blood to the heart muscle. Nitrates also reduce the amount of blood returning to the heart, which decreases the heart's demand for oxygen. Nitrates are often given to treat or prevent further episodes of chest pain. Nitrates may be given to patients after CABG if some of the coronary blood vessels could not be bypassed. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?31/1/31766?source=see_link\">",
"        \"Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       ACE inhibitor &mdash; Angiotensin converting enzyme (ACE) inhibitors are often used to treat high blood pressure.",
"       <br/>",
"       Examples of ACE inhibitors include captopril (brand name: Capoten&reg;), enalapril (brand name: Vasotec&reg;), lisinopril (sample brand names: Zestril&reg; or Prinivil&reg;), and ramipril (brand name: Altace&reg;).",
"       <br/>",
"       <br/>",
"       Some patients who cannot tolerate an ACE inhibitor (often because of a chronic cough) may be prescribed an angiotensin II receptor blocker (ARB). These related drugs are satisfactory replacements.",
"       <br/>",
"       <br/>",
"       Examples of ARBs include losartan (brand name: Cozaar&reg;), valsartan (brand name: Diovan&reg;), and irbesartan (brand name: Avapro&reg;).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Lipid lowering therapy &mdash; Almost all patients are given a medication to lower lipids after CABG. Cholesterol lowering can be beneficial both before and after CABG because it can halt the progression of atherosclerosis in both native and graft vessels.",
"      </li>",
"      <li>",
"       Other medications ��� Other medications may be given on a short term basis to prevent the development of an irregular heart, to manage discomfort associated with healing incisions, or to allow for regular bowel movements.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Lipid therapies are recommended even for patients who have values that are in the \"normal\" range. The goal level for \"bad\" cholesterol (called LDL or low density lipoprotein) is less than 70",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     (1.8",
"     <span class=\"nowrap\">",
"      mmol/L).",
"     </span>",
"     (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"      \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Statins are the most common medications used to lower cholesterol levels. Other drugs may be used as well (",
"     <a class=\"graphic graphic_table graphicRef70312 \" href=\"UTD.htm?42/50/43819\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Wound care",
"     </span>",
"     &nbsp;&mdash;&nbsp;After discharge from the hospital, the patient is usually given instructions about how to care for their chest",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     leg wounds. It is important to follow these instructions closely and to notify a healthcare provider immediately if there are questions or concerns.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Avoid heavy lifting and extremes of shoulder movement (eg, as in tennis, baseball, and golf) for six to eight weeks after surgery to allow for complete healing of the breast bone (sternum)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      When to seek help",
"     </span>",
"     &nbsp;&mdash;&nbsp;If the patient develops any of the following signs or symptoms of wound infection, a healthcare provider should be contacted immediately. Most wound infections develop within 14 days of the surgery.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Fever greater than 100.4&ordm; F (38&ordm; C)",
"      </li>",
"      <li>",
"       New or worsened pain in the chest or around the incision",
"      </li>",
"      <li>",
"       A rapid heart rate",
"      </li>",
"      <li>",
"       Reddened skin, bleeding or pus-like drainage from the incision",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      CARDIAC REHABILITATION",
"     </span>",
"    </p>",
"    <p>",
"     Most people who have undergone bypass surgery benefit from participating in a structured, comprehensive cardiac rehabilitation program. People who participate in cardiac rehabilitation usually have appointments several times per week in a hospital or clinic, allowing the person to live and sleep at home. The potential benefits of rehabilitation include an improvement in heart function, a lowering of the heart rate at rest and during exercise, and a reduced risk of dying or developing complications from heart disease.",
"    </p>",
"    <p>",
"     There are several components to cardiac rehabilitation, including exercise, reducing risk factors, and dealing with stress, anxiety, and depression. The benefits of cardiac rehabilitation are seen only when this multifactorial approach is used. In other words, one component alone is not enough.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Exercise has consistently been shown to improve cardiovascular health. Importantly, the first step in starting to exercise is to determine the potential risk of heart",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     blood vessel complications from exercise. This is usually done by undergoing a monitored exercise test on a treadmill. Although nearly everyone can exercise safely after discharge, the intensity and duration of exercise should be adjusted according to the severity of a person's heart disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Risk categories for exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Risk categories are a way of describing a person's risk of cardiovascular (heart-related) complications related to activity. Each category has a unique requirement for supervision and exercise restrictions. People in risk category A are generally healthy, do not require medical supervision during exercise, and have no limitations on the duration or intensity of exercise. Conversely, people in exercise category D have strict limits on activity and should not exercise, even with close medical supervision. Most people who have had bypass surgery are in category B or C.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Class A &mdash; Individuals who are apparently healthy and in whom there is no evidence of increased heart-related risk with exercise.",
"      </li>",
"      <li>",
"       Class B &mdash; Individuals with established coronary heart disease that is stable. These individuals are at low risk of heart-related complications with vigorous exercise.",
"      </li>",
"      <li>",
"       Class C &mdash; Individuals who are at moderate or high risk of heart-related complications during exercise. Examples of people who would be in this category are those who have had several heart attacks and those who have chest pain at a relatively low level of exercise. Patients with certain positive findings on an exercise test may also be in this group.",
"      </li>",
"      <li>",
"       Class D &mdash; Individuals with unstable disease who should not participate in an exercise program.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;During cardiac rehabilitation, a trained clinician will work with the patient and physician to develop an exercise program that is safe and beneficial. The program will consider the patient's fitness level, heart health, any physical limitations, the amount, intensity and duration of exercise needed to improve heart health, and the need for supervision.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Type of exercise &mdash; The exercise should use large muscle groups and include aerobic exercise. Walking, jogging, cycling, rowing, and stair climbing are some examples.",
"      </li>",
"      <li>",
"       Frequency &mdash; The recommended frequency of exercise is three to five times a week.",
"      </li>",
"      <li>",
"       Content and duration &mdash; It is important that each session consist of a 5- to 10-minute warm-up phase, a conditioning phase of at least 20 minutes, and a 5- to 10-minute cool-down phase. Eliminating the cool-down phase can increase the risk of heart-related complications.",
"      </li>",
"      <li>",
"       Intensity &mdash; One of the most important components of the exercise prescription is the intensity of exercise. This is based upon the patient's heart rate or the level of exertion. A number of formulas exist to calculate the appropriate maximum heart rate for each patient.",
"       <br/>",
"       <br/>",
"       The patient gauges the level of exertion during an activity by rating it on a standardized scale called the rating of perceived exertion (RPE) (",
"       <a class=\"graphic graphic_table graphicRef70470 \" href=\"UTD.htm?20/13/20699\">",
"        table 2",
"       </a>",
"       ). Moderate-intensity exercise (an RPE of 12 to 13) is needed to achieve cardiovascular health benefits. The benefits of very high intensity exercise are small; intense exercise is not recommended because it leads to muscle fatigue and increases the risk of physical injury and cardiovascular complications.",
"      </li>",
"      <li>",
"       Exercise progression &mdash; Over time, most people can gradually increase the level of exercise in the workout. Beneficial exercise can also be built in to the daily routine by taking a brisk walk or enjoying active play with children or grandchildren.",
"      </li>",
"      <li>",
"       Supervision &mdash; Patients who are in Class C should be in a medically supervised program where the electrocardiogram (ECG) is monitored during exercise. Advanced life support equipment (eg, a defibrillator, medications, personnel trained to use this equipment) should be on hand. This level of supervision should continue for at least 8 to 12 weeks.",
"       <br/>",
"       <br/>",
"       Lower-risk patients (Class B) benefit from a medically supervised, ECG monitored program for the first 6 to 12 sessions. Following this, a home-based exercise program is safe and effective.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      REDUCE CARDIAC RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     A number of factors increase the risk of developing or speeding the progression of heart disease. Reducing or eliminating these risk factors can be helpful, even if a person already has heart disease or has had a heart attack. Strategies to reduce risks are discussed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Follow a heart healthy diet",
"     </span>",
"     &nbsp;&mdash;&nbsp;Diet counseling is helpful for people who need to lose weight or reduce cholesterol levels. A registered dietitian is the best person to consult about foods that are helpful and harmful, appropriate portion sizes, total calorie recommendations, and realistic ways to change bad eating habits.",
"    </p>",
"    <p>",
"     Most cardiac rehabilitation programs have a dietitian who is knowledgeable and experienced in advising people who are recovering from a heart attack. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=see_link\">",
"      \"Patient information: Diet and health (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Stop smoking",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cigarette smoking significantly increases the risk coronary heart disease and heart attack, and stopping smoking can rapidly reduce these risks. One year after stopping smoking, the risk of dying from coronary heart disease is reduced by about one-half and the risk continues to decline with time. In some studies, the risk of heart attack was reduced to the rate of nonsmokers within two years of quitting smoking.",
"    </p>",
"    <p>",
"     Cardiac rehabilitation programs can recommend a treatment to help stop smoking, such as group programs, nicotine patches, gum, or nasal spray, or a prescription medication . &nbsp;(See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      \"Patient information: Quitting smoking (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Treat high blood pressure and high cholesterol",
"     </span>",
"     &nbsp;&mdash;&nbsp;Medicines to control high blood pressure and high cholesterol are usually recommended after bypass surgery (see",
"     <a class=\"local\" href=\"#H4\">",
"      'Medications'",
"     </a>",
"     above). It is important to take these medications exactly as prescribed. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"      \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"      \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Manage diabetes",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with diabetes are at an increased risk of developing complications after bypass surgery. Tight control of blood glucose levels can help to reduce the risk of these and other types of complications. Tight control can be achieved by losing weight, managing the diet, exercising, monitoring blood glucose levels regularly, and taking oral hypoglycemic medications (for people with type 2 diabetes) or insulin (for people with type 1 and sometimes type 2 diabetes). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"      \"Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Psychosocial treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Feelings of depression, anxiety, and denial are common after bypass surgery, occurring in up to 40 percent of people. Depression can reduce a person's ability to exercise, decrease energy levels, cause more fatigue, or reduce a person's quality of life and sense of well-being. Women, and in particular younger women, are at an especially high risk for depression.",
"    </p>",
"    <p>",
"     These symptoms can cause problems within the family, marriage, and the workplace. Individual or group therapy, and sometimes treatment with an antidepressant medication, can be helpful. Many cardiac rehabilitation programs have trained personnel, including psychologists, psychiatrists, or social workers, to help manage these issues. Treating depression and anxiety can improve a person's long-term outlook and general sense of well-being. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"      \"Patient information: Depression in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Reduce stress",
"     </span>",
"     &nbsp;&mdash;&nbsp;Long-term stress in the home, at work, or with finances can increase the risk of heart attack, stroke, and chest pain. Many cardiac rehabilitation programs teach patients how to reduce stress in an attempt to lower these risks.",
"    </p>",
"    <p>",
"     Stress reduction techniques may include one or more of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Psychotherapy involves meeting with a psychologist, psychiatrist, or social worker to discuss emotional responses to living with stress, treatment successes or failures,",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       personal relationships.",
"      </li>",
"      <li>",
"       Group psychotherapy allows patients to compare their experiences with stress and heart disease, overcome their tendency to withdraw and become isolated, and support one another's attempts at more effective management.",
"      </li>",
"      <li>",
"       Relaxation techniques can relieve musculoskeletal tension, and may include meditation, progressive muscle relaxation, self-hypnosis, and biofeedback. Biofeedback may be especially helpful for people with chronic stress.",
"      </li>",
"      <li>",
"       Group skill-building exercises help patients to learn about living with stress and heart disease, including ways to improve relationships and build strength, ways to avoid negative thinking, and learning to deal with stress.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHEN IS SEX SAFE?",
"     </span>",
"    </p>",
"    <p>",
"     An important issue for many patients who have had bypass surgery is when sexual activity can be safely resumed. In the first two weeks after an",
"     <strong>",
"      uncomplicated",
"     </strong>",
"     heart attack, most people are at high risk of heart-related problems during sex as a result of a rise in the heart rate and blood pressure. However, this risk becomes much smaller by six weeks after the MI.",
"    </p>",
"    <p>",
"     Patients with complications of a heart attack, such as recurrent chest pain, abnormal heart rhythms (arrhythmias), or heart failure are at intermediate or high risk of heart-related problems during sex. People in these risk groups need further evaluation",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     treatment before attempting to have sex. A cardiologist or internal medicine specialist can help a person to know when sex is safe.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Sexual problems",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sexual problems after a bypass surgery are common, occurring in one-half to three-quarters of patients. Both men and women may have less sex or feel less satisfied with sexual activity. A variety of factors may contribute, including side effects of drugs (such as beta blockers), depression, and fears about triggering a new heart attack or dying. Since sexual activity is a type of physical activity, exercise testing can be used to determine if a person is at any risk of heart problems related to sex.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Use of Viagra&reg;, Cialis&reg; or Levitra&reg;",
"     </span>",
"     &nbsp;&mdash;&nbsp;For many men with erectile dysfunction, medications such sildenafil (brand name: Viagra&reg;), tadalafil (brand name: Cialis&reg;) or vardenafil (brand name: Levitra&reg;) are highly effective. There have been concerns that these agents might cause side effects or increase the risk of heart attack in people with CHD. However, if used appropriately, these drugs appear to be well tolerated and safe. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=see_link\">",
"      \"Patient information: Sexual problems in men (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Unfortunately, these medications are not usually helpful for women with sexual problems after a heart attack or bypass surgery. Other treatments are available for women. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=see_link\">",
"      \"Patient information: Sexual problems in women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Nitrates and medications for erectile dysfunction",
"     </span>",
"     &nbsp;&mdash;&nbsp;None of the medications for erectile dysfunction (eg, Viagra, Cialis, Levitra) should be used if a person regularly or intermittently requires nitrates (such as nitroglycerin or isosorbide) for recurrent chest pain. This combination of medications can cause a life-threatening drop in blood pressure.",
"    </p>",
"    <p>",
"     Thus, if a man develops chest pain after taking Viagra, Cialis or Levitra, he should not take nitrates for 24 hours (or longer in some cases). Instead, the man should rest and wait 10 minutes to see if the pain resolves. If the pain does not resolve or if the chest pain is severe, he should immediately call for emergency medical services (in the United States by calling 911).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      FOLLOW-UP CARE",
"     </span>",
"    </p>",
"    <p>",
"     Following the discharge plan and participating in a cardiac rehabilitation program are the best ways to recover from bypass surgery. In addition, it is important to schedule and attend periodic visits with an internal medicine provider",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     cardiac specialist (cardiologist).",
"    </p>",
"    <p>",
"     Follow-up care is of great importance since people who have had bypass surgery have a significantly increased risk of more cardiac events, including recurrent chest pain, heart attack, heart failure, and an increased risk of dying. The risk of these problems is greatly reduced by closely following a clinician's recommendations for rehabilitation, follow-up visits, and treatments. Over time, the treatment plan may change as heart health improves or other medical problems develop.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498586475\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1942887\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1942904\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=see_link\">",
"      Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/54/40803?source=see_link\">",
"      Patient information: Aspirin and cardiovascular disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/1/31766?source=see_link\">",
"      Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=see_link\">",
"      Patient information: Diet and health (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=see_link\">",
"      Patient information: Sexual problems in men (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=see_link\">",
"      Patient information: Sexual problems in women (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=see_link\">",
"      Cardiac rehabilitation in patients with heart failure",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17705?source=see_link\">",
"      Cardiac rehabilitation: Exercise training and secondary prevention of coronary heart disease in older adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=see_link\">",
"      Components of cardiac rehabilitation and exercise prescription",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13977?source=see_link\">",
"      Efficacy of cardiac rehabilitation in patients with coronary heart disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3687?source=see_link\">",
"      Exercise assessment and measurement of exercise capacity in patients with coronary heart disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7783?source=see_link\">",
"      Rehabilitation after cardiac transplantation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=see_link\">",
"      Sexual activity in patients with heart disease",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org/\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Society of Thoracic Surgeons",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.sts.org/\">",
"      www.sts.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?23/16/23813/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 9, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?23/16/23813?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23813/abstract/1\">",
"      Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med 2005; 143:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23813/abstract/2\">",
"      Leon AS, Franklin BA, Costa F, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation. Circulation 2005; 111:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23813/abstract/3\">",
"      Balady GJ, Williams MA, Ades PA, et al. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation 2007; 115:2675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23813/abstract/4\">",
"      Thompson PD, Franklin BA, Balady GJ, et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation 2007; 115:2358.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f23_16_23813=[""].join("\n");
var outline_f23_16_23813=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BYPASS SURGERY OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CARE AT HOME AFTER BYPASS SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           CARDIAC REHABILITATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           REDUCE CARDIAC RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHEN IS SEX SAFE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           FOLLOW-UP CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?42/50/43819\" title=\"table 1\">",
"           Lipid lowering tx PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?20/13/20699\" title=\"table 2\">",
"           Rating of perceived exertion",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f23_16_23814="Prazosin: Drug information";
var content_f23_16_23814=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prazosin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/19/37172?source=see_link\">",
"    see \"Prazosin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/20/30021?source=see_link\">",
"    see \"Prazosin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Minipress&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F212752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Prazo&reg;;",
"     </li>",
"     <li>",
"      Minipress&reg;;",
"     </li>",
"     <li>",
"      Novo-Prazin;",
"     </li>",
"     <li>",
"      Nu-Prazo;",
"     </li>",
"     <li>",
"      Teva-Prazosin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F212770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha",
"      <sub>",
"       1",
"      </sub>",
"      Blocker",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F212756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 1 mg/dose 2-3 times/day; usual maintenance dose: 2-20 mg/day in divided doses 2-3 times/day (JNC 7); maximum daily dose: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      PTSD-related nightmares and sleep disruption (unlabeled use):",
"     </b>",
"     Oral: Initial: 1 mg at bedtime (Raskind, 2002; Raskind, 2007); titrate as tolerated to 2-15 mg at bedtime (Benedek, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Raynaud's (unlabeled use):",
"     </b>",
"     Oral: Dosage range: 1-5 mg twice daily (Bakst, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Benign prostatic hyperplasia (unlabeled use):",
"     </b>",
"     Oral: Initial: 0.5 mg twice daily; titrate as tolerated to 2 mg twice daily (Moran, 2001)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F212764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/20/30021?source=see_link\">",
"      see \"Prazosin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension (unlabeled use):",
"     </b>",
"     Oral: Children: Initial: 0.05-0.1 mg/kg/day in 3 divided doses; maximum: 0.5 mg/kg/day (not to exceed 20 mg) (NHBPEP, Fourth Report)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F212757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. In the management of hypertension, consider lower initial doses and titrate to response (Aronow, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F212728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 1 mg, 2 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minipress&reg;: 1 mg, 2 mg, 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F212712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F212731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F212766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Post-traumatic stress disorder (PTSD) related nightmares and sleep disruption; benign prostatic hyperplasia; Raynaud's syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F212778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Prazosin may be confused with predniSONE",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F212768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;4%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Palpitation (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (10%), headache (8%), drowsiness (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Decreased energy (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 4%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema, orthostatic hypotension, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression, nervousness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision, reddened sclera",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea, epistaxis, nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threating): Abdominal discomfort, allergic reaction, alopecia, angina, arthralgia, bradycardia, cataplexy, cataracts (both development and disappearance have been reported), diaphoresis, enuresis, eye pain, fever, flushing, gynecomastia, hallucinations, impotence, insomnia, leukopenia, lichen planus, liver function abnormalities, malaise, MI, narcolepsy (worsened), pain, pancreatitis, paresthesia, pigmentary mottling and serous retinopathy, positive ANA titer, priapism, pruritus, systemic lupus erythematosus, tachycardia, tinnitus, urticaria, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reported in association with other alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers: Intraoperative floppy iris syndrome (with cataract surgery)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F212734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to prazosin, quinazolines (eg, doxazosin, terazosin) or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F212716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina: Discontinue if symptoms of angina occur or worsen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Floppy iris syndrome: Intraoperative floppy iris syndrome (IFIS) has been observed in cataract surgery patients who were on or were previously treated with alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers; there appears to be no benefit in discontinuing alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers prior to surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension/syncope: May cause significant orthostatic hypotension and syncope, especially with first dose; anticipate a similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, or if another antihypertensive drug (particularly vasodilators) or a PDE-5 inhibitor (eg, sildenafil, tadalafil, vardenafil) is introduced. Patients should be cautioned about performing hazardous tasks when starting new therapy or adjusting dosage upward.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostate cancer: Should rule out prostatic carcinoma before beginning therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use as an antihypertensive due to high risk of orthostatic hypotension; alternative agents preferred due to a more favorable risk/benefit profile (Beers Criteria).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9838452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F212721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers. Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F212747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase vasodilation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food has variable effects on absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai if using for hypertension (has estrogenic activity). Avoid ephedra, yohimbe, ginseng (may worsen hypertension). Avoid saw palmetto (due to limited experience with this combination). Avoid garlic (may have increased antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F212724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13459610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Limited use in pregnant women has not demonstrated any fetal abnormalities or adverse effects (Dommisse, 1983).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F212759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F212736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Minipress Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (250): $285.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (250): $397.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (250): $677.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Prazosin HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $35.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $51.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $85.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F212726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, standing and sitting/supine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F212737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Atodel (MY, PH);",
"     </li>",
"     <li>",
"      Decliten (AR);",
"     </li>",
"     <li>",
"      Deprazolin (CZ);",
"     </li>",
"     <li>",
"      Hypotens (IL);",
"     </li>",
"     <li>",
"      Hypovase (GB, IE);",
"     </li>",
"     <li>",
"      Hyprosin (NZ);",
"     </li>",
"     <li>",
"      Lopress (TH);",
"     </li>",
"     <li>",
"      Minipres (AR, BZ, CR, EC, ES, GT, MX, NI, PA, SV, VE);",
"     </li>",
"     <li>",
"      Minipres Retard (AR);",
"     </li>",
"     <li>",
"      Minipres SR (CO);",
"     </li>",
"     <li>",
"      Minipress (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, FR, GH, GM, GN, GR, GY, HK, HN, ID, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, OM, PK, PL, QA, SA, SC, SD, SG, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Minipress SR (BR);",
"     </li>",
"     <li>",
"      Minipress XL (IN);",
"     </li>",
"     <li>",
"      Minison (MY, TW);",
"     </li>",
"     <li>",
"      Mizosin (MY);",
"     </li>",
"     <li>",
"      Peripress (FI);",
"     </li>",
"     <li>",
"      Polpressin (PL);",
"     </li>",
"     <li>",
"      Polypress (TH);",
"     </li>",
"     <li>",
"      Pratisol (NZ, TW, ZA);",
"     </li>",
"     <li>",
"      Pratsiol (BG, FI);",
"     </li>",
"     <li>",
"      Praxin (PY, UY);",
"     </li>",
"     <li>",
"      Prazopress (IN);",
"     </li>",
"     <li>",
"      Pressin (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F212715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively inhibits postsynaptic alpha-adrenergic receptors which results in vasodilation of veins and arterioles and a decrease in total peripheral resistance and blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F212733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Anithypertensive: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Antihypertensive: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 10-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Hypertensive adults: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 92% to 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 43% to 82%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-3 hours; prolonged with congestive heart failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces; urine (6% to 10% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/16/23814/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/16/23814/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bakst R, Merola JF, Franks AG Jr, et al, \"Raynaud's Phenomenon: Pathogenesis and Management,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2008, 59(4):633-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/16/23814/abstract-text/18656283/pubmed\" id=\"18656283\" target=\"_blank\">",
"        18656283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bandelow B, Zohar J, Hollander E, et al, &ldquo;World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders -- First Revision,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2008, 9(4): 248-312. Available at file://www.wfsbp.org/fileadmin/pdf/guides/Guidelines_Anxiety_revision.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/16/23814/abstract-text/18949648/pubmed\" id=\"18949648\" target=\"_blank\">",
"        18949648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benedek DM, Friedman MJ, Zatzick D, et al, &ldquo;Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder.&rdquo; Available at  file://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=AcuteStressDisorder-PTSD_GuidelineWatch",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/16/23814/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dommisse J, Davey DA, and Roos PJ, \"Prazosin and Oxprenolol Therapy in Pregnancy Hypertension,\"",
"      <i>",
"       S Afr Med J",
"      </i>",
"      , 1983, 64(7):231-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/16/23814/abstract-text/6879369/pubmed\" id=\"6879369\" target=\"_blank\">",
"        6879369",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2000, 283(15):1967-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/16/23814/abstract-text/10789664/pubmed\" id=\"10789664\" target=\"_blank\">",
"        10789664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moran JA, Street PR, and Rogerson JW, \"Pharmacological Management of Benign Prostatic Hypertrophy and Prostate Cancer in Older Men,\"",
"      <i>",
"       Aust J Hosp Pharm",
"      </i>",
"      , 2001, 31(2):115-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program (NHBPEP) Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/16/23814/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peskind ER, Bonner LT, Hoff DJ, et al, &ldquo;Prazosin Reduces Trauma-Related Nightmares in Older Men With Chronic Posttraumatic Stress Disorder,&rdquo;",
"      <i>",
"       J Geriatr Psychiatry Neurol",
"      </i>",
"      , 2003, 16(3):165-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/16/23814/abstract-text/12967060/pubmed\" id=\"12967060\" target=\"_blank\">",
"        12967060",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raskind MA, Dobie DJ, Kanter ED, et al, &ldquo;The Alpha1-Adrenergic Antagonist Prazosin Ameliorates Combat Trauma Nightmares in Veterans With Posttraumatic Stress Disorder: A Report of 4 Cases,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2000, 61(2):129-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/16/23814/abstract-text/10732660/pubmed\" id=\"10732660\" target=\"_blank\">",
"        10732660",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raskind MA, Peskind ER, Kanter ED, et al, &ldquo;Reduction of Nightmares and Other PTSD Symptoms in Combat Veterans by Prazosin: A Placebo-Controlled Study,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2003, 160(2):371-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/16/23814/abstract-text/12562588/pubmed\" id=\"12562588\" target=\"_blank\">",
"        12562588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raskind MA, Thompson C, Petrie EC, et al, &ldquo;Prazosin Reduces Nightmares in Combat Veterans With Posttraumatic Stress Disorder,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2002, 63(7):565-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/16/23814/abstract-text/12143911/pubmed\" id=\"12143911\" target=\"_blank\">",
"        12143911",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raskind MA, Peskind ER, Hoff DJ, et al, &ldquo;A Parallel Group Placebo Controlled Study of Prazosin for Trauma Nightmares and Sleep Disturbance in Combat Veterans With Post-traumatic Stress Disorder,&rdquo;",
"      <i>",
"       Biol Psychiatry",
"      </i>",
"      , 2007, 61(8):928-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/16/23814/abstract-text/17069768/pubmed\" id=\"17069768\" target=\"_blank\">",
"        17069768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9806 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-23EAA62341-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_16_23814=[""].join("\n");
var outline_f23_16_23814=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212751\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212752\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212770\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212756\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212764\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212757\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212728\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212712\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212731\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212766\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212778\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212768\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212734\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212716\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9838452\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212721\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212747\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212724\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13459610\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212759\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212736\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212726\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212737\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212715\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212733\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9806\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9806|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/19/37172?source=related_link\">",
"      Prazosin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/20/30021?source=related_link\">",
"      Prazosin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_16_23815="Treatment of infections due to coagulase-negative staphylococci";
var content_f23_16_23815=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of infections due to coagulase-negative staphylococci",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/16/23815/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/16/23815/contributors\">",
"     JoAnn M Tufariello, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/16/23815/contributors\">",
"     Franklin D Lowy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/16/23815/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/16/23815/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/16/23815/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/16/23815/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/16/23815/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/16/23815/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coagulase-negative staphylococci (CoNS) are part of the normal flora of human skin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/1\">",
"     1",
"    </a>",
"    ]. These organisms have relatively low virulence but are increasingly recognized as agents of clinically significant infection of the bloodstream and other sites. Risk factors for CoNS infection include foreign bodies (such as indwelling prosthetic devices or intravascular catheters) and immune compromise. Treatment of CoNS infections can be challenging given limitations of antimicrobial resistance and the frequent presence of foreign material.",
"   </p>",
"   <p>",
"    Issues related to antimicrobial resistance and treatment of CoNS infections will be reviewed here. The microbiology, pathogenesis, epidemiology of CoNS are discussed separately, as are the clinical features, diagnosis, and treatment of specific infections caused by these organisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9672?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6286044\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL RESISTANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Methicillin",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6285704\">",
"    <span class=\"h3\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistant to methicillin and semisynthetic penicillins has been observed in more than 80 percent of coagulase-negative staphylococcal isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/2\">",
"     2",
"    </a>",
"    ]. Such isolates are often resistant to multiple classes of antibiotics in addition to beta-lactams. The genes responsible for resistance are often found on plasmids, facilitating the horizontal exchange of resistance genes among strains. The mecA gene encoding a low-affinity penicillin-binding protein (PBP 2a) is responsible for mediating methicillin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    resistance in CoNS, as in S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/3\">",
"     3",
"    </a>",
"    ]. This resistance is heterotypic since only a minority of the bacterial population (as few as one in 10(3) or 10(6) organisms) expresses the resistant phenotype; this makes detection of resistance especially challenging [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15575?source=see_link\">",
"     \"Microbiology of methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6285711\">",
"    <span class=\"h3\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies describing the acquisition and spread of resistant organisms have been performed in patients undergoing cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Preoperatively, cardiac surgery patients generally have CoNS skin isolates that are susceptible to methicillin; resistant clones appear to emerge with selective pressure of perioperative antibiotic prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/5\">",
"     5",
"    </a>",
"    ]. In one study including 29 patients who underwent preoperative sampling of the nares, subclavian and inguinal areas, methicillin-resistant CoNS were detected in rare numbers from at least one site in 75 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/6\">",
"     6",
"    </a>",
"    ]. Following surgery, more than half of the clinical sites with baseline evidence of colonization contained high levels of methicillin-resistant staphylococci. Antibiograms and plasmid profile patterns suggested that these resistant organisms were derived from the small number of resistant organisms present preoperatively.",
"   </p>",
"   <p>",
"    Other studies have also demonstrated that patients undergoing cardiac surgery have postoperative skin flora composed primarily of methicillin-resistant CoNS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In one report of 69 patients, colonization with methicillin resistant organisms 10 days postoperatively (a resistance pattern not present preoperatively) was observed in 91 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/7\">",
"     7",
"    </a>",
"    ]. The preoperative and postoperative isolates were distinct on plasmid analysis. Some of the nurses in the cardiothoracic intensive care unit were observed to be colonized with CoNS resistant to methicillin of the matching plasmid type [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6285719\">",
"    <span class=\"h3\">",
"     Laboratory detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reliable detection of methicillin resistance is critical to facilitate initiation of appropriate antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/10\">",
"     10",
"    </a>",
"    ]. Breakpoints for determining the susceptibility of CoNS to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    were revised by the Clinical and Laboratory Standards Institute (CLSI) in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/11\">",
"     11",
"    </a>",
"    ]. The methicillin MIC breakpoints for CoNS (except S. lugdunensis) are &le;0.25",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for susceptibility to oxacillin and &ge;0.5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for resistance to oxacillin. For disk susceptibility testing, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    disk is the preferred method to detect CoNS oxacillin susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accurate detection of resistance in the clinical laboratory requires the use of measures to enhance expression of this phenotype, including [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Incubation at a lower temperature (30 to 35&ordm;C)",
"     </li>",
"     <li>",
"      Incubation for a prolonged period of time (24 to 48 hours)",
"     </li>",
"     <li>",
"      Medium with an increased sodium chloride content (2 percent NaCl)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the results remain uncertain, one can pursue detection of the mecA gene using DNA hybridization or polymerase chain reaction techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. In addition, a latex agglutination test developed for detection of PBP 2a of methicillin-resistant S. aureus (MRSA-Screen, Denka Seiken Co., Niigata, Japan) has been investigated for its applicability in identifying methicillin resistance in a variety of species of CoNS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. This rapid assay has shown 98 percent sensitivity and high specificity in the hands of some investigators for S. epidermidis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/17\">",
"     17",
"    </a>",
"    ], although non-S. epidermidis strains occasionally yielded false-positive results.",
"   </p>",
"   <p>",
"    An isolate determined to be methicillin resistant should be considered resistant to all beta-lactam antibiotics, including beta-lactamase inhibitor combinations, cephalosporins, and carbapenems (regardless of in vitro susceptibility results) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/21\">",
"     21",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"     Ceftaroline",
"    </a>",
"    is an exception; it is a cephalosporin that retains activity against methicillin resistant strains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vancomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been case reports of CoNS with reduced susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    : two in patients on continuous ambulatory peritoneal dialysis (CAPD) and one in a patient with febrile neutropenia on empiric antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. The minimum inhibitory concentrations (MICs) in these isolates were 8 to 16",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"    One of these reports documented the emergence of relative vancomycin resistance (with a stepwise increase in the MIC from 2 to 8",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    in a patient treated with vancomycin for S. haemolyticus peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of glycopeptide resistance among staphylococci appears to be associated with alterations in cell wall metabolism, including cell wall thickening [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Increased cell wall thickness has also been observed in various CoNS clinical strains that demonstrate heterogeneous resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16425?source=see_link\">",
"     \"Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CoNS glycopeptide resistance appears to occur in the form of heteroresistant subpopulations of organisms. Therefore, accurate detection in the laboratory can be difficult. As an example, one group reported the isolation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -intermediate S. epidermidis from peritoneal fluid specimens of a patient undergoing CAPD who developed peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/30\">",
"     30",
"    </a>",
"    ]. The primary isolate had a vancomycin MIC of 12 to 16",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    However subculture and testing by a variety of methods demonstrated strains that appeared to be susceptible to vancomycin. The authors proposed that the phenotype of intermediate vancomycin resistance may have been expressed by only a small subpopulation of organisms in the original specimen, which may have been lost or diluted upon subculture (perhaps due to loss of selective pressure of the antibiotic). To screen for potential vancomycin resistance in CoNS, some investigators have used induction methods such as placement of an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    disk on vancomycin-salt agar to demonstrate growth of satellite colonies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17495?source=see_link&amp;anchor=H10046302#H10046302\">",
"     \"Overview of antibacterial susceptibility testing\", section on 'Heteroresistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MIC cutoffs for CoNS",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    testing are: susceptible if &le;4",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    intermediate if 8 to 16",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    and resistant if &ge;32",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/11\">",
"     11",
"    </a>",
"    ]. The vancomycin MIC breakpoints for CoNS differ from those of S. aureus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16425?source=see_link\">",
"     \"Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6286944\">",
"    <span class=\"h2\">",
"     Other resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    resistance is extremely rare. One outbreak of colonization with linezolid-resistant coagulase-negative staphylococci was reported among 16 ICU patients over a six month period. The resistant strains were isolated from several sites and contained the G2576T mutation conferring linezolid resistance. Nasal screening among ICU staff was negative. Institution and reinforcement of infection control procedures and restrictions on linezolid prescribing were successful in controlling the outbreak [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6286959\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The agent of choice for empiric treatment of infections due to CoNS is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ; it is generally the mainstay of treatment for methicillin-resistant CoNS infections. In the setting of infection due to CoNS that is known to be methicillin susceptible, the preferred agent is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Additional agents with potential activity against CoNS include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/42/27301?source=see_link\">",
"     telavancin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    . Daptomycin appears to have high in vitro activity against clinical CoNS isolates. Linezolid has significant bacteriostatic activity against methicillin-resistant CoNS in vitro and has been successfully used in infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Telavancin has excellent in vitro activity against staphylococci; experience with clinical efficacy is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/36\">",
"     36",
"    </a>",
"    ]. Tigecycline has demonstrated in vitro activity against CoNS; data on clinical efficacy are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Quinupristin-dalfopristin has in vitro activity against multiple-resistant CoNS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Other agents with potential efficacy include teicoplanin (a glycopeptide antibiotic),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/43-46\">",
"     43-46",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"     Ceftaroline",
"    </a>",
"    has excellent in vitro activity against MRSE and MSSE, but clinical data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Antistaphylococcal agents are discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For treatment of some deep-seated infections, addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    may be warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/49\">",
"     49",
"    </a>",
"    ]. Gentamicin is rapidly bactericidal for CoNS, but its clinical utility is limited by resistance (60 to 70 percent of isolates in some studies) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. More than 90 percent of CoNS isolates remain susceptible to rifampin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/4\">",
"     4",
"    </a>",
"    ], although this drug must be used in combination with another antibiotic since resistance develops rapidly with rifampin monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/5,52\">",
"     5,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluoroquinolones and macrolides are not appropriate agents for treatment of CoNS infections [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23815/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6286966\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of therapy depends on the clinical site of infection. Bacteremia in the absence of involvement of other sites may be treated for 14 days. The duration of therapy for other forms of infection is discussed separately. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6287571\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coagulase-negative staphylococci (CoNS) are part of the normal flora of human skin. These organisms have relatively low virulence but are increasingly recognized as agents of clinically significant infection of the bloodstream and other sites. Risk factors for CoNS infection include indwelling foreign devices and immune compromise. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Resistant to methicillin and semisynthetic penicillins has been observed in more than 80 percent of coagulase-negative staphylococcal isolates. The genes responsible for resistance are often found on plasmids, facilitating the horizontal exchange of resistance genes among strains. The methicillin MIC breakpoints for CoNS (except S. lugdunensis) are &le;0.25",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      for susceptibility to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"       oxacillin",
"      </a>",
"      and &ge;0.5",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      for resistance to oxacillin. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Methicillin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There have been case reports of CoNS with reduced susceptibility to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      . CoNS glycopeptide resistance appears to occur in the form of heteroresistant subpopulations of organisms. Therefore, accurate detection in the laboratory can be difficult. The vancomycin MIC breakpoints for CoNS are: susceptible if &le;4",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      intermediate if 8 to 16",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      and resistant if &ge;32",
"      <span class=\"nowrap\">",
"       mg/L.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Vancomycin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The agent of choice for empiric treatment of infections due to CoNS is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      ; it is generally the mainstay of treatment for methicillin-resistant CoNS infections. In the setting of infection due to CoNS that is known to be methicillin susceptible, the preferred agent is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"       nafcillin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"       oxacillin",
"      </a>",
"      . Additional agents with potential activity against CoNS include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"       daptomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/42/27301?source=see_link\">",
"       telavancin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"       tigecycline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"       quinupristin-dalfopristin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of treatment of CoNS infection depends on the clinical site of infection. Bacteremia in the absence of involvement of other sites may be treated for 14 days. The duration of therapy for other forms of infection is discussed separately. (See related topics).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/1\">",
"      Roth RR, James WD. Microbial ecology of the skin. Annu Rev Microbiol 1988; 42:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/2\">",
"      Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 Suppl 2:S114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/3\">",
"      Ryffel C, Tesch W, Birch-Machin I, et al. Sequence comparison of mecA genes isolated from methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. Gene 1990; 94:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/4\">",
"      Archer GL, Climo MW. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother 1994; 38:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/5\">",
"      Archer GL, Armstrong BC. Alteration of staphylococcal flora in cardiac surgery patients receiving antibiotic prophylaxis. J Infect Dis 1983; 147:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/6\">",
"      Kernodle DS, Barg NL, Kaiser AB. Low-level colonization of hospitalized patients with methicillin-resistant coagulase-negative staphylococci and emergence of the organisms during surgical antimicrobial prophylaxis. Antimicrob Agents Chemother 1988; 32:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/7\">",
"      Archer GL, Dietrick DR, Johnston JL. Molecular epidemiology of transmissible gentamicin resistance among coagulase-negative staphylococci in a cardiac surgery unit. J Infect Dis 1985; 151:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/8\">",
"      Archer GL. Alteration of cutaneous staphylococcal flora as a consequence of antimicrobial prophylaxis. Rev Infect Dis 1991; 13 Suppl 10:S805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/9\">",
"      Levy MF, Schmitt DD, Edmiston CE, et al. Sequential analysis of staphylococcal colonization of body surfaces of patients undergoing vascular surgery. J Clin Microbiol 1990; 28:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/10\">",
"      Tenover FC, Jones RN, Swenson JM, et al. Methods for improved detection of oxacillin resistance in coagulase-negative staphylococci: results of a multicenter study. J Clin Microbiol 1999; 37:4051.",
"     </a>",
"    </li>",
"    <li>",
"     National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Tenth Informational Supplement. NCCLS document M100-S17 vol. 27. No. 1, 2007. National Committee for Clinical Laboratory Standards, Wayne, PA.",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth Informational Supplement. CLSI document M100-S19; 29, Clinical and Laboratory Standards Institute, Wayne, PA 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/13\">",
"      Maranan MC, Moreira B, Boyle-Vavra S, Daum RS. Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance. Infect Dis Clin North Am 1997; 11:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/14\">",
"      Archer GL, Pennell E. Detection of methicillin resistance in staphylococci by using a DNA probe. Antimicrob Agents Chemother 1990; 34:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/15\">",
"      Ubukata K, Nakagami S, Nitta A, et al. Rapid detection of the mecA gene in methicillin-resistant staphylococci by enzymatic detection of polymerase chain reaction products. J Clin Microbiol 1992; 30:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/16\">",
"      Unal S, Hoskins J, Flokowitsch JE, et al. Detection of methicillin-resistant staphylococci by using the polymerase chain reaction. J Clin Microbiol 1992; 30:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/17\">",
"      Horstkotte MA, Knobloch JK, Rohde H, Mack D. Rapid detection of methicillin resistance in coagulase-negative staphylococci by a penicillin-binding protein 2a-specific latex agglutination test. J Clin Microbiol 2001; 39:3700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/18\">",
"      Zbinden R, Ritzler M, Ritzler E, Berger-B&auml;chi B. Detection of penicillin-binding protein 2a by rapid slide latex agglutination test in coagulase-negative staphylococci. J Clin Microbiol 2001; 39:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/19\">",
"      Hussain Z, Stoakes L, Garrow S, et al. Rapid detection of mecA-positive and mecA-negative coagulase-negative staphylococci by an anti-penicillin binding protein 2a slide latex agglutination test. J Clin Microbiol 2000; 38:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/20\">",
"      Udo EE, Mokadas EM, Al-Haddad A, et al. Rapid detection of methicillin resistance in staphylococci using a slide latex agglutination kit. Int J Antimicrob Agents 2000; 15:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/21\">",
"      Chambers HF. Methicillin-resistant staphylococci. Clin Microbiol Rev 1988; 1:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/22\">",
"      Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987; 316:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/23\">",
"      Sanyal D, Johnson AP, George RC, et al. Peritonitis due to vancomycin-resistant Staphylococcus epidermidis. Lancet 1991; 337:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/24\">",
"      Veach LA, Pfaller MA, Barrett M, et al. Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J Clin Microbiol 1990; 28:2064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/25\">",
"      Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, et al. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 1998; 42:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/26\">",
"      Cui L, Ma X, Sato K, et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2003; 41:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/27\">",
"      Sieradzki K, Tomasz A. Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J Bacteriol 1999; 181:7566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/28\">",
"      Sieradzki K, Pinho MG, Tomasz A. Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus. J Biol Chem 1999; 274:18942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/29\">",
"      Nunes AP, Teixeira LM, Iorio NL, et al. Heterogeneous resistance to vancomycin in Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus warneri clinical strains: characterisation of glycopeptide susceptibility profiles and cell wall thickening. Int J Antimicrob Agents 2006; 27:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/30\">",
"      Dunne WM Jr, Qureshi H, Pervez H, Nafziger DA. Staphylococcus epidermidis with intermediate resistance to vancomycin: elusive phenotype or laboratory artifact? Clin Infect Dis 2001; 33:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/31\">",
"      Wong SS, Ho PL, Woo PC, Yuen KY. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 1999; 29:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/32\">",
"      Kelly S, Collins J, Maguire M, et al. An outbreak of colonization with linezolid-resistant Staphylococcus epidermidis in an intensive therapy unit. J Antimicrob Chemother 2008; 61:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/33\">",
"      Rybak MJ, Cappelletty DM, Moldovan T, et al. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 1998; 42:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/34\">",
"      Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis 2000; 30:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/35\">",
"      Antony SJ, Diaz-Vasquez E, Stratton C. Clinical experience with linezolid in the treatment of resistant gram-positive infections. J Natl Med Assoc 2001; 93:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/36\">",
"      Saravolatz LD, Stein GE, Johnson LB. Telavancin: a novel lipoglycopeptide. Clin Infect Dis 2009; 49:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/37\">",
"      Kratzer C, Rabitsch W, Hirschl AM, et al. In vitro activity of daptomycin and tigecycline against coagulase-negative staphylococcus blood isolates from bone marrow transplant recipients. Eur J Haematol 2007; 79:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/38\">",
"      Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). Clin Microbiol Infect 2006; 12:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/39\">",
"      Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004; 49:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/40\">",
"      Aldridge KE, Schiro DD, Varner LM. In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods. Antimicrob Agents Chemother 1992; 36:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/41\">",
"      Eliopoulos GM. Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci. Eur J Clin Microbiol Infect Dis 2005; 24:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/42\">",
"      Rubinstein E, Bompart F. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential. J Antimicrob Chemother 1997; 39 Suppl A:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/43\">",
"      Stein A, Bataille JF, Drancourt M, et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998; 42:3086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/44\">",
"      Levitz RE, Quintiliani R. Trimethoprim-sulfamethoxazole for bacterial meningitis. Ann Intern Med 1984; 100:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/45\">",
"      Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/46\">",
"      Frame PT, McLaurin RL. Treatment of CSF shunt infections with intrashunt plus oral antibiotic therapy. J Neurosurg 1984; 60:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/47\">",
"      Flamm RK, Sader HS, Farrell DJ, Jones RN. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. Antimicrob Agents Chemother 2012; 56:2933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/48\">",
"      Flamm RK, Sader HS, Farrell DJ, Jones RN. Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program. Clin Infect Dis 2012; 55 Suppl 3:S194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/49\">",
"      Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/50\">",
"      Archer GL, Johnston JL. Self-transmissible plasmids in staphylococci that encode resistance to aminoglycosides. Antimicrob Agents Chemother 1983; 24:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/51\">",
"      Archer GL, Scott J. Conjugative transfer genes in staphylococcal isolates from the United States. Antimicrob Agents Chemother 1991; 35:2500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/52\">",
"      Mandell GL, Moorman DR. Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance. Antimicrob Agents Chemother 1980; 17:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/53\">",
"      H&oslash;iby N, Jarl&oslash;v JO, Kemp M, et al. Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis. Lancet 1997; 349:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23815/abstract/54\">",
"      Thomson KS, Sanders CC, Hayden ME. In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises. Antimicrob Agents Chemother 1991; 35:2329.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3154 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_16_23815=[""].join("\n");
var outline_f23_16_23815=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6287571\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6286044\">",
"      ANTIMICROBIAL RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Methicillin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6285704\">",
"      - Microbiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6285711\">",
"      - Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6285719\">",
"      - Laboratory detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vancomycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6286944\">",
"      Other resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6286959\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6286966\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6287571\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15575?source=related_link\">",
"      Microbiology of methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9672?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17495?source=related_link\">",
"      Overview of antibacterial susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16425?source=related_link\">",
"      Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_16_23816="Arteriovenous fistulas and grafts for chronic hemodialysis access";
var content_f23_16_23816=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Arteriovenous fistulas and grafts for chronic hemodialysis access",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/16/23816/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/16/23816/contributors\">",
"     Matthew J Oliver, MD, MHS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/16/23816/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/16/23816/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/16/23816/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/16/23816/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/16/23816/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of chronic vascular access is to provide repeated access to the circulation with minimal complications. Chronic hemodialysis vascular access should generally be provided using arteriovenous access to avoid the risks of central venous catheters. Ideally, an autogenous fistula using the patient&rsquo;s native tissues is created, but when suitable vessels are not available, non-autogenous materials can also be used.",
"   </p>",
"   <p>",
"    The types, general characteristics and a comparison of the types of arteriovenous fistulas will be reviewed here. The use of central catheters for acute and chronic hemodialysis and complications of hemodialysis vascular access are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=see_link\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16727?source=see_link\">",
"     \"Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12536?source=see_link\">",
"     \"Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3318?source=see_link\">",
"     \"Arteriovenous fistula recirculation in hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15722?source=see_link\">",
"     \"Thrombosis associated with chronic hemodialysis vascular access: Catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AUTOGENOUS ARTERIOVENOUS FISTULA",
"    </span>",
"    &nbsp;&mdash;&nbsp;AV fistulas are typically constructed with an end-to-side vein-to-artery anastomosis between an artery and vein. The most commonly used fistulas are created by anastomosing the radial artery to the cephalic vein (radiocephalic fistula) or by anastomosing the brachial artery to the cephalic vein (brachiocephalic fistula) or basilic vein (brachiobasilic fistula). For the latter, the basilic vein may be mobilized and tunneled laterally to allow easier cannulation (transposed brachiobasilic fistula) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/1\">",
"     1",
"    </a>",
"    ]. Fistulas are less commonly created between the brachial artery and median antecubital vein [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both Canadian and American guidelines prefer the radiocephalic native vessel fistula as the first choice for vascular access [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The brachiocephalic and brachiobasilic fistulas are the second and third choices, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fistulas in the lower extremity, such as superficial femoral-common femoral thigh transpositions, are rare. However, adequate outcomes (particularly decreased postoperative ischemia) have been reported with good patient selection and selective intraoperative femoral vein tapering [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fistula constructed from other biologic materials, such as saphenous vein, umbilical vein autografts or bovine artery heterografts, have not performed as well as the polytetrafluoroethylene (PTFE) grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/6\">",
"     6",
"    </a>",
"    ]. Subsequently, formaldehyde-fixed arterial deceased donor allografts have undergone evaluation. In a study of 68 such allografts placed into 43 hemodialysis patients, there were no episodes of rejection and the mean access blood flow rate was nearly 700",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/7\">",
"     7",
"    </a>",
"    ]. The median primary and secondary patency rates were 28 and 141 months, respectively. Further studies are required to better understand the role for these allografts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/8\">",
"     8",
"    </a>",
"    ]. The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    work group recommends a graft either of synthetic or biologic material [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ARTERIOVENOUS GRAFTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synthetic grafts are constructed by anastomosing a synthetic conduit, usually expanded polytetrafluoroethylene (ePTFE), between an artery and vein. The conduit can be straight or looped and ranges between 4 to 8 mm in diameter. Grafts can be modified to be tapered [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/9\">",
"     9",
"    </a>",
"    ], thin walled [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/10\">",
"     10",
"    </a>",
"    ], and reinforced [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/11\">",
"     11",
"    </a>",
"    ]. The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    work group recommends a graft either of synthetic or biologic material [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common graft locations are straight forearm (radial artery to cephalic vein), looped forearm (brachial artery to cephalic vein), straight upper arm (brachial artery to axillary vein), or looped upper arm (axillary artery to axillary vein). The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    work group prefers a forearm loop graft to a straight configuration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/4\">",
"     4",
"    </a>",
"    ]. Leg grafts, looped chest grafts, axillary-axillary (necklace), and axillary-atrial grafts have also been constructed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COMPARISON OF FISTULAS AND GRAFTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fistulas and grafts differ according to failure rates, time to use, patency, complications, and perioperative morbidity. Fistulas are preferred to grafts given their long-term patency and lower rate of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Primary failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fistulas are more likely than grafts to experience primary failure, defined as a fistula that never provided reliable access for hemodialysis. The primary failure rates of radiocephalic, brachiocephalic, and brachiobasilic fistulas are approximately 24 to 35 percent, 9 to 12 percent, and 29 to 36 percent respectively, across a range of studies. However, one large study of 877 patients with fistulas reported a primary failure rate of 60 percent to 62 percent, which was unaffected by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    use, suggesting that primary failure rates of AVFs can be quite high in some populations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/14\">",
"     14",
"    </a>",
"    ]. However, this study evaluated fistula suitability approximately six months after creation and more fistulas may have matured with longer follow-up. In contrast, the primary failure rates are 0 to 13 and 0 to 3 percent for forearm and upper arm grafts, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With respect to grafts, the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines suggest that the primary access failure rates should be no more than the following [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      15 percent with forearm straight graft",
"     </li>",
"     <li>",
"      10 percent with forearm loop grafts",
"     </li>",
"     <li>",
"      5 percent upper arm grafts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following factors have been associated with primary failure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased incidence of patients who undergo fistula creation &mdash; One study found that the primary failure of fistulas increased from 14 to 36 percent when fistula attempts were increased from 38 to 72 percent of incident dialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/17\">",
"       17",
"      </a>",
"      ]. Another report noted primary failure rates of 66 and 41 percent for radiocephalic and brachiocephalic, respectively, when fistulas were attempted in 54 percent of incident patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Demographic factors and comorbidity &mdash; The risk of primary failure is increased in wrist fistulas and in patients who are older, obese, nonwhite, female, diabetic,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      have peripheral vascular or cardiovascular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one study of 422 patients undergoing their first fistula creation, the clinical predictors significantly associated with a failure to mature were age greater than 65 years (odds ratio 2.23), peripheral vascular disease (OR 2.97), coronary artery disease (OR 2.83), and white race (OR 0.43) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/20\">",
"       20",
"      </a>",
"      ]. Based upon these variables, a scoring system was developed, which was successfully validated in a subsequent group of 445 patients.",
"     </li>",
"     <li>",
"      A prospective European study of 395 patients found that diabetes and arteriovenous fistula surveillance were associated with primary failure [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anatomy",
"     </li>",
"     <li>",
"      Lower arm fistula are at great risk for primary failure than upper arm fistulae [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/18,22\">",
"       18,22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A cephalic vein diameter less than 2.0 mm on ultrasound in the forearm, and less venous distensibility increases the risk of primary failure [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/1,18,23-29\">",
"       1,18,23-29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low fistula flow after creation is associated with poor maturation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiological or surgical intervention to promote maturation may be required to reduce the risk of primary failure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/30-35\">",
"     30-35",
"    </a>",
"    ]. One study, for example, reported that 99 of 119 (83 percent) poorly maturing fistulas could be salvaged with a combination of vein ligation and angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/35\">",
"     35",
"    </a>",
"    ]. Brachiocephalic fistulas may require a secondary procedure to elevate the cephalic vein if cannulation is difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/36\">",
"     36",
"    </a>",
"    ]. The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines recommend that a fistulogram or other imaging study should be performed if a fistula has not matured by six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Time to use",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grafts can be cannulated for hemodialysis earlier than fistulas. Grafts can usually be cannulated within weeks. Some centers have successfully cannulated grafts within days of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some fistulas mature within weeks, others require up to six months before they provide reliable hemodialysis access so catheters can be removed. One measure of maturity, the time to first cannulation, appears to vary significantly by country, with nearly 30 days being the median period for Japan and Italy and almost 100 days for the United States and United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of timing of first cannulation of an AV fistula has been evaluated in a few different studies. As examples [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/27,38,40\">",
"     27,38,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, cannulation of fistulas any time after 14 days was not associated with an increased risk of failure, suggesting that fistulas may be used sooner than previously thought in selected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/38\">",
"       38",
"      </a>",
"      ]. Similar findings related to success with early cannulation were reported in a second study from the Dialysis Outcomes and Practice Patterns Study database [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective longitudinal Italian study evaluated the effect of timing of first cannulation of an AV fistula among 535 incident dialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/27\">",
"       27",
"      </a>",
"      ]. The time to first cannulation varied widely, with a median period of one month and a range between 3 days to 28 months. Upon multivariate adjustment, a predictor of primary fistula failure included cannulation earlier than one month. More specifically, every two week increase in maturation time was associated with a five percent decrease in probability of primary failure. Overall, this suggested that AV fistulas should be left to mature for at least 30 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these studies, some clinicians have arrived at the following conclusions relating to timing of cannulation of AV fistulas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cannulation before two weeks of age should be avoided.",
"     </li>",
"     <li>",
"      Cannulation between two to four weeks may be attempted but only if the fistula is considered mature.",
"     </li>",
"     <li>",
"      Cannulation after four weeks of maturation may be safe, if the fistula is mature.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Independent of the age of the fistula, clinical examination is required to confirm a fistula is ready for cannulation. Maturation time alone should not be the reason to attempt cannulation if the fistula is determined clinically to be immature [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/41\">",
"     41",
"    </a>",
"    ]; conversely, cannulation of a mature fistula should not be avoided based upon maturation time alone. Cannulation with small gauge needles and limiting blood flow in patients (particularly if residual renal function is high) can also facilitate early fistula use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Patency/secondary failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although native fistulas have a high rate of primary failure, their long-term patency is superior to grafts if they mature. The 5- and 10&ndash;year cumulative patencies for radiocephalic fistulas are reported to be 53 and 45 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/1,42\">",
"     1,42",
"    </a>",
"    ]. By comparison, cumulative patency for PTFE grafts at one, two, and four years is approximately 67, 50 and 43 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/43\">",
"     43",
"    </a>",
"    ]. In general, PTFE forearm grafts have lower cumulative patency than upper arm grafts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common complications of fistulas and grafts include thrombosis, infection, steal, aneurysms, venous hypertension, seromas, heart failure, and local bleeding. Thrombosis, infection, and seromas occur more frequently with grafts than with fistulas.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Dialysis Outcomes and Practice Patterns Study (DOPPS) found that grafts are 3.8 times more likely to require a thrombectomy and 3.0 times more likely to require access intervention than native fistula [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/44\">",
"       44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16727?source=see_link\">",
"       \"Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of infection for grafts averages 10 percent, over their duration of use, compared with 5 percent for transposed fistulas, and less than 2 percent for non-transposed fistulas [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/16,36,45-47\">",
"       16,36,45-47",
"      </a>",
"      ]. Graft infection may require complete excision to eradicate the infection, while fistula infections may resolve with intravenous antibiotics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12536?source=see_link\">",
"       \"Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      True aneurysms and pseudoaneurysms occur in up to 3 and 5 percent of fistulas and grafts, respectively, at sites of repeated cannulation or where the vein wall is thinned. Rotating cannulation sites should reduce the risk of this complication. Using the button-hole technique to cannulate fistulas may also reduce the risk of this complication. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12536?source=see_link\">",
"       \"Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Steal complicates approximately 5 percent of grafts and fistulas on average, but is more likely to occur in brachiocephalic fistulas (6 percent risk) than with radiocephalic fistulas (1 percent risk). Hand ischemia from steal may require a revascularization procedure or complete ligation in severe cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12536?source=see_link\">",
"       \"Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High-output heart failure from fistulas occurs in less than one percent of case series. Patients with severe heart failure may therefore not be eligible for permanent vascular access. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37063?source=see_link\">",
"       \"Heart failure and hemodialysis arteriovenous fistulae\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Venous hypertension occurs in approximately 3 percent of fistulas and grafts and is usually related to central vein stenosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39432?source=see_link\">",
"       \"Central vein stenosis associated with dialysis access\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Anesthesia issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Native fistulas can usually be constructed under local anesthetic. Transposed fistulas and grafts may require regional nerve blocks or general anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Nursing issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fistulas may be more difficult to cannulate than grafts, particularly during initial use, and may explain why some staff in dialysis units actually prefer grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/48\">",
"     48",
"    </a>",
"    ]. Experienced dialysis nurses may be required to successfully cannulate new fistulas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cosmetic issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive dilation of fistulas can be a major concern for patients. These issues should be addressed through education and should not prevent patients from receiving the benefits of a well-functioning fistula. If dilation is excessive, then banding of the fistula may reduce the diameter of the fistula. Resection of aneurysms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    replacement of portions of the fistula with graft material can also improve appearance. Alternatively, a patient may choose an upper arm fistula, which is more easily concealed by their clothing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PATIENT SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis AV fistula use is associated with decreased mortality compared with grafts and tunneled catheters, with hemodialysis catheter use being consistently associated with the worst survival rates [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/49-55\">",
"     49-55",
"    </a>",
"    ]. As an example, in a study of 616 incident dialysis patients, 66, 20, and 14 percent of patients were using a catheter, graft and fistula, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/56\">",
"     56",
"    </a>",
"    ]. At six months, reported rates were 34, 40, and 26 percent. Compared with fistulas, the adjusted relative hazards of death were 1.5 for catheters (95% CI 1.0-2.2) and 1.2 for grafts (95% CI 0.8-1.8). The increased mortality risk with catheters was particularly evident in men.",
"   </p>",
"   <p>",
"    An analysis of the HEMO study found patients who changed from an AV access to a catheter had an increased mortality, and patients who changed from a catheter to AV access had a decreased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TARGETS AND OUTCOMES FOR CHRONIC HEMODIALYSIS ACCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines recommend that fistulas be used for access in greater than 65 percent of prevalent patients in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/3\">",
"     3",
"    </a>",
"    ]. Catheters should be used for chronic access (defined as use for more than three months in the absence of a maturing permanent access) in less than 10 percent of prevalent patients without a contraindication for permanent access.",
"   </p>",
"   <p>",
"    Fistula use appears to be increasing in prevalence in the United States. The most recent United States Renal Data System (USRDS) report found 55 percent of prevalent chronic hemodialysis patients in 2007 used a fistula for vascular access [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     RECOMMENDED STRATEGY FOR CHRONIC HEMODIALYSIS ACCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred type of access is a native fistula because a mature fistula has the lowest risk of complications, lowest need for intervention, and the best long-term patency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/3,59,60\">",
"     3,59,60",
"    </a>",
"    ]. To achieve a well-functioning fistula at the time of initiation of dialysis, timely referral for surgery is important. The minimum time for fistula maturation is one month, but some may require up to six months. Fistulas created at least four months prior to starting hemodialysis were associated with a lower risk of sepsis and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/49\">",
"     49",
"    </a>",
"    ]. Most of the benefit was explained by the avoidance of central venous catheters.",
"   </p>",
"   <p>",
"    Sufficient time should be available for a careful preoperative evaluation including history and physical and diagnostic tests, as required. Doppler ultrasound or venography may help determine the best type and location of the access. The administration of gadolinium during magnetic resonance imaging has been strongly linked to severe and irreversible disease called nephrogenic systemic fibrosis among patients with moderate to severe renal disease, particularly those requiring dialysis. As a result, it is recommended that gadolinium-based imaging be avoided, if possible, in patients with an estimated glomerular filtration rate less than 30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .) Protection of residual renal function also should be considered if the patient receives contrast dye.",
"   </p>",
"   <p>",
"    Intervention may be required to facilitate maturation especially for patients with marginal vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/61\">",
"     61",
"    </a>",
"    ]. If neither a radiocephalic fistula nor a brachiocephalic fistula is possible, then a transposed brachiobasilic fistula should be considered, if the surgical expertise is available and the benefits outweigh the risks of the more extensive surgical procedure.",
"   </p>",
"   <p>",
"    If a fistula is not possible, a graft should be considered.",
"   </p>",
"   <p>",
"    Catheters are the least preferred form of chronic access [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23816/abstract/3\">",
"     3",
"    </a>",
"    ]. They are more acceptable if the duration of dialysis is expected to be less than one year, all other forms of chronic access have been exhausted, a fistula or graft is contraindicated (eg, severe heart failure). Since many patients using catheters for chronic access will experience a serious complication during their use, all patients who are eligible for a fistula or graft should be educated about these risks and offered one. Despite these risks, some well-informed patients still prefer to use catheters for chronic dialysis access.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/22/11619?source=see_link\">",
"       \"Patient information: Preparing for hemodialysis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=see_link\">",
"       \"Patient information: Hemodialysis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The three principal forms of vascular access are native arteriovenous (AV) fistulas, synthetic grafts, and double-lumen tunneled cuffed catheters. AV fistulas are typically constructed with an end-to-side vein-to-artery anastomosis between an artery and vein. Synthetic grafts are constructed by anastomosing a synthetic conduit between an artery and vein. Tunneled cuffed catheters are dual lumen catheters usually composed of silicone or polyurethane composites. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Autogenous arteriovenous fistula'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fistulas and grafts differ according to failure rates, time to use, patency, complications, and perioperative morbidity. Fistulas are more likely than grafts to experience primary failure, defined as a fistula that never provided reliable access for hemodialysis. Despite this, the long-term patency of mature fistulas is superior to grafts. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Primary failure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Patency/secondary failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common complications of fistulas and grafts include thrombosis, infection, steal, aneurysms, venous hypertension, seromas, heart failure, and local bleeding. Thrombosis, infection, and seromas occur more frequently with grafts than with fistulas. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemodialysis AV fistula use is associated with decreased mortality compared with grafts and tunneled catheters, with hemodialysis catheters being consistently associated with the worst survival rates. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Patient survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AV fistulas are preferred over all other forms of chronic hemodialysis access because of a number of benefits. Fistulae are associated with decreased mortality and morbidity among hemodialysis patients compared with grafts and catheters. After fistulae, grafts are the next preferred long-term access. Tunneled catheters are the least desirable access and should be primarily used as intermediate-duration vascular access to allow maturation of fistulas or grafts. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Comparison of fistulas and grafts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To achieve a well-functioning fistula at the time of initiation of dialysis, timely referral for surgery is important. The minimum time for fistula maturation is one month, but some may require up to six months. If neither a radiocephalic fistula nor a brachiocephalic fistula is possible, then a transposed brachiobasilic fistula should be considered. If a fistula is not possible, a graft should be considered. It is debatable whether a transposed brachiobasilic fistula should be offered before a lower forearm graft. Hemodialysis catheters are the least preferred form of chronic access. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Recommended strategy for chronic hemodialysis access'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/1\">",
"      Rodriguez JA, Armadans L, Ferrer E, et al. The function of permanent vascular access. Nephrol Dial Transplant 2000; 15:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/2\">",
"      Chin AI, Chang W, Fitzgerald JT, et al. Intra-access blood flow in patients with newly created upper-arm arteriovenous native fistulae for hemodialysis access. Am J Kidney Dis 2004; 44:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/3\">",
"      Hemodialysis Clinical Practice Guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006; 17(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/4\">",
"      K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/5\">",
"      Gradman WS, Laub J, Cohen W. Femoral vein transposition for arteriovenous hemodialysis access: improved patient selection and intraoperative measures reduce postoperative ischemia. J Vasc Surg 2005; 41:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/6\">",
"      Hurt AV, Batello-Cruz M, Skipper BJ, et al. Bovine carotid artery heterografts versus polytetrafluoroethylene grafts. A prospective, randomized study. Am J Surg 1983; 146:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/7\">",
"      Liu Z, Zhu B, Wang X, et al. Clinical studies of hemodialysis access through formaldehyde-fixed arterial allografts. Kidney Int 2007; 72:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/8\">",
"      Canaud B. Formaldehyde-fixed arterial allograft as a novel vascular access alternative in end-stage renal disease patients. Kidney Int 2007; 72:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/9\">",
"      Hurlbert SN, Mattos MA, Henretta JP, et al. Long-term patency rates, complications and cost-effectiveness of polytetrafluoroethylene (PTFE) grafts for hemodialysis access: a prospective study that compares Impra versus Gore-tex grafts. Cardiovasc Surg 1998; 6:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/10\">",
"      Lenz BJ, Veldenz HC, Dennis JW, et al. A three-year follow-up on standard versus thin wall ePTFE grafts for hemodialysis. J Vasc Surg 1998; 28:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/11\">",
"      Schuman ES, Standage BA, Ragsdale JW, Gross GF. Reinforced versus nonreinforced polytetrafluoroethylene grafts for hemodialysis access. Am J Surg 1997; 173:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/12\">",
"      Miller CD, Robbin ML, Barker J, Allon M. Comparison of arteriovenous grafts in the thigh and upper extremities in hemodialysis patients. J Am Soc Nephrol 2003; 14:2942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/13\">",
"      Ram SJ, Sachdeva BA, Caldito GC, et al. Thigh grafts contribute significantly to patients' time on dialysis. Clin J Am Soc Nephrol 2010; 5:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/14\">",
"      Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA 2008; 299:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/15\">",
"      Kaufman JL, Garb JL, Berman JA, et al. A prospective comparison of two expanded polytetrafluoroethylene grafts for linear forearm hemodialysis access: does the manufacturer matter? J Am Coll Surg 1997; 185:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/16\">",
"      Polo JR, Tejedor A, Polo J, et al. Long-term follow-up of 6-8 mm brachioaxillary polytetrafluorethylene grafts for hemodialysis. Artif Organs 1995; 19:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/17\">",
"      Sands J, Miranda CL. Increasing numbers of AV fistulas for hemodialysis access. Clin Nephrol 1997; 48:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/18\">",
"      Miller PE, Tolwani A, Luscy CP, et al. Predictors of adequacy of arteriovenous fistulas in hemodialysis patients. Kidney Int 1999; 56:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/19\">",
"      Lockhart ME, Robbin ML, McNamara MM, Allon M. Association of pelvic arterial calcification with arteriovenous thigh graft failure in haemodialysis patients. Nephrol Dial Transplant 2004; 19:2564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/20\">",
"      Lok CE, Allon M, Moist L, et al. Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I). J Am Soc Nephrol 2006; 17:3204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/21\">",
"      Huijbregts HJ, Bots ML, Wittens CH, et al. Hemodialysis arteriovenous fistula patency revisited: results of a prospective, multicenter initiative. Clin J Am Soc Nephrol 2008; 3:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/22\">",
"      Monroy-Cuadros M, Yilmaz S, Salazar-Ba&ntilde;uelos A, Doig C. Risk factors associated with patency loss of hemodialysis vascular access within 6 months. Clin J Am Soc Nephrol 2010; 5:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/23\">",
"      Silva MB Jr, Hobson RW 2nd, Pappas PJ, et al. A strategy for increasing use of autogenous hemodialysis access procedures: impact of preoperative noninvasive evaluation. J Vasc Surg 1998; 27:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/24\">",
"      Miller CD, Robbin ML, Allon M. Gender differences in outcomes of arteriovenous fistulas in hemodialysis patients. Kidney Int 2003; 63:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/25\">",
"      Obialo CI, Tagoe AT, Martin PC, Asche-Crowe PE. Adequacy and survival of autogenous arteriovenous fistula in African American hemodialysis patients. ASAIO J 2003; 49:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/26\">",
"      Segal JH, Kayler LK, Henke P, et al. Vascular access outcomes using the transposed basilic vein arteriovenous fistula. Am J Kidney Dis 2003; 42:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/27\">",
"      Ravani P, Brunori G, Mandolfo S, et al. Cardiovascular comorbidity and late referral impact arteriovenous fistula survival: a prospective multicenter study. J Am Soc Nephrol 2004; 15:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/28\">",
"      van der Linden J, Lameris TW, van den Meiracker AH, et al. Forearm venous distensibility predicts successful arteriovenous fistula. Am J Kidney Dis 2006; 47:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/29\">",
"      Lee T, Barker J, Allon M. Comparison of survival of upper arm arteriovenous fistulas and grafts after failed forearm fistula. J Am Soc Nephrol 2007; 18:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/30\">",
"      Beathard GA, Settle SM, Shields MW. Salvage of the nonfunctioning arteriovenous fistula. Am J Kidney Dis 1999; 33:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/31\">",
"      Konner K, Hulbert-Shearon TE, Roys EC, Port FK. Tailoring the initial vascular access for dialysis patients. Kidney Int 2002; 62:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/32\">",
"      Faiyaz R, Abreo K, Zaman F, et al. Salvage of poorly developed arteriovenous fistulae with percutaneous ligation of accessory veins. Am J Kidney Dis 2002; 39:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/33\">",
"      Falk A, Teodorescu V, Lou WY, et al. Treatment of \"swing point stenoses\" in hemodialysis arteriovenous fistulae. Clin Nephrol 2003; 60:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/34\">",
"      Beathard GA, Arnold P, Jackson J, et al. Aggressive treatment of early fistula failure. Kidney Int 2003; 64:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/35\">",
"      Nassar GM, Nguyen B, Rhee E, Achkar K. Endovascular treatment of the \"failing to mature\" arteriovenous fistula. Clin J Am Soc Nephrol 2006; 1:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/36\">",
"      Dunlop MG, Mackinlay JY, Jenkins AM. Vascular access: experience with the brachiocephalic fistula. Ann R Coll Surg Engl 1986; 68:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/37\">",
"      Sottiurai VS, Stephens A, Champagne L, et al. Comparative results of early and delayed cannulation of arteriovenous graft in haemodialysis. Eur J Vasc Endovasc Surg 1997; 13:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/38\">",
"      Rayner HC, Pisoni RL, Gillespie BW, et al. Creation, cannulation and survival of arteriovenous fistulae: data from the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2003; 63:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/39\">",
"      Brunori G, Ravani P, Mandolfo S, et al. Fistula maturation: doesn't time matter at all? Nephrol Dial Transplant 2005; 20:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/40\">",
"      Saran R, Dykstra DM, Pisoni RL, et al. Timing of first cannulation and vascular access failure in haemodialysis: an analysis of practice patterns at dialysis facilities in the DOPPS. Nephrol Dial Transplant 2004; 19:2334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/41\">",
"      Saran R, Pisoni RL, Young EW. Timing of first cannulation of arteriovenous fistula: are we waiting too long? Nephrol Dial Transplant 2005; 20:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/42\">",
"      Bonalumi U, Civalleri D, Rovida S, et al. Nine years' experience with end-to-end arteriovenous fistula at the 'anatomical snuffbox' for maintenance haemodialysis. Br J Surg 1982; 69:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/43\">",
"      Munda R, First MR, Alexander JW, et al. Polytetrafluoroethylene graft survival in hemodialysis. JAMA 1983; 249:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/44\">",
"      Young EW, Dykstra DM, Goodkin DA, et al. Hemodialysis vascular access preferences and outcomes in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 2002; 61:2266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/45\">",
"      Bender MH, Bruyninckx CM, Gerlag PG. The brachiocephalic elbow fistula: a useful alternative angioaccess for permanent hemodialysis. J Vasc Surg 1994; 20:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/46\">",
"      Hodges TC, Fillinger MF, Zwolak RM, et al. Longitudinal comparison of dialysis access methods: risk factors for failure. J Vasc Surg 1997; 26:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/47\">",
"      Coburn MC, Carney WI Jr. Comparison of basilic vein and polytetrafluoroethylene for brachial arteriovenous fistula. J Vasc Surg 1994; 20:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/48\">",
"      Bay WH, Van Cleef S, Owens M. The hemodialysis access: preferences and concerns of patients, dialysis nurses and technicians, and physicians. Am J Nephrol 1998; 18:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/49\">",
"      Oliver MJ, Rothwell DM, Fung K, et al. Late creation of vascular access for hemodialysis and increased risk of sepsis. J Am Soc Nephrol 2004; 15:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/50\">",
"      Dhingra RK, Young EW, Hulbert-Shearon TE, et al. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int 2001; 60:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/51\">",
"      Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among hemodialysis patients. Kidney Int 2002; 62:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/52\">",
"      Xue JL, Dahl D, Ebben JP, Collins AJ. The association of initial hemodialysis access type with mortality outcomes in elderly Medicare ESRD patients. Am J Kidney Dis 2003; 42:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/53\">",
"      Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG. Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol 2004; 15:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/54\">",
"      Thomson PC, Stirling CM, Geddes CC, et al. Vascular access in haemodialysis patients: a modifiable risk factor for bacteraemia and death. QJM 2007; 100:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/55\">",
"      Pisoni RL, Arrington CJ, Albert JM, et al. Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: an instrumental variable analysis. Am J Kidney Dis 2009; 53:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/56\">",
"      Astor BC, Eustace JA, Powe NR, et al. Type of vascular access and survival among incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. J Am Soc Nephrol 2005; 16:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/57\">",
"      Allon M, Daugirdas J, Depner TA, et al. Effect of change in vascular access on patient mortality in hemodialysis patients. Am J Kidney Dis 2006; 47:469.",
"     </a>",
"    </li>",
"    <li>",
"     United States Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/59\">",
"      Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int 2002; 62:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/60\">",
"      Lok CE, Oliver MJ. Overcoming barriers to arteriovenous fistula creation and use. Semin Dial 2003; 16:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23816/abstract/61\">",
"      Asif A, Cherla G, Merrill D, et al. Conversion of tunneled hemodialysis catheter-consigned patients to arteriovenous fistula. Kidney Int 2005; 67:2399.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1984 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_16_23816=[""].join("\n");
var outline_f23_16_23816=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AUTOGENOUS ARTERIOVENOUS FISTULA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ARTERIOVENOUS GRAFTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COMPARISON OF FISTULAS AND GRAFTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Primary failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Time to use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Grafts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Fistulas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patency/secondary failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Anesthesia issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nursing issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cosmetic issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PATIENT SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TARGETS AND OUTCOMES FOR CHRONIC HEMODIALYSIS ACCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      RECOMMENDED STRATEGY FOR CHRONIC HEMODIALYSIS ACCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3318?source=related_link\">",
"      Arteriovenous fistula recirculation in hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39432?source=related_link\">",
"      Central vein stenosis associated with dialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37063?source=related_link\">",
"      Heart failure and hemodialysis arteriovenous fistulae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12536?source=related_link\">",
"      Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16727?source=related_link\">",
"      Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=related_link\">",
"      Patient information: Hemodialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/22/11619?source=related_link\">",
"      Patient information: Preparing for hemodialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15722?source=related_link\">",
"      Thrombosis associated with chronic hemodialysis vascular access: Catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_16_23817="Uveitis: Etiology, clinical manifestations, and diagnosis";
var content_f23_16_23817=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Uveitis: Etiology, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/16/23817/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/16/23817/contributors\">",
"     James T Rosenbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/16/23817/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/16/23817/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/16/23817/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/16/23817/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/16/23817/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/16/23817/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uveitis, the process of intraocular inflammation, may result from many causes. Referral to an ophthalmology specialist is indicated for most patients with symptoms suggesting uveal tract inflammation.",
"   </p>",
"   <p>",
"    This topic considers the definition of uveitis and its subsets, the differential diagnosis in relationship to systemic disease, and the role of the non-ophthalmologist in the diagnostic evaluation of patients with uveitis.",
"   </p>",
"   <p>",
"    Treatment of uveitis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10407?source=see_link\">",
"     \"Uveitis: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The uvea is the middle portion of the eye. The term derives from the Latin word for grape, since anatomists once thought that the peeling of the outside of the eye left a grape-like structure beneath. The anterior portion of the uvea includes the iris and ciliary body; the posterior portion of the uvea is known as the choroid (",
"    <a class=\"graphic graphic_figure graphicRef57690 \" href=\"UTD.htm?41/35/42549\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammation of the anterior uveal tract is called anterior uveitis and is synonymous with iritis. When the adjacent ciliary body is also inflamed, the process is known as iridocyclitis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Terms used to describe forms of uveitis posterior to the lens include vitritis, intermediate uveitis, pars planitis, choroiditis, retinitis, chorioretinitis, and retinochoroiditis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/1\">",
"       1",
"      </a>",
"      ]. Panuveitis refers to simultaneous inflammation anterior and posterior to the lens with a component that affects the retina or choroid.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual forms of uveitis may be distinguished on the basis of location within the eye, onset, symmetry and continuity of inflammation, associated complications, and distribution of cells along the corneal endothelium. The latter changes are known as keratic precipitates (",
"    <a class=\"graphic graphic_picture graphicRef71161 \" href=\"UTD.htm?18/49/19231\">",
"     picture 1",
"    </a>",
"    ). Both the size and distribution of keratic precipitates are helpful in the differential diagnosis. The diversity of keratic precipitates is especially appreciated by magnified images obtained with confocal microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uveitis may be divided into four major subsets based upon the etiology of the inflammation (",
"    <a class=\"graphic graphic_table graphicRef61247 graphicRef75844 graphicRef55902 graphicRef64117 \" href=\"UTD.htm?12/58/13230\">",
"     table 1A-D",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infections",
"     </li>",
"     <li>",
"      Systemic immune-mediated disease",
"     </li>",
"     <li>",
"      Syndromes confined primarily to the eye",
"     </li>",
"     <li>",
"      Masquerade syndromes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our referral population, approximately 40 percent of patients have uveitis associated with a systemic immune-mediated disease. Approximately 30 percent of patients with uveitis do not fit into any well-defined diagnostic category.",
"   </p>",
"   <p>",
"    A genetic predisposition may contribute to the development of uveitis. This was illustrated in a genome-wide scan of 76 pairs of siblings concordant for acute anterior uveitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/3\">",
"     3",
"    </a>",
"    ]. A highly significant linkage was noted between uveitis and a locus on chromosome 9. This study, which included a large proportion of families affected by ankylosing spondylitis, also confirmed a previously noted link between the HLA-B locus and uveitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infectious causes of uveitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infectious causes of uveitis include bacterial and spirochetal diseases, viral diseases, fungal infections, and parasitic infections (",
"    <a class=\"graphic graphic_table graphicRef61247 \" href=\"UTD.htm?5/40/5773\">",
"     table 1A",
"    </a>",
"    ). These infections generally have distinctive presentations and are likely to affect different populations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytomegalovirus (CMV) in adults is found almost exclusively in the immunocompromised host, especially patients with HIV infection who have extremely low CD4 counts (",
"      <a class=\"graphic graphic_picture graphicRef60120 \" href=\"UTD.htm?14/55/15231\">",
"       picture 2",
"      </a>",
"      ). Uveitis (CMV retinitis) in patients with AIDS is discussed in detail elsewhere. CMV infection has also been identified as an uncommon cause of anterior uveitis in patients, most of whom are Asian, who are not immunocompromised. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Toxoplasmosis is a surprisingly common cause of uveitis in the normal host. In many instances, it is presumed to be a reactivation of a congenitally acquired infection. It is suspected on the basis of a typical chorioretinal lesion (",
"      <a class=\"graphic graphic_picture graphicRef69853 \" href=\"UTD.htm?20/40/21120\">",
"       picture 3",
"      </a>",
"      ); the diagnosis is supported by serology. Serologic evidence for previous infection by toxoplasmosis is extremely common in the healthy United States population [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/4\">",
"       4",
"      </a>",
"      ]. Most chorioretinal scarring from toxoplasmosis is due to infection during gestation, but scarring is increasingly recognized as a result of recent infection [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=see_link\">",
"       \"Toxoplasmosis in HIV-infected patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=see_link\">",
"       \"Toxoplasmosis in immunocompetent hosts\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Syphilis accounts for less than 1 percent of patients with uveitis in most large series. It may present in a variety of forms, including posterior uveitis, such as a chorioretinitis or retinal vasculitis (",
"      <a class=\"graphic graphic_picture graphicRef59760 \" href=\"UTD.htm?1/27/1471\">",
"       picture 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/6\">",
"       6",
"      </a>",
"      ]. It is critical to recognize syphilis because of its important therapeutic implications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and treatment of late syphilis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tuberculosis is an uncommon cause of uveitis in North American referral centers. It should be considered in the differential diagnosis when the uveitis worsens despite glucocorticoid therapy. Additional factors that raise suspicion for this diagnosis are active tuberculosis elsewhere in the body, cachexia, homelessness, a granulomatous appearance for the ocular inflammation, or immunosuppression. In some geographic areas such as Saudi Arabia, tuberculosis is considered a common cause of uveitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5767?source=see_link\">",
"       \"Tuberculosis and the eye\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cat scratch disease is increasingly recognized as a cause of uveitis. Although the uveitis associated with cat scratch disease can have a variable presentation, a macular star and optic nerve edema are especially characteristic (",
"      <a class=\"graphic graphic_picture graphicRef69294 \" href=\"UTD.htm?31/62/32736\">",
"       picture 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23289?source=see_link\">",
"       \"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      West Nile viral infection can cause chorioretinitis in association with a retinal vasculitis. Uveitis is a common feature of this viral disease and may be asymptomatic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22264?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations and diagnosis of West Nile virus infection\", section on 'Other clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Both herpes simplex and herpes zoster can cause a keratouveitis, an inflammation of the cornea along with uveitis that is primarily anterior. The presence of cutaneous vesicles, characteristic corneal changes, reduced corneal sensation, elevated intraocular pressure, and iris atrophy may be clues to the diagnosis. Both herpes simplex and zoster can also cause a retinitis known as acute retinal necrosis. This is a rare but treatable cause of visual loss. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\", section on 'Ocular infections'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\", section on 'Herpes zoster ophthalmicus'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Systemic inflammatory diseases associated with uveitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uveitis can occur as a manifestation of many systemic diseases (",
"    <a class=\"graphic graphic_table graphicRef55902 \" href=\"UTD.htm?29/54/30571\">",
"     table 1C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spondyloarthritides (SpA), such as ankylosing spondylitis and reactive arthritis, are the most common systemic immune disorders associated with uveitis in North America and Europe [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/8\">",
"       8",
"      </a>",
"      ]. Twenty to 40 percent of patients with either of these HLA-B27-related disorders develop the sudden onset of anterior uveitis. When it occurs, uveitis is often the manifestation to suggest the diagnosis of the systemic illness. Uveitis in association with spondyloarthritis is twice as common in males as in females.",
"      <br/>",
"      <br/>",
"      Uveitis in association with SpA is typically unilateral and tends to resolve within three months of its onset. Recurrences are common and can occur in the contralateral eye. The prognosis for this form of uveitis is generally excellent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link\">",
"       \"Clinical manifestations of ankylosing spondylitis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"       \"Reactive arthritis (formerly Reiter syndrome)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients with recurrent anterior uveitis without symptoms or the diagnosis of SpA, particularly those who are HLA-B27-positive, may have an incomplete form of SpA. A strong association was seen between patients with recurrent acute anterior uveitis and the presence of inflammation at the tendon or ligament insertion (enthesitis) demonstrated by ultrasound, despite the absence of clinical symptoms of spondyloarthropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Seven percent of patients with psoriatic arthritis and 2 to 9 percent of patients with inflammatory bowel disease (IBD, Crohn's disease, or ulcerative colitis) may develop uveitis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. The uveitis is associated with HLA-B27 in approximately 45 percent of cases with IBD.",
"      <br/>",
"      <br/>",
"      In contrast to the uveitis associated with the spondyloarthropathies, uveitis associated with IBD or psoriatic arthritis is frequently bilateral, posterior to the lens, insidious in onset, chronic in duration, and more common in females than males [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Approximately 75 percent of patients with uveitis and IBD have an associated arthritis that may be axial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      peripheral and may, therefore, simulate a spondyloarthropathy. In 10 of 17 patients in one series, the uveitis preceded signs of IBD [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link\">",
"       \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"       \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sarcoidosis accounts for a significant percentage of patients with uveitis in most series from referral centers [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]. Approximately 20 percent of patients develop eye disease as their initial presentation of sarcoid. The eye disease can take on many forms, including uveitis, dry eyes, optic neuritis, lid inflammation, or orbital disease [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/16\">",
"       16",
"      </a>",
"      ]. Uveitis in patients with sarcoid is frequently associated with retinal vasculitis, which may be either perivascular or involve retinal vascular changes (",
"      <a class=\"graphic graphic_picture graphicRef77545 \" href=\"UTD.htm?24/3/24639\">",
"       picture 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/17\">",
"       17",
"      </a>",
"      ]. The eye disease may persist despite the resolution of adenopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of sarcoidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As many as 80 percent of patients with Beh&ccedil;et's disease develop uveitis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/19\">",
"       19",
"      </a>",
"      ]. Uveitis is often the dominant manifestation of this disease and is typically bilateral. Similar to HLA-B27-associated iritis, it is frequently episodic, but, unlike HLA-B27-associated disease, the uveitis generally does not resolve completely between episodes. Beh&ccedil;et&rsquo;s uveitis often presents as a panuveitis, and retinal vasculitis is a frequent manifestation of Beh&ccedil;et's disease (",
"      <a class=\"graphic graphic_picture graphicRef64705 \" href=\"UTD.htm?0/58/943\">",
"       picture 7",
"      </a>",
"      ). The uveitis typically leads to blindness if the eye inflammation is not treated [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\", section on 'Ocular disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tubulointerstitial nephritis and uveitis (TINU) syndrome is an uncommon disorder that occurs most often in adolescents and young women, who may also exhibit additional systemic symptoms and findings including fever, myalgias, mild anemia, and abnormal liver function tests. Patients may experience recurrent or chronic uveitis. Because interstitial nephritis and uveitis can also occur together in sarcoidosis and in Sj&ouml;gren's syndrome, patients with TINU syndrome should be evaluated for these disorders as well. The TINU syndrome is discussed in more detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20486?source=see_link\">",
"       \"Tubulointerstitial nephritis and uveitis (TINU syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Juvenile idiopathic arthritis (JIA) may be associated with uveitis, particularly in the subset of patients with pauciarticular disease and a positive antinuclear antibody. The onset of uveitis is more common in younger children and, in the majority of patients, can be asymptomatic.",
"      <br/>",
"      <br/>",
"      The uveitis associated with JIA is usually bilateral, insidious in onset, chronic in duration, and anterior. The eye disease is commonly associated with complications such as band keratopathy, posterior synechiae (",
"      <a class=\"graphic graphic_picture graphicRef52468 \" href=\"UTD.htm?41/4/42049\">",
"       picture 8",
"      </a>",
"      ), cataract formation, and glaucoma. The uveitis sometimes lasts for decades, long after the joint disease has disappeared. Uveitis in children with pauciarticular disease and recommendations for screening are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=see_link&amp;anchor=H7#H7\">",
"       \"Pauciarticular onset juvenile idiopathic arthritis\", section on 'Uveitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Kawasaki disease may be associated with a mild anterior uveitis, which may be accompanied by conjunctivitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link&amp;anchor=H4#H4\">",
"       \"Kawasaki disease: Clinical features and diagnosis\", section on 'Conjunctivitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A high percentage of patients with relapsing polychondritis also have ocular involvement. The eye disease occurs in many forms, including episcleritis, scleritis, and uveitis. Ocular involvement in relapsing polychondritis is discussed in more detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/63/26616?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations of relapsing polychondritis\", section on 'Eye involvement'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In Sj&ouml;gren's syndrome, a very small percentage of patients develop chronic anterior and posterior uveitis, and it is possible that uveitis causes secondary ocular dryness [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=see_link\">",
"       \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus (SLE) can involve the eye in a variety of forms [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/22\">",
"       22",
"      </a>",
"      ]. Dryness is the most common ocular manifestation; cotton wool spots (",
"      <a class=\"graphic graphic_picture graphicRef67621 \" href=\"UTD.htm?13/42/13999\">",
"       picture 9",
"      </a>",
"      ) occur in about 7 percent of patients and indicate local retinal ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/23\">",
"       23",
"      </a>",
"      ]. Anterior uveitis is a rare manifestation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=see_link&amp;anchor=H18#H18\">",
"       \"Overview of the clinical manifestations of systemic lupus erythematosus in adults\", section on 'Ophthalmologic'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Uveitis is infrequently associated with other systemic vasculitides, including polyarteritis and granulomatosis with polyangiitis (Wegener&rsquo;s). More typical vision-threatening manifestations of granulomatosis with polyangiitis (Wegener&rsquo;s) are scleritis and orbital disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"       \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"       \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Granulomatous angiitis of the central nervous system may also be accompanied by inflammation of the uvea [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=see_link\">",
"       \"Primary angiitis of the central nervous system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vogt-Koyanagi-Harada syndrome (VKH) is the second leading cause of uveitis in Japan after Beh&ccedil;et&rsquo;s syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/25\">",
"       25",
"      </a>",
"      ]. VKH is presumably an autoimmune disease that is manifested by bilateral posterior uveitis with characteristic fluid accumulation beneath the retina, leading to retinal elevation and detachment. It often presents as a panuveitis. Patients with VKH may also develop vitiligo, poliosis (loss of color from a patch of hair), sterile meningitis, alopecia, and eighth cranial nerve disease. The disease is common among Hispanic populations in addition to Asians. VKH has a strong HLA class II association (specifically with the HLA-D locus and DR4 allele) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/26\">",
"       26",
"      </a>",
"      ]. Similar retinal elevation may occur in central serous chorioretinopathy, a rare disorder that has been associated with glucocorticoid use. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link&amp;anchor=H8#H8\">",
"       \"Major side effects of systemic glucocorticoids\", section on 'Eye'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      One of the rarest forms of uveitis is Blau syndrome. This disease, transmitted in an autosomal dominant pattern, is characterized by the development of noncaseating granulomatous inflammation of the uvea, skin, and joints. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=see_link\">",
"       \"Periodic fever syndromes and other autoinflammatory diseases: An overview\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Uveitis syndromes restricted to the eye",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many forms of uveitis are associated with systemic inflammatory or infectious disease, a variety of uveitis syndromes occur without extraocular or infectious involvement (",
"    <a class=\"graphic graphic_table graphicRef75844 \" href=\"UTD.htm?14/41/15003\">",
"     table 1B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pars planitis is a relatively common form of uveitis, characterized by the presence of inflammatory debris over the pars plana, the portion of the eye just between the retina and the ciliary body [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/27\">",
"       27",
"      </a>",
"      ]. Thus, pars planitis is an anatomic description of the location of inflammation. Pars planitis is sometimes called peripheral uveitis and is a subset of intermediate uveitis.",
"      <br/>",
"      <br/>",
"      Pars planitis is usually not associated with a systemic disease, but it can be a manifestation of systemic conditions including multiple sclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/28\">",
"       28",
"      </a>",
"      ] or sarcoidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/29\">",
"       29",
"      </a>",
"      ]. Because of its association with multiple sclerosis, a thorough neurologic history and examination are indicated in patients with pars planitis, and magnetic resonance imaging (MRI) of the brain may also be appropriate in these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/30\">",
"       30",
"      </a>",
"      ]. The author's preference is to obtain an MRI only in those patients with neurological symptoms and in the subset of pars planitis patients who are at greater risk for multiple sclerosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link\">",
"       \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sympathetic ophthalmia is an inflammation of the contralateral eye of a small percentage of patients who have experienced penetrating trauma to one eye. It usually begins as an anterior uveitis several weeks to a year following the trauma and is thought to result from an autoimmune response to a retinal antigen [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Birdshot choroidopathy is a chronic, bilateral, posterior uveitis associated with multiple focal inflammatory aggregates that resemble tiny birdshot pellets (",
"      <a class=\"graphic graphic_picture graphicRef58904 \" href=\"UTD.htm?35/30/36335\">",
"       picture 10",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/32\">",
"       32",
"      </a>",
"      ]. Ninety-five percent of patients with this disorder possess the HLA-A29 antigen [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Approximately 30 percent of patients with uveitis have disease that does not fit into any apparent etiologic category [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/13\">",
"       13",
"      </a>",
"      ]. Many patients with this disorder, sometimes called idiopathic uveitis, may have a form of sarcoid that is limited to the eye. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Systemic inflammatory diseases associated with uveitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other causes of uveitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug or hypersensitivity reactions are a rare cause of uveitis. The following drugs are among those that have been implicated:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       Rifabutin",
"      </a>",
"      (used in the treatment of atypical mycobacterial infection) appears to be frequently associated with a florid anterior uveitis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/34\">",
"       34",
"      </a>",
"      ]. The inflammation resolves despite continuing the medication, suggesting that the inflammation may result from a hypersensitivity reaction triggered in part by the death of mycobacterial organisms induced by the antibiotic.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"       Cidofovir",
"      </a>",
"      , an antiviral drug, is also frequently associated with uveitis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       Moxifloxacin",
"      </a>",
"      , a fluoroquinolone antibiotic, is implicated in a rare form of uveitis characterized by some loss of pigment in the iris [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bisphosphonates, especially when administered intravenously, are an infrequent cause of uveitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H47#H47\">",
"       \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Ocular side effects'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple sclerosis (MS) is most commonly associated with optic neuritis but may also cause a granulomatous anterior uveitis or pars planitis. Females with pars planitis in association with a periretinal vascular infiltrate, known as periphlebitis (",
"      <a class=\"graphic graphic_picture graphicRef60574 \" href=\"UTD.htm?14/11/14527\">",
"       picture 11",
"      </a>",
"      ), have about a 30 percent risk of developing multiple sclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link\">",
"       \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immune recovery uveitis is a phenomenon most often recognized in association with the use of highly active retroviral therapy for HIV infection. This phenomenon is referred to as the immune reconstitution inflammatory syndrome (IRIS). As this treatment allows recovery of CD4 T cell counts, some patients with prior CMV retinitis develop intraocular inflammation, presumably due to an enhanced immune response. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link&amp;anchor=H11#H11\">",
"       \"Immune reconstitution inflammatory syndrome\", section on 'IRIS associated with cytomegalovirus'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Masquerade syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of noninfectious processes can be mistaken for an inflammatory process; most of these are malignancies (",
"    <a class=\"graphic graphic_table graphicRef64117 \" href=\"UTD.htm?1/27/1467\">",
"     table 1D",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The most common malignancy that presents like uveitis in adults is lymphoma, typically a B cell type that is confined to the eye and the central nervous system (",
"    <a class=\"graphic graphic_picture graphicRef55813 \" href=\"UTD.htm?4/56/5007\">",
"     picture 12",
"    </a>",
"    ). The eye disease is usually bilateral and generally presents as the insidious onset of visual obscuration, such as floaters. Ocular lymphoma may be difficult to diagnose, but should be suspected when inflammation is refractory to glucocorticoids, when neurological symptoms are present, or when bilateral posterior eye inflammation has begun after age 45. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\", section on 'Primary intraocular lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of uveitis depend upon the portion of the uveal tract that is involved. Anterior uveitis may produce pain and redness, although these symptoms are minimal if inflammation begins insidiously (eg, in juvenile idiopathic arthritis). The degree of visual loss associated with anterior uveitis is variable.",
"   </p>",
"   <p>",
"    By contrast, posterior or intermediate uveitis is more likely to be painless but may result in visual changes such as floaters or reduced visual acuity. Floaters or debris in the visual field may also result from noninflammatory processes such as normal aging. Redness of the eye is not a prominent feature of posterior inflammation unless there is an accompanying anterior uveitis.",
"   </p>",
"   <p>",
"    Anterior uveitis is about four times more common than posterior uveitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Red eye",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many patients with anterior uveitis have a red eye, this finding must be distinguished from other causes of a red eye, such as corneal inflammation (keratitis), conjunctival inflammation (conjunctivitis), blood vessel inflammation in the episclera or sclera (episcleritis and scleritis, respectively), or acute closed angle glaucoma. Iritis (anterior uveitis) can usually be distinguished by redness that is primarily noted at the limbus (the junction between the cornea and the sclera), a constricted pupil, and pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link\">",
"     \"Evaluation of the red eye\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultimately, iritis is distinguished from other causes of a red eye by slit lamp examination. This examination allows the trained observer to visualize the anterior segment of the eye. Leukocytes are not normally found in the aqueous humor that fills the space between the cornea and the lens; their presence in the anterior chamber is readily appreciated with the slit lamp and is diagnostic of anterior uveitis. A haze, described by ophthalmologists as \"flare,\" may also be appreciated by slit lamp examination and reflects protein accumulation in the aqueous humor secondary to disruption of the blood aqueous barrier.",
"   </p>",
"   <p>",
"    In comparison to anterior uveitis, posterior or intermediate uveitis is diagnosed by direct visualization of active chorioretinal inflammation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by detection of leukocytes in the vitreous humor on ophthalmic examination. The diagnosis of panuveitis is made when inflammation is detected simultaneously in the anterior chamber, vitreous, and retina or choroid. These findings are identified either by use of a slit lamp in conjunction with special lenses to focus the beam posterior to the lens or with an indirect ophthalmoscope and a handheld lens. Complete examination of the eye posterior to the lens usually includes a technique called scleral depression. This maneuver allows the examiner to look for an inflammatory exudate over the pars plana, the portion of the eye just between the retina and the ciliary body. Exudates or \"snowbanks\" are characteristic of a relatively common form of intermediate uveitis known as pars planitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uveitis can be associated with a variety of complications. These may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Band keratopathy (the deposition of calcium in the epithelium of the cornea)",
"     </li>",
"     <li>",
"      Posterior synechiae (the adhesion of the iris to the lens which lies posterior to it)",
"     </li>",
"     <li>",
"      Cataract (resulting from inflammation in some patients or glucocorticoid treatment in others)",
"     </li>",
"     <li>",
"      Glaucoma",
"     </li>",
"     <li>",
"      Cystoid macular edema (fluid accumulation in the area of central vision). Ocular coherence tomography is frequently used to detect cystoid macular edema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of specific complications can differ, depending on the underlying illness. For example, the uveitis associated with juvenile idiopathic arthritis is frequently associated with band keratopathy. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Systemic inflammatory diseases associated with uveitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed history is the most important step in the initial evaluation of a patient presenting with symptoms suggesting uveitis. This history should include questions regarding risk factors for HIV infection. In general, when uveitis is related to a systemic disorder, the associated diagnosis will be apparent at the time of the initial history and physical examination.",
"   </p>",
"   <p>",
"    A systematic approach using additional testing and guided by the history and examination can be used to identify underlying disorders when an associated condition is not apparent. Sarcoidosis and syphilis are among the most common of the disorders causing uveitis and systemic disease that are clinically silent.",
"   </p>",
"   <p>",
"    In patients with pars planitis, particular attention should be given in the history and physical examination to features suggestive of multiple sclerosis, which is present in increased frequency in such patients. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Other causes of uveitis'",
"    </a>",
"    above.). In patients with panuveitis, the differential diagnosis includes Beh&ccedil;et&rsquo;s disease, Vogt-Koyanagi-Harada syndrome, sarcoidosis, and infection. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Systemic inflammatory diseases associated with uveitis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Infectious causes of uveitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Evaluation by an ophthalmologist is important in the recognition and management of potential complications of uveitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author's approach to evaluation of patients with uveitis of unknown etiology is to first obtain a chest radiograph to look for evidence for sarcoidosis or infection associated with uveitis, such as tuberculosis, and a serologic test for syphilis. Serologic testing for systemic lupus or Lyme disease and skin testing for tuberculosis are not suggested in the absence of other clinical signs of these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human immunodeficiency virus (HIV) testing is not routinely obtained in evaluating patients with uveitis but should be obtained in patients with an opportunistic infection or a presumed infectious or immunologic cause of uveitis that is not responding to therapy in the expected manner.",
"   </p>",
"   <p>",
"    Sarcoidosis is a frequent cause of what would otherwise be labeled idiopathic uveitis. One study found that 57 percent of women with uveitis between the ages of 61 and 83 had hilar adenopathy on chest CT scanning although routine radiographs were unremarkable [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/42\">",
"     42",
"    </a>",
"    ]. Although extrapolation of these findings to other patient populations is uncertain, a CT scan of the chest may be of benefit in some patients with a normal chest radiograph and uveitis in whom the diagnosis is unclear. The diagnostic value of the CT scan must be weighed against the risks from the radiation exposure from the study. As an example, a patient older than 60 with ophthalmic examination findings that suggest granulomatous inflammation, a normal chest radiograph, and no other known etiology for the uveitis is a good candidate for a chest CT scan. In contrast, a patient who is 30 years old with ocular findings described by an ophthalmologist as non-granulomatous might also have sarcoidosis, but the risk of the radiation and the low probability that the eye disease is sarcoid would dissuade the author from ordering a chest CT scan in this setting.",
"   </p>",
"   <p>",
"    The location, acuity, and response to therapy can help guide diagnostic considerations and testing. For example, acute unilateral anterior uveitis suggests the possibility of a spondyloarthropathy, while bilateral chronic anterior and posterior uveitis may suggest sarcoidosis. Opportunistic infection should be considered in an immunocompromised patient.",
"   </p>",
"   <p>",
"    Patients who have had intraocular lens implantation temporally related to the onset of uveitis may have infection, and vitreous humor aspiration and culture should be considered. In rare patients with uveitis, vitreous humor cytology to exclude ocular lymphoma or retinal biopsy could be considered. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Masquerade syndromes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients with intraocular inflammation and suspected infectious retinitis, early polymerase chain reaction testing of ocular fluid for specific infections such as herpes zoster or herpes simplex can be useful in making a timely diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/16/23817/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/13/26833?source=see_link\">",
"       \"Patient information: Uveitis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/3/20529?source=see_link\">",
"       \"Patient information: Chorioretinitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of leukocytes in the anterior chamber of the eye is characteristic of anterior uveitis. The presence of leukocytes in the vitreous humor and evidence of active chorioretinal inflammation are diagnostic of intermediate uveitis and posterior uveitis, respectively. Panuveitis is defined as simultaneous inflammation in the anterior chamber, vitreous humor, and retina or choroid. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 30 percent of patients with uveitis do not have an infectious etiology, a distinct pattern such as pars planitis, or any apparent associated systemic disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatable infections should be considered as a cause of uveitis. Cytomegalovirus (CMV) infection is an important etiology in patients with",
"      <span class=\"nowrap\">",
"       HIV/AIDS.",
"      </span>",
"      Toxoplasmosis can affect both normal and immunocompromised hosts. Multiple other infections may be etiologic as well (",
"      <a class=\"graphic graphic_table graphicRef61247 graphicRef75844 graphicRef55902 graphicRef64117 \" href=\"UTD.htm?12/58/13230\">",
"       table 1A-D",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Infectious causes of uveitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various systemic inflammatory diseases are associated with uveitis, including spondyloarthropathies (eg, ankylosing spondylitis, psoriatic arthritis, and reactive arthritis), inflammatory bowel disease, sarcoidosis, Beh&ccedil;et&rsquo;s disease, and juvenile idiopathic arthritis. Multiple sclerosis, more commonly associated with optic neuritis, may also cause uveitis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Systemic inflammatory diseases associated with uveitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Other causes of uveitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cellular infiltration that is not due to inflammation may occur in hematologic and lymphoproliferative disorders. Central nervous system lymphoma may \"masquerade\" as uveitis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Masquerade syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uveitis symptoms depend on the portion of the uveal tract affected. Anterior uveitis may produce pain and redness; posterior or intermediate uveitis is more likely to be painless but is often associated with floaters",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      some degree of visual loss. Visual loss may occur with anterior, intermediate, or posterior involvement. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Slit lamp and fundoscopic examination are necessary to establish the presence of uveitis. Examination should include scleral depression to assess for inflammation just posterior to the lens (the pars plana of the uveal tract). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A detailed medical history is the most important step to diagnose an associated systemic disease. Because of a strong association between uveitis affecting the pars plana (pars planitis) and multiple sclerosis, particular attention should be given to the neurologic history in patients with pars planitis. In patients in whom there is no apparent cause, a plain chest radiograph and serologic test for syphilis are suggested. Further diagnostic testing may include chest CT scan and evaluation to exclude other infections, systemic inflammatory disease, or multiple sclerosis (",
"      <a class=\"graphic graphic_table graphicRef55902 \" href=\"UTD.htm?29/54/30571\">",
"       table 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Approach to the patient'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/1\">",
"      Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/2\">",
"      Wertheim MS, Mathers WD, Planck SJ, et al. In vivo confocal microscopy of keratic precipitates. Arch Ophthalmol 2004; 122:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/3\">",
"      Martin TM, Zhang G, Luo J, et al. A locus on chromosome 9p predisposes to a specific disease manifestation, acute anterior uveitis, in ankylosing spondylitis, a genetically complex, multisystem, inflammatory disease. Arthritis Rheum 2005; 52:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/4\">",
"      Weiss MJ, Velazquez N, Hofeldt AJ. Serologic tests in the diagnosis of presumed toxoplasmic retinochoroiditis. Am J Ophthalmol 1990; 109:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/5\">",
"      Bosch-Driessen LE, Berendschot TT, Ongkosuwito JV, Rothova A. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology 2002; 109:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/6\">",
"      Margo CE, Hamed LM. Ocular syphilis. Surv Ophthalmol 1992; 37:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/7\">",
"      Suhler EB, Lauer AK, Rosenbaum JT. Prevalence of serologic evidence of cat scratch disease in patients with neuroretinitis. Ophthalmology 2000; 107:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/8\">",
"      Rosenbaum JT. Acute anterior uveitis and spondyloarthropathies. Rheum Dis Clin North Am 1992; 18:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/9\">",
"      Mu&ntilde;oz-Fern&aacute;ndez S, de Miguel E, Cobo-Ib&aacute;&ntilde;ez T, et al. Enthesis inflammation in recurrent acute anterior uveitis without spondylarthritis. Arthritis Rheum 2009; 60:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/10\">",
"      Lambert JR, Wright V. Eye inflammation in psoriatic arthritis. Ann Rheum Dis 1976; 35:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/11\">",
"      Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol 1997; 115:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/12\">",
"      Paiva ES, Macaluso DC, Edwards A, Rosenbaum JT. Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis 2000; 59:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/13\">",
"      Rosenbaum JT. Uveitis. An internist's view. Arch Intern Med 1989; 149:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/14\">",
"      Henderly DE, Genstler AJ, Smith RE, Rao NA. Changing patterns of uveitis. Am J Ophthalmol 1987; 103:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/15\">",
"      Rothova A, Buitenhuis HJ, Meenken C, et al. Uveitis and systemic disease. Br J Ophthalmol 1992; 76:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/16\">",
"      Obenauf CD, Shaw HE, Sydnor CF, Klintworth GK. Sarcoidosis and its ophthalmic manifestations. Am J Ophthalmol 1978; 86:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/17\">",
"      James DG. Ocular sarcoidosis. Ann N Y Acad Sci 1986; 465:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/18\">",
"      Karma A, Huhti E, Poukkula A. Course and outcome of ocular sarcoidosis. Am J Ophthalmol 1988; 106:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/19\">",
"      Criteria for diagnosis of Beh&ccedil;et's disease. International Study Group for Beh&ccedil;et's Disease. Lancet 1990; 335:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/20\">",
"      Mamo JG. The rate of visual loss in Beh&ccedil;et's disease. Arch Ophthalmol 1970; 84:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/21\">",
"      Rosenbaum JT, Bennett RM. Chronic anterior and posterior uveitis and primary Sj&ouml;gren's syndrome. Am J Ophthalmol 1987; 104:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/22\">",
"      Gold DH, Morris DA, Henkind P. Ocular findings in systemic lupus erythematosus. Br J Ophthalmol 1972; 56:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/23\">",
"      Stafford-Brady FJ, Urowitz MB, Gladman DD, Easterbrook M. Lupus retinopathy. Patterns, associations, and prognosis. Arthritis Rheum 1988; 31:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/24\">",
"      Rosenbaum JT, Roman-Goldstein S, Lindquist GR, Rosenbaum RB. Uveitis and central nervous system vasculitis. J Rheumatol 1998; 25:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/25\">",
"      Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome. Arch Ophthalmol 1991; 109:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/26\">",
"      Zhang XY, Wang XM, Hu TS. Profiling human leukocyte antigens in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 1992; 113:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/27\">",
"      Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology 1993; 100:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/28\">",
"      Zein G, Berta A, Foster CS. Multiple sclerosis-associated uveitis. Ocul Immunol Inflamm 2004; 12:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/29\">",
"      Leopold IH. The incidence of uveitis in multiple sclerosis. Am J Ophthalmol 1966; 62:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/30\">",
"      Prieto JF, Dios E, Gutierrez JM, et al. Pars planitis: epidemiology, treatment, and association with multiple sclerosis. Ocul Immunol Inflamm 2001; 9:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/31\">",
"      Lubin JR, Albert DM, Weinstein M. Sixty-five years of sympathetic ophthalmia. A clinicopathologic review of 105 cases (1913--1978). Ophthalmology 1980; 87:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/32\">",
"      Priem HA, Oosterhuis JA. Birdshot chorioretinopathy: clinical characteristics and evolution. Br J Ophthalmol 1988; 72:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/33\">",
"      LeHoang P, Ozdemir N, Benhamou A, et al. HLA-A29.2 subtype associated with birdshot retinochoroidopathy. Am J Ophthalmol 1992; 113:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/34\">",
"      Shafran SD, Desch&ecirc;nes J, Miller M, et al. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC Study Group of the Canadian HIV Trials Network. N Engl J Med 1994; 330:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/35\">",
"      Ambati J, Wynne KB, Angerame MC, Robinson MR. Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis. Br J Ophthalmol 1999; 83:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/36\">",
"      Bainbridge JW, Raina J, Shah SM, et al. Ocular complications of intravenous cidofovir for cytomegalovirus retinitis in patients with AIDS. Eye (Lond) 1999; 13 ( Pt 3a):353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/37\">",
"      Wefers Bettink-Remeijer M, Brouwers K, van Langenhove L, et al. Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin. Eye (Lond) 2009; 23:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/38\">",
"      Malinowski SM, Pulido JS, Goeken NE, et al. The association of HLA-B8, B51, DR2, and multiple sclerosis in pars planitis. Ophthalmology 1993; 100:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/39\">",
"      DARRELL RW, WAGENER HP, KURLAND LT. Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol 1962; 68:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/40\">",
"      Rosenbaum JT, Wernick R. The utility of routine screening of patients with uveitis for systemic lupus erythematosus or tuberculosis. A Bayesian analysis. Arch Ophthalmol 1990; 108:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/41\">",
"      Rosenbaum JT, Rahn DW. Prevalence of Lyme disease among patients with uveitis. Am J Ophthalmol 1991; 112:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/42\">",
"      Kaiser PK, Lowder CY, Sullivan P, et al. Chest computerized tomography in the evaluation of uveitis in elderly women. Am J Ophthalmol 2002; 133:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/16/23817/abstract/43\">",
"      Harper TW, Miller D, Schiffman JC, Davis JL. Polymerase chain reaction analysis of aqueous and vitreous specimens in the diagnosis of posterior segment infectious uveitis. Am J Ophthalmol 2009; 147:140.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5581 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9089A68DA0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_16_23817=[""].join("\n");
var outline_f23_16_23817=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infectious causes of uveitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Systemic inflammatory diseases associated with uveitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Uveitis syndromes restricted to the eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other causes of uveitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Masquerade syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Red eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5581\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5581|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/35/42549\" title=\"figure 1\">",
"      Eye anatomy in cross section",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5581|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/49/19231\" title=\"picture 1\">",
"      Keratic precipitates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/55/15231\" title=\"picture 2\">",
"      CMV retinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/40/21120\" title=\"picture 3\">",
"      Toxoplasma chorioretinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/27/1471\" title=\"picture 4\">",
"      Syphilitic uveitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/62/32736\" title=\"picture 5\">",
"      Cat scratch macular star",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/3/24639\" title=\"picture 6\">",
"      Retinal vasculitis sarcoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/58/943\" title=\"picture 7\">",
"      Behcet disease uveitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/4/42049\" title=\"picture 8\">",
"      Posterior synechiae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/42/13999\" title=\"picture 9\">",
"      Cotton wool spots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/30/36335\" title=\"picture 10\">",
"      Birdshot choroidopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/11/14527\" title=\"picture 11\">",
"      Pars planitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/56/5007\" title=\"picture 12\">",
"      Lymphomatous uveitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5581|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/40/5773\" title=\"table 1A\">",
"      Infectious causes of uveitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/41/15003\" title=\"table 1B\">",
"      Uveitis with eye disease alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/54/30571\" title=\"table 1C\">",
"      Uveitis with systemic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/27/1467\" title=\"table 1D\">",
"      Masquerade syndromes uveitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22264?source=related_link\">",
"      Clinical manifestations and diagnosis of West Nile virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=related_link\">",
"      Clinical manifestations and diagnosis of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=related_link\">",
"      Clinical manifestations of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/63/26616?source=related_link\">",
"      Clinical manifestations of relapsing polychondritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=related_link\">",
"      Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=related_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=related_link\">",
"      Evaluation of the red eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23289?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=related_link\">",
"      Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of late syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/3/20529?source=related_link\">",
"      Patient information: Chorioretinitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/13/26833?source=related_link\">",
"      Patient information: Uveitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=related_link\">",
"      Pauciarticular onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=related_link\">",
"      Primary angiitis of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=related_link\">",
"      Toxoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=related_link\">",
"      Toxoplasmosis in immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5767?source=related_link\">",
"      Tuberculosis and the eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20486?source=related_link\">",
"      Tubulointerstitial nephritis and uveitis (TINU syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10407?source=related_link\">",
"      Uveitis: Treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_16_23818="AITL CD21";
var content_f23_16_23818=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F86425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F86425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Angioimmunoblastic T cell lymphoma dendritic meshwork",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAkADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0Sw+FuiaA+qXSXspkvEaNPM6RZ/nXJWvgs200/wBv1LyrVOY5IHPOOSSDU/gttQ8S6hqATUZ3FvG+4yksGJ4BC9OKuQg2ejDTlki1ZokZZXj5wT/DjtXSuaLcXK7vqZdL2LHg/XLyLxS0MNwLnTWj4LuOVHQj3ro/id4su9D0m0OlGFZblmzNINyxgDOPqa5Lwp4Qsr1re4aSawgtl3FPulQOcZ7V0WnX3he4tNTu9PvI9Rt4cfaIJwWC9gQD0+tZy5facyV7D6WbJfDfiGLxX4Rg1C6tD9qgfy5EYYBbuV9RWRqXifxDPrENrYWyJaEFQUTcxPYGult4UmeC8t4o7ewjT93Eg2qvqSB3rI8L+KWuvFElnZ6Sy2+7/XsM59we1THROVlp+BT1djS8TXsun+ErqXWIJDGsYDiLJYn2rE8DeKNP0vwPdaqdOvLe3iY7hMCzH3A7is7wbf8Aixvibe2XiKK4k05xIzxSpmJFH3Sp6elekymGVCjRIFJxsxkAUptQ/dvXrowWvvGd4d1e38Q2MepKjr9oU+XHKuCq/T3rJub3z7mXRnsTbwudimIbcjv0rn/HNlqw1+21m31B7TTrRAFtoRjzGB6H2rZ0DxxbQNbHxFAYryVDICseQgzxz6Yo5GlzR1/r9B3WzOh0bRtO8PBCttGjYwXJ6/X3roJNQXbtjQvIfTt715N49h1rxpriR6WTbaZDDkSsSu5z0I9afcPqXhfQYzqd9JezbQiFBhif61PslJq8vefQfM0bGm+B7vRNb1bWYtUaeS7BZYmGVjJ55HeqelHxFr+pmzme1t7CIAz+RGIwxPqOp/lVKy14aX4XbVbq8vXu5t2IjJuQduBW1oU+iaToMOqztcR3V5y0TSfvJPw9KitGo/NvqXTaWhh/EnwT4h1rWbaz0ycR6IYhvm8zaoPuOpPtWv4e04eCZ7C1aWOaFeZ3mOGLHgMB247VuN4qY2U93Pp8trY2wDRrL/rJGzjdjsv86yfEq/23oP8AblhbNNqkY2ooOVBz95h3IFEXKpFRk/d2+Yrcj8zvLyztdQtJbZoA1tdJiTHfPevDPG/g2DSdZtdP0Fp9T1C+fcttOoMcYH8bt2AHatzSfEeteH9A1Oe9knuneVYrNZhjnHJH+yKvxaTf+IPAt+z3qwX91KHMpyu9QeVz1ANTGXspcl9GVZuPMUvFK67pGkaFp/h6a3N0xxezWQUZYdFX0Fb2haxf6XpE114mhDtEwVHKYZxjk4Feaaop8MeGrm8OpPd3MEqxm2sZeYQehY+nvV7wTNp+v6bqF8b+8+3lQJLW4cttHGSD0NbyppU9NvQiLvLU63xp4s03xBZRaek6Wylg8kroSI/Q/SuU0Gexs49Xs9AgutfvLqAwSXdqvlLGuPuxg/mTXqGheA7DToGlu5FuI3XfIHTjpWVdXllBayL4LhhF7CS0hK8RpnGeO/tXJKrJR5YbG0Yxbu9zwLwnd6vJ4kTQbJmggBx5Ny+7YwPJY9zXZvY2mn+P2ube6g1vWLVWdrPytkTlRkqrHgsMZxSadp+m2/idrTUY2Gs3O6ZdSHyhJCcggensa57SoLCfUIf7Lubq6aGZ5JYSnyu+Tu2N1K9auC5rt320HJ2slsegx+P/ABP4lXTb3RbBUsZZvJVI485YEbi/p9K9m1DVIdJ0+S81l4ra2gjDPPI2F3Y5GK574a3mmS6TFFpWmHT1fdJJEB91+M5rpta0ew1rT2stYtkubQsGMb9MjoalvXlkrWMm+qPL9G12y8TT6nqOgNcXTeZ5R3JtVh7D0rYFjNpFnC+n2sUVzNKrTNt5K56fSuT+Mfih/CVzZeHfCtvHp/mxiWWSCMAknIVRj6ZJrofCOs3sfw/XU/GjNEY5fLSeb5DIpwAce54HrXROMuVT6PZbsSa2OzvdZt7tJYvIuZICmDJHGSd3sPT3rynx9bazY6taXugW09xEqbVVRtbfnuK9S0rU4bq3VbMkKBgtjBrBv76402W8F7btdZx9nVD98nt7VnSk4vRDkk0cz41v9eHhjSZJg9nqVzGRcWykFhj0PbNZmhWd7p2halrupoL65t4D9msJn5kP+fzrbt1n1C9SW+aaLaGUWp/1gx02+oPrWrDJomnwRyaoxgnj+aQsCVUE8fWlKMlsrlKatYl+HWsQXfgU+I9c0SHS5wT5sajPyjgNg8gVn6wvhfWdBu5vD08TX08Mhhto2wWPQ/LXfQ6ZpzaTcR7d1neJ84/vAjtXmmnfDf8AsDxDJrTXSXFpbANBCud7dsN2A55qYxpTu5Kz6f5E80k9GZfhCCz8Km3VYPMmjVdzHovqBXqqeL9Pe1MkPmTTBd3kxjLE+leaazqHhBNYA1S8uYZpCDtVfkGfWvS9D0LTdIjhnBTL8oW756VpUjGKTad2HNfqcprCahq9wtx4jvbfRrRuIbV5gp545Pcmub8V+E5/DliyaNajUGv8o7s+AgI7ev1pPG/wnvvEHi+51G91aL+z5j5nzEl4wOm0e35Vt6hqmj21pb3GqyzGC0Ait0fIMu0YzitItaODv5WJ9Svo3gnUbfSobVpYpLdYsNhvuk8nn1966XTvCDwxq8skESquIg3OD2JPeotL11tf8LahNpqkW6jAOMH3A9a434v6tqes2Ol2vhiS4Lx4MqKpD547VPv1Hyydu47qOqN/S4dctPFHl38V0tvbYaS5Zw0UqeoHbFel3UKXVo8TKssUq4Kt0YGszR7iW08MafJrI2XawL5qsctnHT61bs9Zs7mNSsoXPY9vasJtyf8AkNHO+HvDWi+EHu79Wunmnc/PctvMYP8ACvoKh+I8Gtapo1mmgtKIJJM3ZhbbIE6/L/gK39R1KBXjjlEZjmkCKX5APvWp5iQ4EjKCeMLRGclLmerE46WPBPGqXukeFIdXure6E8V2EtDdPukRO5P9BXp/g/UbOfwfDrc6Kkske6R2PVh6ZrX8WbZNLMT29tcI5xsnAIPuAeprzezhup717dIXmtLYkkLwEPpsHFdHMqsLS0Fs9CWDxxpul+L7C3i8OrHd6tIYluIhzj1NZni3xh4gtPFgsms45bPfiSIpncucZrQivtUnv7a6g0mBWgYiIyRgug9R6Gu9SBb68ia506FL3YGMrDJHvihyjSs2kws5dTD0k6Zo95Mk6CCOYl8MvGSOlc4dWg0LRNY8VWNq7MJTbwJJwrEdWPtXZ63pksETmVRdQODvfHzA+uK5oy6FP4avNI127SS3twZpPJP3B1wfpXPC85XetjVtJaGBo2q6n4/8O3NxcPDaS2qmSMqNsecdT71xGl+LdW8S6WNH1eNrqxE+0TxD5lKngkeldTqniLw/H8P2vdCecQTS/ZYoVQruxxg+tS/Bfw9caH4ilt9VtQlzPAZYGPQA+3rWkpuE20rLsEVGUdy3p+veHvBulQxMl3fSmTcpKbDu9BnoKkXQD8QNSj13R5HtkzslSYkMnqCO5rY0Xwy02vXkWtwR3FqrFwZBkqT6GvQtGsNN0W3FrYrHArHdt3ct71fOoax+J9TJ6+hLpdnFpelxW4YssK4LHjp1rldO8f6fqet3On26NuiVmjkbgS464rqdRlaM4IBjfgg9x6V534a+H9/p/jS41K4MC6YoYwhT8zBuxqYOLu5id9LFK9h1DxbBfRQJHa3DttR1zytYtj4lj+GcVvpNxY3V9NJLh2XoCT1ruPD6Jo2saje3M6tvJCQqc7VHr715476t4l1TW7+O7jRpDsjjQBigzgEGuiOt19kh/iWvFfivV5tbe3+zuLRioW3K/eB9Pet3x7Hq5+H9lD4fEkO8jz/IGWVfTjmu98K6KbTRbNb3bPcomDI4DNnHrXLaj4tg8IWay3qNIZJWGF/gGetZ+05pKMFt+JVtG2UfCuqa3ovgUHUUd7rDeQZgQSB3NX/BU914q05rnXLDy5ASqblwCPWugj1Ky8Q2dheQESR+ZnPbpVzxBeppdrEY9qmRggHaolJyk1JasaSSTTOJ8TSWtmIbAFC5kChQenNd7aJFBZRRRqCAgGFFeH/EPwxq6a5BqFqXd7iQbSpzivT9GvzYabEdUcRSqm1i570pwXKnF3YXd7Mx9R8NaXe+Iy88LrO2fnHas+/8GItteLqEaXMe0mNpOcD0HpXVHVLad0kgkVw3dTzXnel+P9Tl8YXGja7aKtlMSsKgc/iaPZznFwX3C5uV8x87arAtp4imtom227ORjJC1t+GbUSa9BFZX5heNwW3HAI71teN9OtovFbTw25EKS5IccYzWrq2maabMajZ2MsWBg3AUqCx7ClTqOPK3ubySkmuh2WmRa1qWrxSaFNGunQKRImOWIqIeLL+HxB9m1a1CRA53KmCAKpfDbxTJo8KxSwlkkbAxwR+NekR2o1vWZGu7GCOJU4bqzZ7H0rXmcLcyujFpNuxU8LeO7TWtTeyigkj2nCs38Vcl4y1a+sdflzY74M4DFC1dZb2vhvw7qYQbYbljwN1aHiDVYEliikETJIufmI6VMrcylGJMb6q5k/CPSNTg0vV7fXLZLaS4JQOBtkkBGDVzw/4K0b4fWN7PE08k1437yWdsgDqB7fWvL7fxN4o1z4o6dA0vkeXceWypkKYx1OK9z1LVbXUZ5tLnh32kqGMygZya0rRcJ8sno9X/AF1FHVXXoeWS6pPoovtX1zUI71Lota2Gn2jfu2B+87e4FS/BK2t7y41aGDT2iRwHa4OdrnPC8+npXRaJ4SsvD8N/NqscE+jRZnEk6Z2Y7j0zXReHrU61HDf6brUUmj5O2K2iCfgfpRVqpxaj33/y6bf5hFWYakJrK0nSHN2sYDGILgZ/CsPT9dOh7ora1tnSUmTfGTjPoc9K9LitljUJGFEffjrXnnxP8KapPpG7wt5X9oSTAsG4AXuQKilKMvdnsU01qiH4gaxqMvhWGe0votOLsrTSzHCqD2BqG+1/T9Ms7C3vtWhSW5gDLOgLBs/xnHQVuDwY2veDbTSPFQF0VUGVoztO4dCK5rxl4J0ieKCzj8yz/s62O1IcM08a8hSDTpyhK0fX/gA7q4+fQNcbxXHqF1q0Fx4aEQIgTkvx6frmrniu+8MIsUWphYHCiOF1Gcj0OK4zSdd13fo+n6JFG9jtRY1P7wqmed/oa9D8f6Wl/p9jHa2sLaqsiNHGEH3h1z6ClVcoSXMyoWaOfs9e06GK2UalHtLmNVLYYegA9a1/7Ht720iXVLqT7FCxPmucPJnsK4nWvDGuaNrVveahKlzPLukjEaArE3YbsdhXoPw/0qf+znv9emabnIEnRfepqTsuaL9BpJs53xXHo1vdW0srxW1oqBba3k4ZgPReuPU1N4YENt41I1GBdTuHtlksWthviiHcHPQ+hNcN8QZfDuteO5NQlvLyNYMIyRgEEL/dPavV/hZaiPw7JdFo45p2KqVIYooPAPvUV/dhGKe/3FQ6tkvirXIdGMR8TQrJb3Z2J5S58sdwT6d6s6DrHhzTfD013obiWyVst5R3HcexFHjSLRdS0U2Or38SNkAS5GQ30rziDSLHwrfZgu5ZIJCCik8Stj72PQVLcPZ63uEYtvyNPxdf6hdhL47IVZdyp2VfTn1qK21RNR0m3Gq37w2rx4aOD5STTb/SNU8ciNY7XybKIgK27G/HqK7Pw98O9OtNNij1FWnuV5J3cL7ColOPKktWWtG7nimtWtp4ctVsvB7pIt7N5mo3V+wJKA5CFfT6c5r1Hwhqnhu/N3F4d0Q291JGI5ZWj2gZ46Z4q/4qs/CHhnT5Ir5YYWugYmc4LAnkNzXlo1BvDbzTWl+txeEI8Mi52mPdu+f1Y9MVp71SDctH+ZKsnpsdj8SvFmt+G9WsNC0qKaW2IQz3DjqCei+1c74Z1iDwp4k1aKdpitwPMZHX5Ub0B7jJrsfDesnxlpF5Nq5aB4I/MCFBs8v+8p6/nWBZ+E7TUJBe3V59ninYiNmGZZUz29B71cXGMeSUf67is273ORuNB1rxt4gmhtJTDaSP+8uNuDEnoPQmvSpPCnhuxsrHT4bmayNpGI5FjT55h3IPXJ5pLjxHZ+HYlttPgWS3Q4dlOFz23HvTPE2sXyWNtrUNukAdAEMi7vm7g/0rGNKrdS27Gk5xloOfxJb6eNsCS6bplqNiyou4uVGcZ7n1JrS+GnjO68YaTql1dK0Mds4VWznIIyPxrzCS61TVdMktLhi1sH8ySIYCjJ9OrMc4wK7Pwnr2kWtnb6BK8WmFpNhjgQsPN/229a2lh7Q2vIy57y00R1OqxeGNW1DS5NcQPrFl88KjhmA5GR3FZHxUs4PGOjaZatqUWnwW14ty6sN3monbA7jsKz/ENjcWvxBtyUSRHdCZQDkLj7vpiuzn0i1vBMEaJjKdqhcAn1x/9asJScHFwf8AwC4xTvzGH4Q8Xxa1cXdlpGmyBLYYRiMBh059KuSX5udTbTrqdI5ichNnAH1rk5PFNnBH4h0Dw5ZSx6nZFDPt/dtKufm2tTrS0u9Z+G80uovNbiORw9wT+88sngbu+OlaukormloJSu7I7G8GkeGbQ6jrWprHbyAojKctJ7DHoKu6Tp+h65okMukiO8tWfg3GTj2OefwrgNG8IaZ4u8GQ6Nc3V1BPpjs1vcyHOVb27ivTPh9odt4f8NxWNrOLraxLzgYDt049hjFTJQUbJu5Lcr67HO6x4vvrfx9ZeD9O0m4mjMIknvh8qQKRww7ECtzT7+x1a0ul8PatBf3dsfLl2nPPof8AGuhurfzmI4KspRxjqpGOv41yngnwBp/hLUL2402WY/aQFYMeijoKLxta1n+fqL3rnE60Q1+TJp1mkqSiIbrcSuzdSSD29K7iJtT1vwbI09o0GqxhlgDjZk9A2O1at+IYNRjeOCKS5xhSVGR+NZt7Yv4e/tbxDLqGoXbyqGFpI+YojwAFGOKrn5tEtQascu2h67Z/D+5tLrXFsNYuZQsNxM2WC55Td2zWhY+E9H1bRNM07U9T+339omJpkPMjd+awtD8TXHj3UZtOg/czxA7vNG4IvqMd6PFOg6v4csI5LfWIRcK2Izny/l9MVpablyydnuGiWh6tpelWWnadHZWNskNpGOEAqO5gt7QyXawRo+Pvqo3H2rE+Hup6hceGBJrWDcRg/vMgb1Hc1DLr1je6pYNbavBcPu3fZ4G3Ljpn/wDXXPOLTa3sVE0LvS7nV0BmAiicZ5PzD8Ks6f4etoNrS/vZB7YFeY/EyLx1qfi4J4b1NrfSEVOYnCrH3Yueua1fF2oa/f6fp8fhO/luhHHtlktMbpJBxyewrVQvb3t/wJu9dCr8VtD1JHae1u5TaTDasajlHql4SuPELeNobK9t5xb20RA3tnzOOOf61qeJdb1LwT4I0Z/EaNq9+8n70t0U9eT7V2PhfxHaa7pllqdtasFnGzftGUPpmlGMqact09BufMkux5V8Wtct7vVbB9Rsru3n0+cNBCHPzN7gcH616f8ADi/0280YnTmUyli83dix9aXxd4e0vX1b7czRSJgrMnUVzGh2un+EtTW10KB5JJ2CzTvyG9gKXNGUEnuvuHrfTYu+JviZ4a8MzSoha9uRLsaO2XO098npxVPXfHlro+oW2qwpLd/boE2Qg7RGnUsfeuc1PwLpR1q8u7WzubsTykiJ3Aj39wMckVFrE2g6ZZxaZ49QNJMxe28glWx3jx/d9KpOleKSbFyys9Ts/HPitJPCWn31gT9nupQZRn5gg5ZRWH4P0fwzqGp3t1p8rXlvdRk3Ak4RQeqmudt72XxSsOmWVg6WTofs9rFwyRj1Y8ZPerOn2drYaBq/htblINQkQyeSzguAvPOKuMUrq9r/AJA9kdpfeGdG1Wy0Sy0u3hsrSyufOEaL8rAc/jmtjS7631DxvcoqYksrcRx4HQHkmvL/AAlc3174Bure1uGtns5c28247jgZIOe2ax/BOu+Ibzw9fXOjRTXmtXs5S6ul+8uDgKv90AVE6fv8l9gjbl5j31tJitpZbhpnYSMMg15R8TfCXif/AISaPV9CmuLmKRgAsTf6sfT0q14nv/FGi/D23bVbh4bky7d5ILhe24113wf1e/1vwilzqRLyB2QSEY3gVrFSpr2kXe2hno/dZshJbnQrESyEXEYXzGHPzY5FaF27fZFiJbJTLOOg+tTXQjhtyMJGnPfHNYetxzanpFxb6feRsdm1hGwz7/SsL3ZfQ4+SJ5EvDbnzYckbievrSeErbTtHUR7Vj87LMzcn6Z7CrXh7wxqNlIlvFM/2aQ7me4Ic579Kn8deDZbjT4W064xNGxJV227/AKV0ucU+W+jIs7HeaXcLc2EUqMNpHUVwviLwND4qtXSeX7Oyylo2AzkZ7iqdu2p3V5oWnadqawfYl330C8mQY4FdZc63pulWL380u6NW8skHoe4rFxcZXjuNO61IvDPha38NaLFYQyvOQ27ewxz9K4v4s3Gppp0cukh55o32FVXdtNdpq+vRS6L/AGhYSB1TDJzwSfWsbwbqLGyu/NuI/tDSGTax5I9hTjz3c3ug02RyXw98Yak9pdxeJ7dhJaxmUMI+do+tTy6laeIZluxdJHZMcAsc4rrbW5XxRHe2QthDFIpjkk24JH1rP0/wHp8EUukxLsgiOV/xq5TjzXkrPyEr20ZaudDWKzg/sYbwwyX9a5/x9BcQeFTf6TbwtrMTANN5e51HfFel6bZLp1rHbxklI12jPWuY1uOexuXvLNv3LHEiEZGPWslO8h20PD/G+oTP4X0nUHhX7QWDTAx4L/Wur06+k8ceGodOt4ktpYwNuRxipNc0a4v9S3XeJ4Jc7FOAoPtXM6fHfaJ4hvBBO0LRjGAcjFbSa1svP0HFXSVxNQsI9OWLTQT9vik4bH3j612vh3Ub2FkF/MhcADCVw89pqdzfvfX9yrQTHER6FTXQ+DdO1GzuHjuSJoHPDHkmkm3D3nqDSvoi/wCJfDNvqFybyW6MaMd5UqS34Vy2tWdzqMwltbowiMbNsg5wPSt/xbrd5p10LaOJ2AHGeQK5+3M1++THO0hPI6KPwrSnTdk29CHJLoeq6VY3Mvh7VL68sLePXpEdIm4Vz269qofDSyvtPtry61NGggVswxytuJP8XuBXVpCbKKRixgiUFiX5wPrXN2mt6LqFrdzW12LmWJWfyQ2GYjtisE5Ti423Y9E7nYeIbSPX/Dd9psp8j7XCVV2GV9qy/BWh23grwrDpf2tHmBMkjg8Mx9Paub+H/j698Tax/Zq6WYrEI26Q5ymO5z2PSqHjdINE1pItUuYUS+jbyVdiNnbn0pxpSv7KT21sK6+JHYa/8QbHRwiCCa6mYdY8FR9a3/D+oQalapdmQNIw4yMbR9K8MhjOlXFm+oSwyRIoKKuCXBPUn6Vt+MPEGsWGsRvplo39leUrQG1GSW77varlQT92P3j5ras9smmjhieWVwsagkk+leS+JILbxX4qsdT0rUp4ZLBtsix8Bh/te1dPpesjW9Dkiv4JI52TAQdSSOtHhnw/p2n2csty4TBy5Ztufc1jF+zT77FWucxqV74xtvEs9t4f0SwOmsg2XAGGZscse2fauf1PW7jw/wCJ4tT1XxDCqabEJL7ToE3zu7HGD2xyPpXa+IfGKPpzw+Gbi2mmRwjGI7iv4DpXmesrq9vrcQh0S3n/ALWQDUb6ZN5256f7OMA+9dEVeL50loR10Oh8T6lrfirWtF1nQ9Shi8Mvb+Y1vIQJGbnKFeufSvVPDFzDqOgRwyoygrsaOQbTXG6DdWtnpa2en2ETzJ8rz7eKztG8LXr+O5vEg1K+eNCfs9nJIdikjB9iPSuN/vPeellob25fdRd8VfD7QLiRhb4hnzxh+Aff8a5Xw0NY8C+GNbikj+13Bcyxw+Z8z+p+ldS3gvUT4jjv5LqQW28ylAC2T6fStHWLa2DXOpaZZzPqBURzXLodqL3wD1P0q7wTstRatanHeFdbM2kM+raNbjW52MgWMb9q9iQehqh4p1y4s7COTToBqF3LJ5e6UDbAO+R6e1eiaPY+HbPRBdNOlsbvKedO2Hc9+tV7n4V6FPoVz5WZpp18wSyNuGfapbUZ83KVe6tc5n4h6jrM2haHbaPcm3gngDTfZs5aU9jt/lXrelTvY6Pp0WoOTdi3QSDqdwHJNeP+DPCN5Zas8em3V1Ha428k4VvbPpXqOm2OmW9ybO7vhd6htDyI8uT7EiplUUkoRWiE4qLvfc801DwDqnjLxNcPfSJFoQnMu+UbpHXsFH9a7DXPBGj2el28EFvbm2ZwtyJyTJKuMDYf7wrrx5g1FliIwqfxdAPYV518S9c1y2a6t9EsZri9CZhkCEkepUVcXKrO7f8AkS9FYyhrGiaJdzaImnGx0+YbZpJifMkA7f7vtXQ6tAJ7XzEkjihuUVcqCrpGOQEx0rhPDGoXfiS5i8J+NbaUarNbmVLl1AkiYjKgn6dqq+DNN8SaW99Hq2pw3EiFktYV/eAEHALN0A9q1qLlfu7/AJhCzWp0fiWG20PRYryw0q51K8lYJFAAXweu5gOgq5p+s2HiKLT9O8U28lrfKV/doCVhlPAXI4rAu9S1wQKlpcsL9XAk86Taqr9AK1WtDqaE2ymHU4CJRJGxMbkfxAetW4+77z+ZPXQ6LTtB8O6RrVtdtMkhMjIjM4O1sdcevuak8PfC7SdNvJL65upr1Ml4UZQqx85z7t7mp7bwzpdhBZajqkSpePIpfe+Fkk7Eg8ZPpXbgLNGMfc9B0NcaqTV9XZmkknseU+N/Ec+keJoYFsPOedA0DPGSrjoVBHcYHHvXJa3o+r658QdN1KxmutNktZIyYskquPvbQOmenNfQkkAITaqlk+6SOn0rh/Gln4ha8tU8Pp5ayn99MMAgfU9q3pVUtErabkNX3NHT/DGmWviDUddtreM3t3hZDnOce1ZfxJQ/2HNDKhFtgOwQYBOeMDvzVibxBZaVL9kk1BPtaKo6E72I/wAaTU/FGl2N3aJrTDfOu7y8bjj1x2FYJS51bVmlkldnnMGr3um6C729nMOMDJz5xJ5QcVv6Z401TSLaKyljtISirItpnfJ5bc8EdcV6ReaZpviLSF8va1vIAySR8Y+leZNonhfwF4gutSu7m81XUpATDDt3C3j6E/r/APWrSCUm7rXoJz0S6Hp2n+I9Ou7UzQSu6gDcpU5B9M+tczrnxO0Pw74hXR9UknN7JhiI49yxbugJ9fasHUPiDeWXjPStE0rw59o0a+CYnQHdJu6svb5e+fSqXieHRPDeqTaz4qsobrVoXKWku4t5qfwtIg6sB+dVClZpTXokyHL+U2vFvjIrZtJ4XbzblJds4lTls966PwlrF5rOluuqxxB92wjaQHGOwNVvhnHpl/os17blZ5J5C0rSR4ZT2BFV9O1C+s/E2sPqth9l0W3wY7p/4/8A61ZyV04pWa+8pNINX0O40aG4n0C2srN5jkOrfvGftk965b/hB9f8TIz69qO+ZeOT8uK6fVp9H8bXFm+n62qRWTCR9hxnJwP8K4r4l6X470XxNban4XvLu7s3IVI4zu2HurJ0x71rSTi+Xms/NEyd1sdtp+g3GkeHbzSLiO4mhuYzHutuSi4xx9aZ4dh8MeBNEQzqti8jECa92q8reg9q6zwlJqkvh+zOviNNV8v9+seMK3px3xXF+OfhfB4n1JLy71OSKFU2FMZAGc8elRGzbU5aeQN9lqSaRp6anqd1qt3BGsV5kpGr5DR44bjg1J4a8O2Xh29vdSgunWJBlzuwmPepI9Fh0/SF0ewllSCOPas7n5vyrT0fw3LZadLZzS/ao7lSJN4wMHsBSaik7P8A4Yq76mpe22leLNCktrgJc2U4wcHkH1HoayAND8BaHb6ZGxjhcnYHOST3JNJ4T8OR+Fbu5/0g/ZpBlAx+VT/Ss/4nWmj3b6RLqVykbGfYgDZ3DHJ+lDcU7X0Ek2ynrfim2jvCvnRukg2pGD1J6VieEL/Vr7xvfaZqemzwxWUW+O46K31OPepdbufBui6yl6xF0wRYY7aLlA/Un2PTJrrtT8UoNKWYBIYpYVmVpDtCqf7xqPeau46PRGjstIv1LWnaFc2mrXWpxyrskU7bbHyjvkH1rzPxjc+DPE3iyCx8TW08F9bNtWWJxwD03V6Bput3lzYQzWc8F7aOxL3EByEHp+Fcx49+Eun+J3l1LS717K9ucNJkZV/8Kukoxl+8bIk3bQ6fwH4ZtvD13dTRXK3KTIohkUDGwf19ag1Lwx4esPE8uuNB5l5cgrKuc4U8EgVX8NaCfAvhqwtNQvnnPmMHlBO1CfuqPas3wXr9hc+Pr5Hm824x5alj09QBSWl+R3sP4rNlXxJfR2Wqw6Hovh520yVCz3CAqoyMlifbHOa4zQvEP/CPahca1pEaQWoAFzGp/dz4OCAOze9e9XCaddx6o935c1og2SjPyjAyQcV8w3pj1TxU39j2qWugG42mxkb5nUHG8DstXH3tbdBLs2fSEWs6P4h8Otc6pDH9hMYkljnGQvFT+GNf0K7sxHok8AtIjsVY/lC+2KyvFHgyHU/BUmmabM1q5RWVoz9/byB9K808Pabc2WqWunwwSQNK6xzSEbVGOp9z71dONOd1ezIldanqnjK8stR06e0t7yAzAHcRKBs+vvXBfDzwvextqmy9RGkheOI+aN0rHvgHgCuwv/AGjabbXd9pmnRzXxUufPYsrHqeK4v4Y3Fv4i1me8vbOPTZbN8bYMhXPv6GtKbXJLlZL3VyhD4h1X4XafHb6+XlnuLgGNS2/bH/ABNx/KrPi4eJPFPiHTtR0tJv7KZUaIqDtC9yfetX4n6TpPi/VIftF2wt7ZQWMKlj19q2NF8ZaFc2A8O+H7rfdQx+UBjlQOPzpQqSkvaJe9+gSil7vQxPDkF+nxAaeFHCHKyP/DjFc9q97baRD4ms9faSO2a6LwFec7vSuw+Inh/UtT0WystH1Qae0TB5nDbWI98fyrnVi0//AISaCPV3ivIX2xyCUZX2J96alez+Q7DdD8R6F4c8L6fb3U7TxXjFoSFJBJPel8IadeX/AMQ4pTuSyjzJhVwuD0FeoXHhXQtUWzFzY28tva8wRhcKv5VQ8RataeGJri6mUrGkYEcca/eJ7Ckq127LVicdLM3L28t9KlRIrXBkPVFxzXOa34t0/RtSL3coRpMYXuKk8CeMo/F1nds1q0EsGQVcZI4qhfeCrPxV5N5fSNGUc5C9SBWaioStUQ73V0dRDqbXtrE9quUlxhz6VW8VlV0C8t1IWeSIrGTx81cv4k1qXwte2lhYwmSEAAZ7CuY+LD395d6TPuuAm1XRIgcM5PeiNFSa10YnK3yOVmmudT8GvbavqDWE1rKUZwDk4+nNXNM0stFFexyveW8Kbi5B/eEDvWlrelXN+0SxpEpcr54YUt/40bTPEFj4e0uwiNoMJK57+uPatpc1T3Y7j0hqzP0zXLjWtOuE1a2jtEjY7XxtAWun8P3dtoGhf2nNeC4tycKQc1xmq2lxrsuoQWrLBErkIxOAatanpreG/h7bx6jdRTbZd5VDnaKmaioXWj0BXbS9SHxF4iu9YvrWfTJra3t1bMvmgbm56DNbel6490V+228VkQcDJHI9a8rXxFZ3UkUVtA4Bbq4BP4V2uoeBtc8RtbOIpILDYGBB5NPnULRe3cbhfXqfQuq2322BrYKSkgIfPp9a4/QfAOjaPqLX5uRiE7sMQNo/2jVHw345v5fFU2l6rGqK52xoq/Mnua50+E9b1rX9X067kvbfSboMrzN3AOQR2xQqfLeM5WWhne+qR6rp8uk22otb6bDbRRvH5rSxEYc/WuN+KuhWHie800x3QS9iymFG7ch5x7Vs+E9Cg03TINNtT5kMA8sSPyT2rFvZ38NeIfsoWS4R8yPNIMkD1z2FZ0uZSbjuW7aJ7E2mfDqyvth1Lc1tDgJEvykkdyf6Vsa1b2WgeFb/AFW3t5Z1tYyY7dXIDkcAH8ayx4l1S71qKfSlX+xmjaJgRgpJj7xrm/Buqa2keraT4vlaS0uiUhkTGQSe3+FUoS3m72tp5Cbvoj0P4bav/bfhm2u7mC1gvHG54YRjaM8ZHWrfinQLTU7GdrjO0ROAitt3HHTNeK6FrN34R8Zz2mnWsl2LmTbvlYIFz7dvXFeo6mRqEfnajqLNaRjc8KsFB+uKJ0eSd1sxqV0eb/B6y0m3S8xZz2N6zsCkkmWlAPb1AruHsUvrpJJlZIo2+VV4J9ya5HT/AA1Yw+Kj4kg1K7meNXEKSKAACMBVA6gD1rTg+INjBqEmnGJ5L9Yy7KQcL65PrTqpOTcSo3sju7G2hHyvGBEcAJ/jW2Z7O0g3lokjUDGcACvMIdUvL26uFt7hLZV24lm4Qk9h6VFewSauvnX97Gba2UgRITxID97d0K1k6a36DG/GvXdfik05NHhc6Uy75GyVWU+hYdMelbHww1DUZxfreB20kxI0AnzlXP3kGeSK3PD813c6WkVxDbXFqwGxnIdT74rz7xB8Q9R8PeNzYHTUaC3b95+6OdvYqRwMitYt1YezS2IaUXds6Pxd4Ov9f1GxP2eE6XEPnjY4K+4rduPEWm6bDFpVpLG00IES24cFyR0GOua2PC3iK21/Rl1K3WSGE5BWZdrKR1BrlPEGk+DPCuoS+LtSt915cTDad275z3UVldz9yW62SHtqUPC811aa7qF9r91dIpJCRn7sIPbA4H1rG1Oex0fWtQ1/Qnmv5Y0aZlALFh3UetdL4C8aJ45bWtPl0v7GkaHbIFJDKeOc96ii8H+S0SmaVULYLRNtJUdqmc505NS+ZpFRkrmL4F8beJ/EdreX40OUSM+yCPIUMuOpJ7A1f+J+u+LNK8H29/4Z00LqcTA3avGZXCd9mO2ajvPDGvL4hE+iTCKMLuV1cEjAxjB7V03hG117R9Ku18Wail1JIf3PI3DPXn09qVop+0TT8hSbfu/ieWaLc694l0a91fxdoH9lXewLa3EG6G4n4Pr26cmo7XTtbbQrPStI8prsnMkm7LIOwPqfeuvk0/V9Yurs6iSkW7bDskJIXPU//WrqfDXheOznR/OZnX5l3KFPPoOuKJNPW+vlsVFuK2M7wz4b+yaaYtfmgu7ubBfC42ge9UfGHivQvh/pqXTWcjrPIIkEY3M2Owq/8R7KS3tjM1/Fbqw/ik2see3esLwNr/h28H9l6jI9/NG5kBmi3qrDuuemKcKT5OZ3a6oUp3fmQfEA+IPEmt6E8MC2+h2TR32XHzTyYyq7euRXUfDfXdY1PU76DVIcWiIGR8Y2tn7p966y+itHjQyXJII3Lkj8657xCbrULCO10y+htLbLx3UuPmZCuMj0NEZ8y5GkS1bVHbphhkEGs/W1mntGt7Rtk8gx5g/gHr9a4DTtXj+HHw5M93fXXiBIpSIfKTD7ScY552juTXW+HteTW/DMWsWqm3+1R7oo7r5XDcgBvxqZQaWm17XBPUxbDwhpPhhGu3tpLu6kO+W5lfcxPbGelcf4o059fvxfAJbsvyfdyQo9fUVN4Y8K+Lp9eF1rt5cRwwsXnd5OLg5yNq+narlxYatrXighkEcKECNwT68qR6AVcafs5Nxl8yufmWqOk8G6MbfR4bddSuFjK5CqdvXrxXIfGTd4Yh0240zTorrduEk1whkyRjC56DPXNeoJDa6RYPLeSxxQINzSOcBR9a5PxZ4x0p7RYLK8t7hWI8xdu9sHoVHc1nSlapd6hJOSsjR0l9LvNI0rWVt/s16LffFAjEFGYDI21Q8Q/D238UWCHVZpUuy/mb1Odme34VyHgPwvrlp4km8RXTXl80pwkUp8tQnYAdiK9U1XWYI7RreV2sru4idYTMNo3YPQ9KTlGM/ckHK7WaIvCuhQeHtMNlYyByG3SO2Nzt6nHSs74nCW48Lyaatu1xJfnyFKnAjJP3ifavPfhNYeIZPGqXFxNP8A2TBC+4sSVlcnHXv617Lq9h/aEUcXmFEDZbA5I/pVzj7OV07krXR6Hnvgz4XpoFiIoL91SQh5WUAtJjpz2FdtBpNvHbCOKaWSXP8ArnclvetC1jRLVVWXeqDbuB6YrxXxnqfiXRfiWssSzyaazIlssakqwPXPbHXNTCnKtJuT18xudl5Hf+Itd0Xw3NHbXuuxWl8+NqPk8npuA6ZrXh1Mx2sQvZlkvHA2Kg+Rs9GB9K4/V/BN5q+sm7kuLdbC5Pmujwb5lcj+FjwMDOPSvR7S1htbWG3jjVYoUEaA9gBinKMElyvXqJSd9TBv2Gkyfb9TfzIxgu4wFQD+g9ag8V6w9x4Zln0O4R2lXKPGcnaR1rF+KV7Dp1xatcytNDKh8y1dhs8sfeOD1z6VZ8B2MdwkV1pctqvhnygbe2jBLh885J/hHTFVGHJFTByvoZfhbWLmLwjOniT7R5aknLDe5Tv+dcfol3pfiS91OBtGkW1hgkljRZCZMAE456E11erfFTSLbVpNLsNJN7CsnlTPuAyc4IUck10sfgfTrVJ59GRrO4uPnJ3EEZ5xVVEkm5x1ewQk07Jnzh4XutH1MTxHS9SS9D7oIEQyhst0J4wc9zXpUFrpevRPoms+IIYNUZfLFiB8iEfw7u5HtxU/iCz0vwP4gtby/wBTWO/mYTFRGWVu3zY+6M1M3g7QvF/iBrm0jksbuZVuZLiNwUfB/gHXnvSi9U5XS6WLk7r3de5mSz6f8NNEtdMmubpIbqRnlES5kkTodoPGPevUvCNlA/hQvZapc3dndR+ZBNIRvjUj19qh8d+DPD2v6bby6+siR2CfLKj7WC45BPfNcN4g1m11DS49O8NXhsdA0233zRx5WSRV7Dvipk1NdXLqTG/ojurJn8R+FbvTyrGUJ5Qml/iYdG+vFeHeN4brR9Zs7m7u7bRN4MEskIJllA+8VI6CvRPAfj3TLfw3cP5Lwx2uMhjncD0Oaz/izb2WveEbDXriOPH2hQJdwbyoz19gSfWoUZU5pT+ZpfRuJ0d5Zw23gFdP0RJ5ba5gPmyp88h3D/WH1PqK4/4ceEbfT9eh1TU9UtLlIY3MkryqSwIwF29VwOua5Lwl4x1DQPEwtNIlbUNLAUKgbzGyxxg4r2j/AIQu31DUp9Xv9OtUubqLy2iRypKnqSema2UnSbg3ozOUea0jSsfG2gyH7Ppl4l5Gg2gwDftx2NUP7Ka70rUNRtoidQlkYxknlB6AVm63o3hL4c6MNSWxkRS+0LGSzO5HBNYPwe1bVNU8U3ty135umSxmTYc/uz2Htx6Vcaaac4aJdyObo9zu/AMmtQ6d5WuhmnZjsQnLBfU1mX2gm48V4hBjVs+aqjaqqfTHUn1rI0LxyL3x1d6XYM7M5fy2bkMR/LNb91qGtKWktbSKW437ZRnBX3zUyjPmu9Lgmrdzd1DRrK2sBFAghGwpkdxjvXAeCvDWhWGsyXGjRSNdoX82Vs8nGcCpLX4gWd1qd/FrkwtbW1Hl78/xZ5Hvmlj8RRP4i0lNKKRWE7/KTjMg9TVRpyirdwvd+h5pomq6zbavrE1x5jieYpiXJUHP866LS9Av77VJre8URTsRJ83UjsRXQ/E+O8HiTR4bC2guIjumEMQABYdWY/41znjX4htttrvQlA1Oz+SaQrlQP7p9veo+sOT5reX/AATRU7Kx6v4ekbTLpLC5k3fuwQznnNGujRNcnFtczRzKD5bqp5B7V8vw6x4v8Ua42oNc3Qdm2h0+WFQO1er+A7K+tb/bqmSZwZfN3Ag7etaOlGMVKUtWQ072SN/X9VsfhxJBp+h6aXjuG3SuWJPPv3q3rHjGPwt4VfUJE3GRsxI3HWquleM9F8Q69/ZksCvcQsVRnGeRWn4s8Ew+L9MitGuhC1s55xn9KH7tlUXz8iF1sZ/gTxNB45sJri9s41uYiBkc4rr9buYrbT1igiWW5xiNAu4g+ormdM0Wy8E6YNO05mkuZTvZyMk++PSvNZvFuqv4l3w3UlsqzbfLYAmYZ7+gocFVm1DRBdxV2WvEsHiS2lne4tnTzlOPKbLe3FcoDfWWo2kV1bTXcs2A0ycbM9s969cvNag8R3bWVtFKHiXar9Ax7474qNrMqqwNCUKcDaOlZKUqTtPU10ktNDj7nSryeP7LBAEiPHyt1PvXL+I9CudJjNlqEkksMnJ5J/AV6r4WtZv7cm88740GcVT8ZTLrermwtyq+VwWYD5T6D1ohNprrcJLoeKaLBFZatbyTWQWJnCRK5569TXsd947vrHxPZ6THZKtoyhRITyeO1cxqfheD+1bRbt5Z5Ebeqwj73sT2roBbR3/iSyF3ZSQx26/KxHAx6mtoSgmoy1ImnJXR6SNE0uz1ibUWty17KNm7risLxHrmpWFnc21gsjFBhYtwDkexNUviv4x1HwPa2ElrElys0+2Ysudq4zxS3t7qXjzwZPe+E4rePUWKrBLPgjAPzDJ6GnTi1ac9n3Mm90uhi61pOr6/Y2hsdcvNKihG+dYxl2J7fUV1N8kknhyO3klNzceSFVpuC+B/EfWuj0ezurDQ7FNWSBryKMC4lhXAZ++PauI1DxBZax4huNEaC48+PJGBhSR6GlGpKfvdEXZbdzgtV1640FzDczyT3CupMUC5SJfQkcZPoKtap4fn8duus2GoXVvBBt8i3lUoEYdW/OvT9C0BBauGjiEjEEK6B/z96reOfEVl4f0m7s7M79SRQi5XaMn0xW0K7nJKmtRSiluzy+x0Gy0tLpXvnvNbYbjNIDhPcZ6n3rah037JoL29lfQtrkxGw3rkRjPY+h9M11HgLT4Lrw4mrXUQj1G5Vk82T59hHcE9queG/CyNJHbag0X2eOTzWjiJbznPOWY9B7ClLELW72/EOXsZPiDUPEfhfw94etbPR7XUtQmyl3Jb8Rqw6D8u/Stqx8JWM3iBtQCwG6MY81cZYZ68/Wus1rQbS7linkMimM7gqnj8q5XxFNrtlqqXWkPCmnJFsaMgZMnY+9cnKqlktH18zVSaLOq6Bp0cch1GVIwT9zOM46Zrirbw8+sW93YXMZk0NhsuIo5trSPngjHKir5s7WCSPUPHfiKO3u5lD+Rv+bGeOO1drZS6GuhLfaPOtxayHc00bbiwUEke3A6VvzOCsrvz6fIz0e5h+FNEuNN8iFIHtNNtYdsVsMnbz1z/AErrLaC/vEL3VvbJnhd6AvisbwT49tPFNx9ntLaSGMZKu5GGA9K7C9uUtIXmlPyqOB6n0rnqcylyyWpa20PDvjRr13ppTSNHW5e8nXDpCMbB6AD1rV8CeC9T1Hw1a6f4sMN7bpiYwXSktEx6AEc9K1Z/FuiaD4nl/teB5NTm2lpwg2R7vuoCe9Qap49vdM1xGexdbeaUL5ajcWB4BB6H1q6jk1GMdPPuOPVvU7ZtNm02BWgkt4beMBWihiCbh0GT1qrrL3qjbbkxgrnf2Pt7VR8f3uoappbaX4YJOqOA5OceUPc+tHh/+1NB8Fx2viSf+0NURWeUx84GflBP9ayULJNPXsPm1s0cn4gvJdHU6hq9y9vZx4RGjBDBj9O5ra8Ia34e1FUu4rv7Q4RmVZ5jJJIVGSdp9KyPBmm2l7qOsWupvNqiuDLcRyyeZDhjwB2yO2K5jTvCWj3PjSO60XT76Hy5gUVZ8LHz1x1x7V0ulBpp7onmkbKfGgx+G9b1lvD8qWlnOkNs2c+ZuJ+8egIx0FX/AA7qGq+JpRrV+y6YsaxzW8qAhZI256etehx6LY3OiS6dfWVpc2rkl0CLsc5z09c1ianFqjoljbwW8MS4RFcAKFAwFwOgrKVaCvyxsOMG92c/4n07QPE/ie1vb2zvJbyGIRBxJiMqT2X+9XUaX4J0vT2i+zW/lqD91R1+vtUFgtrZ+JLTSbkpHrMsDXCeSCVRFODnPetq/wDEFpp3iXSNAnWaS71KOR4pAOB5YBO4/jUuUpJKN7WCyiYuvwtBdIHkcRMdruucKPwqXwzb2TS3vmqpVmCQ5yd69yAff+VW/Hk7aXos1/F5m2AZYxjLKvc81jfC7xB4f12yvbrR7ppp4nWKZpgVIJGR19faplzcl7aDVjUudNewQr9phS1bJYyDiNT169qxdY1JNNsXuL7UbJLN5MRMRuZwOQFUVlfFbU5Jkls9PRp5FQtJtBbn+WPauD0O01m4ktLbUdEuLmVpQ0stwdqqn8lHsKxV56rc2SUVqd7p/jya/lnk0rTppHACteXXCH2UdABWtrWvf2JoLa5Le28ccWC/7skSuRwABzWV4r1TRNLsF0qSZYIoULyRxH5to749P51x+qfEfw/qHhiHTdO0q61Ga8bZ5My/LkHAPt+FaQg52fLp1E7L1O60DxBpWr6NHqXiK/W7s9RAnihk4RNvUBOuAfWrUHizwjJeW50/T9xi4SX7L5Srn0JArzXRVj0FLe/1xA07xYtLdYwyKTkKdvoD2qn4V8Q+LYZ7uxbOozFw8b3MeVtG7sDjoc/dp1KSfvL5Chroz2nQPiPoOu3c9rpL3N08L+U7RwMyq3pmsLX/AIk+F38TRaRd2r6hLbOxlcKClsQOSfU89qztPk1bS41SzjgIuC0k9xEgiXJ68Dqaw9MvvDEOuyNeQwW9wcyjz8J5zDuR1/OtYUr3vG69TN2XU9VtPFXh2a0HkSlIWGAohZDj6YqfwxqH24XcauWts/uG/wBj3968U1/TtR1nUpdVe3ksQxDQThy0QA6DA+lb1rq+seDcatr01o9vPGF2W8TANnp8o+6f503hkkuV6iUt0z1zRtOOnrMjNvVjkZOa0JURgN6BsdMjOK88HxR0yyuILbUIJ0kmQOGB456Dmszwvr3jDXPGckrweVois2BtwoX3Pc1Hs2782nqD0PRdf1RNI017plDsowsZbG4/Wm6BrI1bS4b3yJIFkz8j8FceteJeNviC2txa/wCHbyEwLKDHYTKMHdnAzVz4X/FN4dOtPDWs2sk2u2/+iqqLgPjoSemPeonTnDcuKUo6bnqvjPw1pXiXS2j1W2aURKXjaM4ccdAfQ+leaWWtXfh3SUie3+zWds5SKOI/MwPr6k96g8S+L/EthZ5W9W0cykxRrGGDMD9wHqR7Vi3msahqZLavbY1Jtri3liMTMCMfKOlEK1lyy2K9i90zr/Beq6FeXFzqWmaLCl2nzvLLjIP+yP61Xv8A4kavY64qPEjQsxyjcAD2xyTVRtU0fwp4de8u0KXMrAQwIcyFjwePSvLPEGoJrni+K/sIpxNAq+Usj7VXH8RUd+fpWkJxcndX7CdN2uexarfeEfHEkVzq962manCnlBm6Mh5xg8H+dX9J0G21O0sk8J3XkRWOYzczElpPoB/+qvKNO8GzX1gddZpEhtZFN7bl8+YrHGVz0IznFepax4cXwpBHeeGUuLaGNQ0ytKSrg/xHPpWNSUvhfQqMYXvHqXPEvw/1/U7NLax8X3CQlt0kdxCHDeuD1FcBLYXPhjxPc2Wuva3FoIgLjyTtPltjBAPcEZr2zw/rP2vwymoTMJSqksU74rgvGOj23iPSdQ8RxqkUgi2zROc+Yq9ADV0Wlq3oZycvhPNvGo0PT47XStFe8j064n8y/up1+ZgOQqgfwjOTXb/DPwtomn+ELu5v9TbUtKumDiFifLAHT5T0Ncxf+HNM07whpk3i25umlvHDRtajf5anon6jml1nUtNudMi8N2DXVjZJJ5hKD55cdj6ZrohB1Ita6vX0FNpOy6Haan4V0uxtLrxD4Ss2gKKGRYVyrMeCwX1Aqj4Dk8Wv4j099QW4hsm3NKly5ZmTsT6GvSvArlfD1qBayQW+zKK/Jx7/AFoj8QaVqF5MfPUJakoQRgl//rVlGfs04pCacmmWde0uy160+y6nbRzW4O8K56e9R2NvY+H9PaPTtOEcGOsQyG+tYEMZ1jWZXj1gRQMNhgiPIFPv/FdvoeoQ6ZrE5J25VIIyzbOgd/QVmlJ+6imktTH0258I6J4qkl0LTprjWbrcCwBKoe4HYVk694s1rSPFJimsoRbSEF4zkO+7+6fatfXbufTvFenJoNqFt52DSSCPOQeep6VB8VfF+nWrG0t4IrnUgu0z7ciDI9fX2rpTScXa9zO17o5DxrovgnUdLkvLrWzp86SFzEvLSk/whepPauR8Kvfajc3MMOnT2ttbbRDJIp8xT2UZ7kc1k2ulXF9fpqCWoeO1OYmlJzLIT1NeuW/i6+i8MvcatbC2vIcxwN5fDORwfwp8zs7ar1K5UmM+GLtP461rT5zcSRtbKgeUYKAjkc9Ki1b4caf4QFxqWpXRudP+bbCoIZiegJrU+BDXOqXeq6vfu00zSeX5zLguQKu/tESofByWomZZJpAoUfzPsK5qknHRddPxKSTaOb1fWtP0PwEthYwq9xN87GPBWIHplvWr3wsZLq2KzOxEa7AW5IB6muc+GvhWKXQYrbX72GDSHl3xFvla4f0Gf4R61s69YXHgRNQm0bdLHMBtQclRjk1r7OEb2foJyb0Oi0/wZpmk65JqVtIjSglwiHJJ9Se1WI/ELQi6ispP9KXLSN1GaX4Y+ItJ1jw1NdxgLdAbZUk+8Hx0ripdNlj/ALWlvbiOw89DEJnOOc9BVpSbaqboz0+ybngrxRpseo30ut6jE11O+xFZ84X09qxNe0fRb3xE82g75pAd00ufkU56A1wE/hHTNOtvNju2ubg/NkNxH6sxrsvDWu6TZ6AJrQXF0Q22QKnQ1UoXd6fTcpaayO18P3GkaVqscr24t55RtJZs5Nd9PJaPD5h8tiR1FeQ6n4ctvE8dvqtndyW7Yz5bcc9hTtKt7+1j8ifUUlnZseXv+4tZ1IJq7eolvpsQeLvEz2uqtb6XiEnlpBWT4M1K98QarNFcWKwiEkrcxk5l+tXrzwrq9/4kdYJbRNKkj2mRsM7H6daNCmu9C8THSjAv2RFO1gMZIraEY8tlvYmTdyTw9rOsXPjGaxlsQLJMkOYzlT9a6vWr6PVIZ9OEoik6AKOSal07xAdQtZFmsGtpWbywwHzN7157qev6bpPiyRXW5Z7dvnJXCnPvUqPPJK1nYn4Vc9X8S6dZ+KbabT9RQNA3zLOvBjYdCPWquj3Fl4K8LTWukwveQWCl32nGeefxrrorFWsWjj/dsYTHGzcleMA/WvIfhvZ65Z61rWnTq7eTGd+8f6yTd1B75FRC04XeytoGzsjc+HXizVPGWua7PLEYtBjUJD5g27X9j396s+MftumRRzaPa27PLkPMiZJPbkVL4ks5/E/gTUNM05xZXaEYSMeXvI5KnHc1nfBLTdZtrHUYNQWZLIEfZxPywPetHyq9TTfYavt+Jp/De81LVrSY36bLuIbfOKbQ/t+Fbusaat9mTU9LtLmdeEYMeSOhrUvHv7fT7hbS2jabadjJjhuxIrjvhtP4uMuox+MmtZnRS9si/KzHn9Kxk73mtPIpdjUMT/ZlRVVpWARY0XbHAuOoHesx9SOjbpLk+U2RiHJbPq3tXHad8RvFU3ii3t7vThG73CwGz8nAKluoJ54FeteI/DOmawjG7Qq+0rlWK7h6GrkvZPlqfgCfMroydK8b2V8/2dnZJDzuZeCPrTNR1/SEUG6uVMfmLgjn5voOlZv/AAryylVobYTRxY2sXkI49ABWZe+El0C3jnF7bQxQOGy4wGYdAc9c1hNxb/dmsUvtFXxp8LrnxN4ik1SzvIHtroqWEpPyr7Cu28M+ELTw5on2KzkaSEFnmZ/42YYOB2FP0vXbvUtOSa2W2dD8rmCQE/8A1qyvEFxrcXhvUpoVk82FMxL94kZ5Ix1wO1X7SdS0ZSIcVHUoeE9L0Tw004tpJJrwltigcDnO1R61f0+w1/VtThvNVu7fT1ViYtPzvO3sW9/auR+GBlh1Oe9u/Mks5Iw6POp8xJM9OfxrvbTw/LeeIW1NrtXtidwA+9n0+lFZJyabHF2V0jivjzo+l6ZYQ69dJfs8kqR3Bt+UG0cOR2P060zxPrEMmn+G7Pw1Z/bbuVIjayuvI4+83pjrXqPinUNPtrFrbUlilScbfJkXcGH0rgfC5ub7xw4/s3y7SLfFlVwNhXA57cdqicnOml2Kp+67s1tFi0Hw9Yq+qeIUbUJmAmnWbG5z2HtXGeJ9f8U2nirUV01nVUm8qCNYfMSSAgYc+pPvW1rXwhS48QNc2mqR22nTJ5bW8ke9kGfm2Z7n17V1/jbWbXwjo0NythLdT/Lb28cS5ZmxgAnsOOta0+SDSh7zfczbctZaDLbWYdJ0LT21eJLS+nG6SK3iAwOm5gOlael6baieS6QhhIOMccGvI77W/EmpW1jrFpod1M9y4tZYY3CeWu75gc84HPNdFpeh6fH8Q59ZsrrVJJJoPIW1L/uITtAPHcDHHvSnTUU9dRp30PQYvsmkq8NnHt8xy5G7+I1xSa7r83xJn0xNHH9jQIrS6jK20EMM5Xscelbj6pYvrUGjoJLrUEGXMa5WP3Y9qxPHd9pN14f1TTNR8QLpDxLmRyxDRj+oPtUwi27Nb/1cb0Wh1ElvE+pJqul2sF3drEYPtHmcmPOSo7daztV037X4k0zxGtjdNqNlC8CxlsIqt1OPWuZ8E6poXhLSrLwvpWtRXmpSKLqJGYs0gfnj6jtWlqPi/U4tUe1JiR4gCyKpGSelT7GbbUX/AMMNNdUc98RJtUluFn1dZPKdStvYruKt67gvX8aq+DfBVpqEEM+oTz2gjfK2kLmNcn24z9TV1vGp1HxBHbajceRAzbBLAvAPYE+h9RUPhrxRqHiDxw2k6b4ali0+DIub66yGXH8Wen4Vq6Mow5Zeo/aa6Ha6r4bWJIV06BZbUA+ZCz4Zj2YHuR715b4j1C806WWznv47i5JKr5anbAvsO7fpXX+M/E8OjX62U80i72VGdR03dMVynxE0S80LTY7zTDE9zOwEEzn5lVuSQO9ZrmiklpcqPK3d6nA2sMd7rrqryySSDZK9xy8hz029hWzqNtceGFZYpI7NXBVlChmAPp6Z9qpaVfRRzyXlnBd3UkCrFJO0RyHJwCD35rtbjwl4iu7F9Vv7INGqCQh5QWbjuPT2rNQfNyzdjZ1ElzI4XTNR1We1tI3YzzxyeXFGQRtXPG4nrjrXtHh/T9TutONvbQB4nO6SckLubv7muHspvP0h5bezAubWJnZQuTKFPI9QRxXZ+B31HxJottPdX0+kxvkRWyRbX4PUk9v50588NWtiOaMtmWL3wwhCW+t3U1uu3fC0LEAH3IrmNUg8Lapr62s1nJLdgCL58Ey44ABPr612niDRNet4J5ZNWiu7NBvLSqVkjA9AOorh764uQm97O2V9xMdwzDD/AO0q5zx3relVvvcxlFGb4pNpfTW2k6xLNowi5h8tz5aL02t9Oma6W+0yH+xdOsV8y7jtxgTliwkB56egrntOvLR4LhdQSx1FyMmO4BLAeo4zip/Ffi+DTvC17ZaBFiRIiHkhJPlE9NhPFVKvHRLp9wKjLcj1jwPdeINLMNjdIt6swkBl+VYk7/Qe1bvgvx1H4O8OajYeI5kuJ9McRqLQFzLkZBH4dTXG2fhe6+Hvh1Nf1+6uNW1fUwq29s0jPFESM7pOfnIzwB3rs3awT4c2+oeLdLjhv71/JaONRBNLHk4ZR/Dxz9KipLntPeN/mEdE49Tk/G/iHQPENsl9oFsINcmm8s+aRsi43Fz6+wFYun+IIfCmos+n2Et3qImaOW8kH72SQgbvlPAX0FN8R6VoENyn2FZ47HyPMiSaQb2fON5YVf8AB2n3U+r2qaxJBcaipLxec5DEjoWPfIxyKFGNS7d3FFtuCS2Z0Ph++2eKbbXfElvnTW3i3g++YGP8ZX+vas34l+JbzxS8kehWlpGizhLS5uZwkzMv8SA/w9s969S0O6ltrktd6bp8ltJHsaS3O4/Tng1znxJ0rwp4oXyLbWbXSdYRNgSX5FK+47EdiKwo023746lRLWJ4zFDc3eunT9fkmtr8QtmY/OySY4JPQD6V0fw3tdPstafStemeTbEXWeVMb2PTnqQOtbXxE0y3s9D0fQnlN1f+SqJeIvzT47bvSuR1SbUpbfStPskkjFqpWW5mXBYA5b6AcCnFXVk+v9Mty1vJdDrL3xLo0FxdeGdO1Evpc0izX0/O9uclEz24GTVq48YapdsdGnv99ncK21xjCwgcAk8k1l6p4fW9tRf6jawXEaFQLqFghQ4HBA7fzrz/AMRfa5EddQtnt57gH7JOjg4QHg7eo49aPaOzTWoKnFu57P8ADnxjp3h2C70jxFItvawkIszNuR88gce1S6rZax4t8XGw0wLa+G1jBMoOI3QnORjqcV414N8Daz4m0e81aO5je007IdZDgzkdcehx61698Gte1DWb+60qZdlhpkaoojGQgHQE9yalqHKrPXqDupNnq2taPZzeHhaGJPJgQCI7QSuB1FeMeKDbaGFSxhEuoShnBfHyqBz16V0fxJ+I9/pfi2w8N6JBbHzlDPLMflKnrz0ArgNSurDxB4ymjuLx5bHyijS2gOA3YLnt2z3rZRkorszKFru/Q3tL8W+LL3TraHSZ4/Nu4hGJGH+qZuMgew6V6ZqGg/2N4HWOFDc31vGC7j70rnqSe9eSeA9ZudF0oNrfkabpdpOsRlmG6aQA5CoBzkivdtG8R6Rr+kPe2V2jWTZV3k+TH1z0qKl5rmSsg+B2ufO2meKP7J18XBCJ5chyN5PPo2K6rXby+17WYdTuNMlWMoo8iFwfOAORk+nrXIeJ/BnhXSdQuDN4jGq3c8h+zadp43TSsx4ViCQPc1pJq1z8PNSGneKzLFbXlsd0ka7vKyOETucdPc1vP3muSWpKas+ZG5rni/xRbwPcN/ZVyiod9pYspntkH97P8xXGaLDquuX1ne6pC9h4d8/zQGXcZBnks3em+EdCfxV4wjsvDMl1ZWEtuxub25t9jlCfmRV759TXtWr6LcWGjT6TbhRbQ2+23ll9cccVhNuHwMuLT+JHHeIPGOmz+K7a18H2drcvbpuL4Cxq3bjufSuY+IvjS58SHSdMFqLeeOQy3ESL1YdD9Paqb+EEhkZpPtlnq8qgGUf6vJ7EeldF8NPCtnb3GpS+JpmN1IPLQueUUdx9apKKik15j6tpnSfCrxRpuh+G7qHUZUtIYpC7TN/G55I+vtXnfi7xe+veJ57i9fZZSkRwRg/cj/vfU1rfEu68OQWtnp+jSLK0TeYx253k8DmuXlvNA0iwkN7ZG+1g8AxqWjxjoCKmfLJ83TsOCaV3ua0lk+uzw6do9xNNY6YwxIzE/KeTk/WvXNaazn0eygklaO52KqO4wZCB05rzj4Na5Lp2n3Ftd6DcmyuJPMe4iiJVB6H6VP8AFfxdo80ccGiTNcXSOCCFP7rHv61U5ymlBaonlipXY7U7g6FNLeQ24i8sZMUC8ufXHrVO88Yab4x0GNNS064truLJjU8lvc1xvh+bUfEHiS2+0Tyxo7YLs+MCvTrfwl5GpTXV3b+bahdoGfv/AErRRcdHv3JbW/Q5fwnHZa3YXUFnEzGD5XaQ4BNd5pC2Nlo6afpdraxlv9aVwSWrlzoC3Mc+n6I8NjbqS8yrJ8w9STTfDsWl6BqcUUGofbbpvlUSvtU59B3rqcVbT7jG7O3ldbOxkRiuU5baOlcfDpf9pX32y1kczMdobOABXYzWwS1nlnkAVlPy+lcJpml6vfz20ulThbeCchlzwRnvWSindhexoaubbw7eWcV49xc3Nw4BMb4CD1NdtqFq9xarcW1ussgXh9vJrm9K0B5vFobV498P3lLHv7Vq/EHxRf6Be29rpkcawqoJ3d/YUmlpGO4NvVsn0+88h4o7q2kS4YFg23hQPWooRpXie4ntrvTo5I1OZJCm0sR796o22qXniGVZQ/kW4A35XAPrT9e1KXRDYx6Kkc6SsPNfr9azXvO1htWVz0bwvqqazo9teIoAcZI96yPEuu2OlXcL28iGdWJkSIZbA6k1LaavoOi+XY29xFEcZMeeRn1ridW8Iwvc6jqOj3zPd3OcAjIUHtTpQjf3tES32Ov8ReJtOi8NvqtntlunIjhjU7S0p6A1w3w28X+Ir7xDeJqpzZIhlmUKP3JzgL9c1peAvCE00d9aeJoHurO4RWxLwyuO+R0P0roNZ8MWmi6bcXFhOmnWEamSZ2JOfcnqa0/dpOkt+4a35mdRp+sWN1bmSK5iOPvc9KxdR1vSLtnmLHfADtlUcn2rg/hvaT65qT3/ANrhvNL5Rpl53N/StT4jaZr9pc2Ft4VsYE06Zh9omCgtnuDnoPes1SipuDZV9LoktvFU97eiOJIzIQdlxtBY4H+ea6WwikuIDLJdO84wQpb7prOu4bG2sZV0SGCK/wBgUNt4J781h+HYrjTWnuNZvUjyCCA2SSehAolGM1eOnkNNrQy/iJq3irT9ZS3triaKzkX928PO8kew6565rW8YaZfeJfhzYW1zhNZQLIYSwBkx1J+o5rRj0rWdV0oJaXQBLEieYdM9MCqC/D+6s1kur3VZb66SPcqKNpZhzhWJ4z0q1OPu6pNE8r1Mz4ZWMnhKHULjVXFrb3CokMchwWcdTg961212S9uSJL5tPAMrWsKj99NtHOF6fnXBXmg6x4yvox41WLSre3Zmtlhl3MF7lv8AGtO81rwvrfiLT4NPurh9U0x0ihaPlZVHUFj39TSlDnlffvbby1Li+VHpWgXlvq3hKS90zfNcojKfNA3iQDoQOK8z+H3ivXW1y7s7+SQxjcSfLI8sj19a9Sh1Cz0SCSCwtItrMZGS3YHDH1rgdUTWdcv0adEs7ItkopC7h6tjrSpwVpK2j77ibd0zc8QXd3Po7azJo0189uQsUSt80rHocdlHc1S8GSeIzp9zeeINVis7qaYSR24XiOP8O3tWT4muNSdbDTvD2pJHKCRMWOcAHjA70eLte1iSxitNKsjPfeT5ZnAxH15OPWnCi7KPf+uo3K7udH4+8d/2TY20miwPqepSnZHGqnaWqK08a3KaJHd+LDbaRMAS0M2GfP8AsrXl2m6l4re6itbOyWW83bTdlCq49h3rRvIbrV9WlYadFczJAyxmVeDKDj5j2+la/V4LT/hyeds6nQ/iXDe6kLSzs7q5jlb5ZRHtwvrj0rPe3vX+KEGvQaysWkqNhtPM2hzjBGPrzmovhfp2o6S+oXniLU4Z7iaPyvsUGNsS5+9x0/Cue8W20Ns8hhuoftRfEUCNvf6irjCLlKMdOgm3ZNnr3hRbDUru+mtrlkugxLuox17Z7ivL/FvgPU/Evi82c18lxYM25ppD932rY+G2l61YJJLcSuPtAwsLDGAf4j6H2q34m1C10KwZNTvfLuLpjHF5IySfY/j1qI3hUagy3ZrU6Dw74L8K2b2VyFt9R1LTiFjuFblSOmcdSKn8b6BHq9h9uhaZLxXAYwdSvv649a47T/Bmrb7CCzvPs1uria6kQ4JYdB78V6Rp0wt9UupLrUYZIn27IRyyfgK56j5JcylcqKurWPMINFtdNSP+17URzFMxwo2MgN/rDnnH8zXpWgT6pqPhyO5SQ2sQ3HZckZdR3LDoK5z4haTd6pYnVLS3c3Aby+D8oQHI3e2aZ4Znu7zwvrVr4guilldW5t4pGHXKkZUf56UT/exU/wCvuD4dDO+IXizwq+m2UuruYLiF9okgO/K+xHDDNcG/iA+IdZ0yTTftyBHAt2ulwoVf4+fWp9U8B3Gh+B7V7G5juhZzNLukQZKnsoPT1rTfxvYad4T0oafp9mup3JZXlvf3gUjGMAetZNJv2cH95rG8VzWNrSry1tdZS81jWoDax7gbWNABK/ZvrU3iXXI9esLa3l8RnStIeUec6nEpXPCr7e+K5Wz8ca3HezO8Ntqk3kttsI4EeFZP4GDAfKO5z9K4V9C1PVdUu9X8S6n9ovkyXVUwEY9FUexwMUnH2Tv177jVqmj0PRpviRY6T45XS49FEeh26eT/AGmZD5zrj75xwc+h5p3h/wCK+mv4xlTWybbRn4tppB83tn0FebX+na4LCKCVo7NUQ+b9p4HrkDqeKo+GILHTfE0d54iMGr6QIiuxf4c98dTilN82jVioxUU7an0Lq/jPT5LqP/hGXa6UjMju37sr3HPWs3wX4j8Pa7dazpUNrFZeI443Nql0oKsSOsZPB59K8sv9Q8P286y+H7y/25yLW6X5Y1759RjpSrpuq+K9Ogij0vyE370vkby3jUdwe4qFaG/9f5g4c0dNDotQ8L6tNA/2uS5thp8Zfz7hT8zk/wCrUjls56Cue8QWOqaPpEitqdpeWdxgGBcxuPUgd/Tmri33jDwrZstzrKagtsM201w2VQZ9+faszXtTn1JrfVNTjt7e4ZPldMsrfh605VOed+hUIOMbXPffhb4l07U9Ct9P1ERxzWqK8SXSgHaOjAngkeorivjjf6d4i1PT7fTdTto2jykt2cssZ/u//XrzVlmNq1zZWVvdx3KBAr3DKx9go/Gui+FGhaN4ulu9O1ZHttnL2izZYf3dpPamnbXZEOCTv1ODOha5f3k0djdHUJbZ0gkYEFf9lV9VI5FeueErXRvEKXFlJFdQ31nD5M0pJ3xkjGVHYCub8RaDBpN2n/CO2cmmraz+TLdCZjLJKDhFAPB5NbPimXXPhfNDdW80OqNq2DcK0e2aKRcZOB95cHr61s24cutrmd1O63LHw1mt/CGq65aPqbXWnShTawsrMwx/EcjC1X+I/g2+8SDT7nRLFVuJ583Em/7sfYg9MetcXcePLyS4jnkH2lkkPmzxWuxcZyBtPXHerdx8QLm6YR6PLqV+x6sYmKqfZegwK3nUXxp6kRpvZo7C+vLmO8ukj1eGV9NtD9jWZd0bSAYBzj1/lXIXtt4vuNLjk1LFzPzNMqAKvPTdjr9Kh8E+d4hutSa9t768+wjctrESgx1If0Bq/q/ikyQxTWVlNpdtBjz7fzCw3g989AK5qspS0h5G1NJP3ibwzPNaaRLpVwr28+pSea8cnVwo6r6CvRNE+ELiAy6nqkckbxDdsTBYY+8zH24wK8P8feIIYBDe2kom1KRkeOfdu2Adh7e1W5viL4i8U31rb6jqUiaHZxh7lbTKGVO4YdyemKiEpvZ7jqU0J4ul1jQZNe0rw/f3L+HRKA/lDAJJwOe4ruPhdevpXw+eKO3le9u90twzS7HYA4Cqep4rG17QNSfR73V7tStrPIi2AztQqRleB6DFeb2eo67pc91ax6u4tIGHmyOoYR55yqmqVl+7lrYT95cy0PQfHuofa5tO0/wzpTy60qkFXzKyA9ck/wBa83sRNbWt5fT6qbW5tpGXaoyGbuBXYeFtSvbT+1rfw7K9xqN7FvmuCf3kY7j0Gc9RWXffDzxFZeErWLWLiC1guXa7WAx7nQZxuZ+2c9KbVm4rTyDmtqbnhPUbHXNDitvEE87vZStMs1uQzSBx93nv79q0tTltb3QZ9N0ad7a1UH9wZt7N6k46mvPNG02LTL220+7vRHHNPtmKdhjk0a+9jLNKmkxFLgERWyxtye24n1NNTdrdBuCvfqen/BG8tdD8UwbbWxjs5EIE0kYDxkD5m3Hke9VPiJ4x0vxR8RLy881DptgggtJpBlJXHUj15ziuYm8K6ppWgieYSSvc4R4V6/QH1rqvhN8K5te1u5m1VZbK2tmBVMgsPYf40VJKUr2JjFRV7nQeB/FOp6RZ3+q3JhnvZY1jtLdvl2Rr/E3pn0retfiW/iOaS0ubVYljiDgq33nHJ/Cpfih8P7fTPDtvPpM5V0m/ftPINzqenXHA9K4zwzo76xpF7YaYhvdcjyCbX/Uwq3Zn6ZI7UmvcdTr2JTTla2nc9IvpoPE2n2VymqWkNqVBePeAykevevI/FPiiLTdaJ0y+S70tSVkcnLykcYGOgroNa+Hk9rpKza1DBpFrZw8vAS8sh7nPStDwD4I8KWiW9zNbvdAfvh554Oe5FNNtXeyFonoeYa7rKzQ7odJEfmRh8Z2hfw61r/DXxEtreW8awQz72/1Kx7mP0FdZc+HYPiV49mg0c/ZvD9ooWSaJMea3cA+leseEfAOheF54jp1iI7yMHM+Mlx6E1zx21RtKaSsX/wDhKNO06zj+2wyafuTIR4cAj8K8J+J2p6BLfqdPRorq5J5SPAb3x/Wtvxr4n1PX4Ne0SV5Ld4X/AHckY5TB6ZrzvwfFdancCzkEl/PbHb9pk52ewNddOjK97/8ADHPzK17F+28PNq0UFql01qEYNKVzlz7V61rdtqbaJZadp7sFCBfMP8IA6k1ztlHp+jXZW/uVjdv+WjnOPoKt+L9L17VtNsZrHWItP0kn94zNtZlz19+O1bK0eWLIk7tyINHS8sHbS7ay3pN/rrknPHfn3qs/h/TRfyX8CifU7Vt20ciMfSm20lv4UsnbSriW6+0NuZrl/lbHoK6u41ywtNFW4W1t4Ly7UbtowzVc73UkQuzKC6kbvTGS9iMLSfKMdD7irOlppWknTrW5nkSaVjIqr0I/2qzIUl1F7dI2DLkBkPVT/WqniYWeo+J7caReCa/s1EM0C87cdx607K6QuhsfEbUDq2nxxaNK9tdJJgN06d81i+LdcuvDsGlR6nbJqcxQM0svQew9TUvi+wkuPDNxNqyz2hjHySRjDk+uK3PAczXvg+1l1EWuoeSMrNcIBsHbOaxhFRTb1SZUnskYF94rnkvrbT1sTFbXcfzgDBWtWwlj0+ze006J5mGT+85P4V0dnp0OtrJdO1vMyjCSRAYHsCK4O8v5dD1S7fyHcQgnA53Gqi4u8dhPueoXvhvwvZW0A1QQooKoslxLhmOcAZ7nJridLuPEdn8QNSh+yRWfh61GxHkOQ47bT3q14+0C/wDE3xa8NWtzbXLaBZR/apCuPLMgPGfxxxXZ+M9MfUrTybeQiRjgqD1rNSStBu91v2Er7lqy1KZyCqRGPGchutc9418TRiyvNPvbRZbV08uc7tow3vVpfs/hTQ1bVp/KtowBubmti70uw1nQmhjaJ/tUYdJiM5B5B+lTFxjJSa0KeqseceGde0TQPBz/ANjwNaWcDYEQyzNIe5Pc1ur4knuvBkutpF9p8vAWInGfdvasG68OQeGtHvNOYrfXt7JvALErGBxx789K6LQ3j0HR7TTvILu4JkUr8o9q2kobpX1/ASbOJ0XxbrfiXXLCK1gMVtuHmWpg2qVz97dXU/EO5g0+BZLeLKphXCJnB966SbV7OxjlG63gaNMsqABsV5vf/FLSN0sItHuQW2GPbkt9aIpzlzRjohvRWudb4b8bSHSyJ7QhoSFGOMjtWV4o+JOmvpk0Vpfw29+wKoJD901J4l1/SrXwqt0bRUh2AlVxxkdCBXnfhFtJ1W7lkm0CO3sypZbiVMlz7ZqoU4W53ELu9i7pc02t6Bc211eLIrNtluI8jze+0HuB7V0emWVtovhTy7HSFd1537AGPqfWorZtPEUbSGO2s0YiMO23P4V2GhNbXenbrGZZYDlSc8fSlP3emg1qcp4f1MzCaMxi2kHHPOfxrolgWaIuZ92RjchzWD4nsjIhjhgZfJ3M7KCA+PWudu9Tu9G8HW83hch3iuCblJOWYnnj/ZqnDm1iF7bnWGz0e31mWb7V5l0gEqws43bgOuOv4VZ0nxjaTzra3NrJatI7RxM4ADEdq56w0XTJ/FUOuQ2syavNaNctZb8xiVh0z6n0qz4F0/V9b0zULzxHpVpZ6ihP9nuy7SG56qT2OOamXLa8vIFcu+KtL1W5e4exvPs4KDyyp2hfUGsOK31aws5haSxT3k0flEo2QCe5NWrzR/El9p0UGsXCJcoxaR1YbFHvjqa1tPv9H0zRnmaRZ4+jXO8Bcjj/ADirTaVlqFr6nDWPhLXfDUMuo65qMVlZSIf3hm3O+f4VUckmptO1fWlP2rRdAso9z7POuIwZQPXmtHUdUg8TvbRwteQR7wn237LlQpPRS3T64rT1nwwb6aPRPCOpy20sg3Xk7He8gHZWPT8KqU/+fm/4Al2MnSr7UvCtprT+NdTimN/hbS1t5d0ik9WGPu5rnbh3bX9D1HV9PupY5WENlabd4QKfvN688mug0vRfCehGf7T4gg1a+tH/AH0ikSSKf7uen4ivR/C+mW3inR4L43LHTST9nigO04HBy3WsqlZU7tLf5DUb9TO168mtLKW2t7+I3bNlvKPU9wPeovA2jXIniudUEdsjMZRnhnXPTPU+9cv8Q/CY8OSi70O2uZW1GVljjmkJWMgDC8/dB5OT9Kg8Y38Wt+DbLTLK6ubbVYipE9qSdjD73PpXMm+Rdma2Teh3OnfE2x1bxBd6RpceyC3GftDIWDIDg4H1p+s6Nql5qFvfWF8ILNY2Dq0OS5bgbR2NeevZ6h4O8NLd+E7SS/1K6aO3imePzGDt1Zl7f/Xr1+z8W6Yb+Dw5LqNofEixK09sp+6wUFvpU2V+emtP8uonp7r3PO7q+8OX/iB/Bk99cNqlspkfClo42AyQzdM//qrL8T/C3w/LpVleW13L9t3lghbcpPsvaur1bRNP1LU5biSSQ3kku5441EIcr3kcckcV0FmyyW6pp1hah4/mcTNhenUeooqx0TiVCVtzyG18K6jpmkxSvqd1b2gBKpBEIvMU8Hjuc9DW3oFompWsGh6fpewt/pH2t5sycHBdm79eldxqa2uoaRPJebbt2QiSeQ7EjI7KPQdsV5lr1vFYXKajZSSW2mNiDz2lKszY+4PUdSaiKc3ZvXoXey20NfXLyy8Ka75Nvpb6jNHiPz7sl5LgkgMFzwOtdH438B2badZnSba0guppcvJcgZgQjLMMYyR6VjaZfziyt9elvoJtOth5jXEsQd/l4CIP73ua67wd4k0vxPe31nMsiXskPnJ5kiurxHjKEcDHcdaJx51zKO27IvyPc891rwz4e1m2XTrXV7a7u7Uk7fKEMkpHUe/Han6Z47n0bw59hbS2t9NjgeGCfHmNvHb6VP4u8OaJZTm60k6lcXZwJbeBFJXB+8SeVz6965i112K1kmnjikttNinW3MbncxbhmCr64PWnJJ2jT1RcdnKZZ8B2mn6npl3deKtUQiT/AFKyx7jsGc7x2qe9j8LWmiT6bo+Z5zlllZCMenJ6V71a2Wj6jpMTwWtvJZ3EYIwg+YEViNomj6Ve2GlWGnwq07b3LLnCjsCazm3LcUJpHzjovgZtW1a3soYZUdpBtckqBx611Pin4EavpLw6v4V1GaS7h+9HAxWUH/ZJPP411nirxQui/EY2UNmUtLRYx5XlbTMzclwe+MivUbLxDbajcyW+leXdSRH94RIAF+vv7VpKE42k9Li9pf4Twi3+EvjDR7a28QjXWuNYRvtE8E37xVPUcHgkVX8Q6fqHiCCXVtd8TWMk0du32cRMIsv18rB6ZPrXtuveKbWYXukaXeW/9reWytubiLsze5HpXjuj6B4P8KazPqN9cXXiWIJj94gcRydScdDU+83dvX0/rQcZabHKeHtdmtvD9tcavY2b2LS7ZLbdiUgcBx365474rtvEuh3XjXRNOuvh60UWltEY5oPNEDxTZ5Zx34rivG1hD4j1GR9E0mLR9PuXRvM3bih7sAOOfbpXL6Nqd34E1m6t4I7q6TaJHjhcsjg9Cw7GlCVpc8dzSUeaKTZ2vinULvwLp9g3hjUUk8Q2yPBf3DRhkuFzwvodpzzXl2palqfiLUlXVdRaCO6G+ZEXgn6V33hm/XV9ZgOsXMWlafqUvlxWtzGWHXClAPc4ye5rC+M3gq18F6m5tL2GcSniPOXT2NCck/e6h7q0RyN7Pa6ZYyW1sytIVwmU3Ejvz/DVCz1PU9MK31syCNgoKuoZWweMrUMV5Etg4aPMx4Ln+LNWrDQppdMi1CO7iVxKESFuWJzgcd61grbkyd9j3vwd8TdX1nwC1vdWtuLyK4WJQ0fJQgneAeOxGe1cT4u06zvrF77UdQ26nOpltoYIsmT5uEbHp1zXWxaVrnh+L+wLTT21bW72BJZ5nTPkjGRt7KBXT6f4B07wVDZaxrt39o1u5GPKf5lXjJCjuRU88UttX1Js77nE+CvEOleHfEFhfG2ijtRAFuTGudsh9vz4rqvi3r+m6hPHqVtqdtdaTNaiDZ5gxEc5YleuelcT430SbVLO41DS7SOJpWaTYGwzL64HSvG5bZTA7ESCQg5GM7WHWlTfvNp6lzipJaGpqVxHqmsTXlpKVtxMEjDnDFegNd9oHhy5s9d0uLSri3lhnzdbymSGUcqSfcVyukz6ZJ4X8u3tAb9h5bErk59fx7V2PhvUZSsFu11FH9lZfNbZkhe6kdz71d0ly2FZvW5215q6J4R1S+8V2KxXfWxRWIbzB3A9BVT4cePLnwnoE2p6sBO97IQse/5mPrj0rM1PWtL1SaW21iG588v+6mjj3BcDhQPTvWv4d8DaZr2j2s08lyXtpWaI7hGJWJyBzyMUXjK7ehHK46bjdYuvEnxF3atf2b2uhQgrGZlxGD6qOrGvZPhFa6TpfhKCz028t7mXJeeRBgu/fIrDl8a6e7/8IvqltE1yExIEysaYGeCevFeax6ZeXfiiVNEvZdOtcn5Ijk7e/Si6jG0tBcrlsev+P9dd510vT9Mm1RipaQQjdsPavPYbgXWnf8I/ppuJfEl+5W5HQwJnnPoB0rYsPH+jeC7A6dDaz3GoZAaWRuZWP8TE84+lZsWuWmha4+rpdC71fUWEkzqmFC/3V7496yheWjehTXKtENtNV1rwr4ntdE0mLyrKGRYfsiwf63PVi3U9zmvXNY8VaPY2tyLi/iikjX5zn7pIrzO48faj4j1c2PhmK3WcHbJNIm5kHc57V494rk1bxPr9zpemyNcCJtkj4xvbPJPtXQk6qSStYyceV3kzc13XYtb1q40rRr2OPz23TXjMASvovqa9B0rTrfQtAjtdHjj+0FeCx+8x7muP8C/CzQkuzDJrqXOtIvmNHCMquO2a9V8KeHrW2tbvU9Zk3rDkKCeFUVtOpyxsv+HJsrnCw+C9RctqGuScZ3Dvisnx3ql3bWltPqaXP9lq4jiji+84FdwfHMOJY7m2V7NpPLgAPOPU1t69ZC70mDyZIUiGHCOgOT7Zqk5RalNEbqyPN/HP2Sy8N6e9pDIrTIJBHMMmLI6fWsTwZpmqas4v79z5UfCA/wCFbOoXc+oarFZMFnYMFbIzmu40a/0SxlTTUlRrsjG1DwD6V0ObhHTVkWuO0yyW2V724PlxxjINS+EdM0H+0ptS0ixUajMSZJySfyrmPFF/PeeIV0mKRooXcKfm2r7k+teieEtIlsbksoUW6oECDv71wy5r8z6o10tYp+MPDV1rMUDvNgx9QK4y/Nxea8/gy909o9GlhDtcxEqTjrz0xXp/i7V7fRtKnuLiTYoXvXnOmeLp/FGgahcQxeXDbqV3bfmf2zRTcnFvoiXv6nXeEIbOxslsNEhP2SD5Fz3981F45mtNK0aW6lgTzn+QYUEsT2ryH4ca3rM/ikRwyytBuw8ZHyoK9e13UbXzGmv4TcQwjEaBc/N61dam4yTve4oy7FbxP47ksCllF5KXs2PLZj8i59TTvA7apb6ncz+IbmMtJymG+XHtVC80Wx8YtbjUYRb3MaqZpIDgM/cD2zVXxlpviH/hI7C10O6a30eONMBAuFI+8XJ5P0pRUZR5I6aa3DZ3ZD8V/C3irxHrsEml3NtLobrgrJKFWPIwSR3/AArcu9esfDugR20V2qW2jwLHLK4OOmB+tWNW1WG2Mg+zAhQFUk7Vdj7Vy6azH4mg1HQ9MtrLVrgMouoQu1cZ9e+PWtEnNR59kLbY6vwq2n69pf8AwkFpqFpdQOSGuJFK+WR1HPTFZUXjTQ5tdawtdQS8cHb52PkB9z3NW7j4d6S3heGzvHm0u0jBY2ttOUTJ67vWuRt/hHpVnctd200rWygMiq/3j9amCptNtvyK1udJP4Etr/U3uIbyKfzDmbexJI7gCvNb/wAN2MPiBRBpJso97bfMlIZv94GuyR4PD99awWsr273BKqHlyzmmeKrpLOG51O/eIukWd7HHPat6bmna97kuxyPiPxFYeHrc6ba2TT3EyBjvGU3Ee9YOnaD4g1iBLy7vPs8Z5VAcbR6AVm6zqd7qepW9xewRrGCDHlf4fUGu6sfEcLNFEA7LjaGC/eOOgFdDTglyiTvuY+p+G9UnuCQGex8sSOR/Fj+EH1NepeBr60XSYLWKJLYwIDJAucBj7nqa0NK0i7n0y2nlimiyuVidcH8R71ka54c16WGQ2d7FZE5IQRAkj8a5J1FU91stRtqjotXFveWcsTOVhljKHnBGa4C/8KCGwb7JqLjynEjNtyCR2OO1S/D3wtruozzXuufbmiViEaaXYDj/AGPSu7vvD9pBo1zcxzzTJBGzta27f60qM7fWs+dUnyplWurnm+n6m+i6RewK7f2hdHfDKITtiBHOD7mpPBGqapZyS3/iS9kayWMgNP8AKGb2zitnwDe3Hia6VDpghjCF5mlt/lh9EBzyaoeLtKnTxBbR6Vor6leu22OW6UvDEfXZ0yPU1q5RbcGT5mX4l1EX9nc+RPqElpKBtitIiBIT2aU9vXFULHSX0vQro6mHWTCSyrGBiOLPyogb8ya9d8TeN9H8MaDDFfJb3uoogVra3ChQ+OT6AV5Nr3xKW9sH1HV1tLWCRTEsMNv5jBTxtbIqIV7paWRfs2y3qOv6F4l+H97GbpLSPTZVYPbSHzVc9M8fNkUx/jDrV5oaJ4Y8PIssEYia+nT5QMY3dO/WuD0O70yxvrPU4LyVdLjnDR21vBtaaTrsYHjn+VbcsOqeK9SaKDStUgEz/MGcR28S5zgqDzxWNS0no1Y0iuVe8tTloLnTLTRWgxHPfSSM1wiDYxZjkgt02+lbemeOvEugaNHaWLQWNi7kRRIdzRjPJPr9TV2e00axvbnS9SIieBNyhFA2nPA9/wClaHi268MXei6Z9h00ST5MRNvlVZeOvqSe1TVlJtc2xcEvsrU7rwb4M1jxNY2WqeLdYeeMfvILZGO0/wC0x/pXURfDbT7O+TUI7+e2eJGXbx5QU9cg/wBa4a1f4g2emw2OkQQ2VqIwqK7KZEHtnoapSaFqeqTQ2uu6rqbyRn95Zu/ykZ7ngVy03JPRlTjfdnfeHNSsYrp30y6UpA7RLIXzHPHnlj6c1TsLDw7Zatq+s2Vg/wBrvZTJPMz5Oc9FJ6LnnHeuN1DxHoej6Pd2ujaW7XMK/wCpwQS4PP0xUOk+KYfiH4Ml0xYJdJ1C0mD+YwAR+2W46f1FbQlZtN2u9SZQ62O/8KPqur6nqpvZLGWxPCWtqQXznhmbPFT+PPtunaCsWjLHZanM6ojzRmVXH8Q46H61Q8BeF9O8FafLrEV4dU1DyvJZbVvkOWGTjuc9T2rtNA1M6jNM92E8yNtqYHA+lOo9eaGy8v0M46bnK/D6215bKWHxwLO5mV2MSllVsdgFHb61ifGJPD9jaacuqpNbQeY5gFuiuI2ZeTs7n3HQ1o3Pg7XZfEwuFupPJ83czsR8y5z+ldb44h0KTRphq4tNyRlY3mUEp9Kl8sJqpe/oNNy92x5dp0NrceDtK07QWAsriRhDdXDASSSNwQyHp9K6G6+H+l+EfDVzqEN55V3axmSSUYRW9QPTNeX+P5pLPw9Y2nh68PmLPvuPNXIMeBjYw6D1xzUWlW/iHxHqMa2z3t3bbWkggv5WkC4Ax8nfnON1ZuX2ubR/1qbcnTsVUiGuatql3pzz2V1foHklkkbdLjoFUdqbpWhw6bDbNqN9Pe213J/plmh23MM38Lxg85wOc8Yr0HUbW60zSILCe3+w6pKQ0srLgyL/AHFYdPwq1LpNrcWOlyGaGDXY7jdEVO6Qwgc7u5HvVczUfaXE7N8qWhg+L/ixD4PtdF0bwlHcnTomxcTTJmbGclVB4z15r2H/AIS7TZNEttTRN8zBSsBI8wZHIz9K8A8b3VnbeIFGpRsWgBKBo96A+317VxviHxbq8NtBf2msW4id2QWVugIjGPvOfX27UkuZJvccqa2R9oWxstSgivVhilLLw7KCyj0z2rwXxjYW3hrxxHc6L4kjSKZvMa3V8+SwPfbwe/WvH7DxrqclxZxzXdxdQDmYeayLIuecgY3V3Gh6/pGpw30z21vb/Z5QsQXGwIeN5z3rWnNxb1siPZL1H63pd5q9+91pE11p+lTblluZUALFmydg6kn+VO0Lwhc6jrUmm6VqzXem2EQnvJrhQoz/AHQB1Nbt34m8OPYxW9zq0dxaRRjbHFkEEHkg9B1rhvHWqX9lpN7BoiXVnp88iM88KkqyHpucd/alUk20k9e5UFo3ayNLwrIdQ/tO4W6mvDYB4LeCTASJeu4gdcelL4SbThqmo37lLqVwDDJ0QeuR156AGsy3k0TwldQQWF+t3b2pR7lcfvZt4y20DrjnrUfhDxfodtqWpvf2s0OmXEbNb4i3MPmJVfrjHNRUi1HlWqKg7u7HWuuJbeINNu9Ys7eF7a42w3IBzDDuySE6FuTgnpXOfGjVfDOta7bT+Fob3c243U1wxzK5PXnpUXie91fxKsuo2GgyQ2NkOZY1Y4B7tXHma3eLdOsyygfwkbSfTHWnGLVm3sJ2YajEkdhbRxg5GSxPqe1a3h++t7W2tbi8LNdxTj7Px8qKOcn19KxLq488QqU2pGuPrnuaIsJLGRvdo/mAI4WrW2oWu7o99b4h/wDCT+LLI6f5lmfJjjLM5hO5RySc9M/pUcmr698RfE39jSJd29+83kG/jP7mKH+IIMcZxnPU1zWn32heINFa8fZFqMaCJ4MYLHPL5+n5VnaLqut3+so9rrV7ZxWUe1LhBwqg44H9abX2WtkQu6PT/H/w30v4Z+F/7cstY1CaZWEM0dzJuSfPoo6V434ZtIfEfjaCykcC1nkIVwMBgew9q3PGuvzeKpYLTxF4gubi2tiQigDaT6nAwTVDwFBpyajq7XV1MLa0tf3UpOGiOf4TWaStzPcpKUdDp7jQAdRn0/Sbcw3MLtCDE33ioJJA9AK4aDXo7O5uIdQsV8sv5UssbfOCOh9/evSIvHdnbeErx9G0eS58TNCbc6nGuVwerZPAOK8VDRgm4uo5XnMoYyOeM5yRjvWjSk7pdhRbjoz1LwrcF7U3GmwQzTujJHLccvk8ZGehrRj1PQtKuE03WrjXZrmJPkQjy0L9eCOg964ODxFHb30sl5Dc2qvGhgVQArn+8fQY9K6PTNevtaspdRbTRLDbnH2mY5G1TnaDj2pp91oDj2PVvB8N94rnDa5IkFkF3RIyAHHRdp6n6mur0rS/DXgK8mu5tWa9v5lKRwsV3ZPYgfzNYGl/EC2sPDGj6n/ZsM91qAZxuO1IUXgLnufQVyHxb1m1vNcsZ7Mm3kkgSWbyowPn6jP0zRNybu1ZPQyUV8K1sanjH4beJdbeXxT9ohiuA4dLSMdUzgLVqP4X3J1i2/tcSFCgaScN8seexPaup8LS6vaz6Kl3rUt3ZMPMuC0GxVGOBk9s10PjLUf+EgspNG0W4A8zBnuA2BGoPrXPG8fhNG23Y0PDfg7QvCemTfZLdIgVJklJySD3zXMW+gaA+ia1J4aj/f3CMWlzlmPoD2q5oMerHTdRtbyWObSo02xS7tzOfXNeay+MbPTp30nSHl++fOn649cV0xg7tR/r1MdHqzV+FOgv4VjvLu5hkkv7osFHUonqayb7x1Brmqt4bLXKL5uG2IRu9fwrtvCerWlpYzySSMJChdt4ySK5zw7rL3+sXV3e+H47KMsRbSuoEki+/pW8eZzcpohpJWiVZJNOvNcstKhtpBBC4ye7Y6kn0ruJnS+BhgmXavygA5KivJvC/iWdvG88d9orxLLKYoygJ2r65r2Lw14AbTb++vnuN8dyMpEOoP1q6rUUm+xK12OGv/C1/wCcyRXC2kRJaa+Bwsaen1NdR4L0Xwo29tHu4r3UIR87s2X+uP61Q1XW4LbVJPDmrIzpcfI6gcKp759a6Tw/4K0PwnpN/qGiF2unhOJ5H3bR6CsnVbhq7dh8tnoZGp+DdP8AEOom71WeS3No/mZjONwHrW3oPjrRr+e7s7DezWUZbkfeUD1ridZ8UNDpVvZ3fmot8TF9qYbR+J+tSeCbZvDzPZm3imurs54GTs9z6U3C8XzP09Q63R2dyLPxD4ae61qMxWs/zBDwcVwtp4s07T9NvLXQNJE9hbfI0akB2Y/zr0/VLC31HTBa3hVSRgKnAH0rkNC8MaPodwSSqyl9/wC9OCT24rOEotNMNVYyfh39qurqWe40FdKtm5JY/M31NdR4g+xSWkqxXlvbled2d2PqKbr9w91p0kOnz7Hm+RX/ALvuK8vttCaHXo7Cyma53H9/LK2dx71pFe0lfawvhR6Fpltq8FtJc3n7lG+VGVdrH1OK4vWde1yzu7g6XDJNADgOw3Zr0L4oahN/wjcw0e5BvrMrI6IQW29+K808J22s6rr8OrWky3GlSAmdd2BGMc5H1rWl8HtJInd2K2na1qOr61DHrikwM/LdNp7V1ngqfw54NuLtdKlM087mS5upiCxGfuj0FTeIrKy8lbXzYhM4LhAwDsPUetYcvhOwm0xIY5Xhk+8SDktnsauXJUVpbArrY7Dxfct4tsIlt7lba1IO5ie3rXmviDxVfC3h0Hw7dyC0tx5ZmXkuR712FvapZ6QtjFl4UXaSepzWVd2smiWltb6Po0kl3KMh1jzjnrmnT5Y6W22BjfC+lSLpkM+sSRrdlsJPKf3hHYAmt3W/D1prlj9h1tJ5LRGEg2NtLD0PqK5mfwtca3qVlF4h1pLdLeQPLDGCWxkHjHRv5VpzeNdN1jxlrHhy5t5bXT7eI+RfrLkPtAzn2Pas5Sad0/8AgFJabD7nwfYa9Jugfyp44xFbRR8rGBwM+tS6H8OY9H1q1a71S2ub2NjItqHVce2Cc5rIs7/WdJ8SwyeCrqyuvD0UYEwkx5m4/eLE85z0xxWNdad4U0vxANX1BdXmvYpBLy4ILZznIOetRKrypxctLaf5eRcYSlqke96l4qgs7F7iZobSFDseW5cIqt6Z71xXjTW7vTbeK+soxqKypvJU5Dg9ApHT1zXm/wARfG+meN9GOmS28mzzRPEYyF2t0wc1nJrnijSvD9pY21iINMgj2Rtjc2303e9c6lCnbq+xqqUpb6I9f8BeI9X1u4Fp4mMOneaCba3Eo3yoO/rXMW+pa3a+OLtdTiax0eOZgBt2qIx0bd3JrxyHW9Yur77JYw2/25BkGQfvV28nk9CPSulXwl4716zuJX1qO6twgaWKOTDE/wB0ntWXOk3zJa/1oaez2szqvCfxH1a11XVRrV0YIFPmW/kwmTzV3d1HQY71X134ua5q4uLLw8I3Lbg5jj2ylB1YDrnFc34V1jUvBdjcONMspI3yj+dLmQY65z1ri/GXiiPVdcjvdMtotMkj4d7aTJPqcijmcm3y2Q1BLrc9Ot72x8a2SSGwXTre0ZY5kk/1s7gZOCe1UdX1bR7S2m00i3vEnYxLZ20e+UOR1B749TXG+G7vR7nU45/EF3qEtiG+ZI5cGU9ye+P513Pwa0ia48Z6hJbGxv7QI6Rq0Pku0UmQShIyMDjNLmgk2+mwNSWxj+GfDcvjsx6Rb39lZ3NtGZre35JcqMHkDG7FM0Lw/qcGm32oatqlzpq6bd/Zo2dmPmMB82xe5Hf616r4P8Fp4C8V391pNq99OylI4dy4t1PJYnOScVyz6DqXxL1+efWfEMEcVoXxbW6jMSjncQOmfzpz5FdQ2FCU370jjJNdthcSXI05Lsk7XuLybHHckDua6jwz4g0G81aC6vrcpY28YaKNPuIQeDgfnXL2nga11XxFawLHI2jToY45edxkzgMf72T1rt/hb8KY7DXNVh1u4RoLYK/kBjjk8k/hWdWn7Ne9uaRqKWqMXUfDGpXuq3aanqt5NJLN5ltcRXQMbbuc5z8oAx1r0q4sU1VdKuLfWVng0a2Ec2oFtsbzDqST1A961fihp0fhzwU0vhfTLeNlPzuqBiqdcgHqScVn+FrK48W+ABbSQpaJqFq6XaPFhfMzgOF9D1/CumVWbjGcrJbHNGMdVHcLLw5pOk6DqOv65NBqY8zMTxShVfPGMj6/pXF3l1Lr2nXMXh6Q6SLdTO8qglWQHAAPUHP51tXstv8ADf4a23hnVbCDXZ5JCEt7cFD8zZ3eufevR7Dwzo6eF4Fi037KsyrPLEGzIH2jhm7kenSi0Ie+1dt6MOeT0PGNIvtS8PJbT2GpQuzxD7cHQlZHJP3R646+9eseENWfxT4anuNKSOK9gIQL91c9evSra+GNNvdIlt7exSMRuJFOcOzjqCfQ+lO0++uNGWDS9H8LSwKzZyGAT3Yn/GsZyjqXeTtY2fDl3MbaVNSZmuRIQygZ2+3Fcf8AFl7y4S3hhCW9hGwfIAMt3LnHkhT/AAkdTV5b7UvB013davC11p93IH3xOC8LehB6j3rgdX8XS634g03V57zTrHS4rlhZpPIRLPsPzgDHH1NRByWqV2Vypyu3odRdeF7yHT3kuNGtzAIQ6RwHLwNjkY74rB+Fuv6XoWuanFc3SK12ykRHPmJjvg9R613V58TvDqaXLNb3qNd+WWW3YHcD79se+a8P1K6hv9ej16C3lvtVjUSCeJQoVccjaO45xWtlJe9p/mTFyejPYviTqvh/W/DcsNteQ3l6BuhW1IeQf4fjXkV1Jd+GdOttft7qCCF/3aQyR7ppsHDbSen4Vk6zo1neTyyaSb3TYbpV8sksrCQ85YD7wz6/Wucvk1r+0obfxissunWbrFuiOREp4Bz2PeplLTkvp/WxpCCWqOr8QSN4kuNMXUr0XFs6mSWGGLZ5eTja7e2M15zr+m2MV1c2dvOJURyPPAwGOcAZ9PevX9R8HSaVcQ21xr8H2N1HlhW/hI6kj7xqjpnhrw5eXGoQ29w0UluAiOIGZXfrnHPPc0pOKs4FRb15iLwh4BS68LfYdW0mHWr+Yg2s9nNt+yxkfdkbgHnnHavNfE3gjU/D+oT2VrLJOS/lSxWz+ZsP918V3cOuwaJpMcVpqU+javDOQVdX8ubHXHXHbHatSxlub28XXbG4WwvXVlvpoMoykDIYKeDu4/pV0oSk25O1zOclHRanncMOqSeHp9J1DStPijsoy/2qRcSkA/dAHepvFnxEvNR8IWfhmzVbVQfLuPKGBOOOGzXT/FDxDqDx+HLW4021l126jaSW6XrKoOFJH6kmvFDHI90WdizmXDMv15Io5W5Xl0Kvp7vU9U8HeAtSvfOX7Va29rLHlps5aYKOVB7Y7ipfh7pKwajrN9erBeppqj7LDL/qmfPVh3GO1Z2u+INc0vT4YJbqOPT4oWt4I4QMrkdS3c1qfAjxDDa+IpE12GCPSL1BbzSTj93jnB+ue9T/AHnqhvZrqe9eCfEf9vx21jaaTA9hcIYr0JHsjQY5AHcV8wfGbwzpvhPx/f2GlT+daKgl2Z5iJ/hJr27xz8VtE8JxpYeAIbK4uCG853LCOAdjx94+1fNGp3M0+rtf6zMLm8nl+0TRHnOTnBPbPp6VSs5c0VZfmZq63Ox8K+CtHvbGe48W64NMmNm13a2mf3kigZBPoDjjua4mKKeKCe5mgm8hyEV3G0H0/Suys7fXPFniS21y60u0ktZAIIVnbZCABhQD3xXY6zZ2zeIpE8dTW9pbW0OLa1tMyIZCOD+VNaju0zyHQZp1u5LeKQQx3HyytjPy+lbXii4vdNlSG1nQ20qbA9ucCRe4+lS6bpllPqGpMrzRW5JjhAGCT71W8SpLaSadI7BY0Qp8oIIx61KfNNWNGrR1M+40nUbHRhesF8h3xgHLD/AU61u55NPvAHWO3kTDDtx296k1D7fJLttWLwSpzGjbgvc5qSD7PJo0ET2xa68wgLuwq49fXNDd0JKx6Np+piDwrbeFtCmspLSVfNeYpiQkjLKT69qtaPp+kw+AZrfUtPt21ieR0gR8bo1zx+Necatr95pd/bokFqghAcBF749a6y4Go65pcWpIihJEEyxx4BbJwTn29KpQnKXcluKTNLVfDNnceEwJZEe9UbY4Q254z7Vz9jpeoadYJpst2Z7NCJJLdH2rkn0/i+lbvgbQLGbxYmn3DM5niWSV0nO6MemfWum1/QPD2g680q3d06FxHH9nUN5J78nqR7U4XdTSN/ImVlHcdpWhWiyx6ZeOY96pIwkkLLaZ5xjsaz/EVloVh4wVL7VLiQMFMX7vfuOeK9b1Ow8OeDfAkzrEs7XCecjy/NNPIRkE965f4N/DO5vtRHi3xeh85zvtLR+iDszD+VTCCbcpvRdAlUsrI231a/sfC0t1f22IZPlgeYhWIxxgdhWf4W0y21zwrO+myXDXXn+ZPAz4z7AjtVbX/C/iHVvGBtr6C+ngecvJMW/chM8bR9K7DSLjwf4PefTYNThiupcvKsj5YkdQK2UIU4qUdZGLm5vyPOk1e40eXUNKF68Ruz91s4hOOntxWn4V0rw/ua1gaC51AkFgpBbHrjrWb/Zdj4r8R310Lz7FYYbbLjDP7fSuw8LeE/Dnhhjqunxg30qFPtRlMhb12CojUlNPm09C5KMLWLCeG9L02aeWG6zcSjcscjdD6D2rmQ2uWE0l35Ec1sCclvuqPxrpZNWs48p5EbSuSVZ/nbPuf6VBtll083cr5Ik2iDGFeuqLa+IwdjldZ8SW2p20UGmX1vpmqhxlmG38ia9YefU5PBUMWlXttLqhjCmYtxn1rkNa8MWOsacsr29qt1ENzKoG7HvXPWlxe29zJbxqyWQGA6H7p7U5RjUVkK9tyCK/vk8ZxweJ7ISyINhnWPqexz3r1gWSWWmtI9w32ZxnYxwp9sV5RZ+NLrQfFENl4rjgnsJmzFclfun3rvfiNp934r0a0j8NXyqM7zsbtWVaGsXt5lRb1RxviOG98VtbaZcWYhjW4DRbRgbRXqelWWlWMvkRyQPqSxhSpcF1A7VwXwztdbfxQ41eR5IrdMEOMDPQYqv4m8Ov4X8V3HiOG8kZXywBXkE9iehpzSbUL+fzEn1OH8Vajq58ZzS3F5fW11HKRDApIU+nHSvTtU8JjX7LStX1a4uIr62iDNFCcCQ9gaTwhrdt4nuyL1Ldr6EZWQxgtj6110ru0flQnc5OMnoKmrNxUY2s0JK7bOeh0K7nijvLm48gxjcIQOAPc1w+kXemWfjW4kikmdt3Q9Ae9exxK7xmK6UD5dpweDXGv4GsbbU3vUBwxLYFKlVSb5hyV0c63hTy/iDe67BqiDTWDSToWJbpypHpXE2Gs2N9Drvhvwl9otrzVOYbiY7VlIPKL6ZrtdL8NeIodNvbqJgkzyBwjHJYY5HvmoPEmvaf4U061vdQ8OLJdxyBUZFCqvHJDCuxNt+7q9LfIytbc57UPDn/AAjR8N+I/GepJavp1t9nktVy7uwztAPfjrXoM1vpknhuDXZLlYLF0EqSyEqADyMj+lcP45v7rxNrVpBP4dWfw9JAtzbTyOUzIVyCX6YzxtrMHj3ULvRdL0rxRosUWlXRktpbZEKg7SArqT0xUckpKL+/030KTtdHo3h+LUNV1+x/s9LefQiPNkvEIZWH932PtW1o83jSfxXqjanZ2dp4bVWjtFfHmsR90596b8PdJ0TwVoiRaYJ8XcolkDksTxgY9AKo/GfSda8R2tnFol+EtEYPJEkmxnPufSuZSVSXK9F39P1Zo00Vh4MIuL6/1i7+yQMS52NyAf61xmi+BZ9S1m6TSLuGSxkOzZIenuw6/lXrceif2j4WtNJ1OR2Z4BFI6H+L696g07wDY+HdNuFsr67M77RG7NzHg54x1/GpqT546vUuD5XZLQhh8IWXhfQLh5mWaTyyuI48ZJ9+przzVNH0KyMDeLtZTTWugXS0VDLKFPQsB0H1ro/F994jtljtv7Rin3AFJFUHaQeQR24rzbWtN0XUtXl1fxVr8tp9qdYHjRCSxwMH6DFOnQVVc9R6eQ3UcPdidpYeBvCvh+zg1GeVdQtb4gw3oOYySeBgdP8A9daviHxOl9ai20fU9D0+CDcN7MsvmFRxxxg1yvxQ1aHRNG0fwj4aSdbC1QE3DDIbcOOfxP51x3hH4eXN+br+37yOxs1TdBJIvLZ/hxXHKMYu50R1V5FYeGU8QG51vT9WH21zI8ryNjcR97Cjkk+1cdeXuteHbiXTrPV5oDMu64SBm24xxkfSva4ZvDOh6FqGgaho63s7RtJamIZcZHDbh93nmvHreN49ahvEaRZ4kZJVnQuznHJx3yP5VspXjeS1/qwknzaFbSvDNzq92iCUyWzYxJI5QMT12gnn616j4Y+C+gahrUFpeas0Mu0ObQFdxUdee5rQ0HwZocXgy28SapcMTFiY2yvnagYcY6g4yavyXmman4tFs1tp9jYRM01pJChjnj2jKv5mfmDenTms9aivFg5Wdmjm/EXg/wAL6L4109dFYy2Ns4e9gn5bbnGQe49q9e1W68K3/kWOnSPpeoRxiSGeGEqQnqcdRXhfjDxvH4n065vYdEayvdLlEsjq331zjA9PUip/CGvax4ke3TRrALMm0faJPmcANnaCOi+1ayoxTvLsTzNpWep0vjzX9c8Na3Z3+oyWd07QmGK8tZCPNypXLr2ODVrwnZXbeG2s/DcVqNV1L/XXoB+7/Eo9D7mq2s2cd74mt4PFVtFbXBBPmQn5BntjtWrqmu638NZbf7TYrJ4XvCF822baysejE/z9RWMpO6S7GiSUfMfoXh/W/D/iGytLqJZ4jwV3kpBn7zIOxNdz4n8P2euwRaPJdXkM1wRMrWzhZfl4O/8A2efzrFtPHVpq/m3NwqW6QIojjLZJ/wBr3Oe1clpninX9O8U6hq809rFbSMUeG74kVM/IoPVfX+dUnOck47ohxSTuegTxKscej+HvEMk2oWEXlNDJJvMu3qGJGMj2rnvGuq6pp9hLpuhXDLcywhp7uWUbgzA8IO5A79u1bXgTTLCXVpb6O3+xT3MeWkaTc7ZOSq9gPfrW5b+ELG58Qx6jGY7i0TcrJMu4g9gCenNC5FUutUu/cltqNmcj8FvC17L4cS98QXTyoQY4mlO5ygY87j0Gc4Fd/aeG47a5+16fqMznONjvuU+1M8aWN2PDqWehqkShwrKo6J6ACuN07T/EenzR+VHIsbuWbYMDb/MVrCF05c2rIcm2ek2byQqI5l+d3KhkHGfesaDxpouo3t/Z200zTWaO7MUKrJs5ba3fpTNEh1OG63SrKYnBDPI/Ce4B/KuW8PfDW+ttdaXVtTM2loJtkSvhiZM9+2AaFCGvMxSvfQ5/R/Guva9q9lDrNrBNp2o3ptpbFyuYYyPkdCOS3cg815x8TdG0+HxdLpgkeztbRmXzXJK7Sc/LjPPtXr8ng7Sfh7I+rxSyahqByLKGRfkic9XAHViMDJrg9Wu4rjQLmaKzvD4jjYvJE0e/zCTywzwMU6k7zTol0kuV85LeXnhNPDek22m3kSx6em0p5RZ5Sepcnvmo7OZtYvbNPB1lJaSkFJGuFwkjZzkEdeP51kQaJp1joVnq+svdyXUpE32OZtsqjODlR1B9a6qL4kaLaQ2Ah0u7ijibZEcqEJ7Aema5tZPlkdCtFXgbR0vV7G6F94iTT4NOW4WdoVyXdsY25PQDHSuT+MniSGLT/wCyvC8USvq8wkciLexlUYKovJ54qt418WWXjLVdKi1DV59M0q2uAbwQsA4Uj7w9x0OM8HNbk0/w18JePfC+paZfCVnDoZmuGmSIFcBjn7pyacWtHLVkO+yOCj8F+IIZ9KutY0idVnAgiLTciTrkoD8vfAr03SdK1TUraHSraxh0V4QzNKfvSk8Hr1riNe8UanY6heS3Mqy2UUv2m1ETZ3/Pw5H613HiDWj4r02wvNCuljmt1E0VwXwBJnlG9q2cOWa5mTzOUNEc7qHg3VLrVIdO1WwhnjaMpHII94xnO4ue+ep7V5/408RweH7U23h3V0uL+YmOaeBsiJQcGMccYP59q9e8U/FTT9H0VoNWvLe/1ryTGtjp4J3OwwSzfwj6V8y27XWl3cd1bwtBqEjl0hkh3cZ6DI5pp8zd/wDgC1Rc8P2et+JPEObGyvdSvdpAiJZmYdyWPQUeK/CniDQn+0axZNZSyybRbkYYehx3Fdn4A8TavbG8i055LSW4dZLhUyJCnOQMc9e1b+q+KLnUrC60rXWGbZx9hkuGy4JwOrckc9KHGSjz6DveXKeQ3+o3d6qvdXCOigIpYYIOOTip9KkiuLIC5uJJZlO2OJBkkfTpWvb+FJtQfUZIbmKWxtHzKYlJQjtg4rFv7+O3lEOlWrQAkcyKS2R6VDT2RomupDBbz6pqDWUM1pYQ8l5Z3CKFH95u/wBBRZ+G7u8vlWMSCzkY+XdyoVWQD+Ie1dL4V17RNHspJNet0v7yaXzfJ2BlKjop9B7VsWvxQe61CU3GirNaSW5t7e38wDy2Y9QB2xxxVc8m9UQ4RRUt0g8N6Q4vt+padwoIdx9nYnoEzxk9653xA+q2S+dqMLqt180McxJdU7Yzz071t2umXms6g2j3l5b6bbSE3rK0m55HHQfX2rU8H+G7i78U6xJqN5Hq01rB+6ad9zSE9FwegHf6UPlbbQLmWjOV0nxlLYJawtYw3Aik8wtLwxGRxnvXsfiDS4fFOmLqtvEsltNFvMAjA8s45x61wmo+HbafTXa8tlGrXEyQwspCrGucZA717g8Wj/DfTbSwlmvdRvWjG5YlUgcZ5J4HrTjtypbkzet2zwL4ceH93jtdNu5fslpNC25ZODtPI49qofELw9d+GNXeRQjW1wx8hk5yBXY65eGDxlYeJFT7fZ3EhihXZtIfGNrAexrlNc+3+I/GdrptxK+y2c5Vvk8iMnJB9KzcXzp+WppF6fkdZ8J/hdaeJbGfVNf1SFb1kPk2zHJjz91m/wAKi8QeHdU8IagICkVxbM2VCnep9Txx+de5+HrLT4IrZLO1TyVRS8qqADgcDNcL8QdR1X/hIr3Uppoo9DgVYLWLIEbOep/Pqa3jV5XdfiYOLb1Nf4ZXXhe10O2vta0+y069Mpi8zGN/ua1NI8OeEtO1CbWNT1u0vrW3dmigL7ssTnJXuR0AFR+FR4BtdPN9qut2ep6gV3SyucIp/uxr0x/OuX8W+IbO61aw1DwzaGzt7f5S5gVUfn7w7mpgpuTcFZMUuWyTOw17xFoZFp4l8RJuty5GmaeB8zhf42HYe1eh+HfFNhrWk299EfJWRcmOQgMn1rwDxYtnqQW+l1K3AihUEM3MYPdRXHXl1fXGlSX0Elz9jjkEMQT5TKvritIUoSiop6ikndt7H0D8RPiAmj3aW63KW9isbSXEoGZHAHCx9uema8UsotK8a65Prw0+S0t0wAsj7i3pgetbOneFrfxH4N0V9XnaKYu+6Wdjt8odAfpmtLUfDFxDsi0OQx2SEBJIU+Vx7HtVUqSjJqT1E5aKyK00n2ixhgsrab7MDtbCkswH4V18luBo4SHYgjQKIs4ZV71o6fpskHh5ZNWkhS4XnzWcLx6N2rObwrr2seW2n3Fq2mSDlg3Dg1pzR2WiRD7soSaio0wmwjEvkqcbVyfcVe0TxGl74Ee8gsJbPUmYxw+eN2cH7yiuU1nUR4V1v+xLO8El4WC4iX7p9N3rXZa8qax4RFw0oi1i0h/1BO0k+uBUykr67MOV20OKtbDV/C6T6t4hupt9y+2BDzvz1J/wr0O8S0i0WCaZ4ovOjB6gHNYngG3tLnwpEniwPODcGS2jkJ+Qf4ZrnPiRpggvBdQ3wIgPmRK5+UD0xWkpc0uWRMdro1datdM1PSHj1lV8uMZ809Vx3p3w/wDE+naNpc9xp7CW1T90gJwXb05rzq7HjDVrGTUXtt2kMApwvDgeld23hB9T+H9j/Y9mLO5zuMbcE5ptxSs3oHXQ9e8PSpc2x1CXZ504BYKc7R6VY1yxtdU0yS3vo90JXJHpXnuhnUPAvgvN7te4JJAJyF/KrfhPxdd+JtKu2ljSJ4yV3JnDCuSdJttweiGntc5nw1/Zeka/cJpaySzFigLcbfwrqvGPiIeGNOtbq5jd5ZThY4+59zXJ+H7/AEV/EstiyzxX7thZjjBPuO1ema5oGn+INPSz1VDIseCGBwQa0rNJxchR62IfBustrukLczRGJm42k5pPEGuWekxFbuZUBHHPNYd/qln4ejjsLHZGIRtUbs/nVbXdKttb0Manf5jKDdnrkVm4Jvm2iNX26nCeMdbbxpZ2FklzeaQYZ/MMkZJB9c4x07VbXxtZ+JvEsHhC50k3mntEFFxP953UcuR26VueJvBrXWqPJDcrAp/h/u49B71U0XVrfSPHVvocOiJdzCLa+oFdrLkZJB9K7JOPLeC1S08jNb69RPiFpFv4q+xaHPrUdgliwKW0XIk4GMgdCO1a3hnw/PqPia1gvyt1punQDy3lUMSenWqupaAq+NJ7hvmkfbOVQfcU/wB76noK9R0i/sLfRVlEkccaghiCD069K56knGKjHt9xcV1Zzes+OfD8Gq2ul7GdpZBAskQ/1bZxXPx38Nx45/s24tJPLR3RZS5w2DycfhXK2mu+HJ/HkNxpli1zBNeAZd/4s43Aeme1dz4jt7K18Tzy2sLLqUqMGk3cBD1IH9406lOMHy26Di29TjvFugeLW+JNlfXF6bbQLa5EkFwJQsMUWRx1+8RxXsviO8j/ALJleyZprp0IiWD52LEce1eL+K5I7ETLrk013YQFXihTktn+H869g+Hd7ZX/AIYtbixtRbRgbCoXHSsKkpz5ZNaLQ0UVHS+p4r4v0DxDpts8rQtGHIkL7i5QjnJ9QfSk8HrovjGwEV9stdSjbcA0e9ZGAzuz26dK948YKo0G8lKCVkiZhGf4uK+Nbq91Tw9eT3uivstvPKvk8Sgn5gPaibqVFdO1jSny2sz1BdV1saiNNv4I7uBpBjzVRomjB7j7wI9uDTPG3jSC51lY7OCAyGMxZ8veqODyQvuBipdO0yLXfC+oa8l3DaXGmRGRrcLuYAjdgknoa8cuvEtrcrc3iW72xmTEcY5yR2z79c1HOm1KC20LjDdSN3S/Gd9Z6FqcU1s8ktxOf3jShHVOQo6ZwK5eKXWL3T3tUnncyTeYixpkb+mc9fyrW8O+BNa12z+13gWGwPzFmYZOe1dvpFovg7xFYaJ/Z0l013CrfazJ8qE87R247/WiU5STS1tqUlGOvc84vrPUtLVbq/mu4p2XBVMqGxxgjNUdIja7kWW+mn3MQibnPyr6/Su/+MHhS8geLU4LqN4zMENuCPk3Hjv09zXN2Gj/ANpai8L6lDYWkUY82d0PAz0T1qHJcqaZS3NrU/DFxZxbtPvrRbaSLL/MTuA5+Ydq2/gt4vuLfX7fT7XT0ZLqYK1zF0A/untVmXXPB9voc+g+GVmvb102y392Nqk93J9uwqT4Y6FpGt6ANKttbisrpN63McibVkfd8siOD1xjilBKWk9BTbtdI9v+IWhSX01vNFZIyICfMjTc4bH6CvJtS1Pxz4ysb/wosWnNZ+UrTTzJtaJc8KP9rivSfiV4kTwZ4KtY4dSjkmhiWILJJmW4wMDGOvqa8i0rQ7m31aLXIPFunzCTFywtrjLxPjLDZ/Ee2KqNNW5nK3YzUna1rmDaaRrcuuC0htri5mRBsWFPlKg8MT06jrXSRJqWuaqbDWoPs88L/vpQR8+OAPrVnTPEk+p2mt2M90bK4u5d0FzbDG6JTyjHt15q94U0m30eVLq5EspE3BUEqVx9457Zoh7q529TSb5ny20PXPAukQwWERnIeVFKgHqBVrX5n0fw1qx0mVXv44Xnhj4zkDOPrwa84u/Eclhq0ckMkxW7crEsZyzgHn5R2Hr2q34F0OTSIN91cSX0l3NJI00rlztYk7f1xW/seX3mczd3Y67w14ivtR+G2m6tf7LfVrm281YSQPNfnav/AALj86yfCHijWZ4LmbxEixXEjFmsw217VRx+IrSm8DxXms6fdu7w2VoMRWyscAdh7CotU8JzHUr6S4ZJNKljkyM4cb+vPoMUL2evn/VhK9zpDf2c9qssVwrI33cHqfSuC8fzawmkSyQyTRWcP7yZYz8+Af4vYipXC2lgsPh6wle8tId1sJfuz7egOe/vVrwV4gvvF3h3VH8Q6Q2k3EZaC4Rh8rptOWGetQ6VlfoaKdn5mJ4ZaTX9FsDJIkcUoZraKSUGZgDgsAeSKo2urW1jqdzAk0ykF42Zu4H+z1Fc54d8P6d4l8eQ+JdF1Zmt9LREh08oRKpQbU9tvf3r1bwl4La1F3qWrRxy6jcfwsM8dTk+prSdOME1f5CjUd7tHjWtXN3eeKJTqV3aXWnzpsgtWhAKf7TN147Dua2rb4M6d4q0VryS8ubaOT5oucBiBwzL274rcjtrnxRrWp/a9FSxudObEb43xTrnAx/tVW8ZXN4ba0tIdSuNPudhV4IYzsyOASTxgVyVHKPutWfc3jaWqZ4tZaP4c8KeMbiw8VmW90phsE8fJib39R9K5nW7ezupZ5dPkjmsoZNiNnaWTnHJ719CeC7rwAnhWW48X+VcatGrC7N3GWLMM8R8dOmMV414NgVvFtzc6ZoX2q3JmlisbtgUiiOcHJ4Bx61Sm2vNDVk/I5WTxBcDTHtIpJXRnB3P1EY6Kx71s6Bot7fLHF/a0Q84bvskN0EDADOXOetRXKfYjPpOq2kVrbandxMZkfd5Ee7pn6V6fo3hCz13XlhsfDq/2ZHlFkGVWOADAkZzxuPLVaSZLk1uefavZNaXS6faQW0E0RB3W7+Y2c/3hXX6R4ZW3nsb7+05byYBl8ySQbYMjkZ/vHNR6dd6Dpjaq+i2xujDK0MNxKMxtgkAg96TRIJtamXS7KN1vJwZZ5FJGeei9h25qYrW+xU3oXb7Sbk3UywaeJH06Ldc6hBJs2bucORzuHt0ri49IsdZuJLi/vJpdqlt7MZCQO6n0r0afwrrWmaPq1tq+qNpOiQRAyRhRvuT/vdQD+tcjoKwWzaYqWD3VzLG3kWy5BmTOA5/ur9etFRuT5luFNJJplvRf7cvPCUOn6DHBpnhmWcwC6kl2tK2eXYHkjtmsnRdC0ayuLgT6lc3WqQNjzIuUIPBIPb611mqadaS6YL7xNdzwaDb5SCxtplI3DkqcdWzxivJfEWtW+pXQh8P6cbKwU/IoyXc/wC2e/sKqacnZExaSuzUuLfS01SW+A22GdrrKnzsQei4+8c+lbyTXOka7Drep6NbiIwCKztpsb0B6MwHRvr0FchHpsmiw2uqalM0cisXhRlyAB/EvbOe1eoafpxstBtvEnidbvUtXv0MlnBIN/lp0Xd6ZppKa5UDfK7sqfbX1eaK7tvBhvw/DvLwrEcfIw6Ae1Wbb4aeJ7PUrTW7WC1sZJJBELaOQjard2Pfr+lez/D68ttc+H9lf3Foq3MJeAm3XG3B6H+tdNMlwmjTbyJI3ACqed3sKwnOVN8ttgXLLU8i1fwBq2pzQ2lreWV1qVkQ5HSPPXAx/WuI8UeItM1bxrMnit7nTktgqXcSEswkUYJUjtx0ruPjx4wvPDekrpz2506/v4grG2cDeoPVWHOfWvna3hfVNYtlgSGN0TfLLcSEhscln9T7VdCU1eVxTSkrHp3iDxjpNvf291oUH/En03H2GO5+V5pmHMzj26CtT4YeDbrxJr13ePNa39jKRPf3mCIyxOViUnkkd6l+FvgTw7qtn/wlnxB1GJ1aZvs1tKfLVkTuy/yHpXbj4q2eseITovhC1U6XapvmdIgsaIONx9BTnLp1FFfynT3c93cakmi6dAijAErjiOOPvyPboK5P4xjQfDnh3dp8cmo60QREocOsI7sy9AP51k+MNYupHuVFxbW+ki2F3shl2zXGSRiRhyOmQBXFRaHK1qbmFpVjvGG1Q+5n9374pNJpBFO7L3wttH1t8a99iWMfObm6ACQgc/KnA4969b1Xw1ot/p8E+jXg1KaWTyi6SArkDoFHArzzSfB9z41+16ZpJMMdtAPOnmJ2mQnhfyr1D4f+EH8J6B9ld4r7U4iZX2NwW6D8hXVPSPxa9jFu8tjw3Wbm58PeK8apZRtJDcCMwPCGSRSen5V6X4Y8S+GD4o8QaVeWkP8AZ0LJOp2/KjY5H4GvQp7W2Tw7c6t4i0uB57RGlQyRb3Ujpj9K8Q8K+HbXV59ZS81K3tY9QTMlyxGVZjnaB7UpTg/dtZpAlJ3e6Oq1LStR8R67dancSzWnhMw+VFaRRYZlHQ+g9ar6jZauPDsdr4cujo1nZsGMk/zEp1OfekiksmmtvCPhzxJdXzaVH+/Zh8rk+jDg4pPAfh61tddk02+u7q/S5fdL5rHa2DkDHeh32T228/US6tonmtp/FtnAyXiTCIcGRtq47sR05rq/D97a/D3SAl/eG4jmP7uGM7tufQ1nXvi/Q/E2p3XgpNNltbaZjAJogFYFe+B24re8W+EtKsPCMVpCERbRPkd2+ZiP50VZyjTs9EKKUpXOY8U2HhGXVE8TXCz+d/rGtwerDn8KwtK0+08eW91fi/nS78/JWIYAHZAe/FWdOvtA+ySaPM8Fxf3Yw0E0nLe3tVzVdMns/CEcXha4trW9LnfHAQpUeg/xpQleye/QqUbXt8x2seEr23tElilJWDiOKOQux/3veoNT8ONeWthceJYSkRwTGG6KPWq3hHXIfAen3U3iW/8AOvbggQ2ofexPrjtXosFk/iXRxcakxXzkzHGvRAfX1NaTbju7ruZpmLpPi2xklTTbG2XyoxtUcEAVK2vWc+srbNOPPXnb0AqxoPgiw0CG4kgDS3TgkO/Y+lcLpfhXVDr9zfXRK8kIzHG4n0pLklJ2DZanea9rNnOosXha53cHb2/GregaJb2kIa3jEKNzsHPPuax/DWk3KzSC8hYKDw/eutMq2igE/KPWsZNx0uVo9jHg8J2EernUWj33Gcg46VpzSXDwzxKArYwrCntfAqWHTsa4/wASeMItGu0jZDIZDn5emKS5pyURWsFt4O+23gk1FQ0KNuwTyxro9T0vz9Ll09TiJl2r7VY0bUFvrGKeJSVkGRWB411680O1NwsKvk4UZqpSk5KLFFdUedz+NY9a18W9kkgvnUhQ4IwV/wAfSu38Na5bapZWV59nIuI90cwZNp+U+v1rUstJ8P61rRudObTRqNv/AKw2/Lg9OTV/U47TTLyG2SCTdJkLjkue+K3qVIPRK1iIpnOWc73yawlwJVmvizNcqmAoxtRU+gq/8KvCUOheGLixvLs3tsDIhL9CG+9mn6pLB4bj/tXXJWaIOFihUfNI3oBU8XifT/EuhtNoWYrmX920LjawJHGRUz5ppcvw3KVkcfqtrong7TNRv/CWjRy3ofy7eeXLrvJwAAO3v7VQ1TUNXs9U0Zb47xPEEuJyMktnkqfTtWla6Frug2Fzc6pdCKOZhAgZshQf4z6AVq6TpVz4m0u1MpK20TMUmkGDtHQjPrWjfLq3ffUFqYHhiwvde8d3EdzahtJVCzGQZU++e2MV13hPx/YXfi1vDttY/Z7NMpa3CH5JGGcgjsTg4rW0K20u50vU9E0rUlN7sKyvGfnTPSvOl8E614RsJb6S7t7m+gkaSziBJLORjcTjgAdqwhGLjLnevRFyk3JW2PQ/FGt2TXE8sT2qjTm8qa8uZSscTt/AAPvNjt2rlV+HfhTxtZtdWmob7gHJktcBVb/dryjTXv7/AEe+spoJLhHl+1vCVbclxnkoR3+tdT4cPifw34Yv5tE05rJZm33N1cx/Mi45KL0J71MoqMVrqXHmvZGZcaINCu5ZN3n6dLbtbzyq21HIJAyO/SsOLwBFrNumr3riyt0+S2g253gDk8enWren6hdR+H59GmDXKzs7QLne4HXcfTJNaOvXM2leEtF8O2l1I2q6gyJ9oK/u4lft65xWEU3Ky8/uR0N2WpBqPieCw0mxtbSGQtA2Y5tuVkPbI9OK5DVdevLm+C6jH59/s3Flk2RhevGa9XsvhJe6O8MFx4lhubc/PJGUEUjDuFOelcv8RPh7Na3VlqGj2hnsLaRZpoicqyg8579M0k7vQE49DhtQbXdRiY3UcDONnlWTP8zgcjI7kisW+1ObVbW5W6BjEaFUQZyp/u/7teoeOI9KtNYF7ol9Ys0lyt0ucmVMANjHTaOx968Qm1O5bUNQ3pumuHYc8bSSTxW3JGycXqTGb6o7vS9P0/Wr+0MSMlgiIsgjIXDE4PtnivUfAnhnwhe+INVM91JPp1kVht3mYRgyYy2MdQDxmvOdOWXQvDFmL20tp5kIZnB2mIv03nuMd+1U9DaebXbm0n8uKASGZfLb5cnrg+grKpFKJcW5X1Padb+Gt5rOpXeoWepww21sr29vaDMpJA5GT90nOOK81udDubTwzcJDpltZPBIyuUViWB4J3VofBb4h2nh3WtTtdSu7mexe7McCqS5JJwDj3NdneePtI1HxFrvh2DThbpchvKunYMWkHYr2Gcj60oxm20un5EuSjv1PGNDtWtdY0u2Fx5TXku0PuyUB459DX1l4O8OtomnXimUXksgwhk5IAHAPauX+Jfw60mfwK9xY2cVvqVkiTrOnBO0fMD7VyehQeI9cstLm0+/lNvCilnefytjd9+fvDHTFQ1zyTbsNyvDQraTNev4d8VabcSO9xozkr5S4OXbj5+oHrXR/CCOSxmuNR8VawsnmbYbKM5CBR1YA9iemayfh7PrXh34s3VjLpckukeIJ5WN7IhO8oD8wPQD2PXNenfEHT7ODTJLw2qSu7LEQwO0Z47V3Qk+X2cupzVLc10dTq63Euk3Q09ytw8Z8tlPQ+1eWfDA65P4gvrHV5L2aCFTHN9oQqCc5BB716jo26HRrUTjyysYGCe3arTklCFBC+orNT5YuPclbmbd3NvZ2MpgVJJo1wo9T6V5b4U+Id34g8Xm30W2N/oSym0vY5YCkttLyN2ehQ4PWtvxZd3NrdwWOmwrcNku7Zzgg8D6966XSLPTbKKX7LaWunapeqJpo4sLI7/3iO4zTSUI3avcp3b0OT0nVvD+i+L7vw/pOlW+nuku93iXG9j3z6Z49q9SjfzYw3Y15npeim71ppr6F2uPtJkdgOAuc/wA69OVQOg49KKqV1YT0Ry2s6VdWekammmTHM0bNECeUf2rz7TfEdto/hpYPFcN1NO825d+PMxjnLdxnOK7nxY+oJqMf2V28tv8Aln2zWD4m8AjxPDay3uLSa1zKsu75Ub3HQjihcrVqmz+8rVK6Z5N8SvBK+IJ7bxD4Au3nsLtcPbR5IVh1BHY/WuRuPC2v2OgpOlq6F5wvyEmSNCOS47A471754Qtv+EXtr+S1ng1G2eQPNc2jjERAx80fUDHerPi/U9I1bT7q4sB9reOAh0QYBz6+uPSseZRnbojdc0onzfrPg3UxpVzfSW8xZk81UZuZV9QvQcd69D+HXgjxF4m0a0tLHxFqOneGY4wJ7TztyM55eNSOSvsT3q62iC58OS3eva5Lb6bGfK+03WQMH+FFHJ9MV6j8NTp+j+GYINGuV1LRQS0Nzbr8wJ6q69c0Semi07hJv59jB1bS/DXh22TQLVw13gIIzApi3HoG9BUQ0q60SzE+2xt7yEfOsDKXjjx1PtTta8B3mv8AjmPU7W8ltrDz1nckbScdR79q5TxZpGnfDGS91291qTUr26aRILTIyxbn5+pwKuUKXJpLX9SIznzWaOe8da87p/aes3ElxZxN5UFuRzduORx2X3qt4d8WaR4Z0681TxNPJc67euJAlog/cKB8sa56AZrz7W5NU1eX+0tZJAkPZvmI7Kidh71PomiaYbVLzxJfmJnQvb2qknAH3d/vmo0ijZq/Qi1a+m8S3K3N6jWWioHkt7OBuQCfmdvQk9T+VYUN/Np9pJc2ywpbyOVgJGSMeg/xrc8a+Lob/SotL0PSUsdPDANOy/vrggckn0+ldl4K+Ams+LPD0WqXd/DpkckebaJlLsw9W9BWkrbyM+blWh5PcXeoahBD9rMs8MLl0V+Fy3XP1r1i3Xxp4n0i30i9utKj0+1VWjaQlGhVRnbuHUAetcv47+GvirwTGZtQ/wBItN2BKhyhx0rkG1nVb50FxM1xGmAY2+VWHocdaIvrG2gPVW7noqfFzxF4Tmi0vRJtMksLNShSKItFNnksSeS2e4put/HPxJrN3ZTJBFZizXAS2Y4J7sc9+lefajdtOVe+tBDGQVRBGVAHqD3NXbi7OvWtlpGi6UYSvAWP52lPvjk0uVS1aC1tmT3ut6h448S3d54huWm1G4iCQsFyEA6Kqj1rf8Z+GLnwdZ+HJnv7dr90DfZkGZhznBXnrVrQPBf9jSi58RL9ilhQFYA20s2eMsO/ermvSf2z4z0SS0Cy3bxi2t/MbEayZyGZj19TVaxatsSldNHF+Jtb1PX7uQTWxRnl2+Sp4VuygD0psMGo+HrJ0JuLS8fdvA+VWTHc967JNPXTtajvNQV4rmC6JuZZ12CZzk8A8Dkdu1c3421O58XeJLu7srUOu0H7NboSFQcDOKajb3Q5r+8aHgLQLvVrKCea4eMXUuxXcFmk9snjGK9yWz0rwjaQW9+8TaiGBgiLbmOBkAf/AF684/tnU7K10W3aeK2+xwrKkCwjy42Hr3/Cu3+HHhq18eWl3q2sXE8Uv2jY1y4AeZupC56L24rKdOU03bRFqaja7Om8EprVjp+qXllag3mqP5pOcpGOgwO5xWr8PJl02fV7rWbz/SpJAHLnaikds9N3tXM/F3QNVsbzw42ha3PawQtjygcdO/HX0q94g8ATeK1spNK1a1+wrGqzK7Ftjg5ZsDgsT3NaU0uXlb0MJu/vWH/Fz4gz29ium6LCxa6QmSYjK+X3wff1rxC1tNR8T6s2kaWiKmVaaaMbcDuPc13vjvSrXU7uz8P+FriW6e0j8l5h9xO7sx6cc8VP8OfD8Zvovs9x5VnYnMswbBkb3PvVQUJLT7+49Yna+F/Bdpodm40bT1ivLgBJZic5wOtcjZ+MhpvjZdH0zSxdCOXbcXMuVfdnkj0FexNrMMelTT6ZC0ypx5g4XP1PWvFNc1jW9M8Yw6hfabbT6RdNhrm2j5gz3Pqaqleb11Ik7eRvfELXtP0nUGuLGwgS/kXdLcRj5s+gxzmszW/A+reJbLSdXtdRuYhNEHNuzltje1GgeBm1HxPJeS3El1Yyof3gycjqMD1qXUfEWppdpa+H5CyxSCCKEHnAPJNXKjCaUYvVCVSUXd7FvRfhNfWsBlkh037cwLC4cM0gJ9T61g3HgTxBbfECwhW1kvNPkUedc8qqDv8ASvctI1R/7LgN8yrcgYl4PBqpPrl7DLM8dmJrYfdEZ+b6msIycZ33KbbVtjwrVPBl94W8RXeo32h/2laAl0k3Ftg7fSvWfBHiZNX8LpfmA26AFRG3qO1dNp18t9aXBngIK53owyCMVw+s6hbs1tZW+nvHZOSU8obQDWjm6i5WtSLWZn+FtQ8R3vim8vL+Q/2ZyEjPAX0AHrS+PNP8QX01td2IISM5ESNgj8K6OAx6dYJLdukafwhjjFO0nVbbVZ2NvcJKsfUKafM78yWwmuhpaLJcJpUH9oFFuNoDgnvXnWu6p4ptfFYQw+fpsjgKqrkYrP8Aidf3Z1kxG5mSFACgTIB9K9D8IfaZPDdo92D520ct1xTUeVe1a36Cf8qLl6Fg0x5SnzLHu2/hXmFtdaZ4oZ49UtXhaF9qSK+Mj0ruNc1KeG8S3VSVP3j14rkbm10/xE8ltCGszA/meYi/epUo/af/AAw2+h3+jFLWCGytY2WJF+Xcc/rVfxFoUusIYb2RTat/d4K1wvjyPXbF7QaS1wbMRABoxkk+5rp/DuuSp4VB1ObzLuFMylutRKm3H2lxJpOx5zpmj+J9I1SO38P2t7DdW3yPdqF2S7mzg+31rvfiB4h1zR4tKl0+3iutXEYSeZE3rCcfNgep6VwP27XIrqWYT3CEt/rPNJDnocY4NeueEdKtz9n1SG+dbdI8NaA7vnxyWPUnNbVZe+pTSYkrLQztagtfGfhLSofEkMseqnbOYYDh4W9ceh9KztC8BHRtVt7iPdDaQNuXLZaRj3Pv29qtaroWuyeNdU1vTdUiexlsHS2hVhlZccDHrWD8JbbxFE+oNr1xe+TM6LElySWaTOWIB6ChuUabs9F09RKzltqdr428S2djrtjpN3CLiFkDTjqU3cDIrMt73XT8RprVFE3h14PLURDCxDHX61reOPDema3F9stUhm1ZtkXmh+dueuKr+Bdcil12+8ORWUsI0xQpnkP+uPf/AOtUXSp3iumvl5lrfU8sttSm8JeL79NNjdZ7lvLJbghN3BY9h710njTxTeaBrSadY3FqtysKz3F1fAzM24Z2Rp0xjvR498OXvjC8E3hu9tYonla3ux5gUq6twT3OB2Feg6z4H0fVrXTxfuBe2cSRfaQBubA6c1cp03NTn/T8wtJLlRmeC71de0TTdRtbCOwN47Q3GE252nqo96vfE/xhp3h3Qru0JW41CSBljtEG4gEYBb0H1rZ1eBk0+C00547fySuyQkKBjrj1NeZ6MujXKeKda1zTrn7XEzyobpShlRVx8ueo4rke/Mkax1+I+frKy1TUoZJlu5be8kIVWBKg4PqOgr27w54P1XXdNsbmO8gfVtKKNEZl+WVk6Bu/PPPauS8DQMobVtQmsYtMula6gt1k3vHnoCMcH29a9U+FesiWyurSwSQ6gjDdHOuNgblST6GipNpWtp/maPW7OD8ew3mr+KrZ9Vkl0HWnQKsFy2YWAPJjccGl8afEWbw5psWnWti95bKuJLuQ7Y5QeCFPeug+LGqnXLC50bV9Laz1mxYTWdyp+Qv6qT1UjqK+etb1+/vEFld6cJZoiZPMRyUI6ZCdB0/StVNTjyy6Exg4u66mt4MdrLxrZ+IL/RW/sXnMEr7gR6j2Hoa2/G2n6dP4jOu6NYxGCSUyvC7gKfoP6VwttrWt6lKsMBKXEgwJN2dq9MKvQV13w50fxPomu380Wkx6zAkPlzRytkEOOinoG71jNNS5os2i9LSItb8RxeILODSND00i6ki+ziERfPOSfvE+3asu00vWdPhutA1XTpbC6fYwDrtd0zjAbuM+levfBXV/DOjeLdYi1+xXQ9XlZWszqPykx45VXPHBr1b4l+D7TxtoCGG7FrfW4MlpfxfNtB6jjqpxTdVt2lpYy0i7LY+Xb7wDfPeaVpXhuwnOu71klK/8sOc5kboOxrp7s6npeo32k6jodnba9JH502owLufy+5VegJI617j8D7eGD4c6ZcZ825n8x57g8vK+8gknqenSvGfE/j1P+Fo3fiGO0UpCTp620xA8xQDv3+mTSU7u/YqN5aWLuj3sr/CnxHPqXiC9a9u4vLS0nOSvzAgDPcgduldJ+z9bw6zFqE1/OPtVpIkS2PQIoGQSD1z61yurhPEuoW8hgNhZBM4igYIpPOenPPGam8LeKLrU/Gel2+g6bZvexMUbaSu4DqzH09qmV6zbitNyrezja+p9NhR8vA44FeafEP4kyeHvEMejWNnbzTqiyzPcybVweQF9TgV0niHxtp+hC9F3HO8trGrFY1/1jH+Fa5TS38H/ABeja8kspYdUs8B942zRjtyOGFdNKKXvTXunI79Dr116C+0/T7pZVjjugrhWODjuK6JpFSEuBuUDIA715XoUEOseMzptrbSx6dpagb26bQfu57lm5P0q34m+It5Y/ECz8NaHpK6gDIiXbqxzGG647DA55peyd7R7XKbOt0PRGtb6a8nOXkJIGfXvXGa74I1a++K9lr8F15VpGyM4wScKMbQfQ+9dD4+8eWfg9YI5bWa8uJUMgjiYLhB1Yk/yrl9Z+I8mq/2da+GnkSW8i81QEDS+m3B468frVQVT4l1Qtz0TVtYs9JdBNzNMdqovU1KdWgGlC/bKxkE4PX6VzmvPDpWh219rzLJeqqo6Jj9457D/ABrM0fxjpetJ9gmiUeWOFj5RV/3vX2rmc4rQ1VNyV0cxqfjXUtUuo1LJbRRylv3QyXQHv7mruofErSbSdItXNz9k1GJoljXO1R0JJ7Gqd5fazqniMaP4T0i2tbPJP2pwAwA/iJIPHt3rrPGfgrT9T0eJJRZpqsajFySIwrY5fH9K1qpxs2tPLcIyi/dPIb+50+ztr5PD1+zW90d0+8+W8wz0PtW3pGp2iaAxN3YWywKVNotwq+Z/tHvxRY/BK6S7jmfUEazmH73Em449j2/Csjxf8OfC1lqMEcGoxTTOdphWTPzgcAntXJObk/eOqHKtInOeN/Gtlc20VhmW5h3bzDGNyp7/AEr0f4d+P/AnhTwqlnpV5dXdzI/mzRpAQzSN1xngAAevavK7TwHc3F89npjSM5OG/eCJWB/hBPJFdvdeF7jT7aCDV47SNLWMR+RYWZ8yYMcfM54A96tVLQ5E9BTpRk7tFnx/8XLjXp7fR/AEMgnuDse5mTa7E/wxr6jua5rxl8Mrzwpo0euazqP9r6tMQAlw/ETt12g/exXL+L9EPh6902bTbG70yWN2e3u57ndI5HRVA6Vm6hrPifx1qVvpmo6pPfOgyIpCqRqQOSW4x7+tU4JW5Hp1JhfqivomkS+JvH9tHLfRESZeWSA4VEUcqvYela/iyHS7jU4LDwvZPfW9qwluQpJkmGcFdx9KxzpN/pKRJbWYYxZ8+4tJN4kQ9AT049quNY66fCr3Iv0spJJPJisUXbLMp/2hz+FaXvp2BpLU5zx7q1rd+ImbSYpLa1tsLFDIclPY+9e0eGvjvqGk+C4Rd6LNcG3QRfaVQiMH0Jry+78HzaDo9rc3lm09/e52265chR7Uxvhx4vksI3lsbiIXGZIbENumYevl5yB9aTUJb9CbNCeJviZqXiK4abVHnuVLlktnfFug7YUdSPeuf0XQ21iYT3d1Dp1kW+aV+AO5wKsXtm2lTC1l02dLq2O+db5dhH+yB71Fe6ut1MborAJmG1YwmVjHsOmfc042XwoLX3Zak0+x1DVYtO8MSarq1yMqJLjCKB3IXsPrXV2Fjq3gbTBdwNpiXTuCseS9wxz9wY6DPPFchpMms6ZbT3FjbvHFcDZLI6bWZSfU9BWto2r2Hh6O4uri3Op6hLGVR5HYrDnpgHrj1qubUXLoZ3ia51641VLnxEJo5btzKYF+QHP8qoRapqA1FU03e4hDLDCcPtJGCfTNM1e8utSD6pfb3YyHdJK3LE9FUegHpXo3wj8K6DPZDUvEuqmxn3NItt5R3Og6Ybt71Wlve2JbttueZ6xrOr6xIG1u/ubkwfIFmb7pHGMV9Q/sm2Okw+Dbq8ZIl1dpWW4ZyNwj6jr0GK8OnGm6n4ouSbWZ7aEvOYoVB4HTcfStbwn4N1jXEl1aW4uNN8P4+ZYJSrSL/cGOprJyurWsU4eZ67oGmWvibxpr3iGK0gl0HTC8MAY/LcPzub6Dmoh4iintGh0yCORIMlIIFKbB3Pv9a0dC8oaN/YcLm2tFj2GKNDs2nscdTS2nhL+ytPv9QsirpaRNI9vCm4yYHCl+3qQK3o8tONpfIyn7zOes/Eup6xrcE+q2F1IIcxrbqCzyZGAqgdB7mtHw3pd5ZSPpyW0ml6ddu0zQzXG6Rz/tYPyqOuO9Y3gDUvEt/wCL9LvrAzx2jkJcjy8Qlf4s8frXoXi3wZqesW9xJG4sWnlIkkjOZXiPUe2RSrQ9nJRWz3FGXMrs4WG5isDq48Nz+fYs/lS3R4EzDqkfqo7tWpociWfhi61OCF7uAzKrR7dqlu7H/ZFSa3odhZahpemI5aKJ442toRjEWRknH6mvZTolgbGW1igRYZF27QOMdhisudSlfoVL3Y26s4rw94lt/FGl3egzCG1vzGQkcZwCvqtZlzHD4LsLXTtRaKZZiSVlbO1R3q+bDw/4Q1b+0LmS4l1FvlhtwuT9FrIhvNJ8ReNVbxHC804H7m3P+rhHv71rN8z5aW3Uzire9IisfGX23VLXSvD0sqeY4DMEyo+meKTxHqWi+ENTlu7SOSbU/wCNQNwyev0pvhbxg9/431Cwt9Nt49Mt1YL5cIBj29CW9/SumuNBXxapvf7Pksps43ynAfHfHpSpx9k0pdUOcudXiJD4klvfBMuo6baebqQXKQyjJX8Kw/DVzqtzJNJdzvKjxgGPbt2ueoBHYVHF8OPFH9pSTDV4raHptt84I/GtfWZYvAmio19IzPM4VZHOSzGtHyJNR1bM1e50NpcjStK/0gDYq/Nk1j6bfxanZTzeRGiRMTGyc5rn9Z1a6v8AwzdSQ2skyfxBOTWF4KfVEtpGgtZFtmXJ3Hp9RRGl7rY27Ox22r6EfEmhRRSytA+c59qPC3hux8MRSss/mSyfeJ4HFcrfeJb2wZI0uIgz/dB6Vr6BqyazbyWtzj+0NjFADwTTcZqLtsLS+pun+yb6QNdQRSshypcVz2p+Kpjrn2DTVQRRgbs/0rI8BWOstrd++rxXEcK5wJRgZ9qd4Lvnude1TTotOLz+Yd10y/KF+vrS5eV2eulxbo7G1uF1N2ygCxrlmxyx9BWBp2ssNXezhso4VYkD5eprd0DQ7201SaW4Y+STwueK1L2G1S9ikjijWRPmkkI+6BS5op2etw1PL11Xxdba/wDYriIzW7SfOpTjZ7Guju3srqJ7YxNBFje3qwrpYPFWi3lyLeO4jeQnaOOtRr4ag/tC4ldj5Ug+UE9BTc1ZXVhW1PHdWvI/D0dt4K2Xdy14F+0XMA3NA7H5QMfrXaPdaV4C0xLe6e+uZdm1Qv35PU//AK60tCmGoeD7TVtagtLDUwSnnlvLEgB4b16VQvrXZpyS6teQ6yzyl7d4BtRVxypPeiUouSutOvm+rHFO1luXvCnhK5ntLbUre/uFsJUE0cUhIdQTnketdPE1rc213LdTGIxQvH155GN2fWuf03xaX02RPtSR2sULOVA+cqo5Cj2rnPBfiNPE+qST2W8aW8RjaF8b4zn26isnKU1zy6MtRt7pX0O7k8L3C6ld2qxJAzPLcLIWNxH2GM4z7CvSrO703VYLfX9LQie5AKhhtLZ9aw/E9loM95ZaJPb+askZG5eNpPp71s6rovleGDp2m77JBEIoJQMlfX3HHGfetZyUmns3+REVYpeBfDfhJ7vUZ9NuPt900zSzguQEY+g9Pet+80a1tdYsZn8x4A+EVnJCN6mvOPAjaL8O7q4bUr97rVrldhitwXSNN2eT0Jr0PWPENhqMJs7JvPnZeg7Z7H86yq0vefbuXGT0ON+IHg7xDf8AiK41e0vIhCgHkb5G2qg6ps6ZPPNdbpto2o+F0sdRiV3lDRgSDOFxyap+M49T8P8Aw/vZrW6eW5gAkHGQoGPlX2FeOR/E7W73R7W/a4e2kiVkdgmUkYHtiqU5VeVOyGocqbR0fiLwLD4Zh0mNppp7WEsEjQY2HqCcdRnFaNpDqtloPiGeygNrLdKswvQRvKgdM+1ZMvxQbWYINRSxcxxRbNrL/rXx19hmtfwV4h8VDRNb1LWNPt30OOFmhgUZJ4/PHrms/bu6jvt+Zo6do3Z5l418R3HibS9H0m9uy97Z7w+olgpnXjCf71ZOo/Ce5tvBw8V2GtpdafIQHiVSrhScYz3weoFX11HTdQtp5LjTLRtGdzKidHinPVYiP73oe9ekWWh+KNdttI0NtNTQvDUWJQpfzJJWAyN3p16VVScE7BFSXoeH+Hbex0wXsNxdBoLlA1pcbCCJR0UH1/nXpHwY8WyT6lq1tdrEkxZCIIxjK4xuA/nWh4i03TPBniW2sjYRXssYMwWfhNpHLA9ueM0eCvhPYart8QW2tz2kN1l7Nc/vonLHejHoR6VU6dk59HawvaJ2T3O58S+B9C+INpv1AhLu3Ty0duAoBznHqOa8m8VprngfwFdaXaaxdvp7yAW7QkhtpPr2WugjudS07Rr29v5rrNpcFIknXHmAccnuSM8V3P2fw21mkniS4CpcLG8UDyclcAjcB05P6UpRa1mr22HGVvhZ5PoGueI/BHwwh4uf7MutxiDx7Su7k8/WvOvBenDxH4plvtSu47S0hcSSNKxx16D1Ndp8ZPGNx4i1xPD3h9UfT4UEMCIPTqcenvWBYeFfFPg21TVrqxjltJlPlujg4OCOQfbNc8I6We7Ohuy0PrrT7rRtH8LJdxywyafHGC0infmvJ9Z1/SrbxNDqng/TIornzRGZNoWO4J6rgd/cV5h4Q8Z+JtK0K+0/RtGmuzcjcxlXfH7/AC9yRVe28SeJ47yKZfCkfnwsPIjO4Ij9iF9s9K0jCnFOLMUp35j3fUfHOjahbXkWp6ZELiVBBOrnO0E4P61xWgeJLL4a+I9WW6kEyXastlsIYAdiSPWuGa717XdT+xWmkCbW5Yj9qMZzkseS/p7V1Okfs/eJLmGBdW1yztbdju8lUaV4zjjGeP1qIylGLi5aM0lGmndo6b4efFvTVC2N2kVnqExeSaSUHZJJn+FvTHQV0b6h4Xg8QT+JtPiYanNHiaeRyidMHap/iI4zXzxPqK+FPFGo6DqMdpcy6bMUW9jXcGwOPl9a9M07x34Vi0CcagJtQ1DaqCGaHG/d3PsKpPku22S4KTvFHY6jeeGfiI0X22KWOWzOIryGTbx12j1FZTaWU1OS60JzFcWkXk25ikCeWmOnqzH+dcp4Hhu9R1oq7vaRTnCIVA3IeAoPQAfnXofjj4YWjeGGmtriSG8tpEuFaNiFBXufWsVOVSXs3KyNJKFLW2pxXhzw/rXjfxL5niKe/ttPjJDNMTh8cADPc+teqeOodD8HfDq8aJYbOGKP91ggNI/YZ6kmuR1n4q6d/ZcmnahcR299HENs9uwY7gOSBWDP4H0/xH4ah1zVPGpl8tDLEt5MHjXHYrnj6daXwStITvJXNX4RfEW11TwzPp2oXwsdUMTBLpl5XI4Oe+K5q70S+WS4OoeLNMu7VeQY5y7yMfReufrXKeD9Hh1u6d7kW0RtwQYy5jSZc9Qe30ra1a28KeHNPATUNOVkySkQ86Ryf4S3XGfyrohW5G+V/hcmVK7V0ZmqeIvEsS2nhqWeUWMb4hKsVYqeSxI6/wBK1tO06GS8g+2W1wEOGaVSA0jA+nv61wt74lsxMH06UMzDjMff0Hp9KWO68YiKK7EOpyWs/wAkblP3Zzx17Cs4SablJGsoq1k7HeanpMj2upXSXOn2M1o++2lN5tmjPbdjqfauh8I+KfEGqaM1prMH261nkVPt8CZY7eg46/WvL/D3gyfVby6u761hvXtXBugJWVo8ckMv8XtXqWoa3p+jolx4T1IRwBELQjKPb4+9vToR79qJqNSVtiVeK7nFfFPRvEOseJ1vdTsbi2sFxFbiU/KVHQYHQmuNstN1VYtStoNK328fMm9tpAP3TmvoxPiHour6BNba6GW7ljKRnyshmxgMK8DumSxFyC080jjh2lKxgf7Q7YpwW62sJtvdFrwn8VIvDPhu+8P3+hKXmON4wQPXik0zxBZaxq8UtndRWd3nbGLlerkY4NcbMsA1OxlvCs1r5o811Xjbnn617jrn/CNQSS2mi+G9KuRaQRu9zfZ/fBh/Bjpx3pxipy2vfzCT5Eef3c+taFqW7UoXkugQ0DpLuAXPr1Aqvq3xAl0a+F5o8iNrBORcks7RcY+Yt16ngcV0kvgLUNd0p9YtNbittNcMYYXYs6FOsZPp6GvKrHRLObUmtr24eOPed9wG4VR7Hqa1UlrHaxm1ez3L2kS6XrXiKW88d6zcypIfMLxjJkPfPpWhqmo6Ct0x8HeHjc2kPMk10pOf9oAdB9adonhzwjN4b1SXUtTaO9hnYW8zNtDIOi7e5bn6U218Z3Nn4NudI0LS47KCZttxehtzSr/d21MWun+Q5J9UVJfEGo6zfWUes3kFlpxO0Ag7FUeo71Hf3tvq9xJHawyPbRcNIFwHA6YHbNHhrwfqHiG+aW6zHaRqHdjzx0Ax6129np+nNqkui+G8QxyMq3FxMfuKOuPqetJxja7ZXM72OSNmq3UD22mOqIymEzZI8wY4weDXfX9po/hy3udW1DXG1No4RG1skewecwzsA7dean8c/wDCM6Vd6RH4c1GTW/ECSgPGCWQDGDx0FUm0BdZ1aTUfEbt5k8u5YcbU8zGAx9FAGAO9ZtXV1sO/3mF5hstMaygslkm1Aie8lSImSMHpGp7DFeuah4C1TxB4M0OPw/d2tr5CnzLdpsKMkEHI71W0Dw/e6NNa3M0kdtpN0/lFs/65j069RXI3mqa9oLTWeugS3k94Us4LMbWZBnI4/hweK3VTld4W0MXHm0fU29U/tCDTJNL03XLK4ktvklmik3DcOox3xXqHw+vF0vw3Db6hqtqscClmkRMbu5LE9zXkcfhy50Ozg0u2to1muGEjxyH95zyEz/Ou4tPhVDc24vPHWtu1vgMtjA3lxID2Y9Wqam12wVvhF8PX1hrPxUiEWus2mxZa3s2YRpNJ6qg6gep616d4v8SWegWyG6O6WTIRB1+teKazptjoeuDxQ+nLJa6YoEMsZxtUcLlR3qvdT3Hj++sNUtpZDHexmMxy8eSAcHHrQ4RjBNPT9SdZSszLv9U1i61uXWreIx28jEITxkZr2Lwx8RrK60hfOSUzxJhuMAkVx8Xhp7WFtL1I3F5b3HAKLtCY9PSsK4m0vwjfl9RWWfSoJAqwofnduwJPYdaXLK6hH5Ftxkm30OxvVk1TU31zWYHCEhLSFW7e9Jaafp0WsR6vHIlpM7lY4p3z5jeq+orSvvGtrcWmnXGm2iPZzoGVZEw2K57xP4Mvdd8ZabrttMfscKoY7Mgghh/IVvCPs1yy0MW+Z6Hofh7w1Y6e8txFZxWpun8yVFJPmN6knt7V0mozSW+nTyW8fmSpGWRPUgVwEPirVl8RNpl3prtgf6xc4z6VLrGoeJmdzZx+RsUvlhwAOw9TWbjLeXUPJHLaFr3ie28QC71EXwsmJM/2jAjVf9he1Wr24sPH2qpJqrrdafA5SCzt2yVP9+Q+vtWFpninVvFkOpRa3ZXkdrGphBKbc5/iX1qpo+i6h4fguJNHkLGTBkmdQpRR0G2uh8vXRozV2lbY9XtYNN8N2jWWloJJ3TiPO78xXG+Hde1aPXJoLm2HkvuL/JjaO1ct4dttY0vxQdfuk1ISzLtWOdfkcH+IV3V7qV9dX7gwIsUkR+ZcZJAzg1m4cm+rf4F76LoVH8BWHie/tdTu5pYkh6wRgBWOetbXiDwtp+naVPd6XEYtRiQtFKp5yO3vXMfD/UdVg1PUHuLZxYA8Fgc59ga6aTXLS/vnt5ZHRuioeCamftI2g2Cs9TzK3+Ivii4051g09ZruF9koZe3rivQNM8VaTpWlRy6k8dtPJ8zhVwdx7VDqVjp+nF77yHkDEDy4erGsiTRNN+IGYHtLnTbi0O1kDA5H1q7RktrLqS9Dpb7xbam0Wa2kLrJypLYBq9AtvrmkSIjsjSrhz3zXL3/hzTdJSCzuN3lIOA3OcV0Vu3kaSH0uNUhXqp+9UzUIxvEFduzOdsvA0ttqMc1xdrNHC26OONMdPU1r/EO5ktPCsskTuJGG3emcr9K4+78b6zHqQRpbeK3WQRvbsPnYHvXZ/wBqW4cWLxiRZFDBJBnBqpxqSs5CTS2OG8XaNfeNb6Y2Go21yNixoN4jSEDqdp7+9XdR07SfC3g6LT5Ls3X2TMtw8fWSQ/wJUWh+BrjStWkaWZpJsFUVvukfWutsPIgeC11HToyqkbl2bgP9rmqnLVR3ihRWl1ueNXt3pniBI7qO0udGv1ZUiCZdXB7kevrXqOhaWPCXw+1K6udJgtLyFTLI8bfK+f4s9h3xW14w1DUNP1l4NH8NQXFoti1wNQWMN5TjouO/0qnpviy58QeCVvL2xWZWdre4hK7RMuOcA9KcveUXb3dP6/4cSb111MaDxRcTWk95bWcUt9pexpO++Nhwymuu0b4oeH9StLlriSW3e3QGRJE+9xztx1rnjpkGl6BeSaZbyRxXWGdidxVB0Un0rhdJs7e81C4XTUWSRgWmSY7U8sd/fFc7gqkrw0Rvoo+9uP1nWI9c8Sf8SCyljtxymBywzyT/AIV03g/TNRs/EVihi8i6uR5spbnzVXufQ1s/DbWNMtruTQ7DTwDGu83BALSH1+npXUX2pRXHjrS7aNkHk2zvJJ/dZsBU+p5NOvKSTgKFnrY39cS2u7J7O5kiUzqUVHcDcSPfrXx94c0/7N4quvD12khnW+aFYnPAXcfwGeK9o8efDi/8T+M5boa7CgVR5MLO2UXuOOh75q74m+GGlX3ibRLi8uhHCtuILibeFe4kAwOfU05Wpx913e/oFN3dmYvizVNL8KeGptBsIoLrX/L2xW8KB2Qnu2Og9zXi/hmP4kXSX8OgT3YhibN5BHMNp3Dup9favr3RfCGh6FbeTp9lGHdShkk+aR/XLHk15vofwnvPD3jTUNVi1WKPTZYpljAYhyZBhVYdDgnOainGMovm3KdRq1jxGDRfEFvf2gvnsLRLf97EGwY2lHQMB374NdfoXxP8Zr44sND8XTwq8MweMxxiJZgeBk919qrX+i3XhTSdT0TU0WaW+YbdxyY0BJ8xW65ya4nxnpGsjS7e9u7v7YbUgRXEgPmxpn5fm70qtOmm4de5rFyklNn2D4p8HaP4tNtLq0UhkiGA0T7SV67Se4rMvvAxuUCQXRs47d0NosXAVV7H614p4O+NHiPRvCoOpaLPqEEA+W63gEgdjn+dcz4z+PPifxZbtYaTEulWjqA3ktmV/XLdh9KVOpV5bPoZul71j1z45/ELRdGgtdDQWt/qoO+Tecxwcfef3PpXhvh4+JfGt/PHBPJNKxIXamVVT3z2ArljpDqzuZGnu5eX3gk7vxrvvBPjTXPCVmbPRNORjKPnuGi+dn/2fYCpnOSjaJvCCRua98NH8I+HUt47lrjX791VpIMkx9yD/smr+iXeuR+FJ9PuEN3p9m5+1s8edo9vauk+HOt3SRxajq2l3moXczkzTH52BJ446AVQj+L2j+EPEmunVtPm+13UoX7DabXCgd2PTcalOco28wdou/Ut+G/iCPD9ykmo6PLZ6VNF5dtez25jViO3TpisbxH8Y9MbVN8MNtclAfmb5Rn2qTxf8TNZ+IGgXukaboX9kWMoAmub5t0nln+4uMAn1NeFzmz3T2Wm6TFdTI3lG7yWBP8Ae9KpUEl7xKnzO56JL8ZBp9693p+l2/26YATbWysmOVyR6VDrHxq8QeJ7c295JLbxg5+y2IMRb6yda5DQfDVxZzi6uJ7aNk+baWVio9Steo+FD4Ttry1u7pXvLxG8ya6eMY+UZwqe1ZScIbK5qouWrMTS/hb4w1qxWez0my062u183dcS/vVU+ueST1qbSfA2neG9blvvGuqWa2Ma/uPKlLPdP34H8I/nXQjxT4l8aeLb6LwTbzixnUQPPIxzAp6se2cdK0D8JrU+JodKDpd362v2m7dyfJgQkheOpZiDx7VbkydtJOxw2rePNOg8fQ6hp17J/YQjVfsbpgRkLjKD64Oaf408beLfHVpOul394dEh4c20PlJIoAyXbqRntUfj7wX4Xs7jTotFNzI0zmGad2x845OB2FYqPcNaJoXho3sdsWLLAnzb5TwRn39DWqpqT5rWsRzW03OY0+zEVw5a4eK6j+dmCEsxPRfT8Kt2OhHV7pAYzLc3dwsNvEG2hnY9SK9y+EPhbSJYL23v4YlvW/dXKzKGkAH3juPTk9vSsn4z/Du206/tNT0W++z6eIsHfJjyXHQgdeax53Js1slpYxtf+Gt14d1KxtfE+rpBZSwO8RtztAK4yv15qtqHgrwxpL6VcSSPdW0x8yUxctt/oK4XWNP8XaxDDfXZ1DVovLKxybmmESA9Mfw+tQRReINLWC6uLSfbCxERnVhkjtg9celXCGqcnoS27WW59XeHfhN4bgS31NYX8ox+YIpFBO0jOD+FZ0HxBtfGVjd+GtMtZdJlnVobGSJ0YqR0DLj5c4rN8NfHrwzYeALf7ZJMuuWyeU1g6ncz/wB7P9337Vw+r/Fbw9FLNqvhTRI7DXLlWMkzEEKxByVHr70o8sU1KLuZWnN3uO0LTPFXhPWrl5tLvNU1ixEg8yJ0MMiMM7mOcnHpivKNY8U63r+sSvOyJI7Y8tEC4OfavRPC954etfD9hr03ia5bxT5jySWsCs7MDwUf0z615/5i6fq93ezNHHO7lkt9u4rzkA1cmnK71+RdO6XY3NE8S6tApN/bx3MUZCq0hCkEdDz1HtWtf+PrK/svL1jTYpL7JWOe2IVcdhj2rB1LxHJrDQwzW0EQb5Nmxdi+6ntWXeS6VbWzWz2yzXe4Az7toUd//wBdQnZ2Rpy82rItWudMvJ4/sEjW8bfLJA/3Vb++D2z6V7R8L/AegeMvCKpo3iHUdO1q3Oy4i83zFB9Qh/hPavP/AAzcWEOizxWHhdNRglH/AB9XJIG8HAI9R7VL4M8LeJI9ckvvC17Db69bqzizUkeao+8qk8N9Kvldrx6GcnfRnX+Mvhz4l0LwXq19D4vkmtNLd/MhMZjDjv8AUnIryew1W1EKRXMUX2kx7o2jfAVgOjA9K7Txn8TPGOqaFPoOvEWdtITDdbIfn4P3Tnp71X8Hvplnq6fbrTTZJ/IVYZTEJhGc8yMnRmIxipScvi3HdxVzgrq5t7lY02zxx7wJ50wULHuB/SursvDlzb2CX40kNAnOS4BdexIzn3rvtR8FxePNG8SvbWKf27pqiWCWxASKf/ZZR8uSBkdDXmOhWniG5hj0+K6VRL+72yvtaI+4NVKD+FChUT1PS9H8RTahLZaSIIdNhRS2VOFlwOpPtWX4zm0DTdNlfRpnGpsSsjDpKzdQuKxtU0uxg0GP7Lq81xqSN5bRZyykHBAHYVm6D4PuFujd+I1vrOyV/L81Y+QevQ85qORp7l80Wtj0vSZdB8G+AERLeI+JL5FxOoDSKCQW9x6Vyt74q1j+3bGx03SOLs4gW5PzE/Wsl7uw8J/EK2uGsby602MKyNdxlDj+9g9a9a+KHi7w1r2k6N/widzavrqXKSRyxL/qBj5snp+FK7j53JduhxupeJdbguodL8Z2jTyI/Esrl47dG6Hj09an+GH23xP8VZNb1SUz2lmrojqP3arjC4zyOlcHrDXF3rt7L4j1eWVpSN8qA5m9gOmBWvonipdPhk0fw1YujYy4bl2+p/pWl0o3W4uVtn0P4v1qxk0211LTbO3l15pltLR5WBEbHjeR7CuJulvb3TbrUNa1Z7y/jm2/ZYyPLGP4QByTx1rxK81WYXhg1b7RbQM4Mp2kuuD0HYEivWfDV54dD22n6bpNzBFJFtS/eYhnTOcsfXP6VHsak1cSlCGhesNftbZN+poftBcieKVSEkjI4R1PHHtWhpMhtbyLVC0cFlCB5MMabI1XPIA96wvElzrM97Nozx2FxpiFWFyI974H8efXHFS6lDfNppttDvhM80f7syjgH+h9PStJOfMm9hJRs7bnc+MPiFGsNsujWk8jz4BKpzuPQCuYvtT0XT9Sj0bxvYrfT3DJLIi9Ldj0XPr61b+H2kXlg2mT+I5zcPbMWdlOVJ7DPfFbXiXRvDWq+JpdeWKaV7cjzpmP7lWHQ47mt4KFOVmc8m2tD0N9I0d7ayEVnEAiqYEAxgY44pfEWt2HhvTTcXe0yj5Y4l5Z29AKwNX1AaXpMTx3JLTqNkqHc4B9PSqNlY28l59pKvdmNciSU5+b6muZtydi1FI7LQ0keyj1DUgoupV8xh/zzHZa84+IviVtSu4YPDtyWniJEoTkjnpVfxTr/iQarbwWtqkmkztsdt+Cq98+hrnfD19pX/CcTaPZxXU+oQ53TeXtRfYnufeuqnR+1IzcraI27I6pBCt9qNyHGQPs8nAUdyPeuy0XWtN1yyv4dICm9t4z8jLgs2MjFZnjG20+48PXemS3/wBhu3GfMAyRjtXJfCzTZZtQmtrK4fzIVB+2E4LHsCKiSUkykYegah44sNSuLvVob1rAM25J13A/7uelbN1qmpT2aNpNrIhnbdJLKuWH+yo9Kd4g8V+JPDniw2WrSfbLdnB+zuuVZT0Kn1r0PUfE9jbSxaUIY4ryaESQxAfMoPetpu1pct/QzXa5l22ryaZ4c+zyqo1MgYdk+XPoTVGTw2mpvFq0s5F+q5aKEcA11ms+D49T0gRC4aGQqCWU962/Dmmf2XpMVqZTNtGC571jz2V1uPqcmNEbWdPaydpoT185OChq54Y8Jw+FYmNvM08khzKzdSa6ey2AygcYc85qtqFwqKwQgt9azc5bLqFurOf8R6b/AGpETKwi2HcrNwAabpyhrZLZdjBfvsp4FVPGtpfX/hicRNJHKoyqg8t7CsX4Q6RrEei3x1pnijnysSt94D1q4x/dtvoDeqG6ZZeHNV8cTzQTRXV1AMeWU6Eeh710WpWNpDObqSNFm9Se1cR4f8K2vgnxRc6nf6tHIGz5cYO3r65rm/Hur6zfasr2jM1qx4EZyCKtpylGMHfQSWjk0fQk9lDIgIUB+zd6oara7LTz95UoQUYDJB9/aor2WKxWJ7u/htzJ/q0nkCkn0FLN4l060mjstRZknZQeEJUj1zWEU/UHYqS6xd3+mvBp+2HUkYBkboy/3h7Vx3jLxDqNl4Avb6308RanBL5AkdOFB6tiuo8eWUsmnxXWjfutQtwWiKfxr1wfauR+H3iPXvE8tzpfjXThBbjlJETEc3PRj2NdNNKMVUtdInV6dSfwrdaprfgiFzbbUuU2TFvlCt/eA9KoeG7SLTPElxaQ/ZoNwCNG/Vh3bP17V7IljbpaJbQKIoEG1UQcKK8S8YtY6LrVw88rRoMlLluST3GK5JPR8ulzpp+89TS8W6DdWsSzeH5fs99O4jkKNgFM9vb6VyKW83h3UUtnvJJ3uZxOs7Eg7x1Qeorr/hr4/tfFGrJYDTDCIxtjmdt27HcjtXS+IvCdtLcT3KRS3rOOIlYARkd1PY1rtL95uTzO3LEzNMOj6VqZ13X9cit4tVIghhmbazOf4RV74keCW8eadB9imNpJb5ETMSM+4x0+tVJNP8NaxHYW+uWkIt7EFkjmbDRSA9fXtXoulX9te6bFc2rqbcjAbPGBTdRxkpp6/wBfoRy7oq+FdNn0rw7p1hf3Ju7m2hVHmPJYj/OKq+JbKK50O+hvrgxq5LRyBgpUjpivJvjN8X2sWfRfB93DJqvmKhkj+Yr3IHavPNJu9Y+IN9rA8WapcR29pAC6RkrGG/uhR1P9axbad0axp33Ler/2nrr2mtxRfaLO0LQuvLPIgY/MO1HiXxPo154WnsXkUSqChiHUGsDV5LvRfD9zZaVqMv7v5Fj+7hSOntx1rO0hNDbTUuvEVlc3VzEiz/bVfiVgeImXt7U1CbblbY2copJGXA13qWli1upSIYgGW2RDtPbg+vc1As2nadIDZKqMeWOc4xTvGGrjWNeabTbIaJZFVVItxyB3Yn1NY1tb2RljjacxWrt8904ztAPJA6mo5bl3t0NEazLMZXu7vZDgiNFGGb3x3qumo3e6ANcPHOWwg3YI+voa0p7SC6KW2g2txMGP7zULhNryAf3V7VR8R2txpsNtbNbiIMTzjJZvr3NVy30FzWNYtrVn4YuZLbV7loPM2NbwSFd5PcHqQPasjwr4W8Rza3bzWugXV1PE4kCTptUt1Utnt3rr/hdrmk6ZqkH9uade3RQf6tU4Ujkda1PEPiax03xTZ6x/aJuSJTOEjZldcHIVx644p0re9F/8OTUTbTRc1/wZ4vCNqvjjVIYLeb5mtIpNi/Q4rhLeeD7TPaadE7wq21FX935f1B6/U16F8SPiPpepan4e1TT71tRvVmE9xa7CbdEA4Tnq2a5LxT49uNV1271I6VElxPiNFjXGBjAHHXFQpOdrote6itYaBeLqtvbiFZBcgfvGQsHLHGAfbpT9V8EXOj32qC51RIltnESKrfM+RlgB7d6k0b4m+K7SyTTdBgjZ4DueQW+9gT9fu1iPaXusapcSXk1w99cAtcmQGLaSemPetLq92ide51fg/wCKM/gm5a38LWS3dncxhZLeb+GQcBtw/lVybxP4isdUvvEviHXorHUby2CNb25BVox9yPA6HrVPwn4bsNT1C70/TFMEVrFulu2XILnqoz1PpXpvgf4NeFNa0KO+1Z7yRIpmQ+ZKArbTyQfQ1LirtuOjJbS1vqeGaLcL418WWkfiDUv7L0lnJkdSfqce5r1LWtc0zRNOOjeA9KuiQnN7dfI4HdkB56d6948OeB/DGi2Bi0TTbWOPJKOVEm1j3BNeKeKfDOs+Gra/1nUms4otPkEkUtzybqYtkbeclT3B/pTjCE7uWy6E+0d7Lc4TxH/wkfhiWFbu5htZygeIQktJIH6c92+tepfCr4dWXiKEar4r1mfV7qN8yaY026OHPKiQdSf0rgfDOiaz8XfGMuq6rDPb2qj/AF8UZWGJscEZ6/SvbPBHhS78MeJrnVNZ1awJeHy9kLEGUDGGfPXAFJJcrcnZjqSe0Th9L8NeI/DeveMdWsNSjudGt4JzFGshzubkDy/4doGPwrQ8Cw3Xj3TLXS9aSW4trS4E80z4DRoV/wBXu9zj8K9MXxb4cMN20v7hJiVbzYSv2jjnA78evrXLR+L/AA94B0W0i+ybLrUZHli06yXLouepz2A7mnUrxkrW1IjCaH+OV8AeAbaObU9Ftnu7pXESiEO8pUd2PQcgZr5S8dx6PD4nF1oaRw6bexLcpAvJt93WM/Qj8q9X+MvjG48Y29pJY6FNatYEyqbphvdW4IKehrxZU04TFtSM0srAgKo2qvvnvg+lEeXlVr3NIxknqdxP4bstM0Ky1iz1ayumuOG5GxOnXHP4Vx6qtxPdSzyj7SzYbaMBl7Y9Klub1db0DS9G0rQoYLmOYmTUgSGnJ6A9sAc1614S8B/DuHwzdPr91eT3SQFpbyaTyow+OiDPPOAM9aXJywuyvaa2PJtLnkvZo7LT7Oae4UFQtsgyo9cnv71Jq2m/ZoTLPZ20AkOwvNc7nDd9w6g1p2kEtvZStok1tp9qeZLqd8bz/CucZ3ewrhtRbzpw5uXuZWOGZhznPamlfYG2jqdG8ZTaL+6MNveWhOHtsMAw/wB6ug0nxrPFrsGqeHtLe1lgJMdu250jJ4bHfkVzlp4L1uW2SUaVLEmAwml+8o9SnUCtjU/Clxpmm215aeIU+zzkFkL4KsO5HYCpdoKydrlWcnd6m5quueGtbt7ufxDpUsWrXlz5st7bSEiPPG3Yeh+tYGq+Bb3TvKutKmjm2uJEmiBV417E9R9a5mU6jqGqb4pJ71zIF+0CE/N2zjvX0J8MvAd1ceGJ55/F6wWnzQvEsAXym7ht2CDnqDUSUqSvcOaLOB0nUPiHoMQNhq3lrKPMMexQrg9+nOfWofEPiQeLP7Mi1pf7CurfdE95FCXjkfPViOR79a2/FdtKdXvtGttZ0xZLCNQZlDZZD1IyccZ7Z5rkr651KwtpbRNQ06RYcDMg2iVTyFz6nvTp8ylzWVxS5JRsegeCtMubPxdol29/pP8AZtrzLdZj/ekZwVPVsj1rt/iy0XiCytb3Q9Ut5Gt3dJINwy6sOSB6ivBPCx0TWjHaM4tdQkY7jOMxrx/Dj+da9n4E16W6u5tMJ+y2yM4nhnDmUKOgGetaOpNz5tNDP2cEra6nqs2s6cnhaxtNX06O91GCIpCZAN2P4VPc8V4/PpF5canu02yjhhTmZF4GO5Hoa0/D+sWMfhp7y3Z59cFwIJGuRvaFOuVT9M120eo6bY+EYje6VKniK9kdYXA2F0B4cr0AIqHBpOo+rLUknyI8mvLObULz7HqF39iIJWINHnLDoN3v61q23h6fSEt7uNE85mCkRZdQe43dST61Z+ImmTQz2huRHNZNErebaOC8chHINVfg/pMep+KbeDVtUlsoYsyJC8o3SY5C4PQmrgnHVA5J7ntNnpujahptv9ut4AY4tzoihmLY7n1rkvFMVhptnHPDdSNazMI/s/frwB6CrHiO1sl0O51fwe9zBNDMxubOZv3vHVxnqParXgCJ5NKvtT1Syuna3hMxeaMANjoqg1mlPmDmja42XwzrNr4UuLqMW9os5DRi6lwWyegP8IxWo+hSaZpEFxbyQT5iBwsg5bviqFh43i8cWWpafqsEq29lE92kkMRzEqfwkd6oaTNoeoeF7rUNP1Oaxjsz5XnaipRQx5G3sfpXdyzj8W5ycyd+xHY3eoXcttZ2qTQ+a2CrNvb3PsK9bsrzT/Dfh6S0FqrxKP3hkGfMY881yfw/sbe1H9rtNayRz8ifdww9c1D4w1uPVbeXydwgSbZvjGQw7sPpWNZty5UaRWnkQavLqEtmmv6tfW+maT5gWKHbvdx2VfTitnw74osbq0Oo6a81zZxt5c0bRlTGf8PeqHhHTLaz8Gf2ZI82sp5rXCS7DuQnsAaXSPE/h7QrC+stZW7trmeTIQQMWx26CrUYxTSvciUm9XsN8QazZX0iFW+zhTllDfezXZeD7jRfs5fTFiudVKcnaA2aoaSfDd3pf21tGmuwnzo88GxifYHmvP7bWdA0n4gXmrW17eR3UqGM2RQ4TPYetHvSvHX7hablXxjr1y+ur4cuXa2mup+JmG9956YA7Zqt4J/trwt4ol0qe9kfUhmUx+USHHXhunSumu5rXT3h8T6nHaWrRSYt5buMl2J/hH+PavSPB+qw6hDPqd3biE43faJAMbevyn0pp8ivJevYG76IsaBf6N4r02LU3t4XuISUbzEBeNh1zXmWp6po0Hj2RtSubrFw4RCADs7DB6gVY8S6vpl/4ijk8LtNb3M+Vumi4jlHuPX3o0rw3oOo+KTcaj5wmABCTNhAfUetEVFPmlt2E07abnbjXbaxLJf6hLbWyHYvngAuPb1+tdXb3tqNMF3FKGtVTdvz1AFeceNvhxd+Jr+Ga11FEtUUKA3JwPSovFQn00aR4SsJWYOmJm7lan2cZJcr1Yr2euxf8K+Mf+EmvL1bCE/ZopCvmDoeaXxRpOr315FPp8zxxqRuGa5Xx7pd14T0qztdANzp9gYzvktxlmkJ7mtj4R+Jrp9Ou7LWZJ5RbrvWe4GHI9DV8iS54bIm99H1NHxRpura3b6dDp9yYHt2BlfOCauaVFqNi8r6ndM6kYVPQetdHo13a31h9ptGVkfOWFZ1/LFFv81lbd0BPNY87+GxVr6nmXjXw3Z+LNWja8vZLa3j4wD96qT+H73w95MGnyPLZk4ViN1dH4p083Ecclt8oz0zitTw+txa6Sr3bBVHPJzgV1KfLDTYhrUyvi74V1jxNrGnmxtYrq1SExsC+0qxPf0A68VseK9DOneHNN5kubm1gWByrffOPWp7C01hfFrSw3STWjN+8AORiuu1m1e5sZo4ljYhSQJOhPoax9q04rog5dGYXhSV59J05rgbZo0UNu5OOnWue8cao+haS09tHHIWvBvTHG0k/lxW9pInjtJLi/lS3hRcEsMBQP6VyPizxPawvKLCMXrHrGVypPb8KMP78ttCp6dTdvPEupHSrN7Rdkk8IYRyHaw9ua5zT9FuNReWfxbYebancEy2Qmewx/OsS71LU9Ru7LWEtJJAVWKSEnAz3IzWjZ6omj/ES5g1HWb65Oo24a2tREfJhHu3TI9qc8MrXRcattDLl8NalomrKPCs8JtpAdjAESgehNdx4KsPE9ikjX8AdG53eblsf1Nb2iX8X7vHkfZRGc5X95v9j6Vr3WqXEehXVzFCGuEQ+UoOdx7ZrKTbfKPmOQ8WeGtK1VhNai5S6cHe0Zwfoc8Vwfil30Hw4lrJd3yWSnylEDHI7nNdXpPjeK21ew0zxDbyNqN4+A8K/J16n2qt47gm1PX1gjEVxtXZDZGdY8Z/iYdc9xWiTclCo9EJOyvE8dg8OaVo9pbazEjXdtdbsTyowffngAdvrVzwhp+r6t4oGm258pwVU+XkYA+YM3+Jr1vxHp2nwaMbXUb4WTwxqzFFBDNj7u30PtXLw+LYrSK60jTNP/syG6g8o3KITPI5HDk9cVjOtqrG0YNxdju7Hwj4Lv7lbC+uINS1dW3THzQWdgOmB2HpXg3xN0DWPBHim4luLQXHh5J/Ns42IEZJ+6D3bHp2r0j4c+HFtNb06+ne3hFmm95EyXlJ7Adge+a5n9oG+kuvEttdavei00xo2isl2bjnuxHbJ71Ts21F82gqd0/e0PLvEuoya/efaLlLW0WRQFgi7Y43E/0rtfg34R8Oax4guYtWu4JIbSJXHONx7jmn+HvhL4h8SMG04xWWnDa5knHDnHG3uRXU+Gvh74bstXmj8Uaks9yAVWGxJjRNvUs/c8dBXNJ3judHMtiv8Z/+Ee8N29tF4clSa+ZsmFW+VR1yTVD4P6Xb6hqP/CTeM5YBFEpMaykLHGO2M1ueONS8CwW8FpomkwSXxdVia43KsgzznPUf1rk/Gfw516z0a31VdRZxv3x2qrmMZPQUrc1ktAT01Mf4jafF4h8Yzz6PcpZaazgK87eUZyTglRx8o9TWRreieDdKu2t7fxHPqt5Gu1lCjZvHYOOo/lVxPhf4r1qzk1jVFit7BOQZpcn8AO1cz4i8LaVo2iC5Grm4vmkCpAiALjuc1vdWSuRZ3ujBvZ4EnJtAFZXyDjOK7Tw34ifTNXsNRg0d9Q8hP3yYBVs9SPf0rzreFGFA255B716j8LfEc1jZ3FvJbWz2zfKkewhyx6YPpSqQ0QQne6Mm68Qpe6leTabazWK3t150wLhRtHQfhzmtP4l+If8AhLNZs7vQLKSytLG0SCW5bC+e46se3tWzqV54dl1uKS+0yT7HF5kJEAISSQc54/WseTWtIg1yEQyQppkkWHjYF0iLdSAOpo5m1dFKKT1Of0nUNc2vbQ6iqWwk852UhGcnGRn8K9lvPi9DqGhR6Qmmy2EFsilmD4D4HOT064Jrz3W28KaQ0LaPfx6i067i8alPL56FTW94f8XW+h+H7+w1Lw8Ly0ukzbzuBhXI+lR7TZ2H7NPU6b4f/GW9t3XRbO0bVriab9winaqZ/hLHoo9a07ye01zUobv4ia9ZHyrshdKtJAywAnGWPViOleN2GnKNrXGrw6eDl/LthhyD2G3mhvA9ldXLPZzXUcePMLzggkdz6/iac48zckyUlHSx7Rfxa/rWsaho8FrqCaDKcwPaKFgaMfc2svU+vNehaafDnh7QrSx8RahDNeW0Wyaa4YF1PXB9MV8uP4lv9OsV0vStXvorZn8tXWdghI6r16VmPb6gS08013KwGZJCS3480SlKcVGySBUkm22eneNviVD9t8nQIYp2+ZY55RuJx0Kj6dzXCeEtVZvGCap4o1XyVnjIa9kbPk45ABx69hXFXa51Bljn27sZlY421PBdLda3Db6jcL9hLCNpGXKgev8A9ekqeli3K2p22t6nN4gguNQsbZ7eCWY2z6rdyARsOh2r94kirngPwTpmt+ItLh1G9+1Wlp5gvYt42ELyixkdVbPTr1rQg0+3i0u501UjlsJMorNgsDxgof5VwGurdWOuKtrdmxEZDIbdtvzDo2fXitpSi42vqZKMubTY97+LfhCDQdGk8TxMNPtLZVX7LbgByT8qqOwr5u1TWtU167SC4aads7YbeNcYJ6fKOprtLnxT4t+Jdxp2hazqZm0u0kQzTRxBRgcGR8feYDp7163470Dwn4W0zTbHwlbJa6rdxFPtigvKiEcsxPRj+HeojJxSUtWKx4PbeC9evLmOw1FzbMvIikbO3+ma6TwZ4QufD/iWKe7tEvp43xEAwKrx98Dviu3+HHw6fxfGseq61P8AYLKYuRGxWe4+jHlU9+prqfGHhLwVZ61pq6C9ra6k4NukX2l9pJ4DHn5Tnv3pTnryxf4FRsnqjB0u5lstVg89LW5ujP56XFtP5kkqDqrr29OaztW+FF7rf9q+KLx4JHnZrgWVvIUWNPbt9ayPGfgLV/Cl1JeXPl21mUKu0c7NuI5LA9RXL+G/FXi3WdIXwRoN2JLKR2kMssoRhGSMq0jdFB/GhylU1Q+VQR13gi1stQspLKXXtK0mytfLa6juRtZADw8R/iY9COxrH+O/iK21HxveQ+Gr+SXTpkha4MU2IZnC4ySOrdM1y/xF8AX3gprD+2blJri6BdUjUlf+At0b8K53R9Jnvy8sJiSONh/rOhPpV35rSb0Rny2ehb1u7vYpooJJbeb9yqlbfL7F/ulvWtfw9oN5rVtHaSWMdtBcTBFvJiTKSeiKD/OsWLX7u2vHW1trMEAx7Y485A9609N1zVZ2hv0vWW8hl/cLxsT3xTintbUbknsz1+7+Alvo2rabPqmrn+yJgRKY4xEyOBkAknAzzzXL+CLjw3ZeOdVP228tdCExigkWbByeOvf61X+IjeM9V0ewTV7ySbRpSrIQ+VYnq7eg9q5uLQdCeG4+2anc3moRqfKtYEwhOOOnQVm07e+xx8ifxpp2o2viC71bT7T7PZQORFLCf9amflLEdSRUmhRXviaZtS1XWvLKDAjZy0mPTJ6Vv+F9Z0iy8H31hqgGI3UN5bZ6nlcfTis/V77wnfRJpvh3S3t7yaYM0/mfLGuMAe5oVRX2K5bdTHuGkvrmLTPDzTPfKxG0vlcd2ZjwK6nwRpo0bU59W8U6ZbXVxbuo8t5sbmJxkEcE1N/wg1iLebz75o5igZ5GcKJQOw9a7Dw3YeHJtFU/Zftlgqhbldx3xkcAq3863U4x96XUykm/dR60ZNF1vwDearp9lFavHbycFQGiZRkg+vSuh8Jm31LwxYXnkqBcwrIRt65HpXkd74v0y88Pt4e8N2sthYopM7zDllz0HqWrv/CGrefpWlmzvIjYqgVo2GJFx2rnclzNrYXJJR8yr4rvNM8L3KySPbxwXZEExijRGUE/x4HIrz+G/wBG8V3txo2r6U1toWlO06RQHCyY7tjrmu0+3Prmu3mk6jo1tdaR8xlJUdP72fWvMPhNbXVh4/1k6ZfQyaFkqDdHLYP8GD1Nb004Xb3tch2ehY8UeMdMbRniTTYodJjYC3iibO4+jVq+BfEfh7xTaQ6Pc/8AEu1BpCBahsHjuD71u+KItBmuNMs006zljuroRxWEKbcnqZDj6VzGgaVpVv4yu/EHimxbS0t5QluzjYu7OAo9eK3p8kk52aJlJr3We3eH4LbSNKuUt4fKjt2I2H0A6596u2VzYajBHdBIC7DqwG4V59/aXizVvGIgsI428NSLlnZBhlI459ap69p+qabd+Un7uInhgT09qzVJt6vVk37GN8XdG8U6r4wDaGLl7cxoITC+FUjrml+Ia3fhjwnpTXdlE+py/LLeqgLofrW++meJtQ8Q6VcafO8dhGB5rBsZ9cjvXoPiTRLXxBpEthqEZKOv3l6qfUVftORRTFbVnlHhd7T4g+FzpGtRpfXMDq0ZbIbb/eJrtvE/hGE6KYtPDhggjEZc7FA9FrjINR0z4W6osV6lzc3F1hDM4A2rnjpxXVfEfxhf6Podjd6FEkpuXCl2G4ID0OKmouaScFo2OLtvuec/YG8Fs0l4giluAfLJOenUmp/CPinT/E3iiLS2izGf+WgOcnuQaz7zVr74iS2uk6nGt1BDMDLNEmzyx3r0+x8L6Kbuw/sZYYjZJsTZgZ9Scdah86m3M1XLynX6X5dtZsm5QkbEDnqO1cVruqabo2rrrOqKzO52RADO0Vf8RX+n6NNBDrF55SydFHU0eJNI0jxPp0MIvEjMagqQc5HrUR35pbGbWljU0zU7LxRYs1k6sn8Qdc4/Cs3xT4aa90u5ghnVHkQr+7XaxFX9J0eHQ/DskemndKqE+Yo5Jrg/CvifXI9Uktb23lm3SEb3HIFWoOUmqewr2V5HV+AfDf8AZHhqOyedyQeTnkVevdBsYCZ2Ls47s1Qsmp2sMs8MiHdz5Z7VTR7mX57pgkAGZJHbCr7UScpNyuKySsZ+oQrexEOGZVOVC0lwXudL8lYHRR8vPcVs6Zd6VqNx9nsbyOYpywU9K3Z4Yo7Zgicdhik58ujQWPIfCviGz0SW6l8PrLqUTjMiljkfSuiHivxRqUfn6fpNpDZEbXeSTJye4+lM+HmseHZfDSJDbQ2l5CDGBLFh3PQN71wGv3l5q3jXTvDuizzW9tZy7JpJCQXbdlnwPyHtWdKkpuXS25pOdmtDvdRnt77RXg1eef7NbETMkR5l287T6g1ynhTxtoev+L7fRJNDktkl+WGVW3HI6ZNegR6RaraSjcZ47hipcDoK4rX7mP4ZCG50/Tlup7okRrsz83se3WuqlaUXCL16GUnZ3ex33ixdH0TSpL3ULiK1trcgF3yBk8Acetctf6jpj6cmoNGtxAq7leHksM9Ae1QajqL+IPAtyfF1oYYrkDMCcvnPGPeqngu6hg0uWxh08W+hWCl5TMu5nyOMHuT6CrhFqKb7i6k+r+JIoPD0N7pWnTSOz48lThgPWpLPXdZ1bwv9pi0+WwvZX2xRytjI/vGuj8PWVl4j0+PUdLs44484R3BQjHtW+NBumXbMYWQHOCSc/wCFZyqQWltUUrnMfDqWbVtSubLXdAZbjSseXfyqNrsf7hrI134M2t5rtxrf9uypdNeC6yw+6g525z1969OgeJEksXdoSV2g7un0rP07SGEdy17cGSDdlDnpjrURquLbjpcbV7XPA/icupa1rlzPGZRZRABd3HTjJrkGu49MvLUi7uJrwH96N+0qAM4OeMV2XjC5V/Ft7Y2szpa+arB5m+Vm7ZPYe1cDrTjWdWk3wtJcRKVWWPAXC/xE96yqRvDyOuDs7HVeGPiKVuSsJjLSOEWIAl2Qnrn2re8Rz6BPq0c3imBdQltXMqrgkBCOEx06+teS6Dposrjdbxme/wDM3iXbux6KAO2a9F0X4b6lrHiO1sfEmv29rPcKLg2I5lkxzg+hx29KwUWruL0Lm4/aOquPjRd/Y4I4dHTTbR2EMT+YC20ddi9OnGa6W51yC40S20rSbCW+juIThpFG23yc7mbu2fSuPl+GOpx+LWuNXXy9ItVOyXfkOOiqq9gM1s6/4v07SbK10XSxGbp08qGGMgszdev86dWCptKPYzp+8r2KXhP4YwwXK67r5jubWxffH575wAck/Qeldd8SvFGj3/hC4i0rW9NZ0XzHRZV+6Ow9D7V4z4t8R/EGfw4+kubSx0y9yvy/K5Qfe57D1Necah4Sm0qxt9SaS2uoFwxiIZN7Z6H1/rWlOnOymE7OVmd3oniyfW/D9/Y6nqcwsIX/AHcMQxv/ABPauOHhLUNbviy2yovIV2b5AoP9Kwl1WS61VTd+VYRjOEQYRT9Kp3Guag80yQ38ywMSPlYgEU4ppvQqTVrHS6r4RsdLnEIvo7qTgv5Z+Ue1LDfQWFv+5njR0QBmXjp2Hv71y9xfLHBGto7NvQbyx+YP3J/pXVWyeGrfw5GLm7Eup3Q2vGEJ8gHvnvx+tDT3bGmtki3b6g0MyxWdi1y9wA6ySZCAHj5SeoPrW/YfBLxXfaSurWNtp0sUuZVtxPh8eg44PtXoPw1t/Ct74f0u58X3FrLPpEX2WGVnMXmxbiYw8fcgdCKm8d/G3SfDdkdH8G2iSna0azEkIhP8SnvjNZxnC1oK76ik6jep4L4gszp0gi1WzW0uIzho0PI/+v7VgnUJJgY7hJ3hDZjXcQFHpUmtTyXmpSSXepPeySnc84BxuJ6c1JqAMUUVst2ku/CKw/hX3xVqKRd2zISaUuAhxtyRz933roNOn1PXf9FS7KKzBFDSkB88bf6kmotSj0m0s3t0inivFAB8z+M46nHSm6ZqMX9ly2kiiBnIIljA3cdMVU9rpEw31O3n8D+MNCtYZmsLSa3IyPs7Kxx7ZpzQX+o3gs3sb+3lkjJ2xR5bI9fatXwZd3EllHayG8nhC/vGJIO7HHXsK7Kw1iMXVtPMWuTHiNoQCHcdiWA61jzXdrfcaapbnlN58M77MDpaakgkjMjeZFvVcd8jtXIJo96l5PFGI0eLkJONhYD0B619mWvj/S9Kthaw6ffS7RliCrAMe2a8E+K1/cajrDa6dLFvhhGYtucjsSemavmlflsRHXV6Hj7yXyzlh5kbBsfKSAD7dquWmlajqLssKyShgDyDlh/h713CabqSadJfyeGcwD54pryYIig9fl7+1S6Fp+64l1nxEt5cI8ZW3trbdGjYHGSoztHoKu79CbL1NBfBl54VsrVRqCRzyx+a6253sue/HGMetMl1W40vVILOaR7qSRNxaEiXzi33VJ/hbpn0q14e1LU7oanZ6ZpyWNnJb/6Q8m5mjXoWUnnn0qDSzp+nqselSRrNBIWkkc8/Ug96lOUZasdk4nsHww1fw3Frzabe3y3muXJC/uYSsEeFwI0PVsf3vWsrWfC9ppvjzV9f1vUrODR9MP2gwxsvmseqr69a5PwDq9tpGp3p8NaVcXviG9BCXNwUFtaoPvSAnv7Vi/HGGw0jRNMto9el1bWb12nuyHV0XP3jkc5zxTc1CfLTe/8AWhnyuSvMteLPiJP8TryG1ujBpWh2+6V32kmRh2JPtXC2WseHtNk1NILZpkuYzEnUbTngisHw7b3Wtahp2hR30drBcTAF522xwjoWb8K9G1n4Z6dZ6pPZxRahKkX3bzIRG/2vQLV0o8jsgm00cxqFn4h8WW/9o3Mki6fplusMLyv8kYA6Jn9SK5WGTVLCN7SVZrWK5IYiZCmf9oEjpXcm48NaDcGKNrnXb5FCBFlbyEYHO8jocegqe/8ACnizx2uoeJdVDxQQp5m2XgiIDqgPGOKlzXVaFcr6HD6egRDbx3kMKz5R5DHnKj+61es+GvD+m3mpaTBo9nPeWUYDTLGnzEj724k8VzPw/wDAlt4mudOgku3iguFeWW42Y8oL0Az69TXeS3Fl4CuJ4orx40khZIlDHzLhTkFj6ZqovX3ZWYpOy1Wha+NOm/Z/DNu41K30qKNvLtdIRw7TAn5mYj09K8J0eyvoorm8tvMjiT5S2CN+TgAe/tXWWmtaboci3xdri9kDqVmfzXVCcg85CntxVKz15Lq7hQgIhna9Y4+Vm6BQPako8l1LUE3LYboPhO51PUGsboPaxjbl+ys3dz2Fdp4X+GEK+J4bPzFuyiPMzW/zxyIBwA3Y5o8JeMbnSdSvZLfSJNZ0i6Ia8HlF1XHB5r274NX+k6hot/q2l28dlFPcFAmdoVF6KB+dN1bKyQnF3vc8907wvNdao8GnAosamJRJGSI2xzu3dR7iuk+C1vBY6zd6fqdzA0zxkxRMuATnnrXrenyWkOpXUDzqzSgSxRNj5Vxg49ea4L4oaVaXN/FJp6pHdSKInEa43gdOR3HalKtGem3+ZCUlocZqnhnWLbV9Xk1K0DWzErFJwqsvX5fetD4gTz+B9B0B/C0Xk2tywmmlI3tKeDsyadcale6RYLb3Ep2BW2vc5cBR7HoTXf6bfadc+ELFdWuLKCGYBYormME59lP1rRSfuzktBTVrxTOb8aWp8RaPoWt6FdXFjdXu2OSKI4aVCORt74NczD4Ye3nms3eKS4gk8xbhcq+7HQgVo6zNc6B40hvr6S5NnZARw7FxEB6BR0zXRWjWcVvNrenWravNcSeY1vHKPMQeuM1FO8G7dRy2Vzr/AAjoFnZaZZTyQJLfKnM7r82fb0qPx94NsPGmmR2WpPIixvvRkPQ1r6Xfi40uO5lhNou3JSTjbWRrer301sq6Bam6VzhpkcbVqXNxem5FuYxPEOoJ4F8O2mm2iyTFI9kbnjP196qeB/EMXizT52ljlF5bNh93IY1a0rxDpHiOzvLXWYEa4sQZpgx3YxxkelZHh7xfodxZ3dr4PsntrqNi7xSJguM/eHrXRGOjvH3iW7bbHeqRpdm15eSeVCn8OKfo3iK01iORtODy7DgjGMVm6XNJ4l0J4NVBgk3YJ6Gs2y1DT/Ds19pekW0sl4kZkDMOHPpms+Xe+4XNvVtH0vUUD+I7a2mdTuXf2qpqF7pM+gzWzWkVxAg2iA9wPSuQtr/WPFegpc3sBtb5JCpjXowBqlbaJd226JDeTXcjB90gwsfsD6VcaT2b26C5kS+Dr6JdTn02ztI45JidsccZAC+7etamo21n8LdA1HVbNJru8uH3LFK5Kqx/pV+336S8VwFMswyFUY69zWldX8GoaNcS67Yh7eIFvLZeSfQCnN3d1t1EkcLa2Y+JunWevavbmw8jIdAThgO6+1dCtz4ZsNIkv47v/R4QYyytyCO2Kp+DtY1DVvt9rcaP9i0loiluMY2+ma8/PgvXrmC+gMflxrLvUE8S81ThzNxfuoSdtd2ezeAtX0y/0dv7MuHmUMSd/wB4VzHxH1y90qFJNNgTznPJC5apvBvh+fQrFpiqxSyKN6L0BqLWtc0vRp/tOuyBw4yse3dj3xWajGNT3dUirtq7INA1nVtW0CbzMm8KkRjpk0/xhp+pX3w6SCEul2gBmjH3/fir+la1bTWct9aLE8IXemwYyK4zSvFA1e41e8guZbeSAEESdBVuN27K1tSVstSL4IWV5Df3lzfO6rENg8xcV6Zq/iqxgcRQXMMjrzIob7teXQQa4tpeXLz4huUwi7uuf4q5LRvC1zZ6lLNNcPK8w29Tgj3rSpS9rPmb2FF2R2vw60q9sPCNxf8AiO2MUUpDWce0s+DyT6gVVudduPEV2sFhDbWdy8ywSXQQBgvTJb1xXrPi5dYuNBB0SaGHUBjaW+6Djoa85fURpehp/wAJJZW51wSs0gtVGGI6HiuZxlV9+O7NIzUdJEnjTRdZ0LR7K18JeIp5rtpAHgYBxt7t/sgeprLtPGOgedsv5tT1m5t8I5jT90rjqVro9K8f22paRc2tzbIjzoYQkf3mBHNcTp/g/R/La51K7uoIoZMsIRsJA6bqKcKUV+80a7Dbm9tT1c2thr/h+C605lktZwGjx8rKc8j69a4/x1oV6baw0vSBJHaGNt5i+ZvNzxk/lzXQMy2+hQQeHj5VhEM5weSeSS3fNZaa/fQyCGzVL9ym99jAMi+vvVU6zjZrUnkud34Ct7nR/C9tZaldteXUQ+aRR0z2qDXPiHpGh30dvqSzxmRcqQmciuS0y2u7vWpL3T7+7LyRj5B/q1H09ao+NtIuZrG5W5VxeGMqt6eWQewP5e1YJSlJrb+uxraK3OyhhHjGI6nZTS2tpkqhkXBbHfFV9QHiDQLJ2/tWwns1U4WXhj9PWuDgtE0nwjb6fqWs6hdxr86xLKUBPZSeuKx7FNQ17Ufs8MZQQD5MsSqD1PtWsKcpK7asiW1FnOeIRNrOqpaW0chiOXcsp6mpbbw6mkWjJqLNaFvkIxlnU9T9Peul+JGvL4a022bQZVmvkG2aUpnt/jXknhrxmdTuJ7LxZI15ZXY8l23bWjUn+E9qhpxd53sbp8y93c95+G1nof242+jhZ5LcZkuVQGJWxwN3fHer2k+DNbtPGq65rs1oLdJzPLdvL82AMKFHQcfpXHeLfE/hrw54e0XwX4AmYy6k8Xn3CfM0cAPOT/eP+NbPinVNR8R+FH0fQQ8sYlDFDJ+8aFeG5NXTm27R+F9fIwnF2u9zsvjDrIl8BSyaLfW/mzyCOJ87lb16egyfwr5ItdTg0jVvt9lHFdxQSBpLi4fDSt3x6Zrb8e6oE0O10bTbxVhsS6zlZMgOx4jU98Dqfwrl/A0ml299NJq2lyao7R7YIUUsqMf4iKznFKLW5tTurHYeMviDr3jW1F3Lp1tZ6fF+6t7ZCcspHUt1P48Vy1lFf316G1bUHjiAwU3cIuMcZ74ro9JsdZ8T6xLY6XZvYWMaM5WRPuY9vX0ra1PwpeeFoY/7XBvb+8CuJHT5IUB/VqqnCV1CwScEr3OQfwzpV6qR2CXstwJCryl8hx22r16VU1b4f6vbXJFvp12YDyhkHJFe2aBZL4j8I3s0drZaQLc7UumOwSkDlSf14rziDxJeHVrLTI9QurqZJhFI6/PHGM4Gw54FXNWvrt0JjZ7o4qwtLPSbuddbt5/OVcwoq5y3ofT61s+DfCEvi3XBmNrW1YZMaj5yvqPr61798YdD0Wy8OW0lmba61ZpVDEAMcY+Y8fpVLTPEHhvwj4KTU9dt/J1uSMxW8MHMrR9jt7DPrWDb5faLqapx+FHlXj/wvF4bXS49Ymex88lZFMnnuqZ4247Y55rz2+eyiE1pasJ4N+6G4IKsoz0Nb/ijxnc+KtfW91rYtsoIihtwMqO2Se9c5IY5NQZbWF5V3fIjLlyPfFUr9g6EljHp8LI9/cSyockRRKevua1bbSZdUWdtEspBAeC0+A2fQfzqLS9NZ76FL+ILFKPkjjOCO2SO1Pk8QXmkyzWEbvGFlKmbG1mXtwaluTfu6lJJfFoF0kiXklxroWS4VVTDjGAOOldDoa+GhdWls1xE01ww3PtysY9M1UbRLe5Mt3qF9Jc3DwGYE/dC9lPvWx8M7zS/Bl+9/q+jx6nNfWxFg330jJOCrrjg4zz7VK1Wg5Ox18V1qWia7fy32t6TqVpCm+3USKq4XhQRj5cDtzmrUNvq11NHeQ3lnGkoDbY3B3KewrF0nwx4Y1PXYjeaOpimBeVo52YI/Xbj0xj6V6NJoyjwtq2y0j0/ykEdtIU6jphc+3etalPkfM7X/rzM4T5vdOZmEen3cEepaiLeSdysas+1SD3JHb361qasdKmm0jSvD0LeINSVgS0z744mJ5IX29TXnul/CrW9Z1WO51ya6s9OOPLkuMmZ1HZF/rX0R8MdI0Dw5A1ro9oUk2jfM5DOfq1ZSg786f3FOSStucB44xoer2NrrudZmiUTmF0xGgA6cfw/Wu/0jWNK/wCEdsUkl8hLhWIQKAkWeyj+6K1PGGgaP4ltSdTRo9wwHMvlbsdj6jvivAPiJruueF7ySwfRjLp8OBHfBDtdB1I7fjU1IqSSprUIPm+M2bwab4OvL6XWtbt7V7tW+zGNTK0yn1X+EH3ryS90SfVNdth4e36pHc/6TKsbEI+08qfTpTfEN1qPxH8aQy6LbW9xfTKkYhiUqvyjGWz0q9HeeI/Advd2toLWK8t90UlxEQ4TP3lU9K6LOb5+pCfKuXoW/iX49uNT0iz0uK1gsJLdv3iWwwirjAX/AOtXnemQJdXaK0E93cyt+7hi6se2ainldrYiWNnmkkLNK+dxJ7e1dp8ItZt/C3iqDVNVXEEJ5+XODjjms0lTjoXrJnunww+CenPpMWreMLNDqE48wWYG2OEY6H3rnPHvh2DT9N1OE6rcWGlRghLI3TFWPZVB5K+1dN4y+MOk+KPDY0bwxdyx6zqVzHZKpBDIrnBYe2M1k+LPA/hDT9Du4pItR1K6jGPtE9wT8w4xj0zSU3MhaP3jy+/0zRdI8KadepbzXE1+pBW2l2hBnG3jnd3xXT22o3Wt+BbBr6T7art9kkinco6shwFIHTC4wOhJpfC3hfT/AA5fC6u7qBI0HmqJiSit6getcT4x1bRb/WriXTY7yGYg+fIj7UZ+zUUqsXJK17Fzg0rtkniy7vvDV1Zw2M7GzngWSGONvmjj3fMn6GvaNS0W48aT2uu+Hha6npl7aiBUJAa3+XGCDyuDnketfOF5YXcF4LnUkmuLNgAswbdsB6dP5V7L8ONSvPD3iHTb2S5V9GucRzzxZ4AXunb61q705c8FcztzqzZ5tr9pJ4Y1TUtO1HTM30kflB2HyFfVSevGOateF/hb4t8UWsN5Zaelpp0S/JNdP5aEd256ivU/iVDp/inxnaS4E1kjJHHIv/PMkbia918TafHqHhG40ewvI7Fp4BDDIeijA4x9OKzjVvuOacVoea+BZNZ8IeEINNto9O1O3B2JeWzBowx6hvYe9cl410/UdJgsBonnfZHDSSpDCQrzMxJwB061618LvAUPhLQLqy1C4hvLi7k8yUR5CKOwUH+ddlfS21lZBWKRKSFXAycn0rVOFKbktTFyclbY850zS7uS30ea8jkGpC1Quedw9R7H2qreQ62mpOdPsJ5/LJZGKjGfdj0xQkn/AAhus32pXmtG/tphtjtwCWDE9cnv2q34j8a3FxotsfCPlXVyci5iIzLH6cU40rT5kr3+4bm+WxV8e3V1o1lpNyLC2nv5iDPA/P8A3yKr6/p76zq2iXMVtbSzj975cnzCP3wKj8A+Jr7xbePpOuaQn2m3j81blsgxMD0bPQn2q9diw0y9n1KeaeO8UbJBGePoB3+tapOErNakXUkUvFWnaxqUVysbSedsLkyISuRyc9selc58PPBd7qWowa3ol5GsDygysrYMTLwyY7ivaPDGsWGv6P5EThwyFHjc/MVPBrkrTQf+FTaNrl/pTXOpWU8gkhs2GWiJ6jI6iiNRxukrPsTLXco+L7i+vItY06yufNubQCTyck/Lnlff1rJ+E9xqFj4qEEMJ/s6aP99tJKh/Ue1angy6h1PUovF0wfT5Jg5ntmGcEcH8DXpdpqNlPpTX1ikYjKk5UAUOSpxcbf8ADis5NM4jwvqHhi/8V+ING0+zngu7hWEsrgbZB3CfzqL4d/DG48L+K7jVbi8ieEKyRRxg5YE9Wz0re8C6dYC+vb+KyaK6LFfMY5yDzxWT8VPGeq+GtQsYNNSJIZVLvNKm5cj+E+lHNLm5IdV1C3VnP/FXwF4t1vxI13ol+32GQKVQT+WISOuV7/Wotd03XNV8PG2luhDPbHZLMvBcAcnI5q745+Imrw2/h2PQ7eMS6iA8wdcjH90VueEPEula9PdaTPatFdwtkhj8r+uD/SqTnGCvHRC0vuYXh1fESWumWuiRR31sgxJdO2Oe4OelaXxO8Rar4Sg01rawOoNO4WQLngdwKf4+urnwn4HuJfDM5SYT/Ox5ZM1e+GniC+1Xwd9v8TRIXiPEpUfOOxqZe/79tE/mw1WnU0U0t/sCajah1meIOIZD91iOhzWZ4C1i+1i9vbXXLVY54CVQY4xXP/FZdc8X6PaHwbLJ5COROivsIPr9K7DwPpTWfhWHTtTnV9U8opNKjZcZ96m1oOT+Xcd9bI4a78DeMZPFk1xY6yiWQlD7RJxjPTFQ658WbnSvEX9mJoguEhYIxPDE9yKyPDfijVfDHj+Xw9bLNqEcsxDS3DEsg9q9j8nTJ7j7Vd6fAL3H3ygyferdo8vOrryFq723OT8b6xJ9ltjbmSCW5iDrD3U+hritV0tNa02N9ba5tpogQJ4+uD1UjvXd6/pC3mupfT3SqqgDyxz0qbNleSpDKnyjvj+lKE4wirLUHds4zw/NpOjw2diZ3itz8imTq2f50fFHwLct4ed/D0nkxSfPJHGMF609e8CQXGrjVk1JXEC5itWGPmq34Z17VZ7aW01SNDMrYXHQL70Snz+9F3fUEuXR7HMfC24nh8MXD+Jkkggs/l86QZ3D0ArXF94Y1xJJNHum8+3G9oujEdziuwvtNtPEOhXGmSypG7dWjHANefr4BtPB63N9BeG5vJIzGikYC57mjnU25Xs+iCzVlub1/wCPY7XUE023tnmi3eWZGPOfUZ6j3qbVfDN14pgC2dwlqSfnlA7f41zvxask8Px6QsVuJJLrPnTg7clR90HsO9dD8Eba9TT7i4nlke1k5j8w9ee3tUzgoU1OGgQldu4zTfhO9rp80EuqjfKu0+XEABg5zk98964RludJ8Yw6draj7BFcKhCkt5nORu9u/Ney+IfFP2VhaaPCby9Z/LIQZRG/2m6CuefwxNKj/apmku52825dGwjNnpz2HtWScZ6VDROUdUcj4Pv/ABZP8S5rW6uJRYTyMHgK/uxEOAQO3atb4kQ6N4cvVvZbQ3N3cMY440byxjvuI6/Suo8L+K7PULuexs7dVls8xPeNjYxHoawfiVoZ8UaJCLJgb2CTzI5OxJ7g1pCrCpV191ESjKMe5Qub/XNd8NadN4BRbA2kzRX0KEZVwOPmPVa9Chs7y68O2h1+4j85YwZiqj941cb4I0qLwz4dtdMuLgLdXd0JJV3bix75rqPFYupZbJncx2UTh5CDjcB2NRUab5V0vqVG5n6vb6fZ2mZ7RblhlV4rm72604aLbTW4mspzL/pEUC7vMA/hPtWR4m+IunnUbnTrVfOdpMcZOB7YrMsfGEttJ9ku7byIFc7ZpIiN1ZKpKD62Rv7LmXmaGmeGNP1Z9VutY0q7trZoi1u4n5b22968Aj0GCTVp438y1tDKUi3D5m56Yr1O8vLa18aSeIk1yW88ok29qwZY1JGOe2KstpED+HbrxPqlpNKFk8yMhSN5zzgelbTqOpJJO9xQj7OLbKWlaxaLapDZ6PD5emwF0dI8zMyd3PoR27Vw2u+K9Uvree/02FbKIyN5ogJBO7qP61r3XiK+vYXTwzatbJODFJaRDdJKT1AI5xXI22n+INLku1n06WOCb93IrLkKPT6ilJW922iKj36mJDAlzNvdGIVdzLIdo/P1rd8I+JG8N3KXsdpE8e8EAnH3TnFXF8JXUSiW+QvLgGOFDkkN346cVPF8PZ72ZCoMCMT97JLH2H9aycVUVnsa35fU3/HvxhvdfuFfwrYyaU9wAs7DBaRh0wQKw4vF/jm0l+zf2t5jMu1lcrIOfrnmsjVNKvtDJtmOJAT+7Xgj15rpdOg8OroawTGddUVxNJJE27yxjo3elZaJr9RW5VoaWieF/EfifVLez8Q3F5cw7S0SDCRR56kDpWvqWl2vgTxLBpl08VzDMhKRiPaWbpkjp+NZem+KL/UNQsrSC/sxHvCIIZcSFugJ9DXbax4U8aNG1zexaJqV0i/6P51xsmPcYJ9PTvUQc+boVJJIraJZmPz42lV3toi7xKA28McKuf72cVwnjDwzJqWgahrpN4l1YOIWtHODGGzt/I5BrW0TXNRn02WMXcVg8UmzUDMgVY3zxsx2BH3jXP6n4qQJcQTXU13pc0v7+aJD87D09R710+0k4vnWpkoJS0eh5/pFvZTXgGrSzQx9Pu/eP9K9j8PN4Z8L+GLuPV7CO0vZoXeG5Vg8yv8AwEHuvIrikaxtrC5u7d7ndMoiVHCmM5+vOazdatIms4JZdJvxIBiWVFPlj0I9KGlJJJ7hrF3ZffXbVLODS9K09jebh59z1M0hPHJ6DPauq1jV/s2h2j+I9DskuJ5N3mM6sJGTjHHSofDukeHvEemx7J491kAskwkEbYAzvYHr6VmeMbfStH0m8soLdJHuSvkqhZgW4+YejY61MoKaUnuOMrOyH2+padql5NdabbQWcj4zFIu6NiO4qN5W0a7jv7i7mnvkObaGK2IEnqCfzrmfDcGr67q1vBpunXd9LB96OGLBUD1Pp9a77XPDXjHUdSt73w3o2oxvbxfOJExscdQM/e/Cp5ZWUGirxu5Iq33jzVI9Jmt9N8MnTt6h3mjicsBnnr0BNVrD4oeJrldGS8uba6t9OlEkMEo5Yr/ePfA9a9W+G+mfFYTXzajY6Ypv0VWub5P9UoHC7F605f2clvb2a81fVoUnlZnZLKExoST6Z4/Ck4p/Fv63JU1HQ5NvidrfjPxHHdwaHczRWi4EMLkSKT1BA/hNdVp/xEk0WGNzol5bRl90kbW5RCO6qenFcdf6Ne/B/wAS+bZ3DTXjRHnzNwkjJ4LL6CtrXfjhpl/FGLvT2V1t/L2HBCSd2A6UubXkd7D5bLmVjp/iBaw+Olt9f0DWrB9O8pVeOefyzbkZzx755HXiuR1/xHb3vgu18F7pbuLzP3+pOu1ETOdkWeSPc15pqfi2wv7y4CWscKT7R5kI2nIGCcdOa1rHSLm/S2vZUl1O0t32mE5XK46j1xVSlOSUOi8v6/QIU4x1bO3+HXi7wv4L1KW3FoCZ18pbpQDlQPXqDXL6hqWmsbxdIhu9SjmDLHJfKEityx5KqOWb0Nc/q+oXFuTLpumR2Js2I2MvzPk47+1ep+HPE3gl/CjTanBJPexRbpY1TaGbpx71kpyh1epo4xetjxqXTBp07S3qC/RwUZG+Ur6MPUVEdKmvoJE0xJnymCh5Ofw6V6BLoWueJonvtP0uOzsghZYhyyKOfnz0yK4y7s/EWmXiRQC52uw2eWhCSZ9PWtIqb0sJ8tjl2sruzkgPkTrJH84dFIZTnqCPSvUfDeq+Mtc08TT2y3X2MDE90SM47sO5HfNS+E01SCZ49VsfLnBISSVSFUj29areLx4rispZNQVLazmXZiGQbJjnuQfT1ol7y13QkuVnOeInuriWZL/VYVbyzMzISU4P3V9ya6n4a6LYyaVGLzSobppn88S303lrKnQ7VHP4muK03QbK5mDa7qropGNkXz7MdAT0/Cu4trrRdPgt0XUZtStoo9wiVTvhK/d3Y7GrpWiRUbZ6RrX/AAiPhWC1hksBfag6+c0Mcu2OFOwYkfN6VQSLSrq7tTpyrb6XdIGdC2JIicjOPY/nXB3Pjyw1a6MD6LIZnXCM8mDj1IxyPau98GaPaeIGjvreQJcqPLa2bgjHYL6VrCdNS6pmcoztuaemeDo2udOX7UJLXzAnnLwSoOeB2Ne2vo1hLFDHLAsiRY27ia8g0HxDG2pXGlS20ZKOVQbuVYevoe9elabqcb6XLDczmKRlIDOenFRXVpXaJTbjozzX4kPqul/Emxk0mOT7PKIwAp+Ut3XA9a6v4g6ro+llLi91COOeNebRG3O7/Ttio9J1zSfD0CnUZnLs52y3K428/wAJPOKxrrwJ4d8Q+MG1xryeaCciU2qjCs577/7pqlKE7KWiXXuTaUdjc/sfSNf0G0vImYx3I3xxuvzZqrrEOn/D6ziuLe0W+1ObLKHITOPesJ9Yu4/F1vAvyadBK0W1ekO0cKB3BHevSdf0XT/F2jpDeZMZXKspwy5HNNtwajJ6MT11Rx2geMv+ElMUF1YRwyXHyvJF6e5rU1yx0jSdMij8Q6mkSNlYyy54/nx61y2vadb+ARZwaT94jmSTk/QCrHjjRtQ8YwaZqWmsqr5IjmhnQjHuKHSg5qa0TGptKxQ07Rbjwxry3trdlreVRLGynKMvqPrXa674j1O+0FP7A06G+vhOiXMAk5SMn761R8O6Tew+HrS1wsws1dA8nO9SemPQdq5zw5b31p8Sr4JY3NrZW6JIZuRHJnqM9KtNVHrrb8SZLl+Y3SvBmtw+P9SutcfzNGvV2KFfGDjgbe2Oa6ebW/CvhK0/sKW7lfzDkgfMQPU+1W/GOq2t+yw6XdBdQiYxn2yOP1ry3w54Wvz4g+1eJLGaVbZW815OPMOeAPWqgnUV5OyQnpse4pd6ZoHhx9QiZ5LMKJNy/MWB6YqlYy6F8QdES68kzQK5UrKMMrDsaw/FFlqfijwdDa6IPsqBws0QAU7B0AzWx8M/DD+F/D32Oc/vncu2O2axtZOTetxdbEPiWC3trywglsg0CkLHIqZKfSnN4fsdNnF/Z222d8h5cYPNdDfyTQTK5Qy2wHzDAP41LqDJLYSBX+V1x8vJ5qfaNIq2p5JZ+K9S0zxXe6Z4osI7nTLk/uZVjyp9AfWuqbxBb/8ACOXKTaa8MSZCQxr2+lXk8I2dnpjeY8t1ID5gaduEP/1q4azjvte1K4t9OvrN5U6MX3EDPpW3uS0ROu5X8LS67eXk7ANpel4PlqwwxPrT9Q8U2vgFY7nVrs3ss8mFSDk/U1r3rRWLppN5qFul1NgOw5CfSud1jwfrTeKIV0/SNOutFx81zOd5bj71aXjJ+X9dWTshNd+I+k3+pCTQ7e2F9IgBudmXJ9BWlYHUdP083/iCaRIpAW3s2WUegWofCfhltBvrm81y4sppA+LaGBV2KO30Ndrey28yxtqVnuVG3p5i5Cn1rOU4RSUdfPcpKT1ZnaFHDNpkVxJcy3McvzrJMNrY7cViXPivTIprqNWRzbnDlW+7VG88aXtx4nfRtN0RrzccJLG3yr9fSrGnaD4fubzUoLh0OpOhe4t4euR2BqNW+aWi6f1/wB7aLctQaraXi7VmWNJf4ic1wvmeKvDXidzPOl5o8z53KvAWqV1aDX5PJ8NvJbNC+14JDgrg+tbfixruztodPtr6CSUoA6MeVNbJKLv3JvfQ1NF8Qj+1nkkkEaN8oAPB+tb1wyzxOshDbx1z615LZ6NdLdR/vPNlb7xQ8V6LqNwfD/htLpoDd3S4CwA8/jTqQUUrAnqd9q1zp17pa22s2qXfmxiUW0i5xx+mK5vUzq/2eyENs0GnMQscNudnyenHTim6jqiIN9tbNPdSBfPw3Iz29q5bxF4uuILlrLTbpnTaH8uTkR9to9a5lFxWv4jVm9DrfF/iW30kabpdrpkkMbuGBQYGffHPXvXL6F4X1XSfE9zrNzrE17aFXl8hXJMgP8O3tXYeGojqWkxNq8kK3OzcAANwArFk8VW9rqAshEIreInfcsflQH1PrUwlaL09f+AW4677HN2HhSLULXXrnSYbuGa4VZFtfMO04PUD0xkgVJ4Zh17TLS+U295PbRJtjjf5nlb1x/DWjrfiaS31rTp/D7pPZMnzPFwCd2CDUfiTWdesvGUtzNdW6eGZIcSJnDk46Adc5rd35XzW11/LQlP3lY5vxV4j8Q+HtSt2udKhtyih/wB8wOD657U6XU/G/j62YxXUFlpaD5nQEbvYHvXJ/wBr3HiTxnHYyQzPbXMyJ+8Yu2Pr6V1nxN1vUdPki8O6MIbeC2UKyQ/M/wBcCuJpXt1OtHbeC08H+B9IVoyt5q7r+9cpucn+6PQVxXiO7uPFHieS4vPOtoYxlYwhYZ7DA6mo/AUkdkR52nteySMu/eclT6YFe5ahqWhaXpY3pbQSuuFhUDdkj/PNUl7NfvOpm5e97h8/T/2VbXe25sZJEQBpHfjJHXjsK6u6+Ig8URQ2Gh6SxsoFCs7rhH7EBay9Ylk1UXT2FjGkB+UEHJJzySe4qPwnZ6dpc5hNz+/ZsMmM7T1x9aTjKbujR8q3O28C+HNMgaaaeKOCUAloFwpb6kc/gKyL28lulns7exiChizOwwD6YFdPN4k0tLBhLZxCVBgY4ZiK868XeKdWZWs9N09/KnADPAnzDPb1FZ7vXUcb+hQtr2y0u9mmu7xbfePmDKCQfXn+Vdjo/ibwjZJHJb3Vxcykbipj4LHrjPbNb3gD4a+G5dGtrrUI11G6ddzmXnYT2+tYvxm07SfDGkwSabawQxxHMwiA8wZ6YB610Rcq9owdjJuEX72pNqNr4X8dahZJoPkxao74uXePJEYGCOeM+lWdV+EWjaLqNnrujiZ7q1G1rV8EXR6AE+vNeWwiRPCR8U6O8sFzHOI3IO3b3ViPfpXo/wAOvGcviHTZT4h1aMToAsBOFAb1JHWs37Sle702KaUrcp5t8R7KHR/InfwjJY3jzYhjhj5Y55y46CtfxH4Knlsk1ZrxUaaDzGt5pyZIiQPkB9iO1ev+OZ7q38IxXLRw380B8xHB3Lnsa838PS6p4l1+wstSjkv9Onj3SSCPZ5Zz1Rh0xXXSvbnh03e5jJp6SPJrDTZ7iK9+2xN5wdpIbdc7QxPV89vTNd3oE2naLpltb+JZbE3E6sJIo8Fki7HjjP8AOvSNX+FOnQX8LaZd3/nlSoTzAcgd2J7Vw3i74TqLd7WXVdPg1OR/PzcTc7fTmocoT9yLt5mib+JnTeBPAPgvU7OOe5uYLuMMZIbXzAFjGeCR613d1rfhPwbpckGr6hp8Ma9VbaWI7Db1NeAaH8FvEemzwXcVzDLBK4KyWNxuBH9RXY+O/Dqafpdqy6TDd6jyZhNEXOAPvVlKlaSSlcfNzJ3Oc+LKeH7m+0rWfBGnRmacGTMVsfLkGeQ44Az61h6hJpd/pVvMmjpb6xbAsypc5Vjn+6elWNK8SNp1+kF6z2OnImIlKncAeoVfSuX8a2+jXGqS6hpEU8EczjbLdttycc4Qc4qGtbSlr+ZqnZe6jtT45afQLDSrWM+H5Zi73l1aqA8uB8oB649q634MfELW77xBb6Jql19stljY/aJAFIQdCx9egryrStGssFDray3zoHhdlwIiO/vR4quZrKwU6ndvJdygxTQxosSnB4YFeTn3rVNKlyuO+zM5Q5p3TPq74i+Ibnw54TvtT02xl1GeJM+TAfmAPV+Ow614f8G/HXiqbxdf3niHUrq48NrZtNcPdR7VjcfdCHA5Pp3rjvh1458e2dtJZ+HLUXVqo5+0jeIx7knpR8QPEerPpht9Zv1kvt25rSIBYUHpx1+lSnKMHGUdX1EqSct9DmPiR4mj8R/ELV9S0+O5vftfyRJk5SMDGAB7Cue0DQ5fE+qTWtpazxSxxFxFBGZCMdS2egq54CF3aaymswRQyqrtEUJx1HJA9K6rRPF1/wCC7q/uLO0f7dfsQjMeSD6n09qJSaWmrLjG/ocBrOgPpk7RC5E7qMsqIcr7H0rd8O6xqWkWsjf2gUtMZWFpCWHsDWRr11eSXN3cXeo+bcXh3zqDjOfpTbCPUpYk1DMqWUbeWZo03FPoKavNK4NKD0Rt/wBuapq2qLPeyZsGYBlcDft9QP613OoHwTZanYx6ZcSXM0qDLupCK2eVYdjjvWd4f0zSn0hNSF5d3kEGEaKWPZICTwiEdc9aXU/D9/b6NZ6pp9hJcQ3FwTBDvBdWzjJHcetT7OUZe7p/n8yueLWrPU7PR9W0nwvPDpml3kkF86pPISDhewQZyRW74a0exufAt3cahaz381hM5W03FWVhg4454/SvOofHHxK0SJWvLUTwx4UfusAccD6iuG8R+M/FSam+oXMrWElxnfHZ5QyE92H9amU6ktGv+CT7NJXR6BJ4s1HXtQEF/bWohYvEbXyCGQDjd5nbj15rz1fDOs38t6JWE1hZkyLHKcFxngZ6EmsKw17X7rVQLqS4mVAZGXOTgDPJr6T+G+m6B408IWGo2vm2t42Y2t2fncOufUd81pJX97lSQJqOjdzO+CvgDRtb0iW/1KBGtw5iXTMgiMjqXxzk1B4bubI/EPUPDM+m2VrpbRyIsSwqjRbeh3dT681z3i7w5L8P/FEj6fql5ZzTf6RELeRsSjPOQeDj3r1JPDMeux20+pa3BJfXcKyFFgSNyhGSDjmrSdOLctnsZN80tz5x8RaBplzr+q/YppJYzKVhnHGADya0dN0/Roru1aW4vzfQugjuYpdkYwcg5HOT3rvviB4U8P8AhnSGuIYrm5lMp+aE5RAD0wOo+teNG3vhrCT3v2r+z7lyUaEYLAnhf9kZwM1nCUviT+ZtJRa5T6m8L+FrXVdTn1S2dYAzhpfLcSbnxzg1zvji68KQ6xdaXq97e2N2g2JdANtz7gdq43w14uv/AABob3McEQuy3lmwjy6OgHDNjoQe/eum0K5h8c6JNqfxAsLe2klkEdvLbsEl2EdSMnge9bRjeX7x7HO20rx6m1qHhSP4iw6JeWOqrEtjGYHki+eNlx1A7HHY16bo+kWOlaDBp2nos0dnF5aFvmJOO5964HwhoNn8O9MvF0vUptQS7YbEkTCxqO5I7+9b2j295pumm70pxLDL87AtldxP5isatVr3E7xQ4wv72zObWwuNQ1YpPALW9lmChgvUd8/h3qTUfiE+geOo/DX9jhrGNo4WnZj5shb+ID0FdRpc812s17diOOaPOMcf5FZ8OvaZea/Cmt6bA91CcR3gj5U+/f8AHpWlO03eSJndaXLvjjwtNqzQ3FmTI0Yw0ZbBPuM11kZFvp8YReUQKF6cgdKZZ6lZ3UjRw3ETSZ4QMMkfSpHtlN4J2PAGMe9S5txURW11MTxFqcPhHw1c6h5DShDuKg4yzevoM1znhLxo/inw7qkl7aRQPDlP3L7lYkcY967rW4bK40m7j1QIbIxnzd/QL3Ned+ELrwfd6df6J4OuszAGRuP9Zj0J61UVHlemotbo4izjubO7vb9FJuC4wWOd3NdB4yvdZ0jw/ZalocE8s9xJ5kgkG8J/s4NJ4j1aw0lFttUV1VWErtEuW47D3r03wnrWmeJ9AgvtMDPaN8myVMMpHYiqVRv3raDkrK3Un0G6kutHsbq5i8ieeJWkQdmxyK0ldWztYHHBxWV4lvU0/SpJAQJMYjUetZXg6RtT0kXDXDJKWOQp4/Ksmr3ktgOX+Imn+L9Y8TWlppLNDpYYFpFOB9TXRJaSaTqH724eSIqPlXnJ7mtK/GrQBxFKjRn7rEc1jXZETrZ3F+Jbq4XBAGCuauMrxUdCba3J9c1rT4tPk+03TrCRtJQ881x1pouj6HFcahpb/Z5rlM+eDg/jU2p+GLuMMJryBIDgru65z3z2rPj8IW3iC6uYbjVXkaNOIomwoPar5UlaMvUe+6JE0+4sZ7Oa6f7XbXrAt5YDY991dF4x1VLWwji0jfIwKhlhGcD3rldO8N3el6VPZm7l3K2FRX3AD0rTgg+z+HrzSpJJY551z58LfMhHPBqaj59L7BFW1Kfi7TI9U8G+XfwyQOHEq+TJhvxrp/Ct5Zaz4O8u5DR/Z08ks7ZPA4Oa4KA6jrWpQQSXjxJbgBi/HmAdyO+a2PE2mS6j4Sa18OTeVeeftcRuAMetazp2hydyE/euXfhy1npmu3Qmu0lkmO2L5QOPTNX7HwNfWnxKuPEMdzGtnOuGixzXB6XYxxX66dHqIXUrUB3yOSfatPxn4s17TLLal8ojAyWQc49KykqkXda9C7RlpsaXiq80+w8WtHZQwxtj955a4LtXn3iyztLj7RqVusxvFbBjPXP09K7jweumazpwv7iTfMRnceoNN1US2txHdbLZ7J2Cs7YqoJJqMtwbtqilZtcweGIrqz0/dfLHkIBzn1rntCi1n+1Jtf8AEjyW5ClEtm4DfQelW30LxddeL4tS0qRlshIMYfC7fpS3bT6l4t1U65cPHbW0fy+gP0roT15n1v8AIy8v6YupahJYSXNvcXHyTKFWFFw31LViaXBq8uk3Ta6Ld4/MU2LRKNw55PHOMetdb4PFhb+IJ49X8uWQAFWl5+oGe1UYIrqz8WavGdRgezvm2xIo+WKMnk+3HFc05W5k2tLf0jaK2tcgtNYuXuQLUxldgh+0TSCNFPoM9TW3r+oaPpQt/DeoxwTalcqsjI2fnzyPmHFV/GXgGz8Qa6t/Za/aWmmxRKojB+aMgc4HvWpJp2g3yafeztHONKj+zx3bEGRyPUdvxqEoKzUm9OnRicm/s2RxV3qdvoGmQwxWjqDIxbyfmZCecf8A16871CfXb7XY71UnnR2DLbo+/AHZj0Ga96i8LW+pSNqOoOq2UrZweBt/CqvjrwhPc6JYTeCIEWCEOs0cZCtu7MfWnyc8lFy37lqqoq6R5D4m1HVUmjuzp9zpf8KuiYVB9a7T4d+FNcjYa+9hHeWdymZLlj50xXodq55rX8F6ZfeJvDPiDQNZWbyTDvjedCpjkHofQ034fazrfhvT/wCyNHW2vo7bcwjnlC4HqMc4qa1Ll82v6vcqFTmVlsQ/a/EfhqWWfU9JsdI0uVitrCrAzSHPDHnPT8qwbgpr2oiSS48mREZnMjnGR2x/St/x3PqXi37PFqn2YeUDIHgQ5Qf3Qe9Q/DZfDlv4kbStSs5/tT42Sychx/StVaUPapa/eRflfI2VNB1c/aBZK6/ZUlXfLJFtjz0wD/Su2j0zwhpOn/bJrqWeRXKhwCdrt3Cjqa0fihLpLeD7yw0W2t5JlwR5SgBWHoe5rx7wlqDTxsnnRyqWxJZliHPvnsc9MVFNSk+bm0Km4221PRpPDr5tdX0S5bUrbcHCNg78Hke1YnhnSrnS9Y1TWFs9RvjcysqqCMJk9G55NOm8RR+F/Dd1oVpNNBdXMgk3TfeUN94DH4V2Hw7uLfw3otxc6pqNr9ruF8z7IhAI9/rSnaKetunqCb0ujkF8UeIdI13ElhLYPgukLj5ZeemaLzxIfEEsr+KdMm0+7AAjaJfME/PQKe/vXa61rFp4x8Hao0stvaS2vz285YblYDIINeZ+HdW0HUJoxr9lJf7IgWnt5mO0f7v8Jz6VLqxg7xVn5FKDmtTJ8Va5qehpL4chsBHpt+Q6/aQNzeze/tXlWqQajpFx5XntHGWJVEzgH0r1jxb/AMI01yNQ8N6bqVzCgOXuHZhv9Vycisf4cahaJ4lGo61bGaPcR5Uo3LEPVhRZSbl0/U0T5UlbUoeEPGGtaeYDHeyqqHasMg3rg+qngiu90r4oa7ZQTQR6jp8rMSN5t1Roz6YFejeINE8B6rocurW8tnCVjLCWH17nb1ry4aVobmKK2vLO5LMCWCkZIPHPesoOktQfNPodro/xBu9GtjealE2oS3CZLqchCO1ZfiKC3+J9yl08D6Zeqg2SEkxyqvIR/wC79aveG/CMV1eyeVqUF/5J2zJbyKfL9AVFTa4brSrx4I7lhDnDrtxke1bQqqndwWpDpqe7L/gm31Lwv4V1m01DUIDcSxP9lhi+YQyEEA5HA5xwK4yx1vxNb+GRp+pa2+o368uegVMfdL9WOe9Qalr19Cs6pEfJUY8xmABNcA15qFxrDPCJQ8mS8aHA+tZ1JTmndLU0p04xejKrXiWmqR6lqD/aJY2LbXJynPTntWBrjDXNVWaz8ySSQ8ogJCn69hV/UNMn1G5ICkLgkqx596t6BrA8LNJG0AeNj0C5x681mvd23Nmr6DtHi1DRJI3u7VLghSqo7YKA+9a9lJazm5g1LTg10AJBcL8wRcdPx9qwL/xSs15A6SsVbqrj+la+i6hcalMRsP2BD8zqvA+pq4zlF3ZLinsddo1/5GiyR6Haos1wRE0qD5znoCO9O8afB7Xm0hNRuZYrhVUPKhYK6j096oalqi6eok8OeZbzKv8ArABge4Hc03TfEPinxBpzSX0lzeWYOVnVvkfHG0j1quaVSV1sRZQVjhk8F3lheSSwbLiCEb2Xz9hX0570XOonXI4tOisWtnaULFK7bm3dD9a6GUtd4/tcPGlwxjCRL82exPc07wn4Ln8Ua0dPso5bCzsIjPcagyksqD09WOOKqcYyfmKMnFeRxcWhafHe3kGoXPmzQk/vAxRCfTpwfrWjon9sWUT6ZpMiPZXG4szplQvqGr6A0zwD4W1nwQmsW8l3cwn5pBOQvm4OCWUfnXYeD/C/hay0H/Rre32yAnGcgfSlJxXxCjLqjxDT7rW9O05opWtZwqKFEW0owA6kHvTNE+Ia6T4igmvtGluZooyixpGeAT1UdBXqHiHwdpMV5HfWk0USDBliYcE+g96574kajcL9gttH0+10+4lBRpyF8/ZjqF/hHvU1I03ZwKhKT0ZmQ3Vl4r8Yz65c6vqel2IUNJaTQsQuBggDoBVHUNVt9B8Uy3d5pdvf6Jfp5do7kPIcDGTjoPY817v4N8Gaba6JavfoNRu5Y1eSacBskjoB0xXKePdO8LQX9vaWd3a2l0rmWW1gTzG9vlHSrVp2Utf68jLmUW+U85TRbZYo7rZ5MszBN0fVc9vcV6j8KNH07SbyQW6NBcYIKbshvUj0pvh6ztZx5l5o9zdKq7RcTwfMPTjoPwqpezR6Ms2rymKxsFJi+1DLSsv91UHerfw8qWoNtt66Ho3iHw5pHiiGKPVrZLiOJ8qQ2CPUZHb1FeAx2Mt98RptGS51KGU3gWSEIVRI1OPlf0217B4B1GC/0ZB4c1WO/ij+aUXKFJMtyDjtUt/qmvxalOkOkWoYDCzlsn6n2p06kopxkr/15mPLreLOF8VfDu5tL8RRau6aVdR+Vy3zo/bA968xu7jSLaZ7aznkvv7OVvMVvvg/dDD2Dda90Twxea9qEs2qajIWUBozG/EZ9hXF/FHwRpdnpV88U0I1W4VVupki2u0WeTx3rKMk07/gb3a0udb4Y+GOgyaJbTaoJL6/ljWSSZXKZJHYDjArCv8A4Z3PhfXl1bQbqa801n3z6bPgqfTBrjfA3i/UvD94ltYRXMGkFhDEt7N5pIH8QPUA+lb3iG78V+IPGcX2SC7EW5VhMDlUjX+8T0I9c1ooVKj5ZMzuoao9i0fU7K60R7q3tjAEGJbeRQChHas6/wBXtI4IwsvlyTDcyDp+VK1sBLM8y7zGFWRlOFdsc/lXA6rqUc15cLYxyNDE2Gkl4AbuB6iudxlPSJceVO7NbxBY3us+FprbTriSKfzd4df4l9KqeF7yxtpI7bXBK93AfL3k8B8cbh/WoPC3jaKPVbLRzDKZZpeCq8Af4V0PxF8FNd+ZqeklUuG2+fF08wA9R7100lyx5JK3mZzavdakXg7wVJBrj6i92wiE5m2fxMT/AEqpL408SxfEObS5rHdpUpKRBYyCoH8Rb1qHSvFmsxeLYrFomWwjQKF8v73416ndzxLEu94UmkGI1kYAkkdKqd4/xFfTQjRv3ThV8TxX1uNK1BUZbgNGVB+Zx02kf1rlIPCfh/4cawL2C8I1G7RvstvIema0v7Dkg1dG1aNdkbHa0XJUnpkjkVtxaBaa14ghvryFHeBNsJkb5j6nBqYPkXLF6dSpK+pyuk6Rb6rp+rXevQu0IUBLhQSQ3XcPpXe/CzSoNI8JRQWl011C0jSB2TaeT0xXRafbwi1aAWqxRA7dhHBqwixWypFFGEToFUYApzqXjy9CLa3PIviB4c15teuLq0lllsnBb73C+2O1L8ILfVoNUljnSZLRV539CfavT49Z0y8vX0+K8hkucHMYP51geLrG4tNLeSzvLi1CkEGHGSPSqjVvHkaE1rcX4gya9FbW7+HokkIb96relcZ4Vtr7UvE4e6jYTlvMlJ6JjsK7DwTNeahFJcXHmRQk4COck+5rqreyhgmkljRVeT7xA5NTGXsk421G1zank/xmsNVvNW0ax0uRxbyNmRU6/jXOaHqU2g+LU0q20u6FxJw9xPwMe3tXrfim7tdPhub1+Jooyyk9K8gXxBqfiSwW6e3W3lD7Y3A5Zc/pWtF3jypaCkupm6rH40vvGFzbWX7vTbhsSS5+UAdeexrsdM8PT2+lSRfbNjojbSzd/XNZes2ut/a7Sz0vzo4ztaSVjx71V8X6Fq9/dq9vfsYFAUhGI3etaxXuqKsiW9dSPRTPqLzxQSg3cZ8uSVuw7kGtr7PcW8MBsPl8qQeYxOM+tdL4F0O2sLeOBUAVFzI8nVj706XToLu9e3sbtSGJ3AEECpnVXNyoSi2jhfEyLYahc32nIs+t3SFY4geQPaudigvtU8ORwaoGFw7nzN45XFdd4r8MWdvq9vqN1eG2mtTlGZsI7DsTXMDxAb/xdBHqkYhBJX9wco4PephPmXu6/oW0luZB8YRC1fQ9BhMUkQ27/wC+RWVqTa/qOiW+k3CytMZC6hcjiu7bwz4e0a9u3029juNRlBZEzzGTVFr7xAPsUdnDE9wrbXlZRnb6VtDklrFXJd1vod14JlvbPwXLZ3l0ovI4uGJyU471xvhDTbvxOdQt9Yu0eSOT5ZUPMi+hr0Hwt8P5FS7u9Xu5HkvEx5SHAQGuXuLOD4f68sRDzi4zsx0/GsVKPPKz1f5hrZEXi/w9daObm4+aXy3MiOTyqn+E/SuVsrbVbfxJbWV/ps09nIguJZ1yoiBGevoK+h9et7e4015plRxlW57jNYHjnVLO78G6tDYurTGHy/k6gngfhWKmqso8y8v+CUnKEXY8e0qPTvEuuTf2PDOTbsOjE+Yc+ld7J8P5bTSBaQuIDcS+fK27ofT8KzPhRp1j8OfDtzf645e6kkVQEG4kt0Ue9a3xG8TQeIfBSvpLSx3ZnVURsq4OccAdacqklNuPwgo3sjU1izWz8NwaXZT+bNGd7gHJGelZ/gG6k0PU71LlZplnKgoTnyzWB8K/EdoviEaLcW3nNJ8j3Urkszj2Pau91W/06x1xNPELNJctywXhfrUNSlFwmtdx6Rej0I/iB4mjjsFs7Abzcny3dDsP+6Ce9eIeGY9OtvF97aeXeW+oEFBDIeoPbdXpHxX8GX+pLcavLqaw6BZ2+UtY1wwPQ/jnvXKW01rrf9l3dnCbaO1Vbd55RuaUL156k1bpv2Puu9/zHCS5tUXvh3oeuX9ndaVfxPb2i3LmAu2JSmckk/3fSu/0nwrpUFvPd3CyQTRHZ5kzctjvzWPoPjbT31+50myjm+0Qx7jO68MB1xV3xdYSeKdHSJLyXzAdwWLgN7E0uRudpe7cTlZaalS706Ka5dBehoT80YAHH41yTeH4PD11Nqlzbu97cSHy0Azt/un9a1BpPiqy0OeSGyV54gsdvGgzn/aNaHw71eHxhezaJqsct1qenIJJ74DbGz5wVA9un4Vbgoe81ddQ529EWPGvg+y8Q6TBgiO72qRIBklscivN9Q+GF3ZxKiyNPKxyDv2uB3CgnmvpqOyihjXaFyo9K8Q+IMWlS+P4dbW+uZmttpFujYVXH9KmnKU1ydh3tqeZX3gTT44GS31+7julBIt51Kxlqbp9nHpOnSXWpb44ovlKwcgt2HrzXt+kW9v4xRhqFg0EakuJMdTUt18PdAu7GSBIWCKSCxJyT/WpcVe0kaKppofOB1e7v7mS30uSdLeQcwu2EDZ9q7XR7HVvD+kOtmsEl3cgPI6AM3HUc9q7258A6R4S8OyalpukHXNQ3KFikBwgJ64HXFZ18PEPiHU9MFzozaYLfHloqeX8vcZ9Paq5Elz01ogVTm92RnXos73RYnmjNlqCHbKFG1X9/wD61cX9kvYLom0eKSVicDjAHrj6V6h4k029i1BBHDA1o33jLKF+b2z2pbD4VXV0y3tzf28IJLq1tLvCZ7elRKTlF3Suy4tRe5y/wc8SaN4RW7h0zS7qfWL1wk8jNujGCTgd8c55rvPE8l/r15HLZ2MkanAPy9M9aueHfCqWwmi06NVaNv3kyr80h7kGtq71lNDtdkkSJGAQxfgk+1YNuT6tlWUXocXpNrpkiSaLqFvFbtbBpZb1zllUdc9q6TwNoPgTXlubjTtM802zBWnuC25s9/pxXJ6XpcWu3+syai17daXq4W2WC3+8hU5B/HvXbWvh+XQdHj0rR7VrWynkDXE9xLumf246cce1V8MHdu/boTJ3krbHhHxWj0+PxFfDw7ZTWfly7HmJ/dtjrjPGa5C0iRrSdbgm5vZD+7VBnaf6mvafjJpdzr+iRQ2lpDa20M4VQpxvHq1eZ+GdPutJe5vpoHhaFWWMgdu+2lFKSubczRm+BfBiXeow3niCVbe1BJfHLLjtj1rs49PtLQ3UOlzyW2lXM+2GFfnkmb/a9KqeGtG1PxMJl0aa0N0zGW4j37mX0yPWusg+GHiqGJEu72wsdKQNPI8eWdCBkmizb1+4TklszG1bShZahCFlVoEXDbSPv+h/Ctm4gTV9Di02xCWFmmGkktztyTz+Zqp4e1Pw3c+JbKxfT7mSwnXabqSXLE5wCV7A4NetazHoUcdhYaPb2lzErmV7OIAq4C8Mx9AamcXTfvbgqilseO6/4Om0uwi1SUTTtg+TIx5cdyvoSO5rsvg3rduml6rJfxS21iq4linAyARjAPeuU+IN7rOrtLY2kqyxW0bTTIjERWkY6DPr6VzGjWmpp4Zluft8V5p8UiNcQIcuFJwGA/iOe1aRlJ0tF8yZRTlqz2qe90e+8PSeHfB+ZEuAQ7J0jTvz7CqmmeDz4Zvkv9SvYV0e3AImdz8y4wFAzyTWBpvh1PCOlSa9Pq8+l2l82Ar/ALuRVb0Tpz6dq4nxVfad/ben2kGr6lreiOqXMkQcnyipwMEHr7Gs4znzNN3v94OEbe6ep/23FJ4pkt1vLPTYJdjQ28kPnSY6/Of4M+lc80CL4l1jW1s49R1G8YorM37qJV449jiszxPpulT+JF8R6ZrNvNa3KpILaE/vVkAwQfQV3mkjSGitxY3C3Klf3rRnIB71onTTVpXuhe81do4HTW+InjLV7uyhuk0a2hQlljnYK3sK9S8BeFrXwppLRrDDNqz/ADzXcibmc5yRuPOBWe+vaV4Yvpv9HbbMmI2A6n39BUmheMrrU5p10i0juWXnA+6PxpyxC+GEbL+tyfYv4mz0BNRZ7dhsbdjgr0rz/wAV6r4ZuGg0e/mSRrlgy+S3KODx+Nbmt3GuadpR1e/4ePCi1tRwgPVmJ61wPh640fW9fNzYW1pcX8DmQxMCjZ7kDoaqkmlztP5EO2yZ3fgvRdG8L31zFo9vfT31zjzWkOQi9QM9AOtZXjnx7pmla41lNf3AvYcI0dsgZY9397PWut8JXkLNcIqyebI+9y64OemD9K8v8a/D7Vbvx9dzWVxax6dfuJZH3ASIT97Pc+2KumlOV6siZe7pFHaaKuuX8bmwmt40ZQ0d0y4yD3wO9cqscH/CRPpWotNqtw8v2e4umlx+8IyQqeg71tQ63qXh/wAQw20Uav4btYhBIAv7xMDlz7d6t+ONe0jw6YtYs7O2e8vCF+0gfeB9/X3rOCg5uy9Cm5JHPJ4X0yW5t4tOsWa6jYrLHksvXhs9hXd6y8HhDwzJPAGUIPu5J+Y/0rKbWItDsrnxB9iYRzWXmrGvVnB5H65qv8LvHiePrXVbPVLe3iu7d9piXnehHXB9Kbg2m7aITnra5z+j/FGK00vUxd2wnhizIkqHh93bmk8LeHYp7A634rv1trO4bzIInfbx15Hc1H488CS6feafcWrRvphlxKoi2+UM9Wx1HvVr4sfDy98S2em3Hh+680xRiLyDJhVH99ffsaUIxc7J2T7lSdoX3O00Cz8MawxutFkinnhGwyqfmX61w/xfbxL/AMJJpI0h7j7MpX/VNgbs/Nuq78MvCWq+Djd3t+Emv7lFjS1gOQqL3zXVa/pl9qWi3q3CrbiVCWZZsFeOoIrXSFTfmSMtWuwlj4o0uNn+3RwwiPCCbIKlvTPbmvHtcXVfFXxEjtGuJkEc6urrwoQHPFc7d+GtdtdNnktbuGXSVYvJIrhlyPX3r2X4XeKdN13TIp3so1u41EDXMa5DEDHXtWygqV5rX9CX72mx1+qWE9+sL6bcojABZGZQQ+PWsDR7R7HxdqV7q95H5VpFuVTxtXHX6VuXuoweE9Flnum81S58pF6uT2rkNE120+IN1q1lcabLZSRwmEzK2RIh/nisIKVnbbuUzpNF+I/hjWdS+w2OoBp84UupVXPoCetdbKu9GXOAQRkdq8L0j4R38Oq+bPeW40+JlZFgGDhTkfQ11ni/xBNrHhm6i0Gd4LqBtkgPDHtxTnSV0oO4k+5n2PgS40XxzDqsepCe3LGQo3AB7c13baxaagLi1MsIK/Kfmzk+1c/8PdOuk8J79c3XDxguqydeBmuP0m08O+KL+4vdMsJ7LV45drIkxKdfvY9faqkueVpPbsStNV1O71TxMuiWbCWA/usZ2jGR6gVas/F9vqtpC+mRs8so4VuCv1rzPW7qLUPG8Oh6qdRSaMgC42/I3/1q6rxJ4IvNQ0a2j8MagtjcxyZZ143D8KTpxsr7sfN26GN8XbvUtOsrCW4WPZczCOSPOSR/hSeH7HT9zMTKi7dxQdBgZ4q54j0gzapp9x4n1FWs9PjzgnHmSDpWXJrraytwmholrJF0kkXAcVcXaPLEN3dmlovi618QXH/EtDi3tZDDNHLx07g10Gv31la2Yms7dZZ05VEHJNeSeBbGNvE93aarO8bwZuDBCm0PjnPvXrPgzxRoviuG9k0+CVJLImJjIuMn1FTUioWtqJO+5yr3UU9j9o8XX01gs78Wtu2GI966nT/DWk2mmR3Xh93SKQBgxYktXmfiTQNX1TXG8+2DK8uBIzcBM9q9WtZLXS9Ct9Lt3LbVAL9h+NFRcsU116AtWcx450X+09I+zShnLHcCD0Nc5plha6XBAJ7ZFaIYUkZavQJbmySIo8pkdVJIx1ry7UtXsrzVI7jUJZra2eTyIlQd/U+1Ok2/dQ3pqzFW20W28RT39pcM97Ln5XbhTXW+GLMypFqV3dIiRNnGeDivJ/iF4dvvD2t/aFcXNjO26OaI5H/667/S9In8UaPpEdu5tREQZPmwW/Cul6wTT8vQh7s9SuvGkMujvJpksc8ygjahyRj2rxi/vdZ8V6jeebJ++Rf3aHqPpXpvhvTdG8L61IrjLXA2gt0z3rideurCTx240d3s7yPJKuvySfQ1zUoU4z0V/MpylY9b1zU9M03w7FfXlztsJWBRhk5zWV/YVjLp8T2s+9Llkk3dipOav+PvDwufAP8AZVhbeekexY16kAcZrmr+0vLLQ9Lso3EUkCqnPt2+uKypx91We97ib1ZzXjy4tpb3VdASXymgZbqKSQ4B/vAGuX+Huqs/i+3ubjZc2FoxGAd3zYwCT65r2yfwz4e8TTY1dUlulj2+Ur4bHfOOtY9j4b0Tw7eSG3gghsrcH91/eJ6H61Ep/u3BM2jvdolsdA8G6dqLa7HuW4BLokknCHqSop/w78SJ4yk1e9udP+zQ2spWGZh9+uG8TWAvvES2spaA3QTa+cLFk/zxXS6zLf8AgvRdN064G/R3Oya7Xhlz6Ada35JSilJ3k/y/UxVovRaCyeLNTOvNam28/T5HMMkTLlWHSovG0NpYRO4gt7PRoxsYfcUknOFx3+lYPhnVrPTPETQ3GqtfWE0odYoojuAPfdXovxP0aTxLoFja6XZw3UfnK58xtoRe5H4VTtGoo7INeW5w+qXa3vw9N74KktzqELCNpQm1mXOSoz1ruvh7dvFoVj/byLHqUkYL45BPt74ridbt11rRY9C0COzsTFLt2xEho2HUuPfFR+KPFd/4M0zRbKxWK6njwLi4YZCjPTn1qakJTSgt9fUcWlr0PWtS1cxxeTaQysW48wrhVrlPCWhX2leI7qe3WEQzfO4UYLMe7U34jW2teINE0o+G75LaN9skxDY3AjPHtWtoD3Gmn7Hc+Yzy4BlZs54rnTcYXWqe5drv0NLWNato4/s9xeQxOSA6g84+tc1f6fo9jqULPZCSSZS6uV+Qj61zc3w31C+8UST3F1K1s8hZ/mzlfQDtXpfiPT7ePwbPalhCsMBEb55UgcVpJKnZRluKL5t0ZtvqZVMRLGkfdUHFZPiLXNLFzDpc+rLYX9yR5UYbDEk8fnXGeDvFTJKY9XgkkihXnjBz2x610WsSaBdXdvrselQ3erbcRM648rHdvofSpp2k9U0y5xcS9dzalZSeUbt4jbqN7v8ALmrMeqRRaRdagSLyeMfOEfc7e3sK5DXvE0CRpB49heRbghlEA8tokJ4Ynrj2p+tWlx4KmtE8FaH9usL2ISS3ExaXdntkdMfrWnsZNpPf+uoudJHKa1qtpretibWZWQTkwxrDJ8sKngAL6+5roPDkFt4Oeew0zW5b1bpCm51Plx9wfdvpWF4g0q106WPUr+zXTDcR+c6OuFHPUDqM+ldD4cfw9qthFqFlPcu0rmKEiPGHA54/xp1aq5XF7eg4U9Uzt/BuuR6bBHa3sbEuMLMBnc3XB+tc54ne08S6psS+AhZv3qAfMhHb8a53UvFcdvMIJ02XKyeWwk6n0YY9a7nwFpsOsGSfafsbYLSKm3zT6ZrKlHk965U3rsZVvqR8MaosOmWbXDRRMx3MFWMdMn61RHxVe98QWGkajavbvdthZFGQq8/NS6pr2jeIPFQ0xNPS1tlLRmdmyXP91l9DWVcJFb+JC93pH2u3ihOHVMBMfdUVpyRd1Jahd6NbGH450zWNR1mOfQ7++W0hYM8ZjOSM8kY45rifHOuaxeXIbU7d7Oyz+7VQVPy9Pzr6B0zV7r+wFmijWScZYW0RAKr2yeprkvHmk+Idf0QNqukI1krmRHjyCnHDE1zpqTStf7jZaFb4X+E/E+maUvifRNO0yG5vo9zCWZg7pnIGMYGTVM/F7xVLLPHPpsDgM8bwxIW2beCp/rXbaJF8Q77w9YWtnLY/YbmAKt5uCmBOnK9S30qlqXwz1nwj4cup/DmtSXsj73u47mMbnDfeKMOh+tPlVR3mvx/4f9DNS5NF+R4NdeI2OoecNPt7AO5Z44FbeT7A9PwrV8JeNptOvLo29/FGJlO5JV529xmok8N6vrOupeXsptbUsIVHQhemTnr9ateNPg42niC40XVIb1ZW2bVHO7rQ4ptt/jqa3srL8Dtdc8X+E9S8CS6ItxLZ3rFJpZoVB3sP73qOaispdP1DwjoK+HbxY9RsJSZh5eCTnht3TP19a8RutLn0m7t1ule3ldjmVkJCsDjB9667SJPGeh6pdWUluDGg2yMsQYc8gg+uKqEakEtdPkTJQbdtz1r4u+JtSt9O06cW9lqFncIBevLGJAGz/qwP4R3z3r55tZd3jGWHS0MFpczkJAOm1uMD2r1ya4n1Czng1a2hgmkj+URnLkepXpz71z/hL4aXuo+JUnvdQis7iCRdsaHLsOu5QPak5wty3BRa1Osi8K6ZoVpGoSRo52+fdyWOOg9u1dl4e021u7uy+wIkE1o5/cQOCVJH/LQCtXXrHToLeG/8uSWS0cJ5ZOEdxzlq8pgvbXwVLqWq6VcBdQviQzStxGGbJ+p9K10lTc0/e/PyIu+bl6Hol+lrfeLIY5Eiulg+SYliUx7+9a2lC00zxstzI8Nrp4zsZOA2RgA46CrXgnWtCuPh9PcaCIdRv7eFppoWA8xpOpz3xmqnh24sPHGnbQjWGoxt80UYBCD0OetY0Fo29vyHUlfTqeqXKW95aSQSOrRTIVOD1BHauN8IfDjTfDepSXsVxNcyMWMfmAfID2rT0zRbjS9C+zmT7RdxkmNuhYZ4Wti6vYLDT/t2pzJaxRpmQyNgLWnM4JqL0ZhYgttOXT7medPuvySW71y99qmg6p43/sDUWI1JoBLbt90gjkhT696wfjDLP4i8M2N5oU9xd6TISHWzb/Wntk9sVz+gaabe60LUdXV/7UiUbWdiJFAPy7vUVcaK5eeTHzNuyOo+KulvfeGLlDPJbyDCyPEDuZl7nHYivPPAGo3EEMlrqFu2qWlshlWGZN3TspPQ+1ezafrVpd3s9rrPkxyAecgPIYDqQaw5PF3giXVRZQX8ENxJJsDIvG48AH0zUwdo8rRTetzZ0nXNK8YeEGlt7eWKLmPyZI9pjcDp9K5bwzD4V8K6rd3a2ssGqyJ5fDFgQewHb8aLqbVNO8YmxjaUW2z92MYVj656ZrN1PRH1DVGuXkuHkfmSFI8sCOOfarUJK6vaLJ0fTU6HxZ8SbDQrOxfXLWWGyvWMasF35A6k+1dFovhywkjS8tZ5mtLhQ8caSER4POQO1YJ0Gw1KC007Vb60j5BS0mCu5b0weh+lYviDW9b0PxvZ2An8vTUaNAkagLtPAGKzjBS0huOUrb7HW/EiPUB4YubPwrNHFqZxlAw3lO+M1wPgVdY0Kxvm8SySvYGH5rYyFua9H/4RGFNdk1lZp2uGQq0ZbIIry7xz4m1fTdUltI9ORIFOQHHzP9RWtJXXIknch73Zv+Fp/DEPg/VNXtrV5rS3kJe1kX5Q307/AFrmrTxVqviXQYk+G+nW2m3dveZurWJAN6H+L0xXW+EvGWgRaGtrd28UIlT54Viypz1zXQeG9B0rQZ573QbCK2+0gFgpwPwBqpNJvnT+exNnpY5/x74k0J7W30zxC0ovIkBk8jja+Oab8LTpckdxD4W1JxKmHkt7qIbyD0+b0qz4j8F6R4k1Ka5u4ZopZeWKkEH8P1rU8G+FtL8HtPPaCWa5uAA00i4IHpileCp2vr2sNpt3sVNQu9R06C+ukEtrqMYJ+zbg8cvoR9a4jwf4h1S71KRtU0X7OZ2/1sY+Un6V6Vr1vdzRNcraPct/CTxj8K5+08MeINSvobq6K2tpEwYwucbwPYU6XLZtikzqNca5uPDc1oomt9y4WeMfzFcn4J0qLw5buVguJXdi00ypyT60nxJ1LUtNH23Q7jzpxhPsrH5cHr9a9B0u8l/4ReG8ktwtwLcO0QOfmxyKz1jC/Rj6nK3GrLdatMstntKRborllxuHpzXK+FfFOvJc6wD5YtIs+SW7mjQ/iBqep+IEgvLO3lspJjEYwOU967rW9M0WxcSGJY93JRe9VyqKtNbhe+zPBfFJvdf1GPVPFU1xZ2G/YqoflY57CpLm+vr3XbbQdA2twCsr/LmvSrvXfC/ie6m0KS0Z7jTx5yccGrnhjW9OE7y3GmW6SxDCSogzxWsaiUdI6LoS733OeudRm8L61ZW99ElzqbqFlmVMbVPH41r32sado0q2liIrb7U25zGuMk9zW0z3PizUFWDT0is0OHuXXnHtWD8SJU8PXVtDaafEdqBklkXd5h7j61HNz2TWrHtqjbuNU0rStPRbpxNPIPlJORXF6x4vvobu4trXSXliRcpIB1Ppiq2p+IVv/CU1zqOmwi5hk/c4GN1UdO+I1ppVvFdyv9pv3TZ9lK8IKzinzuLTb/rYu3u3R3PhiZr2yiutRiFvNIATGw+7VnX9I0jUIMDT47ryX3qYj90nuMVkHX7bxJYRuyi2d+WRuK57UtYv9C1G0g0GSJ7Z32XIJz8vfFP3lKy0fYm2l9yZ/DumWUEkb6gLy2eXzCmd3ln0qbTtL00a6up2WpBfLQgW6PwfwrM0zS7OzubwwR3Zt7tyW84YGfUVZ0fwpp0OpS3u6aNwCNrdM+orZXt7z/AjTojL1jXbmXU0me2eaNZdu0D3rW1rUotN1ixkOmRymYAF9uSAad4gsmjsPOsb7MrOFK7c1ZtUCWiw3Ey/bGT5HYZw1PRLQN9z1Hw6bkaUj37eXIBkgnoK4fUNQu7/AFi5+xQv9li/eLIRkN9fSvSofKmtg5ACSLkfSuY1jS9NUmRVdVB/eBXwD74rhpTirtlSTb0ON0bwrc2niyPV4b5XtlzO6K/znI+6RW9LZQXi3c96jvMxJwM5UAcAV0+meH7G2eS5hJ3zKAWLZAFVvEl1b6HpEtwil2PG7tjvVyq87vuwimtDx/xHfRa0IkkWS1ltQFNxuwHC9N1eh2s+neK/DEVjfyF9i7Q+ec465rlYl07xbY3U2nzQ+WjfvAp5OPUV0uhJoWn6LdfZr2KSS2TzZo4zlgAPSqdRNLl0aeg3G10zLL+EvhvBFNqasZLl/LjkK7iB6/Sus8XeIm0fwlaXuj2cl7FPjbsH3VPO6sbSLe38c6Ukt1p9qbZHJiEw3E4747VV8T+Lta0LWNO0WDTku7S4Co0kSYWNc4/MU/ikm7tq91/kTtpscnqvijX9P00appHh1ClwrfaHZPmDdie5rV1DwfqHjLQtKvWWJvMiK3UZOzvkMK9a1CGCPRpERI2byvlU9zXEatrOp6Vp8VokcX7xM74uOD2FVGrzNOmtfUbj0ZxmteHdfudes9PjmuVsYYo4lkiJCjHU16Nd3NvYyWVhJOZ57dVXJYbnJrH8O6kZ9PkthLcQ3ZUt5cnt6GuK8u7utTiSFZ0mDg3DSciU+qntiqcHU3VrAnyntD3MVlH5s0wXcOua4h/FVpea9NZX04ayxlCGyXb0Ip/iTRm1TTxaxXyRzkg4Y9B3zWHpfw/bUFcafrVlKYiEl8oBiG9/SuXkW8mjVMreK7eLV3hi0eNraRM7iOo9jUDx6hFoN3Z6WZILiNfLhmIDtCT1P/167fS/Ab2DsZLtnLj5j7964TxquqeHPETyXMQk0VxmN4ydzjHIyO9a0eeXu72FNwWqZ2K+EtN8V6Tpg124mk1aziWKW4TGZCOufzqbxTrGpaBYWGkeF4sxQxbC7fMwC9B9TVvw7o81tbWt9pcrpbXUQkEUwJZQR0NXlWKzvFe5tlnlILb1bLfgKmU3onql0BRW63PPNf0zxFr2i290+nvd3LH97FcHK7P4vpUmhQQL4Wvbfwhp9rYJbkyXE/neY28DDdfyr1S+mOq6Bd2yJPbrPC0YkCfdyK5H4W+EZvD/APat3rUlqY54xCI4z8pQd2FN2lBtO3l3BSaequYHi3+w5/hab28jjN6qCQTIAGLeufSuL+CHjq8lsTpMlwgBLGIbtrN9PWu51zwBoviexvINO1S5tbNnyYdwKIM9B7V5VqGh/wDCN6hNplrAt4tuc29zACJFb2+lYqk5R5W72N1KPTqeiaLYW/hnWtR8Q64nl2KFiHYBgxPp711sNwviaxs7zTYyumz/ADLM68uvQrjsfrXmFmNe8S282neIUWyluFX7PKPlw3bcOhB9a6+z+H3jq10+KC18R7bdB8tvhVX8xXQoqouaTs+zMpN03boaF14NFtqUV/YXyWyKc+U5A3Y7ZrYuPibp2n6fKl/ZXiyxrs27Nyv68jjFYkXg3XL14U1JpJSo2u6TKQn09TWhH4RXQNPnldpZ/M+WQyHPHuKmrFWV5fcEWm9jNs/Ht7YWlolrFbtbSoXiHJPrj2NSWniS78Uag9vPezRQqAr28C7SSfUn+lar2Phi0s7R7+5gjfUD5MRZ87z6D05rJtdR0G38Tf2DHMbW5CFklUdxztNZ0qcGr6t/gXKeumhXksPC8esS6LcXt2JZcR8jIic89a4jxJo9z4a8SwRWT3GpWaZMAU5De3+9mu18KP4c8R+JZJpVmk1WMsoP3VkI749an+It7rOjtptxovhv7Xa2EpknWQ5ZwewxW9opqNrvsyFKW9zjCumXupjR4SJrqZxPdWs+CJGHOEP94DjNehah460G1lto4tKnNzCQzK8WMHG0ZNeeWNpea74iju9A0c2U8mWRr1gDETyQnrXp0Xga9kijkvjGZ2X98yHv7VnXholF6f10LhJX945Kw0yO9Gp61qhW327nwFCqo9j3rhPD76nBqE17pGFhlmMav1cK3Q89q7Wxjvtc16bw7bSxLZAkMs6ngj6VoXvhLVfDUof7Pbz2jr5TvACBt91PTHrWHsZXtNGvtIpaMy73xjFYWV5ZNt+5iWUfORLjoB0/GsKw8Da5faRa3LfZPLvEEjXUgEgGTwpXt2p1ppGn2/iYWV2QsLSCQsGBRyemfftXXeP/AAdqemaZDc+HNfax00OrzQdcNnIK/wBRV8sVZQ38/wBCbvqchp/hTUvDV9qF3oN3DDdAhpy2QJD32j8KzdZ8ZPoDrqkMM0Go30ifaBGRsKK3LAdcmvTNb1hfDnhLTNXsbSPULie4xcvN8yjuee2cHFaXxL0vwtrHglryW3to57iESW7qAGBIzScbR5paJi503ypGX8RfGv2qw0CbRtWitortGlWRX5LgcD/61N+ICP418IeH4H1W2glLI16m/AbI/wA8e9eE6Z4RngaN9buri10hVM0M6KZMEHhR2we5r1Dxp4m8LeJPD2l3eg6lZWz2RMc1u67CeAM7e/TrWtKfK4p797GdSG7R6VZ6mPCMNr4f0jw9qU0W0tHOqZhY4ycGqOitY3uk6prHiuJ1uI2bh1KMiDoBW38ItRs7rwjZW1rfJdywx5k2vu2ZJ4zW/wCKNJt9U0i6imUDchyc4z7GpSTnzXfqS3Zctjwvwvpl1rWvXE/h3U/tFvESs9ldHDrG2QSp+lWtD+CLp4oju59RSSwWQShAvztg5Ga6RvD48GTSajp91Ewng8pY1T5j3yfU10HhW91WS3DSlQ7n5DKfvD2Fdsqsopunaxlyp7mJ4x+JyeGvFMmm3WmxSwwgAPu/ekkZDAelbnw88dJ4nvL+0mWGO5hQSr5Rz+7PTPvWn4p8E6R4qMVxqMHl38abUuI+HT29x9a8j1W6j8FyTab4ctLmXWb2XyZrqSPHyKO2KxUKc4WiveHd312Ot1L4d6XrXjlfEE+rFIlkVzbhvmEi+jZ4FeiX1hpl7ImpNawXdzbDMUmMkY7V5R4H04Xllc299JJHeO+8TYOcn2r0Xwt4cOi6VdW5vnl84n5weE+lTNuKtzarQOVX23NS21q1kt2lkcRlB86nqtc9O2jeLbhl+ziV1BRZG+U15xqE/haDV7mwTVNYhZSWkmhlBUn6GrXhXwtc3epwaho3iy9ktCxG2eMbl9RTp02lzN2+/wDyHJrZL8v8z0vSvBGiae3mfZFnm67pfmx9B0o1m6srJ2TzAxb+DPC+1ebeIPFOpRXl5oulXd+TG2JLjy859QtN8GeJ9J0qV4Nc0/VTOeRNcwlg59faqdOo/elr95N4o7gXDPCAbUqG6Sc4qeKG7l++GEfc81o6dcnU9xsAots5DOOntip9RXUbTTZjG8U21TtBXBFZN26FnnPj7WvHOilYtDFq9oVAR5Ey4+vrXB2/xD8Y2hnj1+6V42+UrGgGDXrFhenxBpF0l5C4eAHPYqR/OvP9L0X+0tYMUsTTRlurD5SPrXVShT1Uoq5nKT6MuaLLaXmiyX1/5m9R5gJbkj6U7SfH17b3W2CJ5IF6DOQRXQT6Qto0UVyg8jOwccbfSuNvfDraFr91qepXaadof3YwOQ34U24SvzbBqjqh4k0iTxNp1vB4el+23J3ySouBF/tH2qDxNJd6trDPDK621rnzHx8uO9bGnGeW1hewaKS18sbbkKNzL9awx4h+xeKLbSkiElpdgrKpHWs0tdNQL3ge40a91SeC0s1S9KbWugn3hXTWnghIrrzZrpniHOzbjJrU0LQ9N06UvYw7D6VrX94lpbNJI2MDisZ1tfdY1HuZ2q6vp/h3Ty0zKkca52r1rx7xj4mtvHn2YaIZS8EgBQ9Ca1L/AFjTdY1aVJpzK5JBiPQjuK6Kw0fQPDcceoQxrBDjcSxoUVC05PUbf2UWvC/hCJLKObXYUublgMRkfKg+nrWtceEdBlXzH0mzDJyrCMZFSxa5baxot3NokwlkCHbg85riPBN5qTS3aTzTGJwQwl42v7ZpJzd2nawna6uct4rurHW9bufDcOnzWk8Yyl1EMKK1PD3hvT9K0LyvLFzeq2TOxJ5qYrqvhm31TUNZtxcW5OEZFy+0+9V/DGvLdRXQNtIlopDeYRya295RsvmLRu5s63p0epeGpbZp/s9wy/I6D7priNfsdd8OeDIJHvBdshO6X2966HUPEcVxdJb6FIlxIp+ePuPwqbUo5dcjTS7xNiTDDqpzt96Ip723H8ziPBPiI3B/4mVucsQsbKMg5710PiOF9KB1K4VpViXiOP7xz3qWz8M2HgXTHF3qCSROx2Fx92uW1fUH1a6Ekt2bSS0O5ZM/LInoRWknGcvcenVkpO2qPevEjSQeH7r7KMSJH8nPHFeRvrN3ceHVLTiK5L+Wybslhnriu11zW7l9PtbdkHmzRbzhuAcd68mhvbeHX3luIdwRgpbqM9yK8yLclyxWp0Rik7yO4+ID+IZvBWk2mkLM8U0gW5eFvnCAdM9s+tZs08ieBF0C5up21OFvtG3BOYc/dDd8V2+iCO/0aa3Wdo4pYiqsDwM1Zl0nT7fTE88rLcrbiATIOdg7VrTlFU1C2q/r9bGUk+dvucV4G8HW+hDUL+6f/RNQjChVO0xk963dE8MaRZ6ij21tIBcjZPM/8ajt+NYfiZtajk0qLSY0l03zNlyJDlgM8H6YqTxJ471Ox8X22kabaB7JColXbkOvsa1/ey+auT7qK/xK8Qx6RrP9laJvshFAGdojw4J7D1rH8By32sXU0n2iWUxHJQtk/WodVW0uPE15fFDJ5z7V3tkqnTA/WvWfAfhrSdIsDLp1sUaQHdIzZLCs5Wg/e3Zrf3dDktQ8YWvhzXIrDV4riffF5xzn5V9h3rYudYs/EnhS41PTLdnituXhlHIXsRWL4jXQfE2tGy1Nrm3nhPkR3kPDYzkqfUV2ulaTpnh/w/LpGko1w1wCJGc5LE92PatZuEbPVPsZK7TPL9J1fUZPElium6YLiykYRzNnc0JPU57CvYrfSIYXEnlxu3XNeZavoV3obG00ydY5JQZHKN+9PoK2fhZqep3wnt9WOFjYBZGPLe31orarnhshrszV8X+H0vdE1KPTJhFfTrhQxwTzyB9a4jw/4Y8ReCPAusappcZbWrqQYjIz5cY/ix3Ndp408MaVeyeeNVktbgnoJCfyFa2g2OpaFpr+bI+rqeRg4YLjsDSVW0ErqWuqFy69jj28beJbHSvDwudPD3F2u64k2kjrjHse9eiyadHqMEc3lohdQ2JF3DP0qO21TTbwLFKBBMBnypl2kVx/j7xrfeFLi0jtIRdpIvmHJA+UHnHvWcWpvlpKz9f8y3oveOh8S+IL7w4kRbRZ9QhfgmzGTHj2ryrS/wC1tW8Q6hdKLyCGRw0LXkTRmMZ7fSut8Z+M30u00i+aa7FnqABLRKP3Cnu3etbwpd22v232uw1CeXywWDzDhhWkG4R5uXf+u36i3e50kF8ZEgCXCKFXa57E1w+n6feweK9Sm1HU2l0q6DYiB3cnpgdsVT1rxtplhcyqYBcSpIEYIfkBPepPEnxCXR9AtrzTNKhuZJn2En7sQx3xzRCE1pGO4Nrds6rQ9IsrZGS22nnLe9IugwWmtfbkgjO5t2AOC1c18L/G174pvryDUbC2RAm6GaAFVPsa8zh13xXb+IZLTT7y4jv0uSkFmwLqw38g59auNOq3JdROcdD0DxTBaXOqyG3uPLnDZcFcqOenuK9C0Ly4/DAsoLsC4MLBGZuhIOMZrhviNa2dhs1A24GoOFaVUO5UbGC2B1x6VZ+GVvrOqSSzayUm04xYjk27GLZ4K9xx605e9BST0QJ62OT8LXHiDwx4ltra4jvLmdn2TBELJLlup9MDvXumoRRSxEykYA5Fc5H4Zms9eF895LNY7dpi6MvucdRWtemwR4oxKQ7sFCq2fzrKtOMnccLo8Q/aQsLaCx0RdJAS5WdnWNc8ZHX863/C/h3Rrux0bxZq8dx/aS2y+aqHKO+Nu4+9S/EVbD+1FfW7dobaAgedu++h7iun8P3FlqWlwnQGF1p6jywVHKkVtKbjTik9f8xLWTbOH8UC98JeJYF8J6V532gLKt0Y94O48qD2r1zRNVXUrVEvESO6I+eEnPNeYXmtnRtYez1K1u4Yi2I2D/K3uK3zPbT2BngVoArbt6fe/OoqptLmWvfuVG2pxvxH026j+OPha4s+LOOMS7ckIu0ndjHqKqfFDxvf3y2moeH9YuLWBSUktoxjOD94HuD+ldtJqa3MW7Cl1BjEhXlSaxLHTTpWj3N5Jb2crwI7IjDILE+h6HNONSPMlNbaeo3F2bTLnw9137Lq1tHrlmi3N9bedb3u0Deccqfc1rah8QJrS4hjurAvFLN5WApPHrXF6ZrN9rfh65l1jTXuLnTmWWBbdBvZT1AA44rv9AvEv9OtZMIjcM3mqN0eex96zklCT51+Ow/iV4mB4l+GOiTatNqjXU8MdwQwhR8bW68elTarbLPoXkWUqeRAeTJLkynGDk9j6Vt6pHp86TNezvNZ+ZyImOc+vFZN9Z6Z4c0G+1NbFmsoQrRRTvks7HALegqffnJS/QrmilYyNFu7eHw7c2Mmn3F3JMGCwxoXX2z/AI1m2vwy1/xDp1tFqcjWMGOrSHcgz0C9ql+HXxH1DUPF9vpzGGW3mlaKSGODb5XHDqR/D9a9s1S+j06xlup8+XGMnFaSjKnJ8y3I57rQ4LT/AIV2dnY/ZGv557coFKSKCAfb0rlvEXwc0UXduljeWsd+ctFBOgAkx1zivX9C1e31mxW6tc7DwQe1eMftIaY51LQ7zTb+S01OYmFcMQMA9eO/NFJS5uWLsEp3V3qSRW+o+B9WSbT7a3tridBHJbrIBDJ6HB5zXUazc6zr9/pdpNILGz2Ca5WE5Yt6Z9K4XwZo1t8QdDhj1e4uxrPh+fAuXb5ZvQN6ivR7KwuzDLAs4eaQbQFGBnHXPpWlRWd5W5v6+8iLv6HM61r91e64NO0O184x9GK5BxwRXfnRZbjSrOSQmC6iTLDd0NV/CnhWDQbhruZka7dMM+eg9KteOdUtbPwvffaJShmhdEwcEkg4rKc02lErfcwvE/jGx8P2UF3cyTyXMoGYImxu9D7cVheJJrrXo9O1DQIjBDdRh5JLhlQg5xtye/0rV8Jadofi3wzpt1fqlzdWMKwzNG2Q2B0PrWV8U/DbeKYNOHh68tsaepV7Jm2Aqe4HqKuHs4yS6+exLlJmvo8dzpkam4j3XkikBiQRj/e6VP4X36RDqR1bUD5NwWKBjkJ9DXIWeop4R02w8Oa+st3LcnckyHd5SnoAa6OX+zPDi+VqGpJHaStvYSfMTn09KmorJ+f9aDi7s8yTw/oukXlxqWoapFceczJEbfJ3ZPVga9W8DX+jQXi6ZaZjfyg6LJwX9xWHdr4cuhPeWulvdLEhlhkYfum9TiuJ0Xxra6x4u0vTItMiaORzG8gyssa+oPanKVStGyv91kCUYbnp3ifwtrt/4xhurW7t49GIBkXO1wR/Oup1idW0K5XT4Uvp4oiEGAQSB61zvjSSG30PUbPQ/Mm1lICIQ7E5/wDr4ql8FbC98P8AhRY9fuSl7dymYxTNnaT6VLu4cz0S/EE9bFL4F6/qmpWOqx6pYywG3uSOVIznsM1ueIvH1vazS2cMBaTkENxiu1VTDvkJTywCxCrXm3iG20G9me5uHl8ybcWaPqo7E0JwnO7WgapHU+EZV1DTPtNqiosmd6MP4qh0zWtJttXksGEUd0GIK4wQaf4Etr3S9LFtcJE9uTuimjP3gfUVieItAs7nxVHqbwypNkDch4J96fuubjfQV9LlHQ9Z1f8A4THVNG1PTpJLH55Y5WXIXHIIPvVO0vNC+I2mXml3qtK9pMfk+6y//Wr1KxQpAvmEEAYyeuKx4PDOkaTcX2p6baKs84PmFD39aSqRvpp/mFn1Kfh3+yTB/ZNnKqtbIFMQPIFeZfEHV7TT9cS10S0+06mrYVuuyuw1OK18NW+oaza27SXnl7pCDwRWZ8HNPstfgn8RXkO25nc4VjnHuK0ho3OTduvqD2sjqfCV+8OiRfanLXxGX9jVzVSbmxZbyTbC3/LQDpntXE6ZfJceKdTtFkOEfAOcCtTxdfG703+xrS4SC7bkNnpWcleSa6jXYxr3S9I0e6aVEZyx/wBYV4z9aeTJ4msp9NfgY+QnoPatPwRBZzeGJ9Mv9Ug1G7gfErZ5X0BrctLK3tHE0UahgccdDVc+t5O7Wwumiscv4dt1+Hum3k2rTIiPwgVuv4VY0tp7y9S5uJdsE43RjPr0NS+IdDstY1a2m1Au6QHcIc/KT7ite00eymnjuwTttzhIk6Cm5J+/Ld/194ttEZdvc6rqF1NaamIjZRHhv74980610+OI3M0ceI0BJiQZDAVf8R2g1mxuLW1Z7dpBjevBFReHdNfQNAhtrm5MpTgzSHr+NZKVo9v63K6nn0Wv6RGuoappGkSwX8IJdGjwT71R8Ba7d3fiO6vr2JoFlQFVY9K6X4jXcumaY9zp0aMz8MUA5rzLwzNNb6gLrUpn8+QfJH2PtiuunFTTlr21Iemh1PjQ/wBoN9l1Uu6mXfCEPJHvXMarbTa9eNBY2rpZwR4kIHJIrs/D2kXniTUJrq9BghQbEf09619SWPw4YoYtrRHmaXuafMqaUXuGsnof/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A follicular dendritic meshwork is demonstrated by CD21 staining. Immunoperoxidase, x20.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_16_23818=[""].join("\n");
var outline_f23_16_23818=null;
var title_f23_16_23819="Differential diagnosis of tall (peaked) T waves";
var content_f23_16_23819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of tall (peaked) T waves",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ischemic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperacute phase of myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute transient transmural ischemia (Prinzmetal's angina)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic (evolving) phase of myocardial infarction (tall positive T waves reciprocal to primary deep T wave inversions)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nonischemic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal variants (\"early repolarization\" patterns)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperkalemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute hemopericardium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebrovascular hemorrhage (more commonly T wave inversions)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Left ventricular hypertrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Right precordial leads, usually in conjunction with left precordial ST depressions and T wave inversions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Left precordial leads, particularly in association with \"diastolic\" volume overload conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left bundle branch block (right precordial leads)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute pericarditis (occasionally)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_16_23819=[""].join("\n");
var outline_f23_16_23819=null;
var title_f23_16_23820="Contraindications to fibrinolytic therapy";
var content_f23_16_23820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Absolute and relative contraindications to the use of thrombolytic therapy in patients with acute ST elevation myocardial infarction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Absolute contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of any intracranial hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of ischemic stroke within the preceding three months, with the important exception of acute ischemic stroke seen within three hours which may be treated with thrombolytic therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of a cerebral vascular malformation or a primary or metastatic intracranial malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms or signs suggestive of an aortic dissection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A bleeding diathesis or active bleeding, with the exception of menses; thrombolytic therapy may increase the risk of moderate bleeding, which is offset by the benefits of thrombolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significant closed-head or facial trauma within the preceding three months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Relative contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of chronic, severe, poorly controlled hypertension or uncontrolled hypertension at presentiaton (blood pressure &gt;180 mmHg systolic and/or &gt;110 mmHg diastolic; severe hypertension at presentation can be an absolute contraindication in patients at low risk)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of ischemic stroke more than three months previously",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dementia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any known intracranial disease that is not an absolute contraindication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Traumatic or prolonged (&gt;10 min) cardiopulmonary resuscitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Major surgery within the preceding three weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Internal bleeding within the preceding two to four weeks or an active peptic ulcer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Noncompressible vascular punctures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Current warfarin therapy - the risk of bleeding increases as the INR increases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For streptokinase or anistreplase - a prior exposure (more than five days previously) or allergic reaction to these drugs",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * May not be all-inclusive or definitive.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_16_23820=[""].join("\n");
var outline_f23_16_23820=null;
var title_f23_16_23821="Classification glaucoma children";
var content_f23_16_23821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologic classification of pediatric glaucoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Primary infantile or congenital glaucoma (open angle)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Juvenile glaucoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Secondary glaucoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Angle anomaly",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sturge-Weber",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Klippel-Trenaunay-Weber",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Aniridia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Neurocrestopathies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lowe syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Neurofibromatosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Marfan's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pierre-Robin sequence",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rubinstein-Taybi syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Epidermal nevus syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Trisomy 13",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Skeletal dysplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diamond-Blackfan syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Oculodermal melanocytosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Stickler syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rubella",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Secondary glaucoma (continued)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Lens-iris diaphragm abnormalities",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Aphakia*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Weill-Marchesani syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Homocystinuria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Persistent fetal vasculature",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ectopia lentis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Retinopathy of prematurity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Inflammation (uveitis)*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Idiopathic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Juvenile idiopathic arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sarcoid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rubella",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Tumors*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Retinoblastoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Juvenile xanthogranuloma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Histiocytosis X",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Leukemia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Secondary glaucoma (continued)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Trauma*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hyphema",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Angle recession",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Traumatic trabeculitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lens induced",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Drugs*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Steroid induced",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These types of glaucomas are sometimes referred to as acquired childhood glaucomas.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_16_23821=[""].join("\n");
var outline_f23_16_23821=null;
var title_f23_16_23822="FV curves after treatment";
var content_f23_16_23822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flow-volume loops following acute bronchodilator treatment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 337px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The dashed flow volume curve in each panel is the predicted relationship. A: The TLC is unchanged after bronchodilator therapy, but there is a fall in residual volume (RV) and an increase in total flow but not in peak expiratory flow (PEF). B: The bronchodilator causes an increase in flow rates without a shift in lung volume. In these first two examples, the measurement of lung volume is essentially noncontributory, as the FEV1 alone would be sensitive to the changes. C: The pre-bronchodilator flow-volume curve is shifted right and down, indicating hyperinflation and airflow limitation. The post-bronchodilator loop is markedly improved, although airflow is not totally normal. D: The change caused by bronchodilation is solely a fall in lung volumes, but flow at any given absolute volume (eg, dashed vertical line indicates an isovolume point for comparison) is significantly improved. The FEV1 may not change in this situation which is an example of an \"isovolume shift.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_16_23822=[""].join("\n");
var outline_f23_16_23822=null;
var title_f23_16_23823="Type I supracondylar fracture";
var content_f23_16_23823=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Undisplaced supracondylar fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 4-year-old girl fell on her right arm and was diagnosed with a nurse-maid's elbow. Close review of the radiograph shows the presence of a posterior fat pad (arrowheads) that is due to an effusion and suggests a high likelihood of a fracture. In addition, a subtle cortical defect is visible (arrow) on the anterior surface of the distal humeral metaphysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baskin M. Trauma: Extremeties. In: Atlas of pediatric emergency medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_16_23823=[""].join("\n");
var outline_f23_16_23823=null;
